<!DOCTYPE html>
 <!--[if lt IE 7]> <html dir="ltr" lang="en-US" class="aui ltr no-js lt-ie9 lt-ie8 lt-ie7"> <![endif]--> <!--[if IE 7]> <html dir="ltr" lang="en-US" class="aui ltr no-js lt-ie9 lt-ie8"> <![endif]--> <!--[if IE 8]> <html dir="ltr" lang="en-US" class="aui ltr no-js lt-ie9"> <![endif]--> <!--[if gt IE 8]><!--> <html class="aui ltr" dir="ltr" lang="en-US" prefix="og: http://ogp.me/ns#"> <!--<![endif]--> <head> <title>Inhaled steroids and risk of pneumonia for chronic obstructive pulmonary disease - Kew, KM - 2014 | Cochrane Library</title> <meta content="Inhaled steroids and risk of pneumonia for chronic obstructive pulmonary disease - Kew, KM - 2014 | Cochrane Library" property="og:title"/> <meta content="https://www.cochranelibrary.com/cdsr/doi/10.1002/14651858.CD010115.pub2/full" property="og:url"/> <meta content="article" property="og:type"/> <meta content="https://www.cochranelibrary.com/cochrane-theme/images/cochrane_circulargraphic.png" property="og:image"/> <meta content="summary_large_image" name="twitter:card"/> <meta content="Inhaled steroids and risk of pneumonia for chronic obstructive pulmonary disease - Kew, KM - 2014 | Cochrane Library" name="twitter:title"/> <meta content="https://www.cochranelibrary.com/cdsr/doi/10.1002/14651858.CD010115.pub2/full" name="twitter:url"/> <meta content="https://www.cochranelibrary.com/cochrane-theme/images/cochrane_circulargraphic.png" name="twitter:image"/> <meta content="initial-scale=1.0, width=device-width" name="viewport"/> <meta content="10.1002/14651858.CD010115.pub2" name="dc.identifier" scheme="DOI"/> <meta content="Inhaled steroids and risk of pneumonia for chronic obstructive pulmonary disease" name="citation_title"/> <meta content="Kayleigh M Kew" name="citation_author"/> <meta content="St George's, University of London" name="citation_author_institution"/> <meta content="kkew@sgul.ac.uk" name="citation_author_email"/> <meta content="Alieksei Seniukovich" name="citation_author"/> <meta content="Grodno Clinic Hospital #2" name="citation_author_institution"/> <meta content="Cochrane Database of Systematic Reviews" name="citation_journal_title"/> <meta content="John Wiley &amp; Sons, Ltd" name="citation_publisher"/> <meta content="3" name="citation_issue"/> <meta content="10.1002/14651858.CD010115.pub2" name="citation_doi"/> <meta content="2014" name="citation_date"/> <meta content="2014/03/10" name="citation_online_date"/> <meta content="https://www.cochranelibrary.com/cdsr/doi/10.1002/14651858.CD010115.pub2/abstract" name="citation_abstract_html_url"/> <meta content="https://www.cochranelibrary.com/cdsr/doi/10.1002/14651858.CD010115.pub2/full" name="citation_fulltext_html_url"/> <meta content="https://www.cochranelibrary.com/cdsr/doi/10.1002/14651858.CD010115.pub2/pdf/full" name="citation_pdf_url"/> <meta content="1465-1858" name="citation_issn"/> <meta content="en" name="citation_language"/> <meta content="Administration, Inhalation; Adrenergic beta‐2 Receptor Agonists [administration &amp; dosage, adverse effects]; Androstadienes [administration &amp; dosage, *adverse effects]; Anti‐Inflammatory Agents [administration &amp; dosage, *adverse effects]; Bronchodilator Agents [administration &amp; dosage, *adverse effects]; Budesonide [administration &amp; dosage, *adverse effects]; Drug Therapy, Combination [methods]; Fluticasone; Pneumonia [chemically induced]; Pulmonary Disease, Chronic Obstructive [*drug therapy]; Randomized Controlled Trials as Topic" name="citation_keywords"/> <link href="https://fonts.googleapis.com/css?family=Source+Sans+Pro:400,700,600,900" rel="stylesheet"/> <script src="https://cmp.osano.com/AzZdRbSORDOOzF9W/d594efc1-9663-477d-9528-6576640e64fd/osano.js"></script> <style> .osano-cm-widget{display: none;} </style> <script src="https://static.addtoany.com/menu/page.js"></script> <script async="" charset="utf-8" src="https://platform.twitter.com/widgets.js"></script> <script async="async" src="//script.crazyegg.com/pages/scripts/0056/6375.js" type="text/javascript"></script> <script type="text/javascript">window.dataLayer={};var xtend=function(){var a={};var b=false;var c=0;var d=arguments.length;if(Object.prototype.toString.call(arguments[0])==="[object Boolean]"){b=arguments[0];c++}var f=function(g){for(var h in g){if(Object.prototype.hasOwnProperty.call(g,h)){if(b&&Object.prototype.toString.call(g[h])==="[object Object]"){a[h]=xtend(true,a[h],g[h])}else{a[h]=g[h]}}}};for(;c<d;c++){var e=arguments[c];f(e)}return a};</script> <!-- Global site tag (gtag.js) - Google Analytics --> <script src="https://www.googletagmanager.com/gtag/js?id=UA-189672-63&amp;l=gDataLayer"></script> <script>window.gDataLayer=window.gDataLayer||[];function gtag(){gDataLayer.push(arguments)}gtag("js",new Date());gtag("config","UA-189672-63");</script> <script type="text/javascript">var o={auth:{customerIds:[],individualId:null,brandedCustomer:null,roles:["Guest"]}};window.dataLayer=xtend(true,window.dataLayer,o);</script> <script type="text/javascript">var o={page:{siteSection:"Content",languageCode:"en",cms:{pageTitle:"Content"}}};window.dataLayer=xtend(true,window.dataLayer,o);</script> <meta content="text/html; charset=utf-8" http-equiv="content-type"/> <link href="https://www.cochranelibrary.com/cochrane-theme/images/favicon.ico" rel="Shortcut Icon"/> <link href="https://www.cochranelibrary.com/web/cochrane/content?templateType=full&amp;urlTitle=/cdsr/doi/10.1002/14651858.CD010115.pub2&amp;doi=10.1002/14651858.CD010115.pub2&amp;type=cdsr&amp;contentLanguage=" rel="canonical"/> <link href="https://www.cochranelibrary.com/zh/web/cochrane/content?templateType=full&amp;urlTitle=/cdsr/doi/10.1002/14651858.CD010115.pub2&amp;doi=10.1002/14651858.CD010115.pub2&amp;type=cdsr&amp;contentLanguage=" hreflang="zh-HANS" rel="alternate"/> <link href="https://www.cochranelibrary.com/zh_HANT/web/cochrane/content?templateType=full&amp;urlTitle=/cdsr/doi/10.1002/14651858.CD010115.pub2&amp;doi=10.1002/14651858.CD010115.pub2&amp;type=cdsr&amp;contentLanguage=" hreflang="zh-HANT" rel="alternate"/> <link href="https://www.cochranelibrary.com/hr/web/cochrane/content?templateType=full&amp;urlTitle=/cdsr/doi/10.1002/14651858.CD010115.pub2&amp;doi=10.1002/14651858.CD010115.pub2&amp;type=cdsr&amp;contentLanguage=" hreflang="hr-HR" rel="alternate"/> <link href="https://www.cochranelibrary.com/nl/web/cochrane/content?templateType=full&amp;urlTitle=/cdsr/doi/10.1002/14651858.CD010115.pub2&amp;doi=10.1002/14651858.CD010115.pub2&amp;type=cdsr&amp;contentLanguage=" hreflang="nl-NL" rel="alternate"/> <link href="https://www.cochranelibrary.com/web/cochrane/content?templateType=full&amp;urlTitle=/cdsr/doi/10.1002/14651858.CD010115.pub2&amp;doi=10.1002/14651858.CD010115.pub2&amp;type=cdsr&amp;contentLanguage=" hreflang="x-default" rel="alternate"/> <link href="https://www.cochranelibrary.com/web/cochrane/content?templateType=full&amp;urlTitle=/cdsr/doi/10.1002/14651858.CD010115.pub2&amp;doi=10.1002/14651858.CD010115.pub2&amp;type=cdsr&amp;contentLanguage=" hreflang="en-US" rel="alternate"/> <link href="https://www.cochranelibrary.com/fr/web/cochrane/content?templateType=full&amp;urlTitle=/cdsr/doi/10.1002/14651858.CD010115.pub2&amp;doi=10.1002/14651858.CD010115.pub2&amp;type=cdsr&amp;contentLanguage=" hreflang="fr-FR" rel="alternate"/> <link href="https://www.cochranelibrary.com/de/web/cochrane/content?templateType=full&amp;urlTitle=/cdsr/doi/10.1002/14651858.CD010115.pub2&amp;doi=10.1002/14651858.CD010115.pub2&amp;type=cdsr&amp;contentLanguage=" hreflang="de-DE" rel="alternate"/> <link href="https://www.cochranelibrary.com/hi/web/cochrane/content?templateType=full&amp;urlTitle=/cdsr/doi/10.1002/14651858.CD010115.pub2&amp;doi=10.1002/14651858.CD010115.pub2&amp;type=cdsr&amp;contentLanguage=" hreflang="hi-HI" rel="alternate"/> <link href="https://www.cochranelibrary.com/hu/web/cochrane/content?templateType=full&amp;urlTitle=/cdsr/doi/10.1002/14651858.CD010115.pub2&amp;doi=10.1002/14651858.CD010115.pub2&amp;type=cdsr&amp;contentLanguage=" hreflang="hu-HU" rel="alternate"/> <link href="https://www.cochranelibrary.com/in/web/cochrane/content?templateType=full&amp;urlTitle=/cdsr/doi/10.1002/14651858.CD010115.pub2&amp;doi=10.1002/14651858.CD010115.pub2&amp;type=cdsr&amp;contentLanguage=" hreflang="in-ID" rel="alternate"/> <link href="https://www.cochranelibrary.com/ja/web/cochrane/content?templateType=full&amp;urlTitle=/cdsr/doi/10.1002/14651858.CD010115.pub2&amp;doi=10.1002/14651858.CD010115.pub2&amp;type=cdsr&amp;contentLanguage=" hreflang="ja-JP" rel="alternate"/> <link href="https://www.cochranelibrary.com/ko/web/cochrane/content?templateType=full&amp;urlTitle=/cdsr/doi/10.1002/14651858.CD010115.pub2&amp;doi=10.1002/14651858.CD010115.pub2&amp;type=cdsr&amp;contentLanguage=" hreflang="ko-KR" rel="alternate"/> <link href="https://www.cochranelibrary.com/ms/web/cochrane/content?templateType=full&amp;urlTitle=/cdsr/doi/10.1002/14651858.CD010115.pub2&amp;doi=10.1002/14651858.CD010115.pub2&amp;type=cdsr&amp;contentLanguage=" hreflang="ms-MY" rel="alternate"/> <link href="https://www.cochranelibrary.com/fa/web/cochrane/content?templateType=full&amp;urlTitle=/cdsr/doi/10.1002/14651858.CD010115.pub2&amp;doi=10.1002/14651858.CD010115.pub2&amp;type=cdsr&amp;contentLanguage=" hreflang="fa-IR" rel="alternate"/> <link href="https://www.cochranelibrary.com/pl/web/cochrane/content?templateType=full&amp;urlTitle=/cdsr/doi/10.1002/14651858.CD010115.pub2&amp;doi=10.1002/14651858.CD010115.pub2&amp;type=cdsr&amp;contentLanguage=" hreflang="pl-PL" rel="alternate"/> <link href="https://www.cochranelibrary.com/pt/web/cochrane/content?templateType=full&amp;urlTitle=/cdsr/doi/10.1002/14651858.CD010115.pub2&amp;doi=10.1002/14651858.CD010115.pub2&amp;type=cdsr&amp;contentLanguage=" hreflang="pt-PT" rel="alternate"/> <link href="https://www.cochranelibrary.com/ro/web/cochrane/content?templateType=full&amp;urlTitle=/cdsr/doi/10.1002/14651858.CD010115.pub2&amp;doi=10.1002/14651858.CD010115.pub2&amp;type=cdsr&amp;contentLanguage=" hreflang="ro-RO" rel="alternate"/> <link href="https://www.cochranelibrary.com/ru/web/cochrane/content?templateType=full&amp;urlTitle=/cdsr/doi/10.1002/14651858.CD010115.pub2&amp;doi=10.1002/14651858.CD010115.pub2&amp;type=cdsr&amp;contentLanguage=" hreflang="ru-RU" rel="alternate"/> <link href="https://www.cochranelibrary.com/es/web/cochrane/content?templateType=full&amp;urlTitle=/cdsr/doi/10.1002/14651858.CD010115.pub2&amp;doi=10.1002/14651858.CD010115.pub2&amp;type=cdsr&amp;contentLanguage=" hreflang="es-ES" rel="alternate"/> <link href="https://www.cochranelibrary.com/ta/web/cochrane/content?templateType=full&amp;urlTitle=/cdsr/doi/10.1002/14651858.CD010115.pub2&amp;doi=10.1002/14651858.CD010115.pub2&amp;type=cdsr&amp;contentLanguage=" hreflang="ta-IN" rel="alternate"/> <link href="https://www.cochranelibrary.com/th/web/cochrane/content?templateType=full&amp;urlTitle=/cdsr/doi/10.1002/14651858.CD010115.pub2&amp;doi=10.1002/14651858.CD010115.pub2&amp;type=cdsr&amp;contentLanguage=" hreflang="th-TH" rel="alternate"/> <link class="lfr-css-file" href="https://www.cochranelibrary.com/cochrane-theme/css/main.css?browserId=other&amp;themeId=cochrane_WAR_cochranetheme&amp;minifierType=css&amp;languageId=en_US&amp;b=6210&amp;t=1738735355000" rel="stylesheet" type="text/css"/> <link class="lfr-css-file" href="https://www.cochranelibrary.com/cochrane-theme/css/aui.css?browserId=other&amp;themeId=cochrane_WAR_cochranetheme&amp;minifierType=css&amp;languageId=en_US&amp;b=6210&amp;t=1738735355000" rel="stylesheet" type="text/css"/> <link href="/html/css/main.css?browserId=other&amp;themeId=cochrane_WAR_cochranetheme&amp;minifierType=css&amp;languageId=en_US&amp;b=6210&amp;t=1739774054000" rel="stylesheet" type="text/css"/> <link href="https://www.cochranelibrary.com/scolaris-content-display/css/main.css?browserId=other&amp;themeId=cochrane_WAR_cochranetheme&amp;minifierType=css&amp;languageId=en_US&amp;b=6210&amp;t=1739773978000" rel="stylesheet" type="text/css"/> <link href="https://www.cochranelibrary.com/notifications-portlet/notifications/css/main.css?browserId=other&amp;themeId=cochrane_WAR_cochranetheme&amp;minifierType=css&amp;languageId=en_US&amp;b=6210&amp;t=1739774000000" rel="stylesheet" type="text/css"/> <link href="https://www.cochranelibrary.com/html/portlet/login/css/main.css?browserId=other&amp;themeId=cochrane_WAR_cochranetheme&amp;minifierType=css&amp;languageId=en_US&amp;b=6210&amp;t=1739774081000" rel="stylesheet" type="text/css"/> <script type="text/javascript">var Liferay={Browser:{acceptsGzip:function(){return false},getMajorVersion:function(){return 80},getRevision:function(){return"537.36"},getVersion:function(){return"80.0"},isAir:function(){return false},isChrome:function(){return true},isFirefox:function(){return false},isGecko:function(){return true},isIe:function(){return false},isIphone:function(){return false},isLinux:function(){return true},isMac:function(){return false},isMobile:function(){return false},isMozilla:function(){return false},isOpera:function(){return false},isRtf:function(){return true},isSafari:function(){return true},isSun:function(){return false},isWap:function(){return false},isWapXhtml:function(){return false},isWebKit:function(){return true},isWindows:function(){return false},isWml:function(){return false}},Data:{NAV_SELECTOR:"#navigation",isCustomizationView:function(){return false},notices:[null]},ThemeDisplay:{getLayoutId:function(){return"7"},getLayoutURL:function(){return"https://www.cochranelibrary.com/en/content"},getParentLayoutId:function(){return"0"},isPrivateLayout:function(){return"false"},isVirtualLayout:function(){return false},getBCP47LanguageId:function(){return"en-US"},getCDNBaseURL:function(){return"https://www.cochranelibrary.com"},getCDNDynamicResourcesHost:function(){return""},getCDNHost:function(){return""},getCompanyId:function(){return"20155"},getCompanyGroupId:function(){return"20195"},getDefaultLanguageId:function(){return"en_US"},getDoAsUserIdEncoded:function(){return""},getLanguageId:function(){return"en_US"},getParentGroupId:function(){return"20182"},getPathContext:function(){return""},getPathImage:function(){return"/image"},getPathJavaScript:function(){return"/html/js"},getPathMain:function(){return"/en/c"},getPathThemeImages:function(){return"https://www.cochranelibrary.com/cochrane-theme/images"},getPathThemeRoot:function(){return"/cochrane-theme"},getPlid:function(){return"20757"},getPortalURL:function(){return"https://www.cochranelibrary.com"},getPortletSetupShowBordersDefault:function(){return true},getScopeGroupId:function(){return"20182"},getScopeGroupIdOrLiveGroupId:function(){return"20182"},getSessionId:function(){return""},getSiteGroupId:function(){return"20182"},getURLControlPanel:function(){return"/group/control_panel?refererPlid=20757"},getURLHome:function(){return"https\x3a\x2f\x2fwww\x2ecochranelibrary\x2ecom\x2fweb\x2fcochrane"},getUserId:function(){return"20159"},getUserName:function(){return""},isAddSessionIdToURL:function(){return false},isFreeformLayout:function(){return false},isImpersonated:function(){return false},isSignedIn:function(){return false},isStateExclusive:function(){return false},isStateMaximized:function(){return false},isStatePopUp:function(){return false}},PropsValues:{NTLM_AUTH_ENABLED:false}};var themeDisplay=Liferay.ThemeDisplay;Liferay.AUI={getAvailableLangPath:function(){return"available_languages.jsp?browserId=other&themeId=cochrane_WAR_cochranetheme&colorSchemeId=01&minifierType=js&languageId=en_US&b=6210&t=1559916434000"},getCombine:function(){return true},getComboPath:function(){return"/combo/?browserId=other&minifierType=&languageId=en_US&b=6210&t=1559916434000&"},getFilter:function(){return"min"},getJavaScriptRootPath:function(){return"/html/js"},getLangPath:function(){return"aui_lang.jsp?browserId=other&themeId=cochrane_WAR_cochranetheme&colorSchemeId=01&minifierType=js&languageId=en_US&b=6210&t=1559916434000"},getStaticResourceURLParams:function(){return"?browserId=other&minifierType=&languageId=en_US&b=6210&t=1559916434000"}};Liferay.authToken="afU96cMv";Liferay.currentURL="\x2fweb\x2fcochrane\x2fcontent\x3ftemplateType\x3dfull\x26urlTitle\x3d\x2fcdsr\x2fdoi\x2f10\x2e1002\x2f14651858\x2eCD010115\x2epub2\x26doi\x3d10\x2e1002\x2f14651858\x2eCD010115\x2epub2\x26type\x3dcdsr\x26contentLanguage\x3d";Liferay.currentURLEncoded="\x252Fweb\x252Fcochrane\x252Fcontent\x253FtemplateType\x253Dfull\x2526urlTitle\x253D\x252Fcdsr\x252Fdoi\x252F10\x2e1002\x252F14651858\x2eCD010115\x2epub2\x2526doi\x253D10\x2e1002\x252F14651858\x2eCD010115\x2epub2\x2526type\x253Dcdsr\x2526contentLanguage\x253D";</script> <script src="/html/js/barebone.jsp?browserId=other&amp;themeId=cochrane_WAR_cochranetheme&amp;colorSchemeId=01&amp;minifierType=js&amp;minifierBundleId=javascript.barebone.files&amp;languageId=en_US&amp;b=6210&amp;t=1559916434000" type="text/javascript"></script> <script type="text/javascript"></script> <script type="text/javascript">var o={database:"CDSR",page:{pageType:"Article Full Text HTML"},article:{availableLanguage:["en","es","zh_HANT","ru","pt","fa"],languageCode:"en",accessStatus:"delayed-free",doi:"10.1002/14651858.CD010115.pub2",title:"Inhaled steroids and risk of pneumonia for chronic obstructive pulmonary disease",firstPublishedDate:"Mar 10, 2014 12:00:00 AM",isCurrentVersion:true,editorialGroup:"Cochrane Airways Group",availableParts:["PDF Full","PDF Standard","PDF Abstract","HTML","Comments","Information","References","Stats","Related Content"]}};window.dataLayer=xtend(true,window.dataLayer,o);</script> <link class="lfr-css-file" href="https://www.cochranelibrary.com/cochrane-theme/css/custom.css?browserId=other&amp;themeId=cochrane_WAR_cochranetheme&amp;minifierType=css&amp;languageId=en_US&amp;b=6210&amp;t=1738735355000" rel="stylesheet" type="text/css"/> <style type="text/css"></style> <script async="" src="https://assets.adobedtm.com/59640f9fa510/7cad07cf7779/launch-a215d9c51521.min.js"></script> <!--[if lt IE 9]> <script src="/cochrane-theme/vendor/respond/dest/respond.min.js?t=1738735355000" type="text/javascript"></script> <![endif]--> </head> <body class="yui3-skin-sam controls-visible guest-site signed-out public-page site"> <div class="site-container"> <a href="#main-content" id="skip-to-content">Skip to Content</a> <div class="cookie-message cookie-message--hidden system-message-container" id="js-cookie-message"> <div class="container"> <a aria-label="Close cookies message" class="fa fa-times js-cookie-close pull-right" href="#"></a> <div class="system-message-wrapper container"> <i aria-hidden="true" class="fa fa-exclamation-triangle"></i> <div class="system-message-title">Cookies</div> <div class="system-message-description"> <p> Our site uses cookies to improve your experience. You can find out more about our use of cookies in About Cookies, including instructions on how to turn off cookies if you wish to do so. By continuing to browse this site you agree to us using cookies as described in <a href="http://olabout.wiley.com/WileyCDA/Section/id-813473.html">About Cookies</a>. </p> <a class="btn secondary js-cookie-close js-cookie-accept" href="#">I accept</a> </div> </div> </div> </div> <script>document.body.className=document.body.className+" js_enabled";</script><header> <div class="container"> <div class="branding"> <h1 class="brand-container"> <a href="https://www.cochranelibrary.com/en/"> <span class="brand-name">The Cochrane Library</span> <img alt="Cochrane Library logo" class="brand-logo" src="https://www.cochranelibrary.com/cochrane-theme/images/en-US_logo.png" title="Cochrane Library"/> </a> </h1> <span class="additional-branding"> <p class="brand-message"> <em>Trusted evidence.</em> <em>Informed decisions.</em> <em>Better health.</em> </p> </span> </div> <div class="desktop-search basic-search-container"> <div class="desktop-search-form"> <div class="portlet-boundary portlet-boundary_scolarissearchportlet_WAR_scolarissearch_ portlet-static portlet-static-end" id="p_p_id_scolarissearchportlet_WAR_scolarissearch_"> <span id="p_scolarissearchportlet_WAR_scolarissearch"></span> <section class="portlet" id="portlet_scolarissearchportlet_WAR_scolarissearch"> <header class="portlet-topper"> <h1 class="portlet-title"> <span class="" onmouseover="Liferay.Portal.ToolTip.show(this, 'Scolaris\x20Search\x20Portlet')"> <img alt="" id="owel__null__null" src="/scolaris-search/icon.png"/> <span class="taglib-text hide-accessible">Scolaris Search Portlet</span> </span> <span class="portlet-title-text">Scolaris Search Portlet</span> </h1> <menu class="portlet-topper-toolbar" id="portlet-topper-toolbar_scolarissearchportlet_WAR_scolarissearch" type="toolbar"> </menu> </header> <div class="portlet-content"> <div class="portlet-content-container"> <div class="portlet-body"> <div class="header-search"> <form action="https://www.cochranelibrary.com/en/content?p_auth=afU96cMv&amp;p_p_id=scolarissearchportlet_WAR_scolarissearch&amp;p_p_lifecycle=1&amp;p_p_state=normal&amp;p_p_mode=view&amp;_scolarissearchportlet_WAR_scolarissearch_scolarisAction=redirectSearchResult" method="post"> <input name="searchType" type="hidden" value="basic"/> <input name="facetDisplayName" type="hidden" value=""/> <input name="facetQueryTerm" type="hidden" value=""/> <input name="facetQueryField" type="hidden" value=""/> <input name="facetCategory" type="hidden" value=""/> <fieldset class="fieldset"> <legend class="sr-only">Basic Search</legend> <div class="select search-by"> <select aria-label="Search by options" class="custom-select-enabled search-type" name="searchBy" title="Search by options"> <option value="1">Title Abstract Keyword</option> <option value="2">Record Title</option> <option value="3">Abstract</option> <option value="4">Author</option> <option value="5">Keyword</option> <option value="6">All Text</option> <option value="7">Publication Type</option> <option value="8">Source</option> <option value="9">DOI</option> <option value="14">Language</option> <option value="10">Accession Number</option> <option value="11">Trial Registry Number</option> <option value="12">Cochrane Group</option> <option value="13">Cochrane Topic</option> </select> </div> <div class="search-select-crg-container select" style="display: none;"> <select class="search-select-crg-list"></select> </div> <div class="search-select-topic-container select" data-topic-list-url="https://www.cochranelibrary.com/en/content?p_p_id=scolaristopics_WAR_scolaristopics&amp;p_p_lifecycle=2&amp;p_p_state=normal&amp;p_p_mode=view&amp;p_p_resource_id=topics-list&amp;p_p_cacheability=cacheLevelPage" style="display: none;"> <select class="search-select-topic-list"></select> </div> <div class="search-select-cl-container select" style="display: none;"> <select class="search-select-cl-list"></select> </div> <div class="search-text-container"> <div class="control-group control-group-inline search-input-wrapper"> <input aria-label="Enter search term" class="field browser-search search-text ui-autocomplete-input" id="searchText" name="searchText" placeholder="Search" size="30" type="text" value=""/>
<div id="autocomplete-results"></div>
</div>
<div class="control-group control-group-inline search-button-wrapper">
<button aria-label="Search" class="searchByBtn" type="submit">
<i aria-hidden="true" class="fa fa-search"></i>
</button>
</div>
</div>
</fieldset>
</form>
</div>
<script>
    window.displayResultURL = 'https://www.cochranelibrary.com/en/content?p_p_id=scolarissearchportlet_WAR_scolarissearch&p_p_lifecycle=2&p_p_state=normal&p_p_mode=view&p_p_resource_id=getSuggestions&p_p_cacheability=cacheLevelPage&_scolarissearchportlet_WAR_scolarissearch_templateType=full&_scolarissearchportlet_WAR_scolarissearch_urlTitle=%2Fcdsr%2Fdoi%2F10.1002%2F14651858.CD010115.pub2&_scolarissearchportlet_WAR_scolarissearch_contentLanguage=&_scolarissearchportlet_WAR_scolarissearch_type=cdsr&_scolarissearchportlet_WAR_scolarissearch_doi=10.1002%2F14651858.CD010115.pub2';
    window.searchByOption = '';
</script>
</div>
</div>
</div>
<div style="display:none">
<input id="freelabel" name="freelabel" type="hidden" value="Free access"/>
<input id="openlabel" name="openlabel" type="hidden" value="Open access"/>
</div>
</section>
</div>
</div>
<div class="search-tools-nav">
<a class="btn secondary" href="/en/browse-by-topic">Browse</a>
<a class="btn primary advanced-search-button" href="/en/advanced-search">Advanced search</a>
</div>
</div>
<a class="toggle-menu-switch" href="#"><i aria-hidden="true" class="fa fa-bars"></i> <div class="toggle-menu-text">Open menu</div></a>
</div>
<div class="auxiliary-container">
<div class="container">
<div class="header-auxiliary-menu">
<div class="auxiliary-menu-item language-selector">
<div class="portlet-boundary portlet-boundary_scolarislanguageselector_WAR_scolarislanguageportlet_ portlet-static portlet-static-end" id="p_p_id_scolarislanguageselector_WAR_scolarislanguageportlet_INSTANCE_header_">
<span id="p_scolarislanguageselector_WAR_scolarislanguageportlet_INSTANCE_header"></span>
<section class="portlet" id="portlet_scolarislanguageselector_WAR_scolarislanguageportlet_INSTANCE_header">
<header class="portlet-topper">
<h1 class="portlet-title">
<span class="" onmouseover="Liferay.Portal.ToolTip.show(this, 'Scolaris\x20Language\x20Selector')">
<img alt="" id="bvrs__null__null" src="/scolaris-language-portlet/icon.png"/> <span class="taglib-text hide-accessible">Scolaris Language Selector</span> </span> <span class="portlet-title-text">Scolaris Language Selector</span> </h1> <menu class="portlet-topper-toolbar" id="portlet-topper-toolbar_scolarislanguageselector_WAR_scolarislanguageportlet_INSTANCE_header" type="toolbar"> </menu> </header> <div class="portlet-content"> <div class="portlet-content-container"> <div class="portlet-body"> <div class="language-display" data-content-languages="[de, en, es, fa, fr, hi, hr, id, ja, ko, hu, ms, nl, pl, pt, ru, ro, ta, th, zh_HANT, zh_HANS]"> <a class="open-language-modal" href="#" title="Select your preferred language"> <i class="fa fa-file-text"></i> Review language : English </a> <a class="open-language-modal" href="#" title="Select your preferred language"> <i class="fa fa-globe"></i> Website language : English </a> </div> <div class="language-selector-modal-content" data-modal-title="Language selection" data-size="large" style="display: none;"> <div class="form-content language-selector-modal"> <div class="row-fluid"> <div> <table class="mytable" style="border: 1px solid #f0f0f0" width="90%"> <tbody> <tr class="row-box"> <td><i class="fa fa-file-text icon-size"></i></td> <td><h3>Cochrane review language</h3> <p>Select your preferred language for Cochrane reviews and other content. Sections without translation will be in English.</p> </td> <td> <div> <select id="contentLanguageSelector" onchange="updateLang(this.value)"> <option class="content-language-option" data-languagecode="de" value="de"> Deutsch </option> <option class="content-language-option" data-languagecode="en" selected="" value="en"> English </option> <option class="content-language-option" data-languagecode="es" value="es"> Español </option> <option class="content-language-option" data-languagecode="fa" value="fa"> فارسی </option> <option class="content-language-option" data-languagecode="fr" value="fr"> Français </option> <option class="content-language-option" data-languagecode="hi" value="hi"> हिन्दी </option> <option class="content-language-option" data-languagecode="hr" value="hr"> Hrvatski </option> <option class="content-language-option" data-languagecode="id" value="id"> Bahasa Indonesia </option> <option class="content-language-option" data-languagecode="ja" value="ja"> 日本語 </option> <option class="content-language-option" data-languagecode="ko" value="ko"> 한국어 </option> <option class="content-language-option" data-languagecode="hu" value="hu"> Magyar </option> <option class="content-language-option" data-languagecode="ms" value="ms"> Bahasa Malaysia </option> <option class="content-language-option" data-languagecode="nl" value="nl"> Nederlands </option> <option class="content-language-option" data-languagecode="pl" value="pl"> Polski </option> <option class="content-language-option" data-languagecode="pt" value="pt"> Português </option> <option class="content-language-option" data-languagecode="ru" value="ru"> Русский </option> <option class="content-language-option" data-languagecode="ro" value="ro"> Română </option> <option class="content-language-option" data-languagecode="ta" value="ta"> தமிழ் </option> <option class="content-language-option" data-languagecode="th" value="th"> ภาษาไทย </option> <option class="content-language-option" data-languagecode="zh_HANT" value="zh_HANT"> 繁體中文 </option> <option class="content-language-option" data-languagecode="zh_HANS" value="zh_HANS"> 简体中文 </option> </select> </div> </td> </tr> <tr> <td colspan="1" style="height: 10px"></td> </tr> <tr class="row-box"> <td><i class="fa fa-globe icon-size"></i></td> <td> <div class="language-info"> <h3>Website language</h3> <p>Select your preferred language for the Cochrane Library website.</p> </div> </td> <td> <div class="language-dropdown"> <select id="portalLanguageSelector"> <option class="portal-language-selector" data-portallanguage="en" selected="" value="/en/cdsr/doi/10.1002/14651858.CD010115.pub2/full/en"> English </option> <option class="portal-language-selector" data-portallanguage="es" value="/es/cdsr/doi/10.1002/14651858.CD010115.pub2/full/es"> Español </option> </select> </div> </td> </tr> <tr> <td colspan="1" style="height: 10px"></td> </tr> </tbody> </table> </div> </div> <div style="text-align: right;"> <button class="btn primary btn-cancel" style="margin-left: 10px;" type="button">Cancel</button> <a class="btn secondary ok-btn" href="https://www.cochranelibrary.com/en/content?p_p_id=scolariscontentlanguagebanner_WAR_scolarislanguageportlet&amp;p_p_lifecycle=2&amp;p_p_state=normal&amp;p_p_mode=view&amp;p_p_resource_id=set-content-language&amp;p_p_cacheability=cacheLevelPage">Save</a> </div> </div> </div> </div> </div> </div> <div style="display:none"> <input id="freelabel" name="freelabel" type="hidden" value="Free access"/>
<input id="openlabel" name="openlabel" type="hidden" value="Open access"/>
</div>
</section>
</div>
</div>
<a class="auxiliary-menu-item signin last" href="https://www.cochranelibrary.com/c/portal/login?p_l_id=20757&amp;redirect=%2Fcdsr%2Fdoi%2F10.1002%2F14651858.CD010115.pub2%2Ffull" rel="nofollow">
<i class="icon fa fa-user"></i> Sign In
    </a>
<span class="auxiliary-container-extended"></span>
</div>
</div>
</div>
</header>
<div class="main-nav-wrapper">
<span class="main-nav-left-extended"></span>
<nav class="main container">
<ul>
<li class="nav-root-item parent">
<a href="#">Cochrane reviews<span class="icon fa fa-caret-down"></span></a>
<ul class="child">
<li class="child-nav-item" id="layout_nav_child_attr_14" role="presentation">
<a aria-labelledby="layout_14" href="https://www.cochranelibrary.com/en/cdsr/reviews" role="menuitem">
            Search reviews (CDSR)
        </a>
</li>
<li class="child-nav-item" id="layout_nav_child_attr_15" role="presentation">
<a aria-labelledby="layout_15" href="https://www.cochranelibrary.com/en/cdsr/reviews/topics" role="menuitem">
            Browse reviews
        </a>
</li>
<li class="child-nav-item" id="layout_nav_child_attr_18" role="presentation">
<a aria-labelledby="layout_18" href="https://www.cochranelibrary.com/en/cdsr/table-of-contents" role="menuitem">
            Issues
        </a>
</li>
<li class="child-nav-item" id="layout_nav_child_attr_17" role="presentation">
<a aria-labelledby="layout_17" href="https://www.cochranelibrary.com/en/cdsr/editorials" role="menuitem">
            Editorials
        </a>
</li>
<li class="child-nav-item" id="layout_nav_child_attr_19" role="presentation">
<a aria-labelledby="layout_19" href="https://www.cochranelibrary.com/en/special-collections" role="menuitem">
            Special Collections
        </a>
</li>
<li class="child-nav-item" id="layout_nav_child_attr_20" role="presentation">
<a aria-labelledby="layout_20" href="https://www.cochranelibrary.com/en/cdsr/supplements" role="menuitem">
            Supplements
        </a>
</li>
<li class="child-nav-item" id="layout_nav_child_attr_121" role="presentation">
<a aria-labelledby="layout_121" href="https://www.cochranelibrary.com/en/about/about-cochrane-reviews" role="menuitem">
            About Cochrane reviews
        </a>
</li>
</ul>
</li>
<li class="nav-root-item parent">
<a href="#">Searching for trials<span class="icon fa fa-caret-down"></span></a>
<ul class="child">
<li class="child-nav-item" id="layout_nav_child_attr_254" role="presentation">
<a aria-labelledby="layout_254" href="https://www.cochranelibrary.com/en/search/releases" role="menuitem">
            What's new (search and CENTRAL)
        </a>
</li>
<li class="child-nav-item" id="layout_nav_child_attr_266" role="presentation">
<a aria-labelledby="layout_266" href="https://www.cochranelibrary.com/en/search-help" role="menuitem">
            Search help
        </a>
</li>
<li class="child-nav-item" id="layout_nav_child_attr_252" role="presentation">
<a aria-labelledby="layout_252" href="https://www.cochranelibrary.com/en/search-help-quick-guides" role="menuitem">
            Search help quick guides
        </a>
</li>
<li class="child-nav-item" id="layout_nav_child_attr_251" role="presentation">
<a aria-labelledby="layout_251" href="https://www.cochranelibrary.com/en/search-faqs" role="menuitem">
            Search FAQs
        </a>
</li>
<li class="child-nav-item" id="layout_nav_child_attr_114" role="presentation">
<a aria-labelledby="layout_114" href="https://www.cochranelibrary.com/en/central/about-central" role="menuitem">
            About CENTRAL
        </a>
</li>
<li class="child-nav-item" id="layout_nav_child_attr_115" role="presentation">
<a aria-labelledby="layout_115" href="https://www.cochranelibrary.com/en/central/central-creation" role="menuitem">
            How CENTRAL is created
        </a>
</li>
<li class="child-nav-item" id="layout_nav_child_attr_241" role="presentation">
<a aria-labelledby="layout_241" href="https://www.cochranelibrary.com/en/retracted-trials" role="menuitem">
            Retracted publications in CENTRAL
        </a>
</li>
</ul>
</li>
<li class="nav-root-item parent">
<a href="#">Clinical Answers<span class="icon fa fa-caret-down"></span></a>
<ul class="child">
<li class="child-nav-item" id="layout_nav_child_attr_29" role="presentation">
<a aria-labelledby="layout_29" href="https://www.cochranelibrary.com/en/cca" role="menuitem">
            Browse Clinical Answers
        </a>
</li>
<li class="child-nav-item" id="layout_nav_child_attr_91" role="presentation">
<a aria-labelledby="layout_91" href="https://www.cochranelibrary.com/en/cca/about" role="menuitem">
            About Clinical Answers
        </a>
</li>
</ul>
</li>
<li class="nav-root-item parent">
<a href="#">About<span class="icon fa fa-caret-down"></span></a>
<ul class="child">
<li class="child-nav-item" id="layout_nav_child_attr_116" role="presentation">
<a aria-labelledby="layout_116" href="https://www.cochranelibrary.com/en/about/about-cochrane-library" role="menuitem">
            About the Cochrane Library
        </a>
</li>
<li class="child-nav-item" id="layout_nav_child_attr_13" role="presentation">
<a aria-labelledby="layout_13" href="https://www.cochranelibrary.com/en/cdsr/about-cdsr" role="menuitem">
            Cochrane Database of Systematic reviews
        </a>
</li>
<li class="child-nav-item" id="layout_nav_child_attr_198" role="presentation">
<a aria-labelledby="layout_198" href="https://www.cochranelibrary.com/en/cdsr/editorial-policies" role="menuitem">
            Editorial policies
        </a>
</li>
<li class="child-nav-item" id="layout_nav_child_attr_92" role="presentation">
<a aria-labelledby="layout_92" href="https://www.cochranelibrary.com/en/about/author-information" role="menuitem">
            Information for authors
        </a>
</li>
<li class="child-nav-item" id="layout_nav_child_attr_212" role="presentation">
<a aria-labelledby="layout_212" href="https://www.cochranelibrary.com/en/about-pico" role="menuitem">
            About PICO
        </a>
</li>
<li class="child-nav-item" id="layout_nav_child_attr_207" role="presentation">
<a aria-labelledby="layout_207" href="https://www.cochranelibrary.com/en/about/about-translations" role="menuitem">
            About translations
        </a>
</li>
<li class="child-nav-item" id="layout_nav_child_attr_188" role="presentation">
<a aria-labelledby="layout_188" href="https://www.cochranelibrary.com/en/about/releases" role="menuitem">
            What's new
        </a>
</li>
<li class="child-nav-item" id="layout_nav_child_attr_216" role="presentation">
<a aria-labelledby="layout_216" href="https://www.cochranelibrary.com/en/data" role="menuitem">
            Data reuse
        </a>
</li>
<li class="child-nav-item" id="layout_nav_child_attr_235" role="presentation">
<a aria-labelledby="layout_235" href="https://www.cochranelibrary.com/en/about/about-cochrane-library/editorial-board" role="menuitem">
            Cochrane Library Editorial Board
        </a>
</li>
</ul>
</li>
<li class="nav-root-item parent">
<a href="#">Help<span class="icon fa fa-caret-down"></span></a>
<ul class="child">
<li class="child-nav-item" id="layout_nav_child_attr_259" role="presentation">
<a aria-labelledby="layout_259" href="https://m.info.wiley.com/webApp/cochranenewsletter?id=0" role="menuitem">
            Newsletter
        </a>
</li>
<li class="child-nav-item" id="layout_nav_child_attr_177" role="presentation">
<a aria-labelledby="layout_177" href="https://www.wiley.com/en-us/customer-success/cochrane-library-training-hub" role="menuitem">
            Cochrane Library Training
        </a>
</li>
<li class="child-nav-item" id="layout_nav_child_attr_44" role="presentation">
<a aria-labelledby="layout_44" href="https://www.cochranelibrary.com/en/help/access" role="menuitem">
            Access
        </a>
</li>
<li class="child-nav-item" id="layout_nav_child_attr_150" role="presentation">
<a aria-labelledby="layout_150" href="https://www.cochranelibrary.com/en/help/permissions" role="menuitem">
            Permissions and reprints
        </a>
</li>
<li class="child-nav-item" id="layout_nav_child_attr_93" role="presentation">
<a aria-labelledby="layout_93" href="https://www.cochranelibrary.com/en/help/media" role="menuitem">
            Media information
        </a>
</li>
<li class="child-nav-item" id="layout_nav_child_attr_97" role="presentation">
<a aria-labelledby="layout_97" href="https://www.cochranelibrary.com/en/help/contact-us" role="menuitem">
            Contact us
        </a>
</li>
<li class="child-nav-item" id="layout_nav_child_attr_125" role="presentation">
<a aria-labelledby="layout_125" href="https://www.cochranelibrary.com/en/about/terms-and-conditions" role="menuitem">
            Terms and conditions
        </a>
</li>
<li class="child-nav-item" id="layout_nav_child_attr_176" role="presentation">
<a aria-labelledby="layout_176" href="https://cochranesupport.wiley.com/s/article/cochrane-library-known-issues" role="menuitem">
            Known issues
        </a>
</li>
<li class="child-nav-item" id="layout_nav_child_attr_270" role="presentation">
<a aria-labelledby="layout_270" href="https://www.cochranelibrary.com/search-help" role="menuitem">
            Search help
        </a>
</li>
</ul>
</li>
<li class="about-link"><a href="https://www.cochrane.org/about-us" target="_blank"><span>About Cochrane</span><i class="fa fa-caret-right"></i></a></li>
</ul>
</nav>
</div>
<div class="portlet-boundary portlet-boundary_scolariscontentlanguagebanner_WAR_scolarislanguageportlet_ portlet-static portlet-static-end" id="p_p_id_scolariscontentlanguagebanner_WAR_scolarislanguageportlet_">
<span id="p_scolariscontentlanguagebanner_WAR_scolarislanguageportlet"></span>
<section class="portlet" id="portlet_scolariscontentlanguagebanner_WAR_scolarislanguageportlet">
<header class="portlet-topper">
<h1 class="portlet-title">
<span class="" onmouseover="Liferay.Portal.ToolTip.show(this, 'Scolaris\x20Content\x20Language\x20Banner\x20Portlet')">
<img alt="" id="etlj__null__null" src="/scolaris-language-portlet/icon.png"/> <span class="taglib-text hide-accessible">Scolaris Content Language Banner Portlet</span> </span> <span class="portlet-title-text">Scolaris Content Language Banner Portlet</span> </h1> <menu class="portlet-topper-toolbar" id="portlet-topper-toolbar_scolariscontentlanguagebanner_WAR_scolarislanguageportlet" type="toolbar"> </menu> </header> <div class="portlet-content"> <div class="portlet-content-container"> <div class="portlet-body"> </div> </div> </div> <div style="display:none"> <input id="freelabel" name="freelabel" type="hidden" value="Free access"/>
<input id="openlabel" name="openlabel" type="hidden" value="Open access"/>
</div>
</section>
</div>
<div class="" id="content">
<div class="columns-1" id="main-content" role="main">
<div class="portlet-layout row-fluid">
<div class="portlet-column portlet-column-only span12" id="column-1">
<div class="portlet-dropzone portlet-column-content portlet-column-content-only" id="layout-column_column-1">
<div class="portlet-boundary portlet-boundary_scolariscontentdisplay_WAR_scolariscontentdisplay_ portlet-static portlet-static-end scolaris-content-display-portlet" id="p_p_id_scolariscontentdisplay_WAR_scolariscontentdisplay_">
<span id="p_scolariscontentdisplay_WAR_scolariscontentdisplay"></span>
<section class="portlet" id="portlet_scolariscontentdisplay_WAR_scolariscontentdisplay">
<header class="portlet-topper">
<h1 class="portlet-title">
<span class="" onmouseover="Liferay.Portal.ToolTip.show(this, 'Scolaris\x20Content\x20Display')">
<img alt="" id="rjus__column1__0" src="/scolaris-content-display/icon.png"/> <span class="taglib-text hide-accessible">Scolaris Content Display</span> </span> <span class="portlet-title-text">Scolaris Content Display</span> </h1> <menu class="portlet-topper-toolbar" id="portlet-topper-toolbar_scolariscontentdisplay_WAR_scolariscontentdisplay" type="toolbar"> </menu> </header> <div class="portlet-content"> <div class="portlet-content-container"> <div class="portlet-body"> <div class="publication cdsr container"> <div class="article-navigation-container" id="cdsr-nav"> <nav class="article-navigation"> <ul class="tools-row"> <li> <li class="tools pdf pulldown-menu readcube-menu closed en_US"> <a class="pulldown-menu-trigger" href="#0"> <span class="pdf-icon"> <i class="icon fa fa-file-pdf-o"></i> <span>Download PDF</span> </span> <i aria-hidden="true" class="fa fa-caret-down"></i> </a> <ul class="pulldown-menu-items"> <li class=""> <a class="download media pdf-link-full pdf-link" href="/cdsr/doi/10.1002/14651858.CD010115.pub2/pdf/full/en" title="Article in PDF format"> <span class="readcube-label"> Full </span> <span class="readcube-description"> All content </span> </a> <a class="download media pdf-link-full readcube-epdf-link" href="/cdsr/doi/10.1002/14651858.CD010115.pub2/epdf/full/en" title="Article in PDF format"> <span class="readcube-label"> Full </span> <span class="readcube-description"> All content </span> </a> </li> <li class=""> <a class="download media pdf-link-abstract pdf-link" href="/cdsr/doi/10.1002/14651858.CD010115.pub2/pdf/abstract/en" title="Article in PDF format"> <span class="readcube-label"> Summary </span> <span class="readcube-description"> Abstract and plain language summary only </span> </a> <a class="download media pdf-link-abstract readcube-epdf-link" href="/cdsr/doi/10.1002/14651858.CD010115.pub2/epdf/abstract/en" title="Article in PDF format"> <span class="readcube-label"> Summary </span> <span class="readcube-description"> Abstract and plain language summary only </span> </a> </li> </ul> </li> <li class="tools cite cite-article-link" data-article-id="CD010115.PUB2" data-modal-title="Cite this review"> <span><i aria-hidden="true" class="icon fa fa-share"></i></span> <span>Cite this review</span> </li> </li> </ul> <ul class="tools-row tools-secondary"> <li> <li class="tools print print-cdsr-link" data-content-language="en" data-indicator-tooltip="scolaris.print.modal.language.tooltip.en" data-print-options="[{&quot;param&quot;: &quot;abstract&quot;,&quot;titles&quot;:[{&quot;language&quot;:&quot;en&quot;,&quot;title&quot;:&quot;Abstract&quot;},{&quot;language&quot;:&quot;es&quot;,&quot;title&quot;:&quot;Resumen&quot;},{&quot;language&quot;:&quot;fa&quot;,&quot;title&quot;:&quot;چکیده&quot;},{&quot;language&quot;:&quot;pt&quot;,&quot;title&quot;:&quot;Resumo&quot;},{&quot;language&quot;:&quot;zh_HANT&quot;,&quot;title&quot;:&quot;Abstract&quot;}]},{&quot;param&quot;: &quot;pls&quot;,&quot;titles&quot;:[{&quot;language&quot;:&quot;en&quot;,&quot;title&quot;:&quot;Plain language summary&quot;},{&quot;language&quot;:&quot;es&quot;,&quot;title&quot;:&quot;Resumen en términos sencillos&quot;},{&quot;language&quot;:&quot;fa&quot;,&quot;title&quot;:&quot;خلاصه به زبان ساده&quot;},{&quot;language&quot;:&quot;pt&quot;,&quot;title&quot;:&quot;Resumo para leigos&quot;},{&quot;language&quot;:&quot;ru&quot;,&quot;title&quot;:&quot;Резюме на простом языке&quot;},{&quot;language&quot;:&quot;zh_HANT&quot;,&quot;title&quot;:&quot;Plain language summary&quot;}]},{&quot;param&quot;: &quot;conclusions&quot;,&quot;titles&quot;:[{&quot;language&quot;:&quot;en&quot;,&quot;title&quot;:&quot;Authors' conclusions&quot;}]},{&quot;param&quot;: &quot;summaryOfFindings&quot;,&quot;titles&quot;:[{&quot;language&quot;:&quot;en&quot;,&quot;title&quot;:&quot;Summary of findings&quot;}]},{&quot;param&quot;: &quot;background&quot;,&quot;titles&quot;:[{&quot;language&quot;:&quot;en&quot;,&quot;title&quot;:&quot;Background&quot;}]},{&quot;param&quot;: &quot;objectives&quot;,&quot;titles&quot;:[{&quot;language&quot;:&quot;en&quot;,&quot;title&quot;:&quot;Objectives&quot;}]},{&quot;param&quot;: &quot;methods&quot;,&quot;titles&quot;:[{&quot;language&quot;:&quot;en&quot;,&quot;title&quot;:&quot;Methods&quot;}]},{&quot;param&quot;: &quot;results&quot;,&quot;titles&quot;:[{&quot;language&quot;:&quot;en&quot;,&quot;title&quot;:&quot;Results&quot;}]},{&quot;param&quot;: &quot;discussion&quot;,&quot;titles&quot;:[{&quot;language&quot;:&quot;en&quot;,&quot;title&quot;:&quot;Discussion&quot;}]},{&quot;param&quot;: &quot;references&quot;,&quot;titles&quot;:[{&quot;language&quot;:&quot;en&quot;,&quot;title&quot;:&quot;References&quot;}]},{&quot;param&quot;: &quot;appendices&quot;,&quot;titles&quot;:[{&quot;language&quot;:&quot;en&quot;,&quot;title&quot;:&quot;Appendices&quot;},{&quot;language&quot;:&quot;en&quot;,&quot;title&quot;:&quot;Search strategies&quot;}]},{&quot;param&quot;: &quot;characteristics&quot;,&quot;titles&quot;:[{&quot;language&quot;:&quot;en&quot;,&quot;title&quot;:&quot;Characteristics of studies&quot;}]},{&quot;param&quot;: &quot;data&quot;,&quot;titles&quot;:[{&quot;language&quot;:&quot;en&quot;,&quot;title&quot;:&quot;Analyses&quot;}]},{&quot;param&quot;: &quot;information&quot;,&quot;titles&quot;:[{&quot;language&quot;:&quot;en&quot;,&quot;title&quot;:&quot;Information&quot;}]},{&quot;param&quot;: &quot;authors&quot;,&quot;titles&quot;:[{&quot;language&quot;:&quot;en&quot;,&quot;title&quot;:&quot;Authors&quot;}]},{&quot;param&quot;: &quot;history&quot;,&quot;titles&quot;:[{&quot;language&quot;:&quot;en&quot;,&quot;title&quot;:&quot;History&quot;},{&quot;language&quot;:&quot;en&quot;,&quot;title&quot;:&quot;History&quot;}]},{&quot;param&quot;: &quot;comments&quot;,&quot;titles&quot;:[{&quot;language&quot;:&quot;en&quot;,&quot;title&quot;:&quot;Comments&quot;}]}]" data-print-urlbase="/cdsr/doi/10.1002/14651858.CD010115.pub2/print"> <span><i class="icon fa fa-print"></i></span> <span>Print</span> </li> <li class="js-old-version-modal-trigger tools comments comment-on-review" data-article-id="CD010115.PUB2" data-english-only-message="Please note, that commenting is available in English only. Apologies for any inconvenience." data-href="/cdsr/doi/10.1002/14651858.CD010115.pub2/read-comments" data-new-version="" id="comment-on-review"> <span class="comment-icon"><i class="icon fa fa-comment"></i></span> <span class="comments-count">0</span> <span>Comment</span> </li> <li class="tools share-cdsr-link" data-share-url="/cdsr/doi/10.1002/14651858.CD010115.pub2/full"> <span><i class="icon fa fa-share-alt"></i></span> <span>Share</span> </li> <li class="tools follow"> <span class="article-not-followed cochrane-link signin follow-wrapper"> <span> <i class="icon fa fa-plus"></i> </span> <span> Follow </span> </span> </li> </li> </ul> <div class="metrics-wrapper"> <div class="metrics-count"> <span>Full text views: </span> <span>9648 <i class="icon fa fa-info-circle custom-tooltip" style="padding-left: 2px;color: #962d91;" title="Usage represents full text views on Cochrane Library since January 2022 or 2023. For articles published after this date, the usage represents views since the article was first published on Cochrane Library."> </i> </span> </div> </div> <div class="metrics-wrapper nav-link-section"> <div class="altmetric-embed" data-badge-type="1" data-condensed="true" data-doi="10.1002/14651858.CD010115.pub2" data-link-target="_blank"></div> <div class="inline-status-wrapper guidelines-count" data-count-plural="Cited in $1 guidelines" data-count-single="Cited in 1 guideline"> <a href="related-content#guidelines_data" title="Guidelines"></a> </div> </div> <ul class="nav-section-header"> <li> <h3>Contents</h3> </li> </ul> <ul class="nav-long-form nav-link-section"> <li class="cdsr-nav-link bold-nav-link" lang="en"> <a href="/cdsr/doi/10.1002/14651858.CD010115.pub2/full"> Abstract </a> </li> <li class="cdsr-nav-link bold-nav-link" lang="en"> <a href="/cdsr/doi/10.1002/14651858.CD010115.pub2/full#pico"> PICOs </a> </li> <li class="cdsr-nav-link bold-nav-link" lang="en"> <a href="/cdsr/doi/10.1002/14651858.CD010115.pub2/full#CD010115-abs-0004"> Plain language summary </a> </li> <li class="cdsr-nav-link bold-nav-link" lang="en"> <a href="/cdsr/doi/10.1002/14651858.CD010115.pub2/full#CD010115-sec-0112"> Authors' conclusions </a> </li> <li class="cdsr-nav-link bold-nav-link" lang="en"> <a href="/cdsr/doi/10.1002/14651858.CD010115.pub2/full#CD010115-sec-0029"> Summary of findings </a> </li> <li class="cdsr-nav-link" lang="en"> <a href="/cdsr/doi/10.1002/14651858.CD010115.pub2/full#CD010115-sec-0030"> Background </a> </li> <li class="cdsr-nav-link" lang="en"> <a href="/cdsr/doi/10.1002/14651858.CD010115.pub2/full#CD010115-sec-0035"> Objectives </a> </li> <li class="cdsr-nav-link" lang="en"> <a href="/cdsr/doi/10.1002/14651858.CD010115.pub2/full#CD010115-sec-0036"> Methods </a> </li> <li class="cdsr-nav-link" lang="en"> <a href="/cdsr/doi/10.1002/14651858.CD010115.pub2/full#CD010115-sec-0062"> Results </a> </li> <li class="cdsr-nav-link" lang="en"> <a href="/cdsr/doi/10.1002/14651858.CD010115.pub2/full#CD010115-sec-0106"> Discussion </a> </li> <li class="cdsr-nav-link"> <a class="figures-and-tables-link" href="/cdsr/doi/10.1002/14651858.CD010115.pub2/#"> Figures and tables </a> </li> <li class="cdsr-nav-link" lang="en"> <a href="/cdsr/doi/10.1002/14651858.CD010115.pub2/references"> References </a> </li> </ul> <div class="nav-section-header"> <h3>Supplementary materials</h3> </div> <ul class="nav-long-form nav-link-section"> <li class="cdsr-nav-link" lang="en"> <a href="/cdsr/doi/10.1002/14651858.CD010115.pub2/appendices#CD010115-sec-0117"> Search strategies </a> </li> <li class="cdsr-nav-link" lang="en"> <a href="/cdsr/doi/10.1002/14651858.CD010115.pub2/references#characteristicStudies"> Characteristics of studies </a> </li> <li class="cdsr-nav-link" lang="en"> <a href="/cdsr/doi/10.1002/14651858.CD010115.pub2/references#dataAndAnalyses"> Analyses </a> </li> <li class="cdsr-nav-link download-stats-data-link" data-download-href="/cdsr/doi/10.1002/14651858.CD010115.pub2/media/CDSR/CD010115/table_n/CD010115StatsDataOnly.rm5?content-disposition=attachment&amp;mime-type=application/octet-stream"> <a href="/cdsr/doi/10.1002/14651858.CD010115.pub2/media/CDSR/CD010115/table_n/CD010115StatsDataOnly.rm5?content-disposition=attachment&amp;mime-type=application/octet-stream"> Download data </a> </li> </ul> <ul class="tools-row"> <li> </li> </ul> <ul class="nav-section-header"> <li><h3>Related</h3></li> </ul> <ul class="linked-content linked-content-dropdown" id="linked-content-articles" tabindex="0"> <li class="linked-cca" data-type="cca"> <div class="linked-content-section"> <span class="linked-type">Cochrane Clinical Answers<span class="count"></span></span> <i aria-hidden="true" class="fa fa-caret-down"></i> </div> <div class="articles"></div> </li> <li class="linked-editorials" data-type="editorial"> <div class="linked-content-section"> <span class="linked-type">Editorials<span class="count"></span></span> <i aria-hidden="true" class="fa fa-caret-down"></i> </div> <div class="articles"></div> </li> <li class="linked-podcasts" data-type="podcast"> <div class="linked-content-section"> <span class="linked-type">Podcasts<span class="count"></span></span> <i aria-hidden="true" class="fa fa-caret-down"></i> </div> <div class="articles"></div> </li> <li class="linked-sc" data-type="sc"> <div class="linked-content-section"> <span class="linked-type">Special Collections<span class="count"></span></span> <i aria-hidden="true" class="fa fa-caret-down"></i> </div> <div class="articles"></div> </li> </ul> <div class="nav-section-header"> <h3>About this review</h3> </div> <ul class="nav-long-form nav-info nav-link-section"> <li class="cdsr-nav-link" lang="en"> <a href="/cdsr/doi/10.1002/14651858.CD010115.pub2/information"> <i> <svg viewbox="0 0 24 24"> <path d="M11,9H13V7H11M12,20C7.59,20 4,16.41 4,12C4,7.59 7.59,4 12,4C16.41,4 20,7.59 20,12C20,16.41 16.41,20 12,20M12,2A10,10 0 0,0 2,12A10,10 0 0,0 12,22A10,10 0 0,0 22,12A10,10 0 0,0 12,2M11,17H13V11H11V17Z"></path> </svg> </i> Information </a> </li> <li class="cdsr-nav-link" lang="en"> <a href="/cdsr/doi/10.1002/14651858.CD010115.pub2/information#authors"> <i> <svg viewbox="0 0 24 24"> <path d="M12,5.5A3.5,3.5 0 0,1 15.5,9A3.5,3.5 0 0,1 12,12.5A3.5,3.5 0 0,1 8.5,9A3.5,3.5 0 0,1 12,5.5M5,8C5.56,8 6.08,8.15 6.53,8.42C6.38,9.85 6.8,11.27 7.66,12.38C7.16,13.34 6.16,14 5,14A3,3 0 0,1 2,11A3,3 0 0,1 5,8M19,8A3,3 0 0,1 22,11A3,3 0 0,1 19,14C17.84,14 16.84,13.34 16.34,12.38C17.2,11.27 17.62,9.85 17.47,8.42C17.92,8.15 18.44,8 19,8M5.5,18.25C5.5,16.18 8.41,14.5 12,14.5C15.59,14.5 18.5,16.18 18.5,18.25V20H5.5V18.25M0,20V18.5C0,17.11 1.89,15.94 4.45,15.6C3.86,16.28 3.5,17.22 3.5,18.25V20H0M24,20H20.5V18.25C20.5,17.22 20.14,16.28 19.55,15.6C22.11,15.94 24,17.11 24,18.5V20Z"></path> </svg> </i> Authors </a> </li> <li class="cdsr-nav-link" lang="en"> <a href="/cdsr/doi/10.1002/14651858.CD010115.pub2/information#history"> <i> <svg viewbox="0 0 24 24"> <path d="M13.5,8H12V13L16.28,15.54L17,14.33L13.5,12.25V8M13,3A9,9 0 0,0 4,12H1L4.96,16.03L9,12H6A7,7 0 0,1 13,5A7,7 0 0,1 20,12A7,7 0 0,1 13,19C11.07,19 9.32,18.21 8.06,16.94L6.64,18.36C8.27,20 10.5,21 13,21A9,9 0 0,0 22,12A9,9 0 0,0 13,3"></path> </svg> </i> Version history </a> </li> <li class="cdsr-nav-link"> <a href="/cdsr/doi/10.1002/14651858.CD010115.pub2/information#keywords"> <i> <svg viewbox="0 0 24 24"> <path d="M11 3C10.18 3 9.44 3.5 9.14 4.27L3.64 18.27C3.12 19.58 4.09 21 5.5 21H7.75C8.59 21 9.33 20.5 9.62 19.7L10.26 18H13.74L14.38 19.7C14.67 20.5 15.42 21 16.25 21H18.5C19.91 21 20.88 19.58 20.36 18.27L14.86 4.27C14.56 3.5 13.82 3 13 3M11 5H13L18.5 19H16.25L15.12 16H8.87L7.75 19H5.5M12 7.67L9.62 14H14.37Z"></path> </svg> </i> Keywords (MeSH, PICOs) </a> </li> <li class="cdsr-nav-link"> <a href="/cdsr/doi/10.1002/14651858.CD010115.pub2/related-content"> <i class="icon fa fa-sitemap fa-rotate-270"></i> Related content </a> </li> <li class="cdsr-nav-link translation-notes-link"> <a href="/cdsr/doi/10.1002/14651858.CD010115.pub2/#"> <i> <svg viewbox="0 0 24 24"> <path d="M12.87,15.07L10.33,12.56L10.36,12.53C12.1,10.59 13.34,8.36 14.07,6H17V4H10V2H8V4H1V6H12.17C11.5,7.92 10.44,9.75 9,11.35C8.07,10.32 7.3,9.19 6.69,8H4.69C5.42,9.63 6.42,11.17 7.67,12.56L2.58,17.58L4,19L9,14L12.11,17.11L12.87,15.07M18.5,10H16.5L12,22H14L15.12,19H19.87L21,22H23L18.5,10M15.88,17L17.5,12.67L19.12,17H15.88Z"></path> </svg> </i> Translation notes </a> </li> <li class="cdsr-nav-link"> <a class="request-permissions" data-copyright="Copyright © 2014 The Cochrane Collaboration. Published by John Wiley &amp; Sons, Ltd." data-creative-commons="false" href="/cdsr/doi/10.1002/14651858.CD010115.pub2/#"> <span class="request-permissions-icon"></span> Request permissions </a> </li> <li class="cdsr-nav-link"> <a href="/data"> <i class="icon fa fa-database"></i> Request data reuse </a> </li> </ul> </nav> </div> <article> <div class="cdsr-header-top"> <div class="cdsr-header-left"> <a class="publish-database" href="/">Cochrane Database of Systematic reviews</a> <span class="publish-type">Review - Intervention</span> </div> <div class="cdsr-header-right"> </div> </div> <header class="publication-header"> <h1 class="publication-title" lang="en">Inhaled steroids and risk of pneumonia for chronic obstructive pulmonary disease</h1> <div class="publication-metadata-block"> <div class="publication-authors"> <div class="publish-meta-wrapper"> <ul class="authors"> <li class="author"><a href="/cdsr/doi/10.1002/14651858.CD010115.pub2/information#CD010115-cr-0002"><i class="icon corresponding-author fa fa-envelope"></i>Kayleigh M Kew</a></li> <li class="author"><a href="/cdsr/doi/10.1002/14651858.CD010115.pub2/information#CD010115-cr-0003">Alieksei Seniukovich</a></li> </ul> <span class="author declaration"> <a class="declarationsOfInterestLink" href="/cdsr/doi/10.1002/14651858.CD010115.pub2/information/en#CD010115-sec-0133">Authors' declarations of interest</a> </span> </div> </div> </div> <div class="publication-metadata-block"> <p> <span class="publish-date">Version published: 10 March 2014 </span> <a class="whatsNewLink" href="/cdsr/doi/10.1002/14651858.CD010115.pub2/information/en#versionTable">Version history</a> </p> <div class="doi-header"> <a href="https://doi.org/10.1002/14651858.CD010115.pub2">https://doi.org/10.1002/14651858.CD010115.pub2</a> </div> </div> </header> <div class="publication-control-bar"> <span class="publication-control-button publication-control-collapse"> Collapse all </span> <span class="publication-control-button publication-control-expand"> Expand all </span> </div> <section class="abstract"> <div class="section-header section-collapse-header" id="CD010115-abs-0001" lang="en"> <h2 class="title section-collapse-title"> Abstract <i aria-hidden="true" class="fa fa-caret-up section-collapse-icon"></i> </h2> <div class="section-language-toggles"> <span class="section-languages-legend">available in</span> <nav class="section-languages"> <li class="section-language"> <a class="is-active" href="full/en#CD010115-abs-0001">English</a> </li> <li class="section-language"> <a class="" href="full/es#CD010115-abs-0008">Español</a> </li> <li class="section-language"> <a class="" href="full/fa#CD010115-abs-0010">فارسی</a> </li> <li class="section-language"> <a class="" href="full/pt#CD010115-abs-0003">Português</a> </li> <li class="section-language"> <a class="" href="full/zh_HANT#CD010115-abs-0002">繁體中文</a> </li> </nav> </div> </div> <div class="abstract full_abstract" id="CD010115-abs-0001" lang="en"> <section id="CD010115-sec-0001"> <h3 class="title" id="CD010115-sec-0001">Background</h3> <p>Inhaled corticosteroids (ICS) are anti‐inflammatory drugs that have proven benefits for people with worsening symptoms of chronic obstructive pulmonary disease (COPD) and repeated exacerbations. They are commonly used as combination inhalers with long‐acting beta<sub>2</sub>‐agonists (LABA) to reduce exacerbation rates and all‐cause mortality, and to improve lung function and quality of life. The most common combinations of ICS and LABA used in combination inhalers are fluticasone and salmeterol, budesonide and formoterol and a new formulation of fluticasone in combination with vilanterol, which is now available. ICS have been associated with increased risk of pneumonia, but the magnitude of risk and how this compares with different ICS remain unclear. Recent reviews conducted to address their safety have not compared the relative safety of these two drugs when used alone or in combination with LABA. </p> </section> <section id="CD010115-sec-0002"> <h3 class="title" id="CD010115-sec-0002">Objectives</h3> <p>To assess the risk of pneumonia associated with the use of fluticasone and budesonide for COPD. </p> </section> <section id="CD010115-sec-0003"> <h3 class="title" id="CD010115-sec-0003">Search methods</h3> <p>We identified trials from the Cochrane Airways Group Specialised Register of trials (CAGR), clinicaltrials.gov, reference lists of existing systematic reviews and manufacturer websites. The most recent searches were conducted in September 2013. </p> </section> <section id="CD010115-sec-0004"> <h3 class="title" id="CD010115-sec-0004">Selection criteria</h3> <p>We included parallel‐group randomised controlled trials (RCTs) of at least 12 weeks' duration. Studies were included if they compared the ICS budesonide or fluticasone versus placebo, or either ICS in combination with a LABA versus the same LABA as monotherapy for people with COPD. </p> </section> <section id="CD010115-sec-0005"> <h3 class="title" id="CD010115-sec-0005">Data collection and analysis</h3> <p>Two review authors independently extracted study characteristics, numerical data and risk of bias information for each included study. </p> <p>We looked at direct comparisons of ICS versus placebo separately from comparisons of ICS/LABA versus LABA for all outcomes, and we combined these with subgroups when no important heterogeneity was noted. After assessing for transitivity, we conducted an indirect comparison to compare budesonide versus fluticasone monotherapy, but we could not do the same for the combination therapies because of systematic differences between the budesonide and fluticasone combination data sets. </p> <p>When appropriate, we explored the effects of ICS dose, duration of ICS therapy and baseline severity on the primary outcome. Findings of all outcomes are presented in 'Summary of findings' tables using GRADEPro. </p> </section> <section id="CD010115-sec-0006"> <h3 class="title" id="CD010115-sec-0006">Main results</h3> <p>We found 43 studies that met the inclusion criteria, and more evidence was provided for fluticasone (26 studies; n = 21,247) than for budesonide (17 studies; n = 10,150). Evidence from the budesonide studies was more inconsistent and less precise, and the studies were shorter. The populations within studies were more often male with a mean age of around 63, mean pack‐years smoked over 40 and mean predicted forced expiratory volume of one second (FEV<sub>1</sub>) less than 50%. </p> <p>High or uneven dropout was considered a high risk of bias in almost 40% of the trials, but conclusions for the primary outcome did not change when the trials at high risk of bias were removed in a sensitivity analysis. </p> <p>Fluticasone increased non‐fatal serious adverse pneumonia events (requiring hospital admission) (odds ratio (OR) 1.78, 95% confidence interval (CI) 1.50 to 2.12; 18 more per 1000 treated over 18 months; high quality), and no evidence suggested that this outcome was reduced by delivering it in combination with salmeterol or vilanterol (subgroup differences: I<sup>2</sup> = 0%, P value 0.51), or that different doses, trial duration or baseline severity significantly affected the estimate. Budesonide also increased non‐fatal serious adverse pneumonia events compared with placebo, but the effect was less precise and was based on shorter trials (OR 1.62, 95% CI 1.00 to 2.62; six more per 1000 treated over nine months; moderate quality). Some of the variation in the budesonide data could be explained by a significant difference between the two commonly used doses: 640 mcg was associated with a larger effect than 320 mcg relative to placebo (subgroup differences: I<sup>2</sup> = 74%, P value 0.05). </p> <p>An indirect comparison of budesonide versus fluticasone monotherapy revealed no significant differences with respect to serious adverse events (pneumonia‐related or all‐cause) or mortality. The risk of any pneumonia event (i.e. less serious cases treated in the community) was higher with fluticasone than with budesonide (OR 1.86, 95% CI 1.04 to 3.34); this was the only significant difference reported between the two drugs. However, this finding should be interpreted with caution because of possible differences in the assignment of pneumonia diagnosis, and because no trials directly compared the two drugs. </p> <p>No significant difference in overall mortality rates was observed between either of the inhaled steroids and the control interventions (both high‐quality evidence), and pneumonia‐related deaths were too rare to permit conclusions to be drawn. </p> </section> <section id="CD010115-sec-0007"> <h3 class="title" id="CD010115-sec-0007">Authors' conclusions</h3> <p>Budesonide and fluticasone, delivered alone or in combination with a LABA, are associated with increased risk of serious adverse pneumonia events, but neither significantly affected mortality compared with controls. The safety concerns highlighted in this review should be balanced with recent cohort data and established randomised evidence of efficacy regarding exacerbations and quality of life. Comparison of the two drugs revealed no statistically significant difference in serious pneumonias, mortality or serious adverse events. Fluticasone was associated with higher risk of any pneumonia when compared with budesonide (i.e. less serious cases dealt with in the community), but variation in the definitions used by the respective manufacturers is a potential confounding factor in their comparison. </p> <p>Primary research should accurately measure pneumonia outcomes and should clarify both the definition and the method of diagnosis used, especially for new formulations and combinations for which little evidence of the associated pneumonia risk is currently available. Similarly, systematic reviews and cohorts should address the reliability of assigning 'pneumonia' as an adverse event or cause of death and should determine how this affects the applicability of findings. </p> </section> </div> </section> <section class="pico-section" id="pico"> <h2 class="title section-collapse-title">PICOs <i class="icon fa fa-info-circle" title="The PICO model is widely used and taught in evidence-based health care as a strategy for formulating questions and search strategies and for characterizing clinical studies or meta-analyses. PICO stands for four different potential components of a clinical question: Patient, Population or Problem; Intervention; Comparison; Outcome."></i> <i aria-hidden="true" class="fa fa-caret-up section-collapse-icon"></i> </h2> <div class="section-content" style="display: block;"> <h3 class="keyword-heading">PICOs</h3> <div class="pico-table"> <div class="pico-column Population"> <h6>Population<span class="pico-count"></span></h6> <ul class="pico-terms"> </ul> </div> <div class="pico-column Intervention"> <h6>Intervention<span class="pico-count"></span></h6> <ul class="pico-terms"> </ul> </div> <div class="pico-column Comparison"> <h6>Comparison<span class="pico-count"></span></h6> <ul class="pico-terms"> </ul> </div> <div class="pico-column Outcome"> <h6>Outcome<span class="pico-count"></span></h6> <ul class="pico-terms"> </ul> </div> </div> <div class="pico-information"> <p><i class="icon fa fa-info-circle"></i> The PICO model is widely used and taught in evidence-based health care as a strategy for formulating questions and search strategies and for characterizing clinical studies or meta-analyses. PICO stands for four different potential components of a clinical question: Patient, Population or Problem; Intervention; Comparison; Outcome.</p> <p>See more on using PICO in the <a href="https://training.cochrane.org/handbook/current/chapter-02#section-2-3">Cochrane Handbook</a>.</p> </div> </div> </section> <section class="pls"> <div class="section-header section-collapse-header" id="CD010115-abs-0004" lang="en"> <h2 class="title section-collapse-title"> Plain language summary <i aria-hidden="true" class="fa fa-caret-up section-collapse-icon"></i> </h2> <div class="section-language-toggles"> <span class="section-languages-legend">available in</span> <nav class="section-languages"> <li class="section-language"> <a class="is-active" href="full/en#CD010115-abs-0004">English</a> </li> <li class="section-language"> <a class="" href="full/es#CD010115-abs-0009">Español</a> </li> <li class="section-language"> <a class="" href="full/fa#CD010115-abs-0011">فارسی</a> </li> <li class="section-language"> <a class="" href="full/pt#CD010115-abs-0007">Português</a> </li> <li class="section-language"> <a class="" href="full/ru#CD010115-abs-0006">Русский</a> </li> <li class="section-language"> <a class="" href="full/zh_HANT#CD010115-abs-0005">繁體中文</a> </li> </nav> </div> </div> <div class="abstract abstract_plainLanguageSummary" id="CD010115-abs-0004" lang="en"> <h3>Do inhaled steroids increase the risk of pneumonia in people with chronic obstructive pulmonary disease (COPD)? </h3> <p><b>Why is this question important?</b> <br/> Inhaled corticosteroids (ICS) are drugs that can reduce the occurrence of COPD flare‐ups and improve quality of life. In COPD, ICS are commonly used alongside long‐acting beta<sub>2</sub>‐agonists (LABA). The most common combinations of ICS and LABA inhalers are fluticasone and salmeterol, and budesonide and formoterol, but fluticasone furoate is also used once daily with a new LABA called vilanterol. Lots of studies have shown benefits of ICS, but they can also increase the risk of pneumonia. Added to this concern, pneumonia can be difficult to diagnose, and the severity of pneumonia can be poorly reported in trials. Therefore even though we have reviews on inhaled steroids for COPD, we wanted to do a review exclusively on pneumonia, so we could take a closer look at the evidence. </p> <p>The overall aim of this review is to assess the risk of pneumonia for people with COPD taking fluticasone or budesonide. </p> <p><b>How did we answer the question?</b> <br/> We looked for all studies comparing budesonide or fluticasone versus a dummy inhaler (placebo), and all studies comparing their use in combination with a LABA (i.e. budesonide/formoterol, fluticasone propionate/salmeterol, and fluticasone furoate/vilanterol) versus the same dose of LABA alone. This allowed us to assess the risk of ICS used alone or in combination with LABA. </p> <p><b>What did we find?</b> <br/> We found 43 studies including more than 30,000 people with COPD. More studies used fluticasone (26 studies; 21,247 people) than budesonide (17 studies; 10,150 people). A higher proportion of people in the studies were male (around 70%), and their COPD was generally classed as severe. The last search for studies to include in the review was done in September 2013. </p> <p>We compared each drug against controls and assessed separately the results of studies that compared ICS versus placebo, and an ICS/LABA combination versus LABA alone. We also conducted an indirect comparison of budesonide and fluticasone based on their effects against placebo, to explore whether one drug was safer than the other. </p> <p>Fluticasone increased 'serious' pneumonias (requiring hospital admission). Over 18 months, 18 more people of every 1000 treated with fluticasone were admitted to hospital for pneumonia. </p> <p>Budesonide also increased pneumonias that were classed as 'serious'. Over nine months, six more hospital admissions were reported for every 1000 individuals treated with budesonide. A lower dose of budesonide (320 mcg) was associated with fewer serious pneumonias than a higher dose (640 mcg). </p> <p>No more deaths overall were reported in the ICS groups compared with controls, and deaths related to pneumonia were too rare to tell either way. </p> <p>When we compared fluticasone and budesonide versus each other, the difference between them was not clear enough to tell whether one was safer (for pneumonia, requiring a hospital stay, general adverse events and death). The risk of any pneumonia event (i.e. less serious cases that could be treated without going to hospital) was higher with fluticasone than with budesonide. </p> <p>Evidence was rated to be of high or moderate quality for most outcomes. When an outcome is rated of high quality, further research is very unlikely to change our confidence in the estimate of effect, but moderate ratings reflect some uncertainty in the findings. Results from the budesonide studies were generally less clear because they were based on fewer people, and the studies were shorter. </p> <p><b>Conclusion</b> <br/> Budesonide and fluticasone, delivered alone or in combination with LABA, can increase serious pneumonias that result in hospitalisation of people. Neither has been shown to affect the chance of dying compared with not taking ICS. Comparison of the two drugs revealed no difference in serious pneumonias or risk of death. Fluticasone was associated with a higher risk of any pneumonia (i.e. cases that could be treated in the community) than budesonide, but potential differences in the definition used by the respective drug manufacturers reduced our confidence in this finding. These concerns need to be balanced with the known benefits of ICS (e.g. fewer exacerbations, improved lung function and quality of life). </p> <p>Researchers should remain aware of the risks associated with ICS and should make sure that pneumonia is properly diagnosed in studies. </p> </div> </section> <section id="vls" style="display: none"> <div class="section-header section-collapse-header"> <h2 class="title section-collapse-title">Visual summary<i aria-hidden="true" class="fa fa-caret-up section-collapse-icon"></i></h2> </div> <a href="" target="_blank"><img alt="visual summary" src=""/></a> </section> <section class="conclusions"> <div class="section-header section-collapse-header" id="CD010115-sec-0112" lang="en"> <h2 class="title section-collapse-title"> Authors' conclusions <i aria-hidden="true" class="fa fa-caret-up section-collapse-icon"></i> </h2> </div> <section class="authorsConclusions" lang="en"> <div class="section-header" id="CD010115-sec-0112"></div> <h3 class="title" id="CD010115-sec-0113">Implications for practice</h3> <section id="CD010115-sec-0113"> <p>Safety concerns related to inhaled steroids highlighted in this review should be balanced with recent cohort data and established randomised evidence of efficacy regarding exacerbations and quality of life. Budesonide and fluticasone, delivered as monotherapy or in combination with a LABA, are associated with increased risk of serious adverse pneumonia events, but neither significantly affected mortality compared with controls. Comparison of the two drugs showed no statistical difference in serious pneumonias, mortality or serious adverse events, but the risk of any pneumonia (i.e. less serious cases dealt with in the community) was higher with fluticasone than with budesonide. However, definitions used by the respective manufacturers is a potential confound in their comparison. </p> </section> <h3 class="title" id="CD010115-sec-0114">Implications for research</h3> <section id="CD010115-sec-0114"> <p>Primary research into the use of inhaled steroids for COPD in particular should accurately measure pneumonia outcomes and clarify both the definition and the method of diagnosis used. This is particularly important for studies conducted on emerging corticosteroid preparations and combinations , for which little evidence is currently available on associated pneumonia risk. Similarly, systematic reviews, meta‐analyses and cohorts should address the reliability of assigning 'pneumonia' as an adverse event or a cause of death and should explain how this affects the applicability of findings. </p> </section> </section> </section> <section class="summaryOfFindings"> <div class="section-header section-collapse-header" id="CD010115-sec-0029" lang="en"> <h2 class="title section-collapse-title"> Summary of findings <i aria-hidden="true" class="fa fa-caret-up section-collapse-icon"></i> </h2> </div> <section class="summaryOfFindings" lang="en"> <div class="section-header" id="CD010115-sec-0029"></div> <div class="table" id="CD010115-tbl-0001"> <table class="summary-of-findings framed"><a class="open-table-viewer open-in-figure-viewer" href="#0">Open in table viewer</a><div class="table-heading"><span class="table-label">Summary of findings for the main comparison.</span> <span class="table-title">Fluticasone for chronic obstructive pulmonary disease</span></div> <tbody> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="6" rowspan="1" valign=""> <p><b>Fluticasone for chronic obstructive pulmonary disease</b> </p> </td> </tr> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="6" rowspan="1" valign=""> <p><b>Patient or population:</b> patients with chronic obstructive pulmonary disease<br/> <b>Intervention:</b> fluticasone (alone or with LABA co‐intervention) </p> <p><b>Comparison:</b> placebo or LABA monotherapy (dependent upon whether fluticasone was given with LABA in the intervention group) </p> <p><b>Setting:</b> community </p> </td> </tr> <tr class="table-header separated"> <td align="left" class="table-header" colspan="1" rowspan="3" valign="top"> <p><b>Outcomes</b> </p> <p><b> Follow‐ups presented as weighted means</b> </p> </td> <td align="left" class="table-tint table-highlight" colspan="2" rowspan="1" valign="top"> <p><b>Illustrative comparative risks* (95% CI)</b> </p> </td> <td align="left" class="table-header" colspan="1" rowspan="3" valign="top"> <p><b>Relative effect<br/> (95% CI)</b> </p> </td> <td align="left" class="table-header" colspan="1" rowspan="3" valign="top"> <p><b>No. of participants<br/> (studies)</b> </p> </td> <td align="left" class="table-header" colspan="1" rowspan="3" valign="top"> <p><b>Quality of the evidence<br/> (GRADE)</b> </p> </td> </tr> <tr class="table-header separated"> <td align="left" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p><b>Assumed risk</b> </p> </td> <td align="left" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p><b>Corresponding risk</b> </p> </td> </tr> <tr class="table-header separated"> <td align="left" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p><b> Control</b> </p> </td> <td align="left" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p><b> Fluticasone</b> </p> </td> </tr> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><b>Non‐fatal, serious adverse pneumonia events (requiring hospital admission)</b> <br/> Follow‐up: 18 months </p> </td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign=""> <p><b>25 per 1000</b> </p> </td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign=""> <p><b>43 per 1000</b> <br/> (37 to 51) </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><b>OR 1.78</b> <br/> (1.50 to 2.12) </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>19,504<br/> (17 studies) </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>⊕⊕⊕⊕<br/> <b>high</b> </p> </td> </tr> <tr class="separated"> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>Mortality, all‐cause</b> <br/> Follow‐up: 19 months </p> </td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p><b>58 per 1000</b> </p> </td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p><b>58 per 1000</b> <br/> (51 to 65) </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>OR 0.99</b> <br/> (0.87 to 1.13) </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>20,861<br/> (22 studies) </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>⊕⊕⊕⊕<br/> <b>high</b> </p> </td> </tr> <tr class="separated"> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>Mortality, due to pneumonia</b> <br/> Follow‐up: 18 months </p> </td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p><b>2 per 1000</b> </p> </td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p><b>3 per 1000</b> <br/> (2 to 5) </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>OR 1.23</b> <br/> (0.70 to 2.15) </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>19,532<br/> (18 studies) </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>⊕⊕⊕⊝<br/> <b>moderate</b><sup>1</sup> </p> </td> </tr> <tr class="separated"> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>Non‐fatal, serious adverse events (all)</b> <br/> Follow‐up: 19 months </p> </td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p><b>227 per 1000</b> </p> </td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p><b>237 per 1000</b> <br/> (225 to 251) </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>OR 1.06</b> <br/> (0.99 to 1.14) </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>20,381<br/> (19 studies) </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>⊕⊕⊕⊕<br/> <b>high</b> </p> </td> </tr> <tr class="separated"> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>All pneumonia events</b> <br/> Follow‐up: 22 months </p> </td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p><b>72 per 1000</b> </p> </td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p><b>116 per 1000</b> <br/> (104 to 129) </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>OR 1.68</b> <br/> (1.49 to 1.90) </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>15,377<br/> (11 studies) </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>⊕⊕⊕⊝<br/> <b>moderate</b><sup>2</sup> </p> </td> </tr> <tr class="separated"> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>Withdrawals</b> <br/> Follow‐up: 18 months </p> </td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p><b>343 per 1000</b> </p> </td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p><b>297 per 1000</b> <br/> (286 to 310) </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>OR 0.81</b> <br/> (0.77 to 0.86) </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>21,243<br/> (26 studies) </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>⊕⊕⊕⊕<br/> <b>high</b> </p> </td> </tr> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="6" rowspan="1" valign=""> <p>*The basis for the <b>assumed risk</b> (e.g. the median control group risk across studies) is provided in footnotes. The <b>corresponding risk</b> (and its 95% confidence interval) is based on the assumed risk in the comparison group and the <b>relative effect</b> of the intervention (and its 95% CI).<br/> <b>CI:</b> Confidence interval; <b>OR:</b> Odds ratio. </p> <p>Unless otherwise stated, subgroup differences between monotherapy studies (fluticasone versus placebo) and combination therapy studies (fluticasone/LABA versus LABA) were not significant. </p> </td> </tr> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="6" rowspan="1" valign=""> <p>GRADE Working Group grades of evidence.<br/> <b>High quality:</b> Further research is very unlikely to change our confidence in the estimate of effect.<br/> <b>Moderate quality:</b> Further research is likely to have an important impact on our confidence in the estimate of effect and may change the estimate.<br/> <b>Low quality:</b> Further research is very likely to have an important impact on our confidence in the estimate of effect and is likely to change the estimate.<br/> <b>Very low quality:</b> We are very uncertain about the estimate. </p> </td> </tr> </tbody> <tfoot> <tr> <td colspan="6"> <div class="table-footnote"> <p><sup>1</sup>Wide confidence intervals include significant benefit and harm, based on very few events (‐1 for imprecision).<br/> <sup>2</sup>More than half the studies did not report the outcome (‐1 for publication bias). </p> </div> </td> </tr> </tfoot> </table> </div> <div class="table" id="CD010115-tbl-0002"> <table class="summary-of-findings framed"><a class="open-table-viewer open-in-figure-viewer" href="#0">Open in table viewer</a><div class="table-heading"><span class="table-label">Summary of findings 2.</span> <span class="table-title">Budesonide for chronic obstructive pulmonary disease</span></div> <tbody> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="6" rowspan="1" valign=""> <p><b>Budesonide for chronic obstructive pulmonary disease</b> </p> </td> </tr> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="6" rowspan="1" valign=""> <p><b>Patient or population:</b> patients with chronic obstructive pulmonary disease<br/> <b>Intervention:</b> budesonide (alone or with LABA co‐intervention) </p> <p><b>Comparison:</b> placebo or LABA monotherapy (dependent upon whether fluticasone was given with LABA in the intervention group) </p> <p><b>Setting:</b> community </p> </td> </tr> <tr class="table-header separated"> <td align="left" class="table-header" colspan="1" rowspan="3" valign="top"> <p><b>Outcomes</b> </p> <p><b> Follow‐ups presented as weighted means</b> </p> </td> <td align="left" class="table-tint table-highlight" colspan="2" rowspan="1" valign="top"> <p><b>Illustrative comparative risks* (95% CI)</b> </p> </td> <td align="left" class="table-header" colspan="1" rowspan="3" valign="top"> <p><b>Relative effect<br/> (95% CI)</b> </p> </td> <td align="left" class="table-header" colspan="1" rowspan="3" valign="top"> <p><b>No of Participants<br/> (studies)</b> </p> </td> <td align="left" class="table-header" colspan="1" rowspan="3" valign="top"> <p><b>Quality of the evidence<br/> (GRADE)</b> </p> </td> </tr> <tr class="table-header separated"> <td align="left" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p><b>Assumed risk</b> </p> </td> <td align="left" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p><b>Corresponding risk</b> </p> </td> </tr> <tr class="table-header separated"> <td align="left" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p><b> Control</b> </p> </td> <td align="left" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p><b> Budesonide</b> </p> </td> </tr> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><b>Non‐fatal, serious adverse pneumonia events (requiring hospital admission)</b> <br/> Follow‐up: 9 months </p> </td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign=""> <p><b>9 per 1000</b> </p> </td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign=""> <p><b>15 per 1000</b> <br/> (9 to 24) </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><b>OR 1.62</b> <br/> (1.00 to 2.62) </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>6472<br/> (7 studies) </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>⊕⊕⊕⊝<br/> <b>moderate</b><sup>1,2</sup> </p> </td> </tr> <tr class="separated"> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>Mortality, all‐cause</b> <br/> Follow‐up: 14 months </p> </td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p><b>17 per 1000</b> </p> </td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p><b>16 per 1000</b> <br/> (11 to 21) </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>OR 0.90</b> <br/> (0.65 to 1.24) </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>10,009<br/> (12 studies) </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>⊕⊕⊕⊝<br/> <b>moderate</b><sup>3</sup> </p> </td> </tr> <tr class="separated"> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>Mortality, due to pneumonia</b> <br/> Follow‐up: 12 months </p> </td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p><b>0 per 1000</b> </p> </td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p><b>0 per 1000</b> <br/> (0 to 0) </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>OR 4.46</b> <br/> (0.07 to 286.99) </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>1511<br/> (3 studies) </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>⊕⊝⊝⊝<br/> <b>very low<sup>2,</sup> </b><sup>4</sup> </p> </td> </tr> <tr class="separated"> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>Non‐fatal, serious adverse events (all)</b> <br/> Follow‐up: 14 months </p> </td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p><b>145 per 1000</b> </p> </td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p><b>146 per 1000</b> <br/> (124 to 172) </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>OR 1.01</b> <br/> (0.83 to 1.22) </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>10,009<br/> (12 studies) </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>⊕⊕⊕⊝<br/> <b>moderate</b><sup>5</sup> </p> </td> </tr> <tr class="separated"> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>All pneumonia events</b> <br/> Follow‐up: 10 months </p> </td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p><b>28 per 1000</b> </p> </td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p><b>31 per 1000</b> <br/> (23 to 41) </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>OR 1.12</b> <br/> (0.83 to 1.51) </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>7011<br/> (6 studies) </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>⊕⊕⊕⊝<br/> <b>moderate</b><sup>1,2</sup> </p> </td> </tr> <tr class="separated"> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>Withdrawals</b> <br/> Follow‐up: 14 months </p> </td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p><b>280 per 1000</b> </p> </td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p><b>232 per 1000</b> <br/> (216 to 248) </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>OR 0.78</b> <br/> (0.71 to 0.85) </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>10150<br/> (15 studies) </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>⊕⊕⊕⊕<br/> <b>high</b> </p> </td> </tr> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="6" rowspan="1" valign=""> <p>*The basis for the <b>assumed risk</b> (e.g. the median control group risk across studies) is provided in footnotes. The <b>corresponding risk</b> (and its 95% confidence interval) is based on the assumed risk in the comparison group and the <b>relative effect</b> of the intervention (and its 95% CI).<br/> <b>CI:</b> Confidence interval; <b>OR:</b> Odds ratio. </p> <p>Unless otherwise stated, subgroup differences between monotherapy studies (budesonide versus placebo) and combination therapy studies (budesonide/LABA versus LABA) were not significant. </p> </td> </tr> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="6" rowspan="1" valign=""> <p>GRADE Working Group grades of evidence.<br/> <b>High quality:</b> Further research is very unlikely to change our confidence in the estimate of effect.<br/> <b>Moderate quality:</b> Further research is likely to have an important impact on our confidence in the estimate of effect and may change the estimate.<br/> <b>Low quality:</b> Further research is very likely to have an important impact on our confidence in the estimate of effect and is likely to change the estimate.<br/> <b>Very low quality:</b> We are very uncertain about the estimate. </p> </td> </tr> </tbody> <tfoot> <tr> <td colspan="6"> <div class="table-footnote"> <p><sup>1</sup>Confidence intervals are quite wide but are not considered serious enough to downgrade.<br/> <sup>2</sup>More than half the studies did not report the outcome (‐1 for publication bias).<br/> <sup>3</sup>Confidence interval includes significant benefit and potential harm.<br/> <sup>4</sup>Very wide confidence intervals. Only one death observed over the three studies (‐2 for imprecision).<br/> <sup>5</sup>I<sup>2</sup> = 59%, P value 0.002 (‐1 for inconsistency). </p> </div> </td> </tr> </tfoot> </table> </div> </section> </section> <section class="background"> <div class="section-header section-collapse-header" id="CD010115-sec-0030" lang="en"> <h2 class="title section-collapse-title"> Background <i aria-hidden="true" class="fa fa-caret-up section-collapse-icon"></i> </h2> </div> <section class="background" lang="en"> <div class="section-header" id="CD010115-sec-0030"></div> <section id="CD010115-sec-0031"> <h3 class="title" id="CD010115-sec-0031">Description of the condition</h3> <p>Chronic obstructive pulmonary disease (COPD) is a respiratory disease characterised by chronic and progressive breathlessness, cough, sputum production and airflow obstruction, which leads to restricted activity and poor quality of life (<a href="./references#CD010115-bbs2-0073" title="GOLD . Global Strategy for the Diagnosis, Management and Prevention of COPD, Global Initiative for Chronic Obstructive Lung Disease (GOLD) 2013. http://www.goldcopd.com(accessed 22 November 13). ">GOLD 2013</a>). The World Health Organization (<a href="./references#CD010115-bbs2-0094" title="World Health Organization. Chronic respiratory diseases. http://www.who.int/respiratory/en/ (accessed 7 February 2012). ">WHO 2012</a>) has estimated that COPD is the fourth or fifth most common single cause of death worldwide, and that the treatment and management costs present a significant burden to public health. In the UK the annual cost of COPD to the National Health Service (NHS) is estimated to be GBP 1.3 million per 100,000 people (<a href="./references#CD010115-bbs2-0082" title="National Institute for Health and Clinical Excellence. Chronic obstructive pulmonary disease, costing report, implementing NICE guidance. http://guidance.nice.org.uk/CG101/CostingReport/pdf/English (accessed 4 February 2012). [URL: http://guidance.nice.org.uk/CG101/CostingReport/pdf/English] ">NICE 2011</a>). Furthermore, because of its slow onset and under‐recognition of the disease by patients and healthcare professionals, COPD is heavily under diagnosed (<a href="./references#CD010115-bbs2-0073" title="GOLD . Global Strategy for the Diagnosis, Management and Prevention of COPD, Global Initiative for Chronic Obstructive Lung Disease (GOLD) 2013. http://www.goldcopd.com(accessed 22 November 13). ">GOLD 2013</a>). COPD comprises a combination of bronchitis and emphysema and involves chronic inflammation and structural changes in the lung. Cigarette smoking is the most important risk factor, but air pollution and occupational dust and chemicals are also recognised risk factors. COPD is a progressive disease that leads to decreased lung function over time, even with the best available care. Currently no cure is known for COPD, although the condition is both preventable and treatable. As yet, apart from smoking cessation and non‐pharmacological treatments such as long‐term oxygen therapy in hypoxic patients and pulmonary rehabilitation, no intervention has been shown to reduce mortality (<a href="./references#CD010115-bbs2-0073" title="GOLD . Global Strategy for the Diagnosis, Management and Prevention of COPD, Global Initiative for Chronic Obstructive Lung Disease (GOLD) 2013. http://www.goldcopd.com(accessed 22 November 13). ">GOLD 2013</a>;<a href="./references#CD010115-bbs2-0084" title="PuhanMA , Gimeno‐SantosE , ScharplatzM , TroostersT , WaltersEH , SteurerJ . Pulmonary rehabilitation following exacerbations of chronic obstructive pulmonary disease. Cochrane Database of Systematic Reviews2011, Issue 10. [DOI: 10.1002/14651858.CD005305.pub3] ">Puhan 2011</a>). Management of the disease is multi‐faceted and includes interventions for smoking cessation (<a href="./references#CD010115-bbs2-0093" title="Van derMeerRM , WagenaE , OsteloRWJG , JacobsAJE , vanSchayckO . Smoking cessation for chronic obstructive pulmonary disease. Cochrane Database of Systematic Reviews2001, Issue 1. [DOI: 10.1002/14651858.CD002999] ">Van der Meer 2001</a>), pharmacological treatments (<a href="./references#CD010115-bbs2-0073" title="GOLD . Global Strategy for the Diagnosis, Management and Prevention of COPD, Global Initiative for Chronic Obstructive Lung Disease (GOLD) 2013. http://www.goldcopd.com(accessed 22 November 13). ">GOLD 2013</a>), education (<a href="./references#CD010115-bbs2-0070" title="EffingT , MonninkhofEEM , van derValkPPDLPM , ZielhuisGGA , WaltersEH , van derPalenJJ , et al. Self‐management education for patients with chronic obstructive pulmonary disease. Cochrane Database of Systematic Reviews2007, Issue 4. [DOI: 10.1002/14651858.CD002990.pub2] ">Effing 2007</a>) and pulmonary rehabilitation (<a href="./references#CD010115-bbs2-0078" title="LacasseY , GoldsteinR , LassersonTJ , MartinS . Pulmonary rehabilitation for chronic obstructive pulmonary disease. Cochrane Database of Systematic Reviews2006, Issue 4. [DOI: 10.1002/14651858.CD003793.pub2] ">Lacasse 2006</a>; <a href="./references#CD010115-bbs2-0084" title="PuhanMA , Gimeno‐SantosE , ScharplatzM , TroostersT , WaltersEH , SteurerJ . Pulmonary rehabilitation following exacerbations of chronic obstructive pulmonary disease. Cochrane Database of Systematic Reviews2011, Issue 10. [DOI: 10.1002/14651858.CD005305.pub3] ">Puhan 2011</a>). Pharmacological therapy is aimed at relieving symptoms, improving exercise tolerance and quality of life, improving lung function and preventing and treating exacerbations. </p> </section> <section id="CD010115-sec-0032"> <h3 class="title" id="CD010115-sec-0032">Description of the intervention</h3> <p>Pharmacological management for COPD is generally a stepwise process, commencing with therapy for symptoms, which is followed by introduction of additional therapeutic agents as needed to achieve control and to reduce the frequency and severity of exacerbations (<a href="./references#CD010115-bbs2-0073" title="GOLD . Global Strategy for the Diagnosis, Management and Prevention of COPD, Global Initiative for Chronic Obstructive Lung Disease (GOLD) 2013. http://www.goldcopd.com(accessed 22 November 13). ">GOLD 2013</a>). Often the first step is to use a short‐acting bronchodilator for control of breathlessness when needed: a short‐acting beta<sub>2</sub>‐agonist (SABA) (e.g. salbutamol) or the short‐acting muscarinic antagonist (SAMA) ipratropium. For persistent or worsening breathlessness associated with lung function decline, long‐acting bronchodilators may be introduced (<a href="./references#CD010115-bbs2-0073" title="GOLD . Global Strategy for the Diagnosis, Management and Prevention of COPD, Global Initiative for Chronic Obstructive Lung Disease (GOLD) 2013. http://www.goldcopd.com(accessed 22 November 13). ">GOLD 2013</a>). These comprise twice‐daily long‐acting beta<sub>2</sub>‐agonists (LABA), such as salmeterol or formoterol; once‐daily beta<sub>2</sub>‐agonists, such as indacaterol; and the long‐acting anticholinergic agent tiotropium. For patients with severe or very severe COPD (forced expiratory volume in one second (FEV<sub>1</sub>) &lt; 50% predicted) and with repeated exacerbations, the Global initiative for chronic Obstructive Lung Disease (<a href="./references#CD010115-bbs2-0073" title="GOLD . Global Strategy for the Diagnosis, Management and Prevention of COPD, Global Initiative for Chronic Obstructive Lung Disease (GOLD) 2013. http://www.goldcopd.com(accessed 22 November 13). ">GOLD 2013</a>) recommends the addition of inhaled corticosteroids (ICS) to bronchodilator treatment. ICS are anti‐inflammatory drugs that are licensed as combination inhalers for use with LABA. The most common ICS and LABA components in combination inhalers are fluticasone propionate and salmeterol, budesonide and formoterol and a new formulation of fluticasone furoate in combination with vilanterol, which is now available for once‐daily use. Patients with severe COPD may also be treated with the phosphodiesterase 4 (PDE<sub>4</sub>) inhibitor roflumilast, which may reduce the risk of exacerbations (GOLD). </p> </section> <section id="CD010115-sec-0033"> <h3 class="title" id="CD010115-sec-0033">How the intervention might work</h3> <p>ICS are anti‐inflammatory drugs. They reduce the rate of exacerbation and improve quality of life, but they have not been found to have an effect on overall mortality or on the long‐term decline in FEV<sub>1</sub> (<a href="./references#CD010115-bbs2-0061" title="AgarwalR , AggarwalAN , GuptaD , JindalSK . Inhaled corticosteroids vs placebo for preventing COPD exacerbations. Chest2010;137(2):318‐25. ">Agarwal 2010</a>; <a href="./references#CD010115-bbs2-0073" title="GOLD . Global Strategy for the Diagnosis, Management and Prevention of COPD, Global Initiative for Chronic Obstructive Lung Disease (GOLD) 2013. http://www.goldcopd.com(accessed 22 November 13). ">GOLD 2013</a>; <a href="./references#CD010115-bbs2-0095" title="YangIA , FongK , SimEHA , BlackPN , LassersonTJ . Inhaled corticosteroids for stable chronic obstructive pulmonary disease. Cochrane Database of Systematic Reviews2009, Issue 3. [DOI: 10.1002/14651858.CD002991.pub2] ">Yang 2009</a>). ICS and LABA combination inhalers reduce exacerbation rates and all‐cause mortality and improve lung function and quality of life (<a href="./references#CD010115-bbs2-0081" title="NanniniLJ , PooleP , MilanSJ , HolmesR , NormansellR . Combined corticosteroid and long‐acting beta2‐agonist in one inhaler versus placebo for chronic obstructive pulmonary disease. Cochrane Database of Systematic Reviews2013, Issue 11. [DOI: 10.1002/14651858.CD003794.pub4] ">Nannini 2013</a>). These effects are thought to be greater for combination inhalers than for the component preparations (<a href="./references#CD010115-bbs2-0073" title="GOLD . Global Strategy for the Diagnosis, Management and Prevention of COPD, Global Initiative for Chronic Obstructive Lung Disease (GOLD) 2013. http://www.goldcopd.com(accessed 22 November 13). ">GOLD 2013</a>; <a href="./references#CD010115-bbs2-0081" title="NanniniLJ , PooleP , MilanSJ , HolmesR , NormansellR . Combined corticosteroid and long‐acting beta2‐agonist in one inhaler versus placebo for chronic obstructive pulmonary disease. Cochrane Database of Systematic Reviews2013, Issue 11. [DOI: 10.1002/14651858.CD003794.pub4] ">Nannini 2013</a>). ICS, alone or in combination with LABA, however, have been associated with increased risk of pneumonia (<a href="./references#CD010115-bbs2-0073" title="GOLD . Global Strategy for the Diagnosis, Management and Prevention of COPD, Global Initiative for Chronic Obstructive Lung Disease (GOLD) 2013. http://www.goldcopd.com(accessed 22 November 13). ">GOLD 2013</a>; <a href="./references#CD010115-bbs2-0090" title="SinghS , AminAV , LokeYK . Long‐term use of inhaled corticosteroids and the risk of pneumonia in chronic obstructive pulmonary disease: a meta‐analysis. Archives of Internal Medicine2009;169(3):219‐29. [1538‐3679: (Electronic)] ">Singh 2009</a>). Several mechanisms have been proposed by which ICS could increase the risk of pneumonia; these mechanisms are principally related to the immunosuppressive effects of ICS and include ICS reaching the lung in high concentrations. Particularly, inhibition of nuclear factor kappa B (NF‐κB) by ICS in COPD, one of the proposed mechanisms for their therapeutic effect, could lead to the suppression of normal host responses to bacterial infection (<a href="./references#CD010115-bbs2-0089" title="SinganayagamA , ChalmersJ , HillA . Inhaled corticosteroids and risk of pneumonia: evidence for and against the proposed association. Quarterly Journal of Medicine2010;103:379‐85. ">Singanayagam 2010</a>). </p> </section> <section id="CD010115-sec-0034"> <h3 class="title" id="CD010115-sec-0034">Why it is important to do this review</h3> <p>Use of ICS for treatment of COPD may be beneficial, at least for some COPD patients. But the role of ICS therapy in patients with stable COPD is controversial, especially as an elevated risk of pneumonia has been found in studies of ICS use. Pneumonia in COPD is associated with high morbidity and mortality (<a href="./references#CD010115-bbs2-0071" title="ErnstP , GonzalezAV , BrassardP , SuissaS . Inhaled corticosteroid use in chronic obstructive pulmonary disease and the risk of hospitalization for pneumonia. American Journal of Respiratory and Critical Care Medicine2007;176:162‐6. ">Ernst 2007</a>) and worsening quality of life and pulmonary function, so it is important to understand the strength and nature of the association between ICS use and this adverse event. </p> <p>Several systematic reviews published in the last few years have looked at the risk of pneumonia with ICS use (<a href="./references#CD010115-bbs2-0069" title="DrummondMB , DasenbrookEC , PitzMW , MurphyDJ , FanE . Inhaled corticosteroids in patients with stable chronic obstructive pulmonary disease: a systematic review and meta‐analysis. JAMA2008;300(20):2407‐16. [1538‐3598: (Electronic)] ">Drummond 2008</a>; <a href="./references#CD010115-bbs2-0074" title="HalpinDM , GrayJ , EdwardsSJ , MoraisJ , SinghD . Budesonide/formoterol vs. salmeterol/fluticasone in COPD: a systematic review and adjusted indirect comparison of pneumonia in randomised controlled trials. International Journal of Clinical Practice2011;65(7):764‐74. [1742‐1241: (Electronic)] ">Halpin 2011</a>; <a href="./references#CD010115-bbs2-0088" title="SinDD , TashkinD , ZhangX , RadnerF , SjobringU , ThorenA , et al. Budesonide and the risk of pneumonia: a meta‐analysis of individual patient data. Lancet2009;374(9691):712‐9. [1474‐547X: (Electronic)] ">Sin 2009</a>; <a href="./references#CD010115-bbs2-0090" title="SinghS , AminAV , LokeYK . Long‐term use of inhaled corticosteroids and the risk of pneumonia in chronic obstructive pulmonary disease: a meta‐analysis. Archives of Internal Medicine2009;169(3):219‐29. [1538‐3679: (Electronic)] ">Singh 2009</a>). Of these, only one compared different ICS versus each other and as combination inhaler therapy together with a LABA (<a href="./references#CD010115-bbs2-0074" title="HalpinDM , GrayJ , EdwardsSJ , MoraisJ , SinghD . Budesonide/formoterol vs. salmeterol/fluticasone in COPD: a systematic review and adjusted indirect comparison of pneumonia in randomised controlled trials. International Journal of Clinical Practice2011;65(7):764‐74. [1742‐1241: (Electronic)] ">Halpin 2011</a>). Although ICS are usually administered in a combination inhaler in clinical practice, we are interested in the most comprehensive evidence on the risk of pneumonia with ICS. Differences in the molecular structures of ICS formulations are known to alter their relative potency ratios and durations of action (<a href="./references#CD010115-bbs2-0077" title="JohnsonM . Development of fluticasone propionate and comparison with other inhaled corticosteroids. Journal of Allergy and Clinical Immunology1998;101(4):S434‐9. ">Johnson 1998</a>; <a href="./references#CD010115-bbs2-0086" title="RossiosC , ToY , ToM , ItoM , BarnesPJ , AdcockIM , JohnsonM , ItoK . Long‐acting fluticasone furoate has a superior pharmacological profile to fluticasone propionate in human respiratory cells. European Journal of Pharmacology2011;670(1):244‐51. ">Rossios 2011</a>), but potential differences between formulations in the magnitude of pneumonia risk remains unclear. It is also uncertain whether the association with pneumonia is altered by LABA in combination inhalers. We therefore included studies that examined ICS treatment both alone and in combination with a LABA. We focused on the risk of pneumonia with the two most frequently prescribed ICS—fluticasone and budesonide—compared with control, and on the difference in risk of pneumonia between these ICS. When there was a paucity of head‐to‐head trials directly comparing fluticasone and budesonide, we planned to complement the direct comparisons with an adjusted indirect comparison of budesonide and fluticasone using placebo as a common comparator (<a href="#CD010115-fig-0001">Figure 1</a>). Indirect comparisons are considered valid if 'clinical and methodological homogeneity' is present between the budesonide and fluticasone studies (<a href="./references#CD010115-bbs2-0068" title="CiprianiA , HigginsJPT , GeddesJR , SalantiGS . Conceptual and technical challenges in network meta‐analysis. Annals of Internal Medicine2013;159(2):130‐7. ">Cipriani 2013</a>). The indirect comparison of budesonide and fluticasone when taken in a combination inhaler with different LABA assumes that the LABA salmeterol, formoterol and vilanterol do not have an important effect on the risk of pneumonia. </p> <div class="figure" id="CD010115-fig-0001"> <div class="figure-caption-wrapper-top"> <nav class="inline-nav-list has-dividers"> <ul> <li><a class="open-in-figure-viewer" href="#0">Open in figure viewer</a></li> </ul> </nav> <div class="figure-label">Figure 1</div> </div> <hr class="top"/><img alt="Direct and indirect comparisons of fluticasone and budesonide covered in the review." data-id="CD010115-fig-0001" src="/cdsr/doi/10.1002/14651858.CD010115.pub2/media/CDSR/CD010115/image_n/nCD010115-AFig-FIG01.png"/><hr class="bottom"/> <div class="figure-caption-wrapper-bottom"> <div class="figure-caption"> <p>Direct and indirect comparisons of fluticasone and budesonide covered in the review.</p> </div> </div> </div> </section> </section> </section> <section class="objectives"> <div class="section-header section-collapse-header" id="CD010115-sec-0035" lang="en"> <h2 class="title section-collapse-title"> Objectives <i aria-hidden="true" class="fa fa-caret-up section-collapse-icon"></i> </h2> </div> <section class="objectives" lang="en"> <div class="section-header" id="CD010115-sec-0035"></div> <p>To assess the risk of pneumonia associated with the use of fluticasone and budesonide for COPD. </p> </section> </section> <section class="methods"> <div class="section-header section-collapse-header" id="CD010115-sec-0036" lang="en"> <h2 class="title section-collapse-title"> Methods <i aria-hidden="true" class="fa fa-caret-up section-collapse-icon"></i> </h2> </div> <section class="methods" lang="en"> <div class="section-header" id="CD010115-sec-0036"></div> <section id="CD010115-sec-0037"> <h3 class="title">Criteria for considering studies for this review</h3> <section id="CD010115-sec-0038"> <h4 class="title">Types of studies</h4> <p>We included randomised controlled trials (RCTs) with a parallel‐group design of at least 12 weeks' duration. We did not exclude studies on the basis of blinding. Cross‐over trials were not included, as ICS can have long‐acting effects, and because the primary outcome is an adverse event. </p> </section> <section id="CD010115-sec-0039"> <h4 class="title">Types of participants</h4> <p>We included RCTs that recruited participants with a diagnosis of COPD (e.g. based on criteria recommended by the American Thoracic Society and the European Respiratory Society) (<a href="./references#CD010115-bbs2-0063" title="American Thoracic Society / European Respiratory Society Task Force. Standards for the diagnosis and management of patients with COPD [Internet]. Version 1.2. http://www.thoracic.org/go/copd. New York: American Thoracic Society, (accessed 4 May 2012). [URL: http://www.thoracic.org/go/copd] ">ATS/ERS 2004</a>). </p> <p> <ol id="CD010115-list-0001"> <li> <p>Forced expiratory volume after one second (FEV<sub>1</sub>)/forced vital capacity (FVC) ratio &lt; 0.7, which confirms the presence of persistent airflow limitation. </p> </li> <li> <p>One or more of the following key indicators.</p> <ol id="CD010115-list-0002"> <li> <p>Progressive and/or persistent dyspnoea.</p> </li> <li> <p>Chronic cough.</p> </li> <li> <p>Chronic sputum production.</p> </li> <li> <p>History of exposure to risk factors (tobacco smoke, smoke from home cooking and heating fuels, occupational dusts and chemicals). </p> </li> </ol> </li> </ol> </p> </section> <section id="CD010115-sec-0040"> <h4 class="title">Types of interventions</h4> <p>We included studies that performed any of the following comparisons.</p> <p> <ol id="CD010115-list-0003"> <li> <p>Fluticasone versus placebo.</p> </li> <li> <p>Budesonide versus placebo.</p> </li> <li> <p>Fluticasone/salmeterol versus salmeterol.</p> </li> <li> <p>Fluticasone/vilanterol versus vilanterol.</p> </li> <li> <p>Budesonide/formoterol versus formoterol.</p> </li> <li> <p>Fluticasone versus budesonide.</p> </li> <li> <p>Fluticasone/salmeterol versus budesonide/formoterol.</p> </li> <li> <p>Fluticasone/vilanterol versus budesonide/formoterol.</p> </li> </ol> </p> <p>We allowed ICS/LABA combination treatment in a single inhaler and in separate inhalers. Participants were allowed to take other concomitant COPD medications as prescribed by their healthcare practitioner provided they were not part of the trial treatment under study. For example, we excluded studies that compared triple therapy of budesonide/formoterol combination inhaler plus tiotropium versus formoterol plus tiotropium. </p> </section> <section id="CD010115-sec-0041"> <h4 class="title">Types of outcome measures</h4> <p>We were interested in events of pneumonia. Pneumonia is usually defined as an acute lower respiratory tract infection that generally includes symptoms and signs from the respiratory tract and noted in the general health of the patient, but the specific definition/diagnosis varies. We recorded the basis of diagnosis, specifically, radiological confirmation, and planned to conduct a subgroup analysis. One example of the definition of diagnostic criteria for pneumonia is found in <a href="./references#CD010115-bbs2-0065" title="British Thoracic Society, Community Acquired Pneumonia in Adults Guideline Group. Guidelines for the management of community acquired pneumonia in adults: update 2009. Thorax2009;64(Suppl III):iii1–iii55. ">BTS 2009</a>. </p> <p> <ol id="CD010115-list-0004"> <li> <p>Symptoms of an acute lower respiratory tract illness (cough and at least one other lower respiratory tract symptom). </p> </li> <li> <p>New focal chest signs on examination.</p> </li> <li> <p>At least one systemic feature (either a symptom complex of sweating, fevers, shivers, aches and pains and/or temperature of 38°C or higher). </p> </li> <li> <p>No other explanation for the illness.</p> </li> </ol> </p> <p>We primarily looked at pneumonia events leading to hospital admissions (i.e. serious adverse pneumonia events), which usually are better documented and diagnosed by imaging studies and laboratory investigations than pneumonia events of any severity, and are associated with substantial morbidity and mortality. One example of the definition of diagnostic criteria for pneumonia in hospital is found in <a href="./references#CD010115-bbs2-0065" title="British Thoracic Society, Community Acquired Pneumonia in Adults Guideline Group. Guidelines for the management of community acquired pneumonia in adults: update 2009. Thorax2009;64(Suppl III):iii1–iii55. ">BTS 2009</a>. </p> <p> <ol id="CD010115-list-0005"> <li> <p>Symptoms and signs consistent with an acute lower respiratory tract infection associated with new radiographic shadowing for which no other explanation is known (e.g. not pulmonary oedema or infarction). </p> </li> <li> <p>The illness is the primary reason for hospital admission and is managed as pneumonia.</p> </li> </ol> </p> <p>We used end of study as the time of analysis for all studies, which ranged from three to 36 months in duration. </p> <section id="CD010115-sec-0042"> <h5 class="title">Primary outcomes</h5> <p> <ol id="CD010115-list-0006"> <li> <p>Non‐fatal, serious adverse pneumonia events (requiring hospital admission).</p> </li> </ol> </p> <p>We chose serious adverse pneumonia events as the primary outcome because of the increased burden these events have on the individual and on healthcare systems. </p> </section> <section id="CD010115-sec-0043"> <h5 class="title">Secondary outcomes</h5> <p> <ol id="CD010115-list-0007"> <li> <p>Mortality: all‐cause and due to pneumonia.</p> </li> <li> <p>Non‐fatal serious adverse events: all‐cause.</p> </li> <li> <p>All pneumonia events.</p> </li> <li> <p>Withdrawals.</p> </li> </ol> </p> </section> </section> </section> <section id="CD010115-sec-0044"> <h3 class="title">Search methods for identification of studies</h3> <section id="CD010115-sec-0045"> <h4 class="title">Electronic searches</h4> <p>We identified trials from the Cochrane Airways Group Specialised Register of trials (CAGR), which is maintained by the Trials Search Co‐ordinator for the Group. The Register contains trial reports identified by systematic searches of bibliographic databases including the Cochrane Central Register of Controlled Trials (CENTRAL), MEDLINE, EMBASE, CINAHL, AMED and PsycINFO, and conference abstracts found through handsearching (see <a href="./appendices#CD010115-sec-0118">Appendix 1</a> for further details). We searched all records in the CAGR coded 'COPD' using the following terms. </p> <p>((steroid* or corticosteroid*) and inhal*) or ICS or budesonide or fluticasone or pulmicort or flovent or flixotide or symbicort or viani or seretide or advair. </p> <p>We also searched ClinicalTrials.gov using search terms provided in <a href="./appendices#CD010115-sec-0124">Appendix 2</a>. We searched all databases with no restriction on date or language of publication up to September 2013. </p> </section> <section id="CD010115-sec-0046"> <h4 class="title">Searching other resources</h4> <p>We checked reference lists of all primary studies and review articles for additional references. We searched the manufacturers' websites (AstraZeneca and GlaxoSmithKline) for additional information on studies identified through the electronic searches. </p> </section> </section> <section id="CD010115-sec-0047"> <h3 class="title" id="CD010115-sec-0047">Data collection and analysis</h3> <section id="CD010115-sec-0048"> <h4 class="title">Selection of studies</h4> <p>Two review authors (AS and CK) independently screened the titles and abstracts of citations retrieved through literature searches and obtained those deemed to be potentially relevant. We assigned all references to a study identifier and assessed them against the inclusion criteria of this protocol. We resolved disagreements by consensus. Subsequent search updates were screened by AS and KMK. </p> </section> <section id="CD010115-sec-0049"> <h4 class="title">Data extraction and management</h4> <p>Two review authors (KMK and AS or CK) independently extracted information from each included study (recording the data source) for the following characteristics. </p> <p> <ol id="CD010115-list-0008"> <li> <p>Design (study design, total duration of study, number of study centres and locations).</p> </li> <li> <p>Participants (number randomly assigned to each treatment, mean age, gender, baseline lung function, smoking history, inclusion criteria, exclusion criteria). </p> </li> <li> <p>Interventions (run‐in, intervention and control treatment including concentration and formulation). </p> </li> <li> <p>Outcomes (definitions of pneumonia events and data on the numbers of participants with one or more events with onset during the treatment period). </p> </li> </ol> </p> <p>We resolved discrepancies in the data by discussion, or by consultation with a third party when necessary. </p> </section> <section id="CD010115-sec-0050"> <h4 class="title">Assessment of risk of bias in included studies</h4> <p>We assessed the risk of bias according to recommendations outlined in the <i>Cochrane Handbook for Systematic Reviews of Interventions</i> (<a href="./references#CD010115-bbs2-0075" title="HigginsJPT , GreenS (editors) . Cochrane Handbook for Systematic Reviews of Interventions Version 5.0.2 [updated September 2009]. The Cochrane Collaboration, 2009. www.cochrane‐handbook.org. ">Higgins 2011</a>) for the following items. </p> <p> <ol id="CD010115-list-0009"> <li> <p>Random sequence generation.</p> </li> <li> <p>Allocation concealment.</p> </li> <li> <p>Blinding of participants and personnel.</p> </li> <li> <p>Blinding of outcome assessment.</p> </li> <li> <p>Incomplete outcome data.</p> </li> <li> <p>Selective outcome reporting.</p> </li> </ol> </p> <p>We graded each potential source of bias as high, low or unclear according to recommendations outlined in the <i>Cochrane Handbook for Systematic Reviews of Interventions</i> (<a href="./references#CD010115-bbs2-0075" title="HigginsJPT , GreenS (editors) . Cochrane Handbook for Systematic Reviews of Interventions Version 5.0.2 [updated September 2009]. The Cochrane Collaboration, 2009. www.cochrane‐handbook.org. ">Higgins 2011</a>). </p> </section> <section id="CD010115-sec-0051"> <h4 class="title">Measures of treatment effect</h4> <section id="CD010115-sec-0052"> <h5 class="title">Direct comparisons (fluticasone vs placebo; budesonide vs placebo; fluticasone/LABA vs LABA; budesonide/LABA vs LABA) </h5> <p>We analysed direct pair‐wise comparisons using Mantel‐Haenszel odds ratios (ORs) with 95% confidence intervals (CIs). When events were rare, we employed the Peto odds ratio. When count data were available as rate ratios, we transformed them into log rate ratios and analysed them using generic inverse variance (GIV). For the primary outcome, the number needed to treat for an additional harmful outcome was calculated from the pooled odds ratio and its confidence interval and was applied to appropriate levels of baseline risk. </p> </section> <section id="CD010115-sec-0053"> <h5 class="title">Indirect comparisons (monotherapy: fluticasone vs budesonide; combination therapy: fluticasone/LABA vs budesonide/LABA) </h5> <p>We also conducted indirect comparisons of fluticasone and budesonide treatments using odds ratios with a 95% CI (<a href="./references#CD010115-bbs2-0066" title="BucherHC , GuyattGH , GriffithLE , WalterSD . The results of direct and indirect treatment comparisons in meta‐analysis of randomized controlled trials. Journal of Clinical Epidemiology1997; Vol. 50, issue 6:683‐91. [0895‐4356: (Print)] ">Bucher 1997</a>). When available, we planned to combine the indirect evidence with randomly assigned head‐to‐head comparisons of fluticasone and budesonide. </p> <section id="CD010115-sec-0054"> <h6 class="title">Assessing transitivity and similarity</h6> <p>To permit valid indirect comparisons of fluticasone and budesonide, the sets of trials for each drug must be similar in their distribution of effect modifiers (<a href="./references#CD010115-bbs2-0068" title="CiprianiA , HigginsJPT , GeddesJR , SalantiGS . Conceptual and technical challenges in network meta‐analysis. Annals of Internal Medicine2013;159(2):130‐7. ">Cipriani 2013</a>). Before conducting indirect comparisons, we constructed summary tables for monotherapy and combination therapy separately to compare the following characteristics between budesonide and fluticasone trials. </p> <p> <ol id="CD010115-list-0010"> <li> <p>Inclusion and exclusion criteria (including allowed co‐medications).</p> </li> <li> <p>Baseline characteristics (smoking history, % predicted FEV<sub>1</sub>, age, percentage male). </p> </li> <li> <p>Intervention characteristics (dose distribution, inhaler device).</p> </li> <li> <p>Methodology (risk of bias, study duration, sample size, funding).</p> </li> <li> <p>Control group event rates.</p> </li> </ol> </p> </section> </section> </section> <section id="CD010115-sec-0055"> <h4 class="title">Unit of analysis issues</h4> <p>The unit of analysis was the individual participant for dichotomous outcomes, but events were used to compare rates of exacerbation. </p> </section> <section id="CD010115-sec-0056"> <h4 class="title">Dealing with missing data</h4> <p>When pneumonia data or key study characteristics were not reported in the primary publication, we searched clinical trial reports and contacted study authors and sponsors for additional information. We used intention‐to‐treat (ITT) analysis on outcomes of all randomly assigned participants when possible. We considered the impact of the unknown status of participants who withdrew from the trials as part of the sensitivity analysis. </p> </section> <section id="CD010115-sec-0057"> <h4 class="title">Assessment of heterogeneity</h4> <p>We assessed clinical and methodological heterogeneity by recording differences in study design, participant characteristics, study sponsorship and pneumonia definition between individual studies. We assessed the extent of statistical variation among study results by using the I<sup>2</sup> measurement. We tested for inconsistency between direct and indirect data by calculating the log ratio of direct and indirect odds ratios (ROR) (<a href="./references#CD010115-bbs2-0091" title="SongF , HarveyI , LilfordR . Adjusted indirect comparison may be less biased than direct comparison for evaluating new pharmaceutical interventions. Journal of Clinical Epidemiology2008;61(5):455‐63. [0895‐4356: (Print)] ">Song 2008</a>). </p> </section> <section id="CD010115-sec-0058"> <h4 class="title">Assessment of reporting biases</h4> <p>We tried to minimise reporting bias from non‐publication of studies or selective outcome reporting by using a broad search strategy, checking references of included studies and relevant systematic reviews and contacting study authors for additional outcome data. We visually inspected funnel plots when 10 or more studies were included. </p> </section> <section id="CD010115-sec-0059"> <h4 class="title">Data synthesis</h4> <p>We looked at direct comparisons of ICS versus placebo separately from comparisons of ICS/LABA versus LABA for all outcomes (<a href="#CD010115-fig-0001">Figure 1</a>). When no important discrepancy was noted between the analyses with and without LABA, we combined the results. When a study comparing ICS/LABA versus LABA included arms for both a single inhaler (ICS/LABA) and separate inhalers (ICS + LABA), we split the control group (LABA) in half to avoid double‐counting. </p> <p>The decision whether to perform indirect comparisons of studies was based on our assessment of their clinical and methodological differences. </p> <p>If both direct and indirect comparison data were available, we planned to combine the estimates using a fixed‐effect model, but when statistical heterogeneity was evident (I<sup>2</sup> &gt; 30%), we used a random‐effects model to analyse the data and explore the heterogeneity (see below). When no important discrepancy was noted between direct and indirect estimates, we combined the resulting odds ratio and 95% CI from the indirect comparison with any direct pair‐wise data for the same comparison using inverse variance weighting (<a href="./references#CD010115-bbs2-0072" title="GlennyAM , AltmanDG , SongF , SakarovitchC , DeeksJJ , D'AmicoR , et al. Indirect comparisons of competing interventions. Health Technology Assessment2005;9(26):1‐134, iii‐iv. [1366‐5278: (Print)] ">Glenny 2005</a>). </p> <p>We presented the findings of all outcomes in 'Summary of findings' tables using GRADEPro software and recommendations provided in the <i>Cochrane Handbook for Systematic Reviews of Interventions</i>. </p> </section> <section id="CD010115-sec-0060"> <h4 class="title">Subgroup analysis and investigation of heterogeneity</h4> <p>When appropriate, we explored heterogeneity between studies by analysing data for the primary outcome by looking at the following subgroups.   </p> <p> <ol id="CD010115-list-0011"> <li> <p>ICS dose (separate subgroups for each of the following drugs and doses: fluticasone 500 and 1000 mcg; budesonide 320, 640 and 1280 mcg). </p> </li> <li> <p>Duration of ICS therapy (≤ one year; &gt; one year).</p> </li> <li> <p>Diagnostic criteria of pneumonia.</p> </li> <li> <p>Disease severity at baseline (FEV<sub>1</sub> &lt; 50% predicted; FEV<sub>1</sub> ≥ 50% predicted). </p> </li> </ol> </p> </section> <section id="CD010115-sec-0061"> <h4 class="title">Sensitivity analysis</h4> <p>We assessed the robustness of our analyses by performing sensitivity analyses, while systematically excluding studies from the overall analysis: </p> <p> <ol id="CD010115-list-0012"> <li> <p>of high risk of bias; or</p> </li> <li> <p>with high and or uneven withdrawal rates.</p> </li> </ol> </p> </section> </section> </section> </section> <section class="results"> <div class="section-header section-collapse-header" id="CD010115-sec-0062" lang="en"> <h2 class="title section-collapse-title"> Results <i aria-hidden="true" class="fa fa-caret-up section-collapse-icon"></i> </h2> </div> <section class="results" lang="en"> <div class="section-header" id="CD010115-sec-0062"></div> <section id="CD010115-sec-0063"> <h3 class="title">Description of studies</h3> <section id="CD010115-sec-0064"> <h4 class="title">Results of the search</h4> <p>Two thousand forty‐seven citations were identified by searching electronic databases. Twenty‐seven additional citations were found by searching reference lists, clinicaltrials.gov and drug company websites. Forty‐two duplicates were removed, and the remaining 2032 titles and abstracts were sifted. Two review authors excluded 1806 references that did not meet the inclusion criteria. Full texts were obtained and scrutinised for the final 226 references, and 195 (representing 43 studies) met all of the inclusion criteria. <a href="#CD010115-fig-0002">Figure 2</a> shows this information as a flow diagram and gives reasons for exclusion of the 31 references that were excluded after the full text was reviewed. </p> <div class="figure" id="CD010115-fig-0002"> <div class="figure-caption-wrapper-top"> <nav class="inline-nav-list has-dividers"> <ul> <li><a class="open-in-figure-viewer" href="#0">Open in figure viewer</a></li> </ul> </nav> <div class="figure-label">Figure 2</div> </div> <hr class="top"/><img alt="Study flow diagram." data-id="CD010115-fig-0002" src="/cdsr/doi/10.1002/14651858.CD010115.pub2/media/CDSR/CD010115/image_n/nCD010115-AFig-FIG02.png"/><hr class="bottom"/> <div class="figure-caption-wrapper-bottom"> <div class="figure-caption"> <p>Study flow diagram.</p> </div> </div> </div> </section> <section id="CD010115-sec-0065"> <h4 class="title">Included studies</h4> <p>Forty‐three studies met all of the inclusion criteria and were included in the review: 26 using fluticasone and 17 using budesonide as the inhaled steroid. The fluticasone studies included more than twice as many people, with 21,247 people randomly assigned to the treatments of interest compared with 10,067 in the budesonide studies. Two of the included budesonide studies reported no data that could be used in the analyses and are not included in these numbers (<a href="./references#CD010115-bbs2-0025" title="LaptsevaIM , LaptsevaEA , BorshchevskyVV , GurevichG , KalechitsO . Inhaled budesonide in the management of chronic obstructive pulmonary disease. European Respiratory Journal2002;20 Suppl 38:244s. ">Laptseva 2002</a>; <a href="./references#CD010115-bbs2-0035" title="SenderovitzT , VestboJ , FrandsenJ , MaltbaekN , NorgaardM , NielsenC , et al. Steroid reversibility test followed by inhaled budesonide or placebo in outpatients with stable chronic obstructive pulmonary disease. Respiratory Medicine1999;93(10):715‐8. ">Senderovitz 1999</a>). </p> <p>No studies directly comparing fluticasone with budesonide met the inclusion criteria (either as monotherapy or in their combination preparations), so only indirect evidence was available for these comparisons. </p> <section id="CD010115-sec-0066"> <h5 class="title">Design and duration</h5> <p>All studies were randomised, double‐blind, parallel‐group trials of at least 12 weeks' duration. Most were funded by pharmaceutical companies, predominantly GlaxoSmithKline for the fluticasone studies and AstraZeneca for the budesonide studies. Duration ranged from three to 36 months for both drugs, but mean duration weighted by sample size was longer for the fluticasone studies (fluticasone, 18 months; budesonide, 14 months). A summary of each study and baseline characteristics can be found in <a href="#CD010115-tbl-0003">Table 1</a> and <a href="#CD010115-tbl-0004">Table 2</a>. </p> <div class="table" id="CD010115-tbl-0003"> <table><a class="open-table-viewer open-in-figure-viewer" href="#0">Open in table viewer</a><div class="table-heading"><span class="table-label">Table 1.</span> <span class="table-title">Fluticasone—summary of studies and baseline characteristics</span></div> <tbody> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><b>Study ID</b> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><b>Duration (m)</b> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><b>N Rand</b> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><b>Funder</b> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><b>ICS dose (mcg)</b> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><b>% Male</b> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><b>Mean age</b> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><b>Pack‐years</b> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><b>% pred FEV<sub>1</sub> </b> </p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="9" rowspan="1" valign=""> <p><b>Fluticasone versus placebo (n = 18)</b> </p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><a href="./references#CD010115-bbs2-0003" title="BourbeauJ , ChristodoulopoulosP , MaltaisF , YamauchiY , OlivensteinR , HamidQ . Effect of salmeterol/fluticasone propionate on airway inflammation in COPD: a randomised controlled trial. Thorax2007;62(11):938‐43. ">Bourbeau 2007</a> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>3</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>41</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>GSK</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>1000</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>78</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>65</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>53</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>57</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><a href="./references#CD010115-bbs2-0004" title="BaleG , Martinez‐CamblorP , BurgePS , SorianoJB . Long‐term mortality follow‐up of the ISOLDE participants: causes of death during 13 years after trial completion. Respiratory Medicine2008;102(10):1468‐72. BaleGA , BurgePS , BurgeC , MooreVC . The ISOLDE Study 11‐13 years on: what were the causes of death? [Abstract]. American Thoracic Society International Conference; 2007 May 18‐23; San Francisco. 2007:Poster H42. BriggsAH , Lozano‐OrtegaG , SpencerS , BaleG , SpencerMD , BurgePS . Estimating the cost‐effectiveness of fluticasone propionate for treating chronic obstructive pulmonary disease in the presence of missing data. Value In Health2006;9(4):227‐35. BurgePS , CalverleyPM , JonesPW , SpencerS , AndersonJA . Prednisolone response in patients with chronic obstructive pulmonary disease: results from the ISOLDE study. Thorax2003;58(8):654‐8. BurgePS , CalverleyPM , JonesPW , SpencerS , AndersonJA , MaslenTK . Randomised, double blind, placebo controlled study of fluticasone propionate in patients with moderate to severe chronic obstructive pulmonary disease: the ISOLDE trial. British Medical Journal2000;320(7245):1297‐303. BurgeS , SondhiS , WilliamsMK , WilsonK , EfthimiouJ . An economic evaluation of fluticasone propionate in patients with moderate to severe chronic obstructive pulmonary disease (COPD) from the isolde trial. American Journal of Respiratory and Critical Care Medicine2000;161 Suppl 3:A491. CalverleyPM , BurgePS , SpencerS , AndersonJA , JonesPW . Bronchodilator reversibility testing in chronic obstructive pulmonary disease. Thorax2003;58(8):659‐64. CalverleyPM , SpencerS , WillitsL , BurgePS , JonesPW . Withdrawal from treatment as an outcome in the ISOLDE study of COPD. Chest2003;124(4):1350. D'UrzoAD , CalverleyPMA . Withdrawal of treatment in the ISOLDE study [letter]. Chest2004;125(6):2368. GlaxoSmithKlineF . A multi‐centre, double‐blind, placebo‐controlled, parallel group study of the efficacy and tolerability of long‐term inhaled fluticasone propionate 500 mcg twice daily via a Volumatic Spacer device in patients with non‐asthmatic chronic obstructive pulmonary disease, including an acute oral corticosteroid trial. FLTB3054. www.gsk‐clinicalstudyregister.com/ (accessed 20 May 2013). JaradNA , WedzichaJA , BurgePS , CalverleyPM . An observational study of inhaled corticosteroid withdrawal in stable chronic obstructive pulmonary disease. ISOLDE Study Group. Respiratory Medicine1999;93(3):161‐6. JebrakG . Corticosteroid therapy and chronic obstructive broncho‐pneumopathies: the ISOLDE study. Presse Medicale2000;29(16):1461‐2. JonesPW , WillitsLR , BurgePS , CalverleyPMA . Disease severity and the effect of fluticasone propionate on chronic obstructive pulmonary disease exacerbations. European Respiratory Journal2003;21(1):68‐73. MarchandE . Withdrawal from and study design of the ISOLDE trial [comment]. Chest2004;126(0012‐3692):659. SpencerS , CalverleyPM , BurgePS , JonesPW . Health status deterioration in patients with chronic obstructive pulmonary disease. American Journal of Respiratory and Critical Care Medicine2001;163(1):122‐8. SpencerS , CalverleyPM , BurgePS , JonesPW . Impact of preventing exacerbations on deterioration of health status in COPD. European Respiratory Journal2004;23(5):698‐702. ">Burge 2000</a> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>36</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>740</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>GSK</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>1000</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>75</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>64</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>44</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>50</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><a href="./references#CD010115-bbs2-0006" title="CalverleyP , PauwelsR , VestboJ , JonesP , PrideN , GulsvikA , et al. Combined salmeterol and fluticasone in the treatment of chronic obstructive pulmonary disease: a randomised controlled trial. Lancet2003;361(9356):449‐56. CalverleyPMA , PauwelsR , VestboJ , JonesP , PrideN , GulsvikA , et al. Safety of salmeterol/fluticasone propionate combination in the treatment of chronic obstructive pulmonary disease. European Respiratory Journal2002;20(Suppl 38):242s [P1572]. CalverleyPMA , PauwelsRA , VestboJ , JonesPW , PrideNB , GulsvikA , et al. Clinical improvements with salmeterol / fluticasone propionate combination in differing severities of COPD [A035] [Poster D50]. http://www.abstracts2view.com (accessed 20 April 2012). CalverleyPMA , PauwelsRA , VestboJ , JonesPW , PrideNB , GulsvikA , et al. Salmeterol/fluticasone propionate combination for one year provides greater clinical benefit than its individual components [A98] [Poster 306]. http://www.abstracts‐on‐line.com/abstracts/ATS (accessed 20 April 2012). HunjanMK , ChandlerF . Numbers needed to treat (NNT) to avoid an exacerbation in patients with chronic obstructive pulmonary disease (COPD) using salmeterol/fluticasone propionate combination (SFC) and associated costs [Abstract]. American Thoracic Society 100th International Conference; 2004 May 21‐26; Orlando. 2004:D22 Poster 503. HunjanMK , WilliamsDT . Costs of avoiding exacerbations in patients with chronic obstructive pulmonary disease (COPD) treated with salmeterol/fluticasone propionate combination (Seretide) and salmeterol. European Respiratory Journal2004;24 Suppl 48:291s. HunjanMK , WilliamsDT . Salmeterol/fluticasone propionate combination is clinically effective in avoiding exacerbations in patients with moderate/severe COPD. European Respiratory Journal2004;24 Suppl 48:513s. JonesPW , EdinHM , AndersonJ . Salmeterol/fluticasone propionate combination improves health status in COPD patients.. http://www.abstracts‐on‐line.com/abstracts/ATS (accessed 21 April 2012). JonesPW , StåhlE . Budesonide/formoterol sustains clinically relevant improvements in health status in COPD [Abstract]. European Respiratory Journal2005;26 Suppl 49:Abstract No. 1352. JonesPW , VestboJ , PauwelsRA , CalverleyPMA , AndersonJA , SpencerMD . Informative drop out in COPD studies. Investigation of health status of withdrawals in the TRISTAN study. European Respiratory Society 13th Annual Congress; 2003 Sep 28‐29; Vienna. 2003:P1593. NitschmannS . Inhalational combination therapy in chronic obstructive lung disease. TRISTAN study. German Internist2004;45(6):727‐8. PauwelsRA , CalverlyPMA , VestboJ , JonesPW , PrideN , GulsvikA , et al. Reduction of exacerbations with salmeterol/fluticasone combination 50/500 mcg bd in the treatment of chronic obstructive pulmonary disease. European Respiratory Journal2002;20 Suppl 38:240 [P1569]. PauwelsRA , VestboJ , CalverleyPMA , JonesPW , PrideNB , GulsvikA . Characterization of exacerbations in the TRISTAN study of salmeterol / fluticasone propionate (SFC) combination in moderate to severe COPD. http://www.abstracts2view.com (accessed 20 April 2012). SFCB3024 . A multi‐centre, randomised, double‐blind, parallel group, placebo‐controlled study to compare the efficacy and safety of the salmeterol/FP combination product at a strength of 50/500mcg bd with salmeterol 50mcg bd alone and FP 500mcg bd alone, delivered via the DISKUS™/ACCUHALER™, in the treatment of subjects with chronic obstructive pulmonary disease (COPD) for 12 months. http://ctr.gsk.co.uk (accessed 21 April 2012). SpencerM , BriggsAH , GrossmanRF , RanceL . Development of an economic model to assess the cost effectiveness of treatment interventions for chronic obstructive pulmonary disease. Pharmacoeconomics2005;23(6):619‐37. SpencerMD , KariaN , AndersonJ . The clinical significance of treatment benefits with the salmeterol/fluticasone propionate 50/500mcg combination in COPD. European Respiratory Journal2004;24 Suppl 48:290s. VestboJ , CalverleyPMA , PauwelsR , JonesP , PrideN , GulsvikA , et al. Absence of gender susceptibility to the combination of salmeterol and fluticasone in the treatment of chronic obstructive pulmonary disease. European Respiratory Journal2002;20 Suppl 38:240 [P1570]. VestboJ , PauwelsR , AndersonJA , JonesP , CalverleyP . Early onset of effect of salmeterol and fluticasone propionate in chronic obstructive pulmonary disease. Thorax2005;60(4):301‐4. VestboJ , PauwelsRA , CalverleyPMA , JonesPW , PrideNB , GulsvikA . Salmeterol/fluticasone propionate combination produces improvement in lung function detectable within 24 hours in moderate to severe COPD. http://www.abstracts2view.com (accessed 20 April 2012). VestboJ , SorianoJB , AndersonJA , CalverleyP , PauwelsR , JonesP . Gender does not influence the response to the combination of salmeterol and fluticasone propionate in COPD. Respiratory Medicine2004;98(11):1045‐50. ">Calverley 2003 TRISTAN</a><sup>a</sup> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>12</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>763</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>GSK</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>1000</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>73</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>63</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>43</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>45</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><a href="./references#CD010115-bbs2-0007" title="AllegraL . TORCH study: An invitation to clinical considerations. GIMT ‐ Giornale Italiano delle Malattie del Torace2007;61(1):15‐23. BriggsAH , GlickHA , Lozano‐OrtegaG , SpencerM , CalverleyPM , JonesPW , et al. Is treatment with ICS and LABA cost‐effective for COPD? Multinational economic analysis of the TORCH study. European Respiratory Journal2010;35(3):532‐9. BriggsAH , Lozano‐OrtegaG , SpencerS , BaleG , SpencerMD , BurgePS . Estimating the cost‐effectiveness of fluticasone propionate for treating chronic obstructive pulmonary disease in the presence of missing data. Value in Health2006;9(4):227‐35. CalverleyP , CelliB , AndersonJ , FergusonG , JenkinsC , JonesP , et al. Salmeterol/fluticasone propionate combination (SFC) improves survival in COPD over three years: on‐treatment analysis from the TORCH study [Abstract]. American Thoracic Society International Conference; 2009 May 15‐20; San Diego. 2009:A6191[Poster #219]. CalverleyP , CelliB , AndersonJA , FergusonGT , JenkinsC , JonesPW , et al. The TOwards a Revolution in COPD Health (TORCH) study: salmeterol/fluticasone propionate improves survival in COPD over three years [Abstract]. Respirology2006;11 Suppl 5:A149 [PS‐3‐8]. CalverleyPM , AndersonJA , CelliB , FergusonGT , JenkinsC , JonesPW , et al. Salmeterol and fluticasone propionate and survival in chronic obstructive pulmonary disease. New England Journal of Medicine2007;356(8):775‐89. CalverleyPM , AndersonJA , CelliB , FergusonGT , JenkinsC , Jones PW et al and TORCH Investigators. Cardiovascular events in patients with COPD: TORCH study results. Thorax2010;65(8):719‐25. CalverleyPM , CelliB , AndersonJA , FergusonGT , JenkinsC , JonesPW , et al. The TOwards a Revolution in COPD Health (TORCH) study: fluticasone propionate /salmeterol improves survival in COPD over three years. Chest2006;130(4):122s. CalverleyPMA , CelliB , AndersenJA , FergusonGT , JenkinsC , JonesPW , et al. The TORCH (TOwards a Revolution in COPD Health) study salmeterol/fluticasone propionate (SFC) improves survival in COPD over three years. European Respiratory Journal2006;28 Suppl 50:34. CelliB , CalverleyPM , AndersonJA , FergusonGT , JenkinsC , JonesP , et al. The TOwards a Revolution in COPD HEalth (TORCH) Study: salmeterol/fluticasone propionate reduces the rate of exacerbations over three years. Respirology2006;11 Suppl 5:A140. CelliB , CalverleyPM , AndersonJA , FergusonGT , JenkinsC , JonesPW , et al. The TOwards a Revolution in COPD Health (TORCH) study: fluticasone propionate/salmeterol reduces the rate of exacerbations over 3 years [Abstract]. Chest2006;130(4):177s. CelliB , CalverleyPMA , AndersonJA , FergusonGT , JenkinsC , JonesPW , et al. The TORCH (TOwards a Revolution in COPD Health) study salmeterol/fluticasone propionate (SFC) improves health status reduces exacerbations and improves lung function over three years [Abstract]. European Respiratory Journal2006;28 Suppl 50:34s [E312]. CelliB , EmmettA , CraterG , KalbergC . Fluticasone propionate/salmeterol (FSC) improves the inspiratory to total lung capacity ratio (IC/TLC) and exercise endurance time in patients with COPD. European Respiratory Society 16th Annual Congress; 2006 Sep 2‐6; Munich. 2006:A320 (Poster 323). CelliB , FergusonGT , AndersonJA , JenkinsCR , JonesPW , VestboJ , et al. Salmeterol/fluticasone propionate (SFC) improves lung function and reduces the rate of decline over three years in the TORCH survival study [Abstract]. American Thoracic Society International Conference; 2007 May 18‐23; San Francisco. 2007:A763. CelliB , VestboJ , JenkinsCR , JonesPW , FergusonGT , CalverleyPMA , et al. Sex differences in mortality and clinical expressions of patients with chronic obstructive pulmonary disease: the TORCH experience. American Journal of Respiratory and Critical Care Medicine2011;183(3):317‐22. CelliBR , ThomasNE , AndersonJA , FergusonGT , JenkinsCR , JonesPW , et al. Effect of pharmacotherapy on rate of decline of lung function in chronic obstructive pulmonary disease: results from the TORCH study. American Journal of Respiratory and Critical Care Medicine2008;178(4):332‐8. CelliD , EmmettA , CraterG , KalbergC . Salmeterol/fluticasone propionate (SFC) improves the inspiratory to total lung capacity ratio (IC/TLC) and exercise endurance time in patients with COPD. European Respiratory Journal2006;28 Suppl 50:764 [4395]. CorhayJL , LouisR . Clinical study of the month: the TORCH study (TOwards a Revolution in COPD Health) [L'étude clinique du mois. L'étude TORCH (TOwards a Revolution in COPD Health): vers une revolution de la santé des patients souffrant de BPCO]. Revue Medicale de Liege2007;62(4):230‐4. FergusonGT , CalverleyPM , AndersonJA , CelliB , JenkinsC , JonesPW , et al. The TOwards a Revolution in COPD Health (TORCH) study: fluticasone propionate/salmeterol is well tolerated in patients with COPD over 3 years [Abstract]. Chest2006;130(4):178s. FergusonGT , CalverleyPM , AndersonJA , CelliB , JenkinsCR , JonesPW , et al. Effect of salmeterol/fluticasone propionate (SFC) on bone mineral density (BMD) and eye disorders over three years in the TORCH trial [Abstract]. American Thoracic Society International Conference; 2007 May 18‐23; San Francisco. 2007:A763. FergusonGT , CalverleyPM , AndersonJA , JenkinsCR , CelliB , et al. Prevalence and progression of osteoporosis in patients with COPD results from the towards a revolution in COPD health study. Chest2009;136(6):1456‐65. FergusonGT , CalverleyPMA , AndersonJA , et al. The TORCH (TOwards a Revolution in COPD Health) study: salmeterol/fluticasone propionate (SFC) improves survival in COPD over three years. European Respiratory Journal2006;28 Suppl 50:34s. GlickH , BriggsA , Lozano‐OrtegaG , SpencerM , VestboJ , CalverleyP . Is treatment with ICS/LABA combination good value for money in COPD? Evidence from the TORCH study [Abstract]. American Thoracic Society International Conference; 2007 May 18‐23; San Francisco. 2007:[C97]. JenkinsC , CelliB , AndersonJ , FergusonG , CalverleyP , JonesP , et al. Salmeterol/fluticasone propionate (SFC) is efficacious in GOLD stage II COPD patients: analysis from the TORCH study [Abstract]. American Thoracic Society International Conference; May 15‐20; San Diego. 2009:A6186 [Poster #213]. JenkinsCR , CelliB , AndersonJA , FergusonGT , JonesPW , VestboJ , et al. Seasonality and determinants of moderate and severe COPD exacerbations in the TORCH study. European Respiratory Journal2012;39:38‐45. JenkinsCR , CelliB , AndersonJA , FergusonGT , JonesPW , VestboJ , et al. The TORCH survival study: consistent efficacy results seen in geographic regions in a multi‐national study [Abstract]. American Thoracic Society International Conference; May 18‐23; San Francisco. 2007:[C97]. JenkinsCR , JonesPW , CalverleyPM , CelliB , AndersonJA , FergusonGT , et al. Efficacy of salmeterol/fluticasone propionate by GOLD stage of chronic obstructive pulmonary disease: analysis from the randomised, placebo‐controlled TORCH study. Respiratory Research2009;10:59. JonesPW , AndersonJA , CalverleyPM , CelliBR , FergusonGT , JenkinsC , et al. Health status in the TORCH study of COPD: treatment efficacy and other determinants of change. Respiratory Research2011;12:71. JonesPW , CalverleyPM , CelliB , AndersonJA , FergusonGT , JenkinsC , et al. The TOwards a Revolution in COPD Health (TORCH) study: fluticasone propionate/salmeterol improves and sustains health status in COPD over 3 years. Chest2006;130(4):177s. JonesPW , VestboJ , AndersonJA , CelliB , FergusonGT , JenkinsCR , et al. Informative withdrawal in a COPD study. An example from the TORCH Study [Abstract]. American Thoracic Society International Conference; 2007 May 18‐23; San Francisco. 2007:[C97]. KeeneON , VestboJ , AndersonJA , CalverleyPM , CelliB , FergusonGT , et al. Methods for therapeutic trials in COPD: Lessons from the TORCH trial. European Respiratory Journal2009;34(5):1018‐23. McDonoughC , BlanchardAR . TORCH study results: pharmacotherapy reduces lung function decline in patients with chronic obstructive pulmonary disease. Hospital Practice2010;38(2):92‐3. McGarveyLP , JohnM , AndersonJA , ZvarichM , WiseRA , Committee TCE et al. Ascertainment of cause‐specific mortality in COPD: operations of the TORCH Clinical Endpoint Committee. Thorax2007;62(5):411‐5. MehtaRS , KathmanSJ , Daley‐YatesPT , CahnT , BeeraheeM , KunkaRL , et al. Pharmacokinetics and pharmacodynamics in COPD patients following long‐term twice‐daily treatment with salmeterol/fluticasone propionate (SFC) 50/500mg and the individual components [Abstract]. American Thoracic Society International Conference; 2007 May 18‐23; San Francisco. 2007:Poster #A41. SCO30003 . A multi‐centre, randomised, double‐blind, parallel group, placebo‐controlled study to investigate the long‐term effects of salmeterol/fluticasone propionate (SERETIDE®/VIANI®/ADVAIR®) 50/500mcg bd, salmeterol 50mcg bd and fluticasone propionate 500mcg bd, all delivered via the DISKUS®/ACCUHALER® inhaler, on the survival of subjects with chronic obstructive pulmonary disease (COPD) over 3 years of treatment. www.ctr.gsk.co.uk (accessed 21 April 2012). SacchettaA . Long term therapy and outcome of chronic obstructive pulmonary disease with or without co‐morbidity: The TORCH Study. Italian Journal of Medicine2008;2(3):11‐5. VestboJ , AndersonJA , CalverleyPM , CelliB , FergusonGT , JenkinsC , et al. Bias due to withdrawal in long‐term randomised trials in COPD: Evidence from the TORCH study. Clinical Respiratory Journal2011;5(1):44‐9. VestboJ , TORCH Study Group. The TORCH (TOwards a Revolution in COPD Health) survival study protocol. European Respiratory Journal2004;24(2):206‐10. ">Calverley 2007 TORCH</a><sup>a</sup> </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>36</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>3097</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>GSK</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>1000</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>76</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>65</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>49</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>44</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><a href="./references#CD010115-bbs2-0009" title="ChoudhuryAB , DawsonCM , KilvingtonHE , EldridgeHE , JamesWY , WedzichaJA , et al. Withdrawal of inhaled corticosteroids in people with chronic obstructive pulmonary disease (COPD) in primary care ‐ a randomised controlled trial [Abstract]. European Respiratory Journal2005;26 Suppl 49:Abstract No. 1328. ChoudhuryAB , DawsonCM , KilvingtonHE , EldridgeS , JamesWY , WedzichaJA , et al. Withdrawal of inhaled corticosteroids in people with COPD in primary care: a randomised controlled trial. Respiratory Research2007;8:93. ">Choudhury 2005</a> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>12</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>260</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Indep.</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>1000</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>52</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>67</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>39</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>54</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><a href="./references#CD010115-bbs2-0015" title="FLTA3025 . A randomized, double‐blind, parallel‐group, comparative trial of inhaled fluticasone propionate 250mcg BID, 500mcg BID, and placebo BID via the DISKUS in subjects with chronic obstructive pulmonary disease (COPD). GlaxoSmithKline Clinical Trial Register (accessed 18 April 2012). ">GSK FLTA3025 2005</a> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>6</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>640</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>GSK</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>500, 1000</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>69</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>64</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>‐</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>‐</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><a href="./references#CD010115-bbs2-0017" title="Evaluation of Novel Endpoints in Subjects with Chronic Obstructive Pulmonary Disease(COPD) in a Randomized, Double‐Blind, Placebo‐Controlled Study of Treatment with FluticasonePropionate/Salmeterol 500/50mcg combination and its individual components, FluticasonePropionate 500mcg and Salmeterol 50mcg. http://www.gsk‐clinicalstudyregister.com/ 2008 (accessed 19 April 2012). SCO104925 . Evaluation of Novel Endpoints in Subjects with Chronic Obstructive Pulmonary Disease(COPD) in a Randomized, Double‐Blind, Placebo‐Controlled Study of Treatment with FluticasonePropionate/Salmeterol 500/50mcg combination and its individual components, FluticasonePropionate 500mcg and Salmeterol 50mcg. http:ctr.gsk.co.uk (accessed 19 April 2012). ">GSK SCO104925 2008</a><sup>a</sup> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>3</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>84</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>GSK</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>1000</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>77</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>64</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>‐</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>‐</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><a href="./references#CD010115-bbs2-0018" title="SCO30002 . A multi‐centre, randomised, double‐blind, parallel group, placebo‐controlled study to compare the efficacy and safety of inhaled salmeterol/fluticasone propionate combination product 25/250 µg two puffs bd and fluticasone propionate 250µg two puffs bd alone, all administered via metered dose inhalers (MDI), in the treatment of subjects with chronic obstructive pulmonary disease (COPD) for 52 weeks. GlaxoSmithKline Clinical Trial Register (accessed 21 April 2012). ">GSK SCO30002 2005</a> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>12</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>256</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>GSK</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>1000</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>82</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>65</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>‐</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>‐</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><a href="./references#CD010115-bbs2-0020" title="HananiaNA , DarkenP , HorstmanD , ReisnerC , LeeB , DavisS , et al. The efficacy and safety of fluticasone propionate (250 mcg)/salmeterol (50 mcg) combined in the Diskus inhaler for the treatment of COPD. Chest2003;124(3):834‐43. HananiaNA , KnobilK , WatkinsM , WireP , YatesJ , DarkenP . Salmeterol and fluticasone propionate therapy administered by a single Diskus in patients with COPD. Chest2002:S129. HananiaNA , RamsdellJ , PayneK , DavisS , HorstmanD , LeeB , et al. Improvements in airflow and dyspnoea in COPD patients following 24 weeks treatment with salmeterol 50mcg and fluticasone propionate 250mcg alone or in combination via the Diskus. American Journal of Respiratory and Critical Care Medicine2001;163 Suppl 5:A279. HorstmanD , DarkenP , DavisS , LeeB . Improvements in FEV1 and symptoms in poorly reversible COPD patients following treatment with salmeterol 50mcg/fluticasone propionate 250mcg combination [Abstract]. European Respiratory Journal2003;22 Suppl 45:P434. MahlerDA , DarkenP , BrownCP , KnobilK . Predicting lung function responses to combination therapy in chronic obstructive pulmonary disease (COPD) [Abstract]. National COPD Conference; 2003 Nov 14‐15; Arlington. 2003:1081. MahlerDA , DarkenP , BrownCP , KnobilK . Predicting lung function responses to salmeterol/fluticasone propionate combination therapy in COPD [Abstract]. European Respiratory Journal2003;22 Suppl 45:P429. SFCA3007 . A randomized, double‐blind, placebo‐controlled, parallel‐group trial evaluating the safety and efficacy of the DISKUS formulations of salmeterol (SAL) 50mcg BID and fluticasone propionate (FP) 250mcg BID individually and in combination as salmeterol 50mcg/fluticasone propionate 250mcg BID (SFC 50/250) compared to placebo in COPD subjects. http://ctr.gsk.co.uk (accessed 20 April 2012). SpencerM , WireP , LeeB , ChangCN , DarkenP , HorstmanD . Patients with COPD using salmeterol/fluticasone propionate combination therapy experience improved quality of life. European Respiratory Journal2003;22 Suppl 45:51s. SpencerMD , KariaN , AndersonJ . The clinical significance of treatment benefits with the salmeterol/fluticasone propionate 50/500mcg combination in COPD. European Respiratory Journal2004;24 Suppl 48:290s. ">Hanania 2003</a><sup>a</sup> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>6</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>368</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>GSK</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>500</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>63</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>64</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>57</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>42</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><a href="./references#CD010115-bbs2-0021" title="GizyckiMJ , HattotuwaKL , BarnesN , JefferyPK . Effects of fluticasone propionate on inflammatory cells in COPD: an ultrastructural examination of endobronchial biopsy tissue. Thorax2002;57(9):799‐803. HattotuwaKL , GizyckiMJ , AnsariTW , JefferyPK , BarnesNC . The effects of inhaled fluticasone on airway inflammation in chronic obstructive pulmonary disease. American Journal of Respiratory and Critical Care Medicine2002;165(12):1592‐9. ">Hattotuwa 2002</a> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>3</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>36</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>GSK</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>1000</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>87</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>65</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>63</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>46</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><a href="./references#CD010115-bbs2-0023" title="KerwinEM , Scott‐WilsonC , SanfordL , RennardS , AgustiA , BarnesN , et al. A randomised trial of fluticasone furoate/vilanterol (50/25 mug; 100/25 mug) on lung function in COPD. Respiratory Medicine2013; Vol. 107, issue 4:560‐9. [0954‐6111] KerwinEM , Scott‐WilsonC , SanfordL , RennardSI , AgustiA , BarnesN , et al. Lung function effects and safety of fluticasone furoate (FF)/vilanterol (VI) in patients with COPD: Low‐mid dose assessment [Abstract]. European Respiratory Society Annual Congress; Sep 1‐5; Vienna. 2012; Vol. 40, issue Suppl 56:545s [3082]. ">Kerwin 2013</a><sup>a,b</sup> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>6</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>413</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>GSK</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>100</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>66</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>62</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>46</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>42</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><a href="./references#CD010115-bbs2-0024" title="KunzLIZ , StrebusJ , BudulacSE , LapperreTS , SterkPJ , PostmaDS , et al. Inhaled Steroids Modulate Extracellular Matrix Composition in Bronchial Biopsies of COPD Patients: A Randomized, Controlled Trial. PloS one2013; Vol. 8, issue 5:e63430. LapperreTS , Snoeck‐StrobandJB , GosmanMM , JansenDF , vanSchadewijkA , ThiadensHA , et al. Effect of fluticasone with and without salmeterol on pulmonary outcomes in chronic obstructive pulmonary disease: a randomized trial. Annals of Internal Medicine2009;151(8):517‐27. ">Lapperre 2009</a> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>30</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>55</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>GSK</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>1000</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>86</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>60</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>43</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>55</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><a href="./references#CD010115-bbs2-0026" title="MahlerDA , DarkenP , BrownCP , KnobilK . Predicting lung function responses to combination therapy in chronic obstructive pulmonary disease (COPD). http://www.abstracts2view.com (accessed 15 April 2012). MahlerDA , WireP , HorstmanD , ChangCN , YatesJ , FischerT , et al. Effectiveness of fluticasone propionate and salmeterol combination delivered via the Diskus device in the treatment of chronic obstructive pulmonary disease. American Journal of Respiratory and Critical Care Medicine2002;166(8):1084‐91. SFCA3006 . A randomized, double‐blind, placebo‐controlled, parallel‐group trial evaluating the safety and efficacy of the DISKUS formulations of salmeterol (SAL) 50mcg BID and fluticasone propionate (FP) 500mcg BID individually and in combination as salmeterol 50mcg/fluticasone propionate 500mcg BID (SFC 50/500) compared to placebo in COPD subjects. http://ctr.gsk.co.uk (accessed 17 April 2012). SpencerM , WireP , LeeB , ChangCN , DarkenP , HorstmanD . Patients with COPD using salmeterol/fluticasone propionate combination therapy experience improved quality of life. European Respiratory Journal2003;22 Suppl 45:51. SpencerMD , AndersonJA . Salmeterol/fluticasone combination produces clinically important benefits in dyspnoea and fatigue [Abstract]. American Thoracic Society 2005 International Conference; 2005 May 20‐25; San Diego. 2005:B93 [Poster 308]. SpencerMD , KariaN , AndersonJ . The clinical significance of treatment benefits with the salmeterol/fluticasone propionate 50/500mcg combination in COPD. European Respiratory Journal2004;24 Suppl 48:290. ">Mahler 2002</a><sup>a</sup> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>6</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>349</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>GSK</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>1000</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>66</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>65</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>55</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>41</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><a href="./references#CD010115-bbs2-0027" title="MartinezF , BosciaJ , FeldmanG , Scott‐WilsonC , KilbrideS , FabbriL , et al. Lung function effects and safety of fluticasone furoate (FF)/vilanterol (VI) in patients with COPD: mid‐high dose assessment [Abstract]. European Respiratory Society Annual Congress, Vienna, Austria, September 1‐5. 2012; Vol. 40, issue Suppl 56:527s [P2887]. MartinezFJ , BosciaJ , FeldmanG , Scott‐WilsonC , KilbrideS , FabbriL , et al. Fluticasone furoate/vilanterol (100/25; 200/25 mug) improves lung function in COPD: a randomised trial. Respiratory Medicine2013;107(4):550‐9. [0954‐6111] ">Martinez 2013</a><sup>a,b</sup> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>6</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>612</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>GSK</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>100, 200</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>72</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>62</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>43</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>48</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><a href="./references#CD010115-bbs2-0030" title="FLIT97 . A multi‐centre, randomised, double‐blind, parallel group study of the efficacy and safety of inhaled fluticasone propionate 1000 µg daily with placebo in chronic obstructive pulmonary disease. http://ctr.gsk.co.uk (accessed 20 April 2012). PaggiaroPL , DahleR , BakranI , FrithL , HollingworthK , EfthimiouJ . Multicentre randomised placebo‐controlled trial of inhaled fluticasone propionate in patients with chronic obstructive pulmonary disease. International COPD Study Group. Lancet1998;351(9105):773‐80. ">Paggiaro 1998</a> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>6</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>281</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>‐</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>1000</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>74</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>63</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>‐</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>57</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><a href="./references#CD010115-bbs2-0034" title="ChavannesNH , SchermerTR , WoutersEF , AkkermansRP , DekhuijzenRP , MurisJW , et al. Predictive value and utility of oral steroid testing for treatment of COPD in primary care: the COOPT study. International Journal of COPD2009;4:431‐6. SchermerT , ChavannesN , DekhuijzenR , WoutersE , MurisJ , AkkermansR , et al. Fluticasone and N‐acetylcysteine in primary care patients with COPD or chronic bronchitis. Respiratory Medicine2009;103(4):542‐51. ">Schermer 2009</a> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>36</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>190</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Indep.</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>1000</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>71</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>59</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>28</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>64</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><a href="./references#CD010115-bbs2-0040" title="vanGrunsvenP , SchermerT , AkkermansR , AlbersM , van denBoomG , vanSchayckO , et al. Short‐ and long‐term efficacy of fluticasone propionate in subjects with early signs and symptoms of chronic obstructive pulmonary disease. Results of the DIMCA study. Respiratory Medicine2003;97(12):1303‐12. ">van Grunsven 2003</a> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>24</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>48</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>GSK</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>500</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>52</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>47</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>9</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>97</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><a href="./references#CD010115-bbs2-0041" title="VerhoevenGT , GarreldsIM , HoogstedenHC , ZijlstraFJ . Effects of fluticasone propionate inhalation on levels of arachidonic acid metabolites in patients with chronic obstructive pulmonary disease. Mediators of Inflammation2001;10(1):21‐6. VerhoevenGT , HegmansJP , MulderPG , BogaardJM , HoogstedenHC , PrinsJB . Effects of fluticasone propionate in COPD patients with bronchial hyper‐responsiveness. Thorax2002;57(8):694‐700. VerhoevenGT , WijkhuijsAJ , HooijkaasH , HoogstedenHC , SluiterW . Effect of an inhaled glucocorticoid on reactive oxygen species production by bronchoalveolar lavage cells from smoking COPD patients. Mediators of Inflammation2000;9(2):109‐13. ">Verhoeven 2002</a> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>6</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>23</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>GSK</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>1000</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>82</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>55</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>26</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>63</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""></td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><b>WM 22 m</b> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><b>459</b> </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><b>‐</b> </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><b>‐</b> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><b>72</b> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><b>62</b> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><b>43</b> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><b>54</b> </p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="9" rowspan="1" valign=""> <p><b>Fluticasone/LABA combination versus LABA monotherapy (n = 15)</b> </p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><a href="./references#CD010115-bbs2-0001" title="AnzuetoA , FergusonGT , FeldmanG , ChinskyK , SeibertA , EmmettA , et al. Effect of fluticasone propionate/salmeterol (250/50) on COPD exacerbations and impact on patient outcomes. Journal of Chronic Obstructive Pulmonary Disease2009;6(5):320‐9. DalalAA , BlanchetteCM , PetersenH , St. CharlesM . Cost‐effectiveness of fluticasone propionate/salmeterol (250/50mcg) compared to salmeterol (50mcg) in patients with chronic obstructive pulmonary disease: economic evaluation of study SCO100250 [Abstract]. American Thoracic Society International Conference; 2009 May 15‐20; San Diego. 2009:A1502 [Poster K54]. DiSantostefanoRL , LiH , RubinDB , StempelDA . Which patients with chronic obstructive pulmonary disease benefit from the addition of an inhaled corticosteroid to their bronchodilator? A cluster analysis. BMJ Open2013;3(4):e001838. [DOI: 10.1136/bmjopen‐2012‐001838] GlaxoSmithKline . A Randomized, Double‐Blind, Parallel‐Group, 52‐Week Study to Compare the Effect of Fluticasone Propionate/Salmeterol DISKUS 250/50mcg BID with Salmeterol DISKUS 50mcg BID on the Annual Rate of Moderate/Severe Exacerbations in Subjects with Chronic Obstructive Pulmonary Disease (COPD). SCO100250. www.gsk‐clinicalstudyregister.com/ (accessed 25 May 2013). GlaxoSmithKline . A randomized, double‐blind, parallel‐group, 52‐week study to compare the effect of fluticasone propionate/salmeterol DISKUS 250/50mcg bid with salmeterol DISKUS 50mcg bid on the annual rate of moderate/severe exacerbations in subjects with chronic obstructive pulmonary disease (COPD). www.gsk‐clinicalstudyregister.com/ (accessed 8 April 2013). ">Anzueto 2009</a> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>12</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>797</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>GSK</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>500</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>54</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>65</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>57</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>34</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><a href="./references#CD010115-bbs2-0006" title="CalverleyP , PauwelsR , VestboJ , JonesP , PrideN , GulsvikA , et al. Combined salmeterol and fluticasone in the treatment of chronic obstructive pulmonary disease: a randomised controlled trial. Lancet2003;361(9356):449‐56. CalverleyPMA , PauwelsR , VestboJ , JonesP , PrideN , GulsvikA , et al. Safety of salmeterol/fluticasone propionate combination in the treatment of chronic obstructive pulmonary disease. European Respiratory Journal2002;20(Suppl 38):242s [P1572]. CalverleyPMA , PauwelsRA , VestboJ , JonesPW , PrideNB , GulsvikA , et al. Clinical improvements with salmeterol / fluticasone propionate combination in differing severities of COPD [A035] [Poster D50]. http://www.abstracts2view.com (accessed 20 April 2012). CalverleyPMA , PauwelsRA , VestboJ , JonesPW , PrideNB , GulsvikA , et al. Salmeterol/fluticasone propionate combination for one year provides greater clinical benefit than its individual components [A98] [Poster 306]. http://www.abstracts‐on‐line.com/abstracts/ATS (accessed 20 April 2012). HunjanMK , ChandlerF . Numbers needed to treat (NNT) to avoid an exacerbation in patients with chronic obstructive pulmonary disease (COPD) using salmeterol/fluticasone propionate combination (SFC) and associated costs [Abstract]. American Thoracic Society 100th International Conference; 2004 May 21‐26; Orlando. 2004:D22 Poster 503. HunjanMK , WilliamsDT . Costs of avoiding exacerbations in patients with chronic obstructive pulmonary disease (COPD) treated with salmeterol/fluticasone propionate combination (Seretide) and salmeterol. European Respiratory Journal2004;24 Suppl 48:291s. HunjanMK , WilliamsDT . Salmeterol/fluticasone propionate combination is clinically effective in avoiding exacerbations in patients with moderate/severe COPD. European Respiratory Journal2004;24 Suppl 48:513s. JonesPW , EdinHM , AndersonJ . Salmeterol/fluticasone propionate combination improves health status in COPD patients.. http://www.abstracts‐on‐line.com/abstracts/ATS (accessed 21 April 2012). JonesPW , StåhlE . Budesonide/formoterol sustains clinically relevant improvements in health status in COPD [Abstract]. European Respiratory Journal2005;26 Suppl 49:Abstract No. 1352. JonesPW , VestboJ , PauwelsRA , CalverleyPMA , AndersonJA , SpencerMD . Informative drop out in COPD studies. Investigation of health status of withdrawals in the TRISTAN study. European Respiratory Society 13th Annual Congress; 2003 Sep 28‐29; Vienna. 2003:P1593. NitschmannS . Inhalational combination therapy in chronic obstructive lung disease. TRISTAN study. German Internist2004;45(6):727‐8. PauwelsRA , CalverlyPMA , VestboJ , JonesPW , PrideN , GulsvikA , et al. Reduction of exacerbations with salmeterol/fluticasone combination 50/500 mcg bd in the treatment of chronic obstructive pulmonary disease. European Respiratory Journal2002;20 Suppl 38:240 [P1569]. PauwelsRA , VestboJ , CalverleyPMA , JonesPW , PrideNB , GulsvikA . Characterization of exacerbations in the TRISTAN study of salmeterol / fluticasone propionate (SFC) combination in moderate to severe COPD. http://www.abstracts2view.com (accessed 20 April 2012). SFCB3024 . A multi‐centre, randomised, double‐blind, parallel group, placebo‐controlled study to compare the efficacy and safety of the salmeterol/FP combination product at a strength of 50/500mcg bd with salmeterol 50mcg bd alone and FP 500mcg bd alone, delivered via the DISKUS™/ACCUHALER™, in the treatment of subjects with chronic obstructive pulmonary disease (COPD) for 12 months. http://ctr.gsk.co.uk (accessed 21 April 2012). SpencerM , BriggsAH , GrossmanRF , RanceL . Development of an economic model to assess the cost effectiveness of treatment interventions for chronic obstructive pulmonary disease. Pharmacoeconomics2005;23(6):619‐37. SpencerMD , KariaN , AndersonJ . The clinical significance of treatment benefits with the salmeterol/fluticasone propionate 50/500mcg combination in COPD. European Respiratory Journal2004;24 Suppl 48:290s. VestboJ , CalverleyPMA , PauwelsR , JonesP , PrideN , GulsvikA , et al. Absence of gender susceptibility to the combination of salmeterol and fluticasone in the treatment of chronic obstructive pulmonary disease. European Respiratory Journal2002;20 Suppl 38:240 [P1570]. VestboJ , PauwelsR , AndersonJA , JonesP , CalverleyP . Early onset of effect of salmeterol and fluticasone propionate in chronic obstructive pulmonary disease. Thorax2005;60(4):301‐4. VestboJ , PauwelsRA , CalverleyPMA , JonesPW , PrideNB , GulsvikA . Salmeterol/fluticasone propionate combination produces improvement in lung function detectable within 24 hours in moderate to severe COPD. http://www.abstracts2view.com (accessed 20 April 2012). VestboJ , SorianoJB , AndersonJA , CalverleyP , PauwelsR , JonesP . Gender does not influence the response to the combination of salmeterol and fluticasone propionate in COPD. Respiratory Medicine2004;98(11):1045‐50. ">Calverley 2003 TRISTAN</a><sup>a</sup> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>12</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>731</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>GSK</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>1000</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>73</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>63</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>43</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>45</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><a href="./references#CD010115-bbs2-0007" title="AllegraL . TORCH study: An invitation to clinical considerations. GIMT ‐ Giornale Italiano delle Malattie del Torace2007;61(1):15‐23. BriggsAH , GlickHA , Lozano‐OrtegaG , SpencerM , CalverleyPM , JonesPW , et al. Is treatment with ICS and LABA cost‐effective for COPD? Multinational economic analysis of the TORCH study. European Respiratory Journal2010;35(3):532‐9. BriggsAH , Lozano‐OrtegaG , SpencerS , BaleG , SpencerMD , BurgePS . Estimating the cost‐effectiveness of fluticasone propionate for treating chronic obstructive pulmonary disease in the presence of missing data. Value in Health2006;9(4):227‐35. CalverleyP , CelliB , AndersonJ , FergusonG , JenkinsC , JonesP , et al. Salmeterol/fluticasone propionate combination (SFC) improves survival in COPD over three years: on‐treatment analysis from the TORCH study [Abstract]. American Thoracic Society International Conference; 2009 May 15‐20; San Diego. 2009:A6191[Poster #219]. CalverleyP , CelliB , AndersonJA , FergusonGT , JenkinsC , JonesPW , et al. The TOwards a Revolution in COPD Health (TORCH) study: salmeterol/fluticasone propionate improves survival in COPD over three years [Abstract]. Respirology2006;11 Suppl 5:A149 [PS‐3‐8]. CalverleyPM , AndersonJA , CelliB , FergusonGT , JenkinsC , JonesPW , et al. Salmeterol and fluticasone propionate and survival in chronic obstructive pulmonary disease. New England Journal of Medicine2007;356(8):775‐89. CalverleyPM , AndersonJA , CelliB , FergusonGT , JenkinsC , Jones PW et al and TORCH Investigators. Cardiovascular events in patients with COPD: TORCH study results. Thorax2010;65(8):719‐25. CalverleyPM , CelliB , AndersonJA , FergusonGT , JenkinsC , JonesPW , et al. The TOwards a Revolution in COPD Health (TORCH) study: fluticasone propionate /salmeterol improves survival in COPD over three years. Chest2006;130(4):122s. CalverleyPMA , CelliB , AndersenJA , FergusonGT , JenkinsC , JonesPW , et al. The TORCH (TOwards a Revolution in COPD Health) study salmeterol/fluticasone propionate (SFC) improves survival in COPD over three years. European Respiratory Journal2006;28 Suppl 50:34. CelliB , CalverleyPM , AndersonJA , FergusonGT , JenkinsC , JonesP , et al. The TOwards a Revolution in COPD HEalth (TORCH) Study: salmeterol/fluticasone propionate reduces the rate of exacerbations over three years. Respirology2006;11 Suppl 5:A140. CelliB , CalverleyPM , AndersonJA , FergusonGT , JenkinsC , JonesPW , et al. The TOwards a Revolution in COPD Health (TORCH) study: fluticasone propionate/salmeterol reduces the rate of exacerbations over 3 years [Abstract]. Chest2006;130(4):177s. CelliB , CalverleyPMA , AndersonJA , FergusonGT , JenkinsC , JonesPW , et al. The TORCH (TOwards a Revolution in COPD Health) study salmeterol/fluticasone propionate (SFC) improves health status reduces exacerbations and improves lung function over three years [Abstract]. European Respiratory Journal2006;28 Suppl 50:34s [E312]. CelliB , EmmettA , CraterG , KalbergC . Fluticasone propionate/salmeterol (FSC) improves the inspiratory to total lung capacity ratio (IC/TLC) and exercise endurance time in patients with COPD. European Respiratory Society 16th Annual Congress; 2006 Sep 2‐6; Munich. 2006:A320 (Poster 323). CelliB , FergusonGT , AndersonJA , JenkinsCR , JonesPW , VestboJ , et al. Salmeterol/fluticasone propionate (SFC) improves lung function and reduces the rate of decline over three years in the TORCH survival study [Abstract]. American Thoracic Society International Conference; 2007 May 18‐23; San Francisco. 2007:A763. CelliB , VestboJ , JenkinsCR , JonesPW , FergusonGT , CalverleyPMA , et al. Sex differences in mortality and clinical expressions of patients with chronic obstructive pulmonary disease: the TORCH experience. American Journal of Respiratory and Critical Care Medicine2011;183(3):317‐22. CelliBR , ThomasNE , AndersonJA , FergusonGT , JenkinsCR , JonesPW , et al. Effect of pharmacotherapy on rate of decline of lung function in chronic obstructive pulmonary disease: results from the TORCH study. American Journal of Respiratory and Critical Care Medicine2008;178(4):332‐8. CelliD , EmmettA , CraterG , KalbergC . Salmeterol/fluticasone propionate (SFC) improves the inspiratory to total lung capacity ratio (IC/TLC) and exercise endurance time in patients with COPD. European Respiratory Journal2006;28 Suppl 50:764 [4395]. CorhayJL , LouisR . Clinical study of the month: the TORCH study (TOwards a Revolution in COPD Health) [L'étude clinique du mois. L'étude TORCH (TOwards a Revolution in COPD Health): vers une revolution de la santé des patients souffrant de BPCO]. Revue Medicale de Liege2007;62(4):230‐4. FergusonGT , CalverleyPM , AndersonJA , CelliB , JenkinsC , JonesPW , et al. The TOwards a Revolution in COPD Health (TORCH) study: fluticasone propionate/salmeterol is well tolerated in patients with COPD over 3 years [Abstract]. Chest2006;130(4):178s. FergusonGT , CalverleyPM , AndersonJA , CelliB , JenkinsCR , JonesPW , et al. Effect of salmeterol/fluticasone propionate (SFC) on bone mineral density (BMD) and eye disorders over three years in the TORCH trial [Abstract]. American Thoracic Society International Conference; 2007 May 18‐23; San Francisco. 2007:A763. FergusonGT , CalverleyPM , AndersonJA , JenkinsCR , CelliB , et al. Prevalence and progression of osteoporosis in patients with COPD results from the towards a revolution in COPD health study. Chest2009;136(6):1456‐65. FergusonGT , CalverleyPMA , AndersonJA , et al. The TORCH (TOwards a Revolution in COPD Health) study: salmeterol/fluticasone propionate (SFC) improves survival in COPD over three years. European Respiratory Journal2006;28 Suppl 50:34s. GlickH , BriggsA , Lozano‐OrtegaG , SpencerM , VestboJ , CalverleyP . Is treatment with ICS/LABA combination good value for money in COPD? Evidence from the TORCH study [Abstract]. American Thoracic Society International Conference; 2007 May 18‐23; San Francisco. 2007:[C97]. JenkinsC , CelliB , AndersonJ , FergusonG , CalverleyP , JonesP , et al. Salmeterol/fluticasone propionate (SFC) is efficacious in GOLD stage II COPD patients: analysis from the TORCH study [Abstract]. American Thoracic Society International Conference; May 15‐20; San Diego. 2009:A6186 [Poster #213]. JenkinsCR , CelliB , AndersonJA , FergusonGT , JonesPW , VestboJ , et al. Seasonality and determinants of moderate and severe COPD exacerbations in the TORCH study. European Respiratory Journal2012;39:38‐45. JenkinsCR , CelliB , AndersonJA , FergusonGT , JonesPW , VestboJ , et al. The TORCH survival study: consistent efficacy results seen in geographic regions in a multi‐national study [Abstract]. American Thoracic Society International Conference; May 18‐23; San Francisco. 2007:[C97]. JenkinsCR , JonesPW , CalverleyPM , CelliB , AndersonJA , FergusonGT , et al. Efficacy of salmeterol/fluticasone propionate by GOLD stage of chronic obstructive pulmonary disease: analysis from the randomised, placebo‐controlled TORCH study. Respiratory Research2009;10:59. JonesPW , AndersonJA , CalverleyPM , CelliBR , FergusonGT , JenkinsC , et al. Health status in the TORCH study of COPD: treatment efficacy and other determinants of change. Respiratory Research2011;12:71. JonesPW , CalverleyPM , CelliB , AndersonJA , FergusonGT , JenkinsC , et al. The TOwards a Revolution in COPD Health (TORCH) study: fluticasone propionate/salmeterol improves and sustains health status in COPD over 3 years. Chest2006;130(4):177s. JonesPW , VestboJ , AndersonJA , CelliB , FergusonGT , JenkinsCR , et al. Informative withdrawal in a COPD study. An example from the TORCH Study [Abstract]. American Thoracic Society International Conference; 2007 May 18‐23; San Francisco. 2007:[C97]. KeeneON , VestboJ , AndersonJA , CalverleyPM , CelliB , FergusonGT , et al. Methods for therapeutic trials in COPD: Lessons from the TORCH trial. European Respiratory Journal2009;34(5):1018‐23. McDonoughC , BlanchardAR . TORCH study results: pharmacotherapy reduces lung function decline in patients with chronic obstructive pulmonary disease. Hospital Practice2010;38(2):92‐3. McGarveyLP , JohnM , AndersonJA , ZvarichM , WiseRA , Committee TCE et al. Ascertainment of cause‐specific mortality in COPD: operations of the TORCH Clinical Endpoint Committee. Thorax2007;62(5):411‐5. MehtaRS , KathmanSJ , Daley‐YatesPT , CahnT , BeeraheeM , KunkaRL , et al. Pharmacokinetics and pharmacodynamics in COPD patients following long‐term twice‐daily treatment with salmeterol/fluticasone propionate (SFC) 50/500mg and the individual components [Abstract]. American Thoracic Society International Conference; 2007 May 18‐23; San Francisco. 2007:Poster #A41. SCO30003 . A multi‐centre, randomised, double‐blind, parallel group, placebo‐controlled study to investigate the long‐term effects of salmeterol/fluticasone propionate (SERETIDE®/VIANI®/ADVAIR®) 50/500mcg bd, salmeterol 50mcg bd and fluticasone propionate 500mcg bd, all delivered via the DISKUS®/ACCUHALER® inhaler, on the survival of subjects with chronic obstructive pulmonary disease (COPD) over 3 years of treatment. www.ctr.gsk.co.uk (accessed 21 April 2012). SacchettaA . Long term therapy and outcome of chronic obstructive pulmonary disease with or without co‐morbidity: The TORCH Study. Italian Journal of Medicine2008;2(3):11‐5. VestboJ , AndersonJA , CalverleyPM , CelliB , FergusonGT , JenkinsC , et al. Bias due to withdrawal in long‐term randomised trials in COPD: Evidence from the TORCH study. Clinical Respiratory Journal2011;5(1):44‐9. VestboJ , TORCH Study Group. The TORCH (TOwards a Revolution in COPD Health) survival study protocol. European Respiratory Journal2004;24(2):206‐10. ">Calverley 2007 TORCH</a><sup>a</sup> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>36</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>3088</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>GSK</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>1000</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>76</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>65</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>49</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>44</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><a href="./references#CD010115-bbs2-0010" title="Dal NegroR , MichelettoC , TrevsianF , TognellaS . Salmeterol and fluticasone 50ug/250ug BiD versus salmeterol 50ug bid and versus placebo in the long term treatment of COPD. American Thoracic Society 98th International Conference; May 17‐22; Georgia. 2002. Dal NegroRW , PomariC , TognellaS , MichelettoC . Salmeterol &amp; fluticasone 50 mcg/250 mcg bid in combination provides a better long‐term control than salmeterol 50 microg bid alone and placebo in COPD patients already treated with theophylline. Pulmonary Pharmacology and Therapeutics2003;16(4):241‐6. ">Dal Negro 2003</a> </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>12</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>12</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>‐</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>500</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>92</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>‐</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>42</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>50</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><a href="./references#CD010115-bbs2-0011" title="DransfieldMT , BourbeauJ , JonesPW , HananiaNA , MahlerDA , VestboJ , et al. Once‐daily inhaled fluticasone furoate and vilanterol versus vilanterol only for prevention of exacerbation of COPD: two replicate double‐blind, parallel‐group, randomised controlled trials. The Lancet: Respiratory Medicine2013;1(3):210‐23. ">Dransfield 2013</a><sup>b</sup> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>12</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>3255</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>GSK</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>50, 100, 200</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>57</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>64</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>‐</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>45</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><a href="./references#CD010115-bbs2-0012" title="DalalAA , BlanchetteCM , PetersenH , ManaviK , St. CharlesM . Cost‐effectiveness of fluticasone propionate/salmeterol (250/50 mcg) compared to salmeterol (50 mcg) in patients with COPD: economic evaluation of a randomized, double‐blind, parallel‐group, multi‐centre trial (Study SCO40043) [Abstract]. Chest2008;134(4):106003s. FergusonG , AnzuetoA , FeiR , EmmettA , CraterG , KnobilK , et al. A randomized, double‐blind trial comparing the effect of fluticasone/salmeterol 250/50 to salmeterol on COPD exacerbations in patients with COPD. Chest2007;132(4):530b‐531. FergusonGT , AnzuetoA , FeiR , EmmettA , KnobilK , KalbergC . Effect of fluticasone propionate/salmeterol (250/50 mcg) or salmeterol (50 mcg) on COPD exacerbations. Respiratory Medicine2008;102:1099‐108. SCO40043 . A randomized, double‐blind, parallel‐group, 52‐week study to compare the effect of fluticasone propionate/salmeterol DISKUS® 250/50mcg bid with salmeterol DISKUS® 50mcg bid on the annual rate of moderate/severe exacerbations in subjects with chronic obstructive pulmonary disease (COPD). http://ctr.gsk.co.uk (accessed 8 April 2008). ">Ferguson 2008</a> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>12</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>782</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>GSK</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>500</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>55</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>65</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>56</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>33</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><a href="./references#CD010115-bbs2-0014" title="FCO30002 . A multi‐centre, randomised, placebo‐controlled, double‐blind comparison with 3 parallel groups to investigate the efficacy and safety of inhaled glucocorticoid fluticasone (500 μg bd via Diskus™) vs. oral glucocorticoid therapy vs. placebo in subjects with chronic obstructive airway disease (COPD) under therapy with Salmeterol (50 μg bd). GlaxoSmithKline Clinical Trial Register (accessed 15 April 2012). ">GSK FCO30002 2005</a> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>3</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>140</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>GSK</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>1000</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>66</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>62</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>‐</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>‐</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><a href="./references#CD010115-bbs2-0016" title="SCO100470 . A multi‐centre, randomised, double‐blind, parallel group, 24‐week study to compare the effect of the salmeterol/fluticasone propionate combination product 50/250mcg, with salmeterol 50mcg both delivered twice daily via the DISKUS/ACCUHALER inhaler on lung function and dyspnoea in subjects with Chronic Obstructive Pulmonary Disease (COPD). http:ctr.gsk.co.uk (accessed 20 April 2012). ">GSK SCO100470 2006</a> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>6</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>1050</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>GSK</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>500</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>78</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>64</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>‐</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>‐</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><a href="./references#CD010115-bbs2-0017" title="Evaluation of Novel Endpoints in Subjects with Chronic Obstructive Pulmonary Disease(COPD) in a Randomized, Double‐Blind, Placebo‐Controlled Study of Treatment with FluticasonePropionate/Salmeterol 500/50mcg combination and its individual components, FluticasonePropionate 500mcg and Salmeterol 50mcg. http://www.gsk‐clinicalstudyregister.com/ 2008 (accessed 19 April 2012). SCO104925 . Evaluation of Novel Endpoints in Subjects with Chronic Obstructive Pulmonary Disease(COPD) in a Randomized, Double‐Blind, Placebo‐Controlled Study of Treatment with FluticasonePropionate/Salmeterol 500/50mcg combination and its individual components, FluticasonePropionate 500mcg and Salmeterol 50mcg. http:ctr.gsk.co.uk (accessed 19 April 2012). ">GSK SCO104925 2008</a><sup>a</sup> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>3</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>77</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>GSK</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>1000</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>77</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>64</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>‐</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>‐</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><a href="./references#CD010115-bbs2-0019" title="NCT00355342 . A Randomized, Double‐Blind, Parallel‐Group Clinical Trial Evaluating the Effect of the Fluticasone Propionate/Salmeterol Combination Product 250/50mcg BID Via DISKUS Versus Salmeterol 50mcg BID Via DISKUS on Bone Mineral Density in Subjects With Chronic Obstructive Pulmonary Disease (COPD). http://clinicaltrials.gov/show/NCT00355342 (accessed 19 April 2012). ">GSK SCO40041 2008</a> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>36</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>186</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>GSK</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>500</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>61</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>66</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>‐</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>‐</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><a href="./references#CD010115-bbs2-0020" title="HananiaNA , DarkenP , HorstmanD , ReisnerC , LeeB , DavisS , et al. The efficacy and safety of fluticasone propionate (250 mcg)/salmeterol (50 mcg) combined in the Diskus inhaler for the treatment of COPD. Chest2003;124(3):834‐43. HananiaNA , KnobilK , WatkinsM , WireP , YatesJ , DarkenP . Salmeterol and fluticasone propionate therapy administered by a single Diskus in patients with COPD. Chest2002:S129. HananiaNA , RamsdellJ , PayneK , DavisS , HorstmanD , LeeB , et al. Improvements in airflow and dyspnoea in COPD patients following 24 weeks treatment with salmeterol 50mcg and fluticasone propionate 250mcg alone or in combination via the Diskus. American Journal of Respiratory and Critical Care Medicine2001;163 Suppl 5:A279. HorstmanD , DarkenP , DavisS , LeeB . Improvements in FEV1 and symptoms in poorly reversible COPD patients following treatment with salmeterol 50mcg/fluticasone propionate 250mcg combination [Abstract]. European Respiratory Journal2003;22 Suppl 45:P434. MahlerDA , DarkenP , BrownCP , KnobilK . Predicting lung function responses to combination therapy in chronic obstructive pulmonary disease (COPD) [Abstract]. National COPD Conference; 2003 Nov 14‐15; Arlington. 2003:1081. MahlerDA , DarkenP , BrownCP , KnobilK . Predicting lung function responses to salmeterol/fluticasone propionate combination therapy in COPD [Abstract]. European Respiratory Journal2003;22 Suppl 45:P429. SFCA3007 . A randomized, double‐blind, placebo‐controlled, parallel‐group trial evaluating the safety and efficacy of the DISKUS formulations of salmeterol (SAL) 50mcg BID and fluticasone propionate (FP) 250mcg BID individually and in combination as salmeterol 50mcg/fluticasone propionate 250mcg BID (SFC 50/250) compared to placebo in COPD subjects. http://ctr.gsk.co.uk (accessed 20 April 2012). SpencerM , WireP , LeeB , ChangCN , DarkenP , HorstmanD . Patients with COPD using salmeterol/fluticasone propionate combination therapy experience improved quality of life. European Respiratory Journal2003;22 Suppl 45:51s. SpencerMD , KariaN , AndersonJ . The clinical significance of treatment benefits with the salmeterol/fluticasone propionate 50/500mcg combination in COPD. European Respiratory Journal2004;24 Suppl 48:290s. ">Hanania 2003</a><sup>a</sup> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>6</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>355</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>GSK</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>500</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>63</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>64</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>57</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>42</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><a href="./references#CD010115-bbs2-0022" title="KardosP , WenckerM . Combination therapy with salmeterol and fluticasone propionate (SFC) is more effective than salmeterol (SAL) alone in reducing exacerbations of COPD. European Respiratory Journal2005;26 Suppl 49:Abstract 1944. KardosP , WenckerM , GlaabT , VogelmeierC . Impact of salmeterol/fluticasone propionate versus salmeterol on exacerbations in severe chronic obstructive pulmonary disease. American Journal of Respiratory and Critical Care Medicine2007;175(2):144‐9. SCO30006 . A randomised, double‐blind, parallel‐group study to investigate the protective effect of the combination of fluticasone and salmeterol (500/50 µg bid via the DISKUS) compared with salmeterol (50 µg bid via the DISKUS) on the incidence of moderate to severe exacerbations in patients with severe chronic obstructive pulmonary disease (COPD) (GOLD III/IV). http:ctr.gsk.co.uk (accessed 21 April 2012). VogelmeierC . Combination therapy with salmeterol and fluticasone propionate (SFC) improves quality of life (QoL) more than salmeterol (SAL) alone in COPD. 42nd Nordic Lung Conference; 2005 Jun 9‐11; Trondheim. 2005; Vol. 13 Suppl 22. VogelmeierCF , WenckerM , GlaabTH , KardosP . Number needed to treat (NNT) to reduce exacerbations in severe COPD comparing salmeterol/fluticasone propionate (SFC) with salmeterol (SAL) treatment.. American Thoracic Society International Conference; May 19‐21; San Diego. 2006:A110. ">Kardos 2007</a> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>10</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>994</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>GSK</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>1000</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>76</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>64</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>37</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>40</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><a href="./references#CD010115-bbs2-0023" title="KerwinEM , Scott‐WilsonC , SanfordL , RennardS , AgustiA , BarnesN , et al. A randomised trial of fluticasone furoate/vilanterol (50/25 mug; 100/25 mug) on lung function in COPD. Respiratory Medicine2013; Vol. 107, issue 4:560‐9. [0954‐6111] KerwinEM , Scott‐WilsonC , SanfordL , RennardSI , AgustiA , BarnesN , et al. Lung function effects and safety of fluticasone furoate (FF)/vilanterol (VI) in patients with COPD: Low‐mid dose assessment [Abstract]. European Respiratory Society Annual Congress; Sep 1‐5; Vienna. 2012; Vol. 40, issue Suppl 56:545s [3082]. ">Kerwin 2013</a><sup>a,b</sup> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>6</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>617</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>GSK</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>100</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>67</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>63</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>46</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>43</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><a href="./references#CD010115-bbs2-0026" title="MahlerDA , DarkenP , BrownCP , KnobilK . Predicting lung function responses to combination therapy in chronic obstructive pulmonary disease (COPD). http://www.abstracts2view.com (accessed 15 April 2012). MahlerDA , WireP , HorstmanD , ChangCN , YatesJ , FischerT , et al. Effectiveness of fluticasone propionate and salmeterol combination delivered via the Diskus device in the treatment of chronic obstructive pulmonary disease. American Journal of Respiratory and Critical Care Medicine2002;166(8):1084‐91. SFCA3006 . A randomized, double‐blind, placebo‐controlled, parallel‐group trial evaluating the safety and efficacy of the DISKUS formulations of salmeterol (SAL) 50mcg BID and fluticasone propionate (FP) 500mcg BID individually and in combination as salmeterol 50mcg/fluticasone propionate 500mcg BID (SFC 50/500) compared to placebo in COPD subjects. http://ctr.gsk.co.uk (accessed 17 April 2012). SpencerM , WireP , LeeB , ChangCN , DarkenP , HorstmanD . Patients with COPD using salmeterol/fluticasone propionate combination therapy experience improved quality of life. European Respiratory Journal2003;22 Suppl 45:51. SpencerMD , AndersonJA . Salmeterol/fluticasone combination produces clinically important benefits in dyspnoea and fatigue [Abstract]. American Thoracic Society 2005 International Conference; 2005 May 20‐25; San Diego. 2005:B93 [Poster 308]. SpencerMD , KariaN , AndersonJ . The clinical significance of treatment benefits with the salmeterol/fluticasone propionate 50/500mcg combination in COPD. European Respiratory Journal2004;24 Suppl 48:290. ">Mahler 2002</a><sup>a</sup> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>6</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>325</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>GSK</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>1000</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>66</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>65</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>55</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>41</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><a href="./references#CD010115-bbs2-0027" title="MartinezF , BosciaJ , FeldmanG , Scott‐WilsonC , KilbrideS , FabbriL , et al. Lung function effects and safety of fluticasone furoate (FF)/vilanterol (VI) in patients with COPD: mid‐high dose assessment [Abstract]. European Respiratory Society Annual Congress, Vienna, Austria, September 1‐5. 2012; Vol. 40, issue Suppl 56:527s [P2887]. MartinezFJ , BosciaJ , FeldmanG , Scott‐WilsonC , KilbrideS , FabbriL , et al. Fluticasone furoate/vilanterol (100/25; 200/25 mug) improves lung function in COPD: a randomised trial. Respiratory Medicine2013;107(4):550‐9. [0954‐6111] ">Martinez 2013</a><sup>a,b</sup> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>6</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>610</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>GSK</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>100, 200</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>72</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>62</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>43</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>48</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""></td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><b>WM 16 m</b> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><b>867</b> </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><b>‐</b> </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><b>‐</b> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><b>69</b> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><b>64</b> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><b>53</b> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><b>42</b> </p> </td> </tr> </tbody> </table> <div class="table-footnote"> <p><sup>a</sup>Multi‐arm studies making both comparisons of interest (ICS vs placebo and ICS/LABA vs LABA). </p> <p><sup>b</sup>Studies using vilanterol as the LABA combination and monotherapy comparator, with fluticasone furoate. </p> <p>Dose is given as the total received per day (i.e. 500 signifies 250 morning and evening).</p> <p>WM = weighted mean.</p> </div> </div> <div class="table" id="CD010115-tbl-0004"> <table><a class="open-table-viewer open-in-figure-viewer" href="#0">Open in table viewer</a><div class="table-heading"><span class="table-label">Table 2.</span> <span class="table-title">Budesonide—summary of studies and baseline characteristics</span></div> <tbody> <tr> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>Study ID</b> </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>Duration (m)</b> </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>N Rand</b> </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>Funder</b> </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>ICS dose (mcg)</b> </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>% Male</b> </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>Mean age</b> </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>Pack‐years</b> </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>% pred FEV<sub>1</sub> </b> </p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="9" rowspan="1" valign=""> <p><b>Budesonide versus placebo (n = 13)</b> </p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><a href="./references#CD010115-bbs2-0002" title="BourbeauJ , RouleauMY , BoucherS . Randomised controlled trial of inhaled corticosteroids in patients with chronic obstructive pulmonary disease. Thorax1998;53(6):477‐82. ">Bourbeau 1998</a> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>6</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>79</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>AZ</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>640</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>79</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>66</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>51</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>37</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><a href="./references#CD010115-bbs2-0005" title="BorgstromL , AskingL , OlssonH , PetersonS . Lack of interaction between disease severity and therapeutic response with budesonide/formoterol in a single inhaler [Abstract]. American Thoracic Society 100th International Conference; 2004 May 21‐26; Orlando. 2004:C22 Poster 505. CalverleyPM , BonsawatW , CsekeZ , ZhongN , PetersonS , OlssonH . Maintenance therapy with budesonide and formoterol in chronic obstructive pulmonary disease. European Respiratory Journal2003;22(6):912‐9. CalverleyPMA . Effect of budesonide/formoterol on severe exacerbations and lung function in moderate to severe COPD. Thorax2002;57 Suppl III:iii44. CalverleyPMA , CsekeZ , PetersonS . Budesonide/formoterol reduces the use of oral corticosteroids in the treatment of COPD [Abstract]. European Respiratory Journal2003;22 Suppl 45:P436. CalverleyPMA , KunaP , OlssonH . COPD exacerbations are reduced by budesonide/formoterol in a single inhaler [Abstract]. European Respiratory Journal2003;22 Suppl 45:P1587. CalverleyPMA , OlssonH , Symbicort International COPD Study Group. Budesonide/formoterol in a single inhaler sustains improvements in lung function over 12 months compared with mono‐components and placebo in patients with COPD [abstract]. American Thoracic Society 99th International Conference; 2003 May 16‐21; Seattle. 2003:B024 Poster 418. CalverleyPMA , PetersonS . Combining budesonide/formoterol in a single inhaler reduces exacerbation frequency in COPD [abstract]. American Thoracic Society 99th International Conference; 2003 May 16‐21; Seattle. 2003:D092 Poster 211. CalverleyPMA , StahlE , JonesPW . Budesonide/formoterol improves the general health status of patients with COPD [Abstract]. American Thoracic Society International Conference; 2005 May 20‐25; San Diego. 2005:B93 Poster 303. CalverleyPMA , SzafranskiW , AnderssonA . Budesonide/formoterol is a well‐tolerated long term maintenance therapy for COPD. European Respiratory Journal2005;26 Suppl 49:Poster 1917. CalverleyPMA , ThompsonNC , OlssonH . Budesonide/formoterol in a single inhaler sustains lung function improvements in COPD [Abstract]. European Respiratory Journal2003;22 Suppl 45:P435. HalpinD , StåhlE , LundbackB , AndersonF , PetersonS . Treatment costs and number needed to treat (NNT) with budesonide/formoterol to avoid one exacerbation of COPD [Abstract]. American Thoracic Society 100th International Conference; 2004 May 21‐26; Orlando. 2004:D22 Poster 525. HalpinDMG , LarssonT , CalverleyPMA . How many patients with COPD must be treated with budesonide/formoterol compared with formoterol alone to avoid 1 day of oral steroid use? [Abstract]. American Thoracic Society International Conference; 2005 May 20‐25; San Diego. 2005:B93 Poster 314. JonesPW , StåhlE . Budesonide/formoterol in a single inhaler improves health status in patients with COPD [abstract]. American Thoracic Society 99th International Conference; 2003 May 16‐21; Seattle. 2003:B024 Poster 419. JonesPW , StåhlE . Budesonide/formoterol sustains clinically relevant improvements in health status in COPD [Abstract]. European Respiratory Journal2005;26(Suppl 49):Abstract No. 1352. JonesPW , StåhlE . Reducing exacerbations leads to a better health‐related quality of life in patients with COPD. European Respiratory Society 13th Annual Congress; 2003 Sep 28‐29; Vienna. 2003:P1586. LofdahlCG . Reducing the impact of COPD exacerbations: clinical efficacy of budesonide/formoterol. European Respiratory Review2004;13(88):14‐21. LofdahlCG , AndreassonE , SvenssonK , EricssonA . Budesonide/formoterol in a single inhaler improves health status in patients with COPD without increasing healthcare costs [Abstract]. European Respiratory Journal2003;22(Suppl 45):P433. LofdahlCG , EricssonA , SvenssonK , AndreassonE . Cost effectiveness of budesonide/formoterol in a single inhaler for COPD compared with each mono‐component used alone. Pharmacoeconomics2005;23(4):365‐75. ">Calverley 2003b</a><sup>a</sup> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>12</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>513</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>GSK</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>640</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>76</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>64</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>35</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>36</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><a href="./references#CD010115-bbs2-0025" title="LaptsevaIM , LaptsevaEA , BorshchevskyVV , GurevichG , KalechitsO . Inhaled budesonide in the management of chronic obstructive pulmonary disease. European Respiratory Journal2002;20 Suppl 38:244s. ">Laptseva 2002</a> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>6</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>49</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>NR</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>640</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>NR</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>NR</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>NR</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>NR</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><a href="./references#CD010115-bbs2-0028" title="MiriciA , BektasY , OzbakisG , ErmanZ . Effect of inhaled corticosteroids on respiratory function tests and airway inflammation in stable chronic obstructive pulmonary disease. Clinical Drug Investigation2001;21(12):835‐42. ">Mirici 2001</a> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>3</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>50</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>NR</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>640</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>75</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>53</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>27</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>62</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><a href="./references#CD010115-bbs2-0029" title="OzolD , AysanT , SolakZA , MogulkocN , VeralA , SebikF . The effect of inhaled corticosteroids on bronchoalveolar lavage cells and IL‐8 levels in stable COPD patients. Respiratory Medicine2005;99(12):1494‐500. ">Ozol 2005</a> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>6</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>26</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>NR</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>640</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>69</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>65</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>45</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>59</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><a href="./references#CD010115-bbs2-0031" title="JohnellO , PauwelsR , LöfdahlC‐G , LaitinenLA , PostmaDS , PrideNB , et al. Bone mineral density in patients with chronic obstructive pulmonary disease treated with budesonide Turbuhaler. European Respiratory Journal2002;19(6):1058‐63. LofdahlCG , PostmaDS , LaitinenLA , OhlssonSV , PauwelsRA , PrideNB . The European Respiratory Society study on chronic obstructive pulmonary disease (EUROSCOP): recruitment methods and strategies. Respiratory Medicine1998;92(3):467‐72. PauwelsRA , LofdahlCG , LaitinenLA , SchoutenJP , PostmaDS , PrideNB , et al. Long‐term treatment with inhaled budesonide in persons with mild chronic obstructive pulmonary disease who continue smoking. European Respiratory Society Study on Chronic Obstructive Pulmonary Disease. New England Journal of Medicine1999;340(25):1948‐53. PauwelsRA , LofdahlCG , PrideNB , PostmaDS , LaitinenLA , OhlssonSV . European Respiratory Society study on chronic obstructive pulmonary disease (EUROSCOP): hypothesis and design. European Respiratory Journal1992;5(10):1254‐61. ">Pauwels 1999</a> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>36</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>1277</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>AZ</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>640</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>73</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>52</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>39</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>77</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><a href="./references#CD010115-bbs2-0032" title="RenkemaTE , SchoutenJP , KoeterGH , PostmaDS . Effects of long‐term treatment with corticosteroids in COPD. Chest1996;109(5):1156‐62. vanGrunsvenPM , vanSchayckCP , DerenneJP , KerstjensHA , RenkemaTE , PostmaDS , et al. Long term effects of inhaled corticosteroids in chronic obstructive pulmonary disease: a meta‐analysis. Thorax1999;54(1):7‐14. ">Renkema 1996</a> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>24</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>39</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>AZ</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>1280</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>100</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>55</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>NR</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>64</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><a href="./references#CD010115-bbs2-0035" title="SenderovitzT , VestboJ , FrandsenJ , MaltbaekN , NorgaardM , NielsenC , et al. Steroid reversibility test followed by inhaled budesonide or placebo in outpatients with stable chronic obstructive pulmonary disease. Respiratory Medicine1999;93(10):715‐8. ">Senderovitz 1999</a> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>6</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>26</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>NR</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>640</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>54</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>61</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>NR</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>NR</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><a href="./references#CD010115-bbs2-0036" title="ShakerSB , DirksenA , UlrikCS , HestadM , StavngaardT , LaursenLC , et al. The effect of inhaled corticosteroids on the development of emphysema in smokers assessed by annual computed tomography. COPD: Journal of Chronic Obstructive Pulmonary Disease2009;6(2):104‐11. ShakerSB , StavngaardT , LaursenLC , StoelBC , DirksenA . Rapid fall in lung density following smoking cessation in COPD. COPD: Journal of Chronic Obstructive Pulmonary Disease2011;8(1):2‐7. ">Shaker 2009</a> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>36</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>254</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>AZ</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>640</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>58</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>64</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>56</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>52</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><a href="./references#CD010115-bbs2-0038" title="AndersonP . Budesonide/formoterol in a single inhaler (Symbicort) provides early and sustained improvement in lung function in moderate to severe COPD. Thorax2002;57 Suppl 3:iii43. BorgstromL , AskingL , OlssonH , PetersonS . Lack of interaction between disease severity and therapeutic response with budesonide/formoterol in a single inhaler [Abstract].. American Thoracic Society 100th International Conference; May 21‐26; Orlando. 2004:C22 [Poster 505]. CalverleyP , Pauwels DaggerR , LöfdahlCG , SvenssonK , HigenbottamT , CarlssonLG , et al. Relationship between respiratory symptoms and medical treatment in exacerbations of COPD. European Respiratory Journal2005;26(3):406‐13. CalverleyPMA . Effect of budesonide/formoterol on severe exacerbations and lung function in moderate to severe COPD. Thorax2002;BTS Winter Meeting 2002:S145. CalverleyPMA , SzafranskiW , AnderssonA . Budesonide/formoterol is a well‐tolerated long term maintenance therapy for COPD. European Respiratory Journal2005;26 Suppl 49:Poster 1917. CalverleyPMA , ThompsonNC , OlssonH . Budesonide/formoterol in a single inhaler sustains lung function improvements in COPD [Abstract]. European Respiratory Journal2003;22 Suppl 45:P435. CampbellLM , SzafranskiW . Budesonide/formoterol in a single inhaler (Symbicort) provides sustained relief from symptoms in moderate to severe COPD. Thorax. 2002; Vol. BTS Winter Meeting 2002:S143. CampbellLW , SzafranskiW . Budesonide/formoterol in a single inhaler (Symbicort) reduces severe exacerbations in patients with moderate‐severe COPD. Thorax. 2002; Vol. BTS Winter Meeting 2002:S141. DahlR , CukierA , OlssonH . Budesonide/formoterol in a single inhaler reduces severe and mild exacerbations in patients with moderate to severe COPD. European Respiratory Journal2002;20 Suppl 38:242 [P1575]. EgedeF , MengaG . Budesonide/formoterol in a single inhaler provides sustained relief from symptoms and night‐time awakenings in moderate‐severe COPD: results from symptoms and night‐time awakenings in moderate to severe COPD: results from a 1‐year study. European Respiratory Journal2002;20 Suppl 38:242 [P1574]. HalpinD , StahlE , LundbackB , AndersonF , PetersonS . Treatment costs and number needed to treat (NNT) with budesonide/formoterol to avoid one exacerbation of COPD [Abstract]. American Thoracic Society 100th International Conference; May 21‐26; Orlando. 2004:D22 Poster 525. JonesPW , StahlE , SvenssonK . Improvement in health status in patients with moderate to severe COPD after treatment with budesonide/formoterol in a single inhaler. European Respiratory Journal2002;20 Suppl 38:250 [P1613]. KorsgaardJ , SansoresR . Budesonide/formoterol (single inhaler) provides sustained relief from shortness of breath and chest tightness in a 1‐year study of patients with moderate to severe COPD. European Respiratory Journal2002;20 Suppl 38:242 [P1577]. LangeP , SaenzC . Budesonide/formoterol in a single inhaler is well tolerated in patients with moderate to severe COPD: results of a 1 year study. European Respiratory Journal2002;20 Suppl 38:242 [P1573]. LofdahlCG . Reducing the impact of COPD exacerbations: clinical efficacy of budesonide/formoterol. European Respiratory Review2004;13(88):14‐21. MilanowskiJ , NahabedianS . Budesonide/formoterol in a single inhaler acts rapidly to improve lung function and relieve symptoms in patients with moderate to severe COPD. European Respiratory Journal2002;20 Suppl 38:242 [P1576]. SzafranskiW , CukierA , RamirezA , MengaG , SansoresR , NahabedianS , et al. Efficacy and safety of budesonide/formoterol in the management of chronic obstructive pulmonary disease. European Respiratory Journal2003;21:74‐81. SzfranskiW , RamirezA , PetersonS . Budesonide/formoterol in single inhaler provides sustained improvements in lung function in patients with moderate to severe COPD [Abstract]. European Respiratory Society Annual Congress; Sep 14‐18; Stockholm. 2002. ">Szafranski 2003</a><sup>a</sup> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>12</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>403</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>AZ</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>640</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>79</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>64</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>45</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>36</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><a href="./references#CD010115-bbs2-0039" title="AstraZeneca . A 6‐month double‐blind, double‐dummy, randomized, parallel group, multicenter efficacy &amp; safety study of SYMBICORT® pMDI 2 x 160/4.5 μg &amp; 80/4.5 μg bid compared to formoterol TBH, budesonide pMDI (&amp; the combination) &amp; placebo in COPD Patients (SHINE) (study number D589900002). www.astrazenecaclinicaltrials.com (accessed 18 April 2012). BleeckerER , MeyersDA , BaileyWC , SimsAM , BujacSR , GoldmanM , et al. Effect of ß2‐Adrenergic Receptor Gene Polymorphism Gly16Arg on Response to Budesonide/Formoterol Pressurized Metered‐Dose Inhaler in Chronic Obstructive Pulmonary Disease [Abstract]. American Journal of Respiratory and Critical Care Medicine2011;183:A4086. TashkinDP , RennardSI , MartinP , RamachandranS , MartinUJ , SilkoffPE . Efficacy and safety of budesonide and formoterol in one pressurized metered‐dose inhaler in patients with moderate to very severe chronic obstructive pulmonary disease: results of a 6‐month randomized clinical trial. Drugs2008;68(14):1975‐2000. ">Tashkin 2008 SHINE</a><sup>a</sup> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>6</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>575</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>AZ</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>640</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>68</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>63</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>41</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>40</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><a href="./references#CD010115-bbs2-0042" title="VestboJ , SorensenT , LangeP , BrixA , TorreP , ViskumK . Long‐term effect of inhaled budesonide in mild and moderate chronic obstructive pulmonary disease: a randomised controlled trial. Lancet1999;353(9167):1819‐23. [MEDLINE: 99285938] ">Vestbo 1999</a> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>36</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>290</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>AZ</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>640</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>88</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>59</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>NR</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>87</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><a href="./references#CD010115-bbs2-0043" title="YildizF , BasyigitI , YildirimE , BoyaciH , IlgazliA . Does addition of inhaled steroids to combined bronchodilator therapy affect health status in patients with COPD?. Respirology2004;9(3):352‐5. ">Yildiz 2004</a> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>3</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>38</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>?</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>1280</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>100</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>67</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>51</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>46</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""></td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><b>WM 23 m</b> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><b>278</b> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><b>‐</b> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><b>‐</b> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><b>77</b> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><b>61</b> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><b>43</b> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><b>54</b> </p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="9" rowspan="1" valign=""> <p><b>Budesonide/LABA combination versus LABA monotherapy (n = 7)</b> </p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><a href="./references#CD010115-bbs2-0005" title="BorgstromL , AskingL , OlssonH , PetersonS . Lack of interaction between disease severity and therapeutic response with budesonide/formoterol in a single inhaler [Abstract]. American Thoracic Society 100th International Conference; 2004 May 21‐26; Orlando. 2004:C22 Poster 505. CalverleyPM , BonsawatW , CsekeZ , ZhongN , PetersonS , OlssonH . Maintenance therapy with budesonide and formoterol in chronic obstructive pulmonary disease. European Respiratory Journal2003;22(6):912‐9. CalverleyPMA . Effect of budesonide/formoterol on severe exacerbations and lung function in moderate to severe COPD. Thorax2002;57 Suppl III:iii44. CalverleyPMA , CsekeZ , PetersonS . Budesonide/formoterol reduces the use of oral corticosteroids in the treatment of COPD [Abstract]. European Respiratory Journal2003;22 Suppl 45:P436. CalverleyPMA , KunaP , OlssonH . COPD exacerbations are reduced by budesonide/formoterol in a single inhaler [Abstract]. European Respiratory Journal2003;22 Suppl 45:P1587. CalverleyPMA , OlssonH , Symbicort International COPD Study Group. Budesonide/formoterol in a single inhaler sustains improvements in lung function over 12 months compared with mono‐components and placebo in patients with COPD [abstract]. American Thoracic Society 99th International Conference; 2003 May 16‐21; Seattle. 2003:B024 Poster 418. CalverleyPMA , PetersonS . Combining budesonide/formoterol in a single inhaler reduces exacerbation frequency in COPD [abstract]. American Thoracic Society 99th International Conference; 2003 May 16‐21; Seattle. 2003:D092 Poster 211. CalverleyPMA , StahlE , JonesPW . Budesonide/formoterol improves the general health status of patients with COPD [Abstract]. American Thoracic Society International Conference; 2005 May 20‐25; San Diego. 2005:B93 Poster 303. CalverleyPMA , SzafranskiW , AnderssonA . Budesonide/formoterol is a well‐tolerated long term maintenance therapy for COPD. European Respiratory Journal2005;26 Suppl 49:Poster 1917. CalverleyPMA , ThompsonNC , OlssonH . Budesonide/formoterol in a single inhaler sustains lung function improvements in COPD [Abstract]. European Respiratory Journal2003;22 Suppl 45:P435. HalpinD , StåhlE , LundbackB , AndersonF , PetersonS . Treatment costs and number needed to treat (NNT) with budesonide/formoterol to avoid one exacerbation of COPD [Abstract]. American Thoracic Society 100th International Conference; 2004 May 21‐26; Orlando. 2004:D22 Poster 525. HalpinDMG , LarssonT , CalverleyPMA . How many patients with COPD must be treated with budesonide/formoterol compared with formoterol alone to avoid 1 day of oral steroid use? [Abstract]. American Thoracic Society International Conference; 2005 May 20‐25; San Diego. 2005:B93 Poster 314. JonesPW , StåhlE . Budesonide/formoterol in a single inhaler improves health status in patients with COPD [abstract]. American Thoracic Society 99th International Conference; 2003 May 16‐21; Seattle. 2003:B024 Poster 419. JonesPW , StåhlE . Budesonide/formoterol sustains clinically relevant improvements in health status in COPD [Abstract]. European Respiratory Journal2005;26(Suppl 49):Abstract No. 1352. JonesPW , StåhlE . Reducing exacerbations leads to a better health‐related quality of life in patients with COPD. European Respiratory Society 13th Annual Congress; 2003 Sep 28‐29; Vienna. 2003:P1586. LofdahlCG . Reducing the impact of COPD exacerbations: clinical efficacy of budesonide/formoterol. European Respiratory Review2004;13(88):14‐21. LofdahlCG , AndreassonE , SvenssonK , EricssonA . Budesonide/formoterol in a single inhaler improves health status in patients with COPD without increasing healthcare costs [Abstract]. European Respiratory Journal2003;22(Suppl 45):P433. LofdahlCG , EricssonA , SvenssonK , AndreassonE . Cost effectiveness of budesonide/formoterol in a single inhaler for COPD compared with each mono‐component used alone. Pharmacoeconomics2005;23(4):365‐75. ">Calverley 2003b</a><sup>a</sup> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>12</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>509</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>GSK</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>640</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>76</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>64</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>35</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>36</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><a href="./references#CD010115-bbs2-0008" title="CalverleyPMA , KunaP , MonsoE , CostantiniM , PetruzzelliSd , SergioF , et al. Beclomethasone/formoterol in the management of COPD: a randomised controlled trial. Respiratory Medicine2010;104:1858‐68. ">Calverley 2010</a> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>11</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>481</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Chiesi</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>640</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>81</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>64</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>39</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>42</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><a href="./references#CD010115-bbs2-0013" title="FukuchiY , SamoroR , FassakhovR , TaniguchiH , EkelundJ , CarlssonLG , et al. Budesonide/formoterol via Turbuhaler® versus formoterol via Turbuhaler® in patients with moderate to severe chronic obstructive pulmonary disease: Phase III multinational study results. Respirology2013; Vol. 18:866‐73. IchinoseM , SamoroR , FassakhovR , OguriM , EkelundJ , CarlssonLG , et al. Budesonide/formoterol vs formoterol, both via Turbuhaler®, in patients with moderate to severe COPD: Phase III study results [Abstract]. European Respiratory Society Annual Congress; 2012 Sep 1‐5; Vienna. 2012; Vol. 40, issue Suppl 56:374s [P2108]. ">Fukuchi 2013</a> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>3</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>1293</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>AZ</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>640</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>89</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>65</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>44</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>41</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><a href="./references#CD010115-bbs2-0033" title="BleeckerER , MeyersDA , BaileyWC , SimsAM , BujacSR , GoldmanM , et al. ADRB2 polymorphisms and budesonide/formoterol responses in COPD. Chest2012; Vol. 142, issue 2:320‐8. RennardSI , TashkinDP , McElhattanJ , GoldmanM , RamachandranS , MartinUJ , et al. Efficacy and tolerability of budesonide/formoterol in one hydrofluoroalkane pressurized metered‐dose inhaler in patients with chronic obstructive pulmonary disease. Results from a 1‐year randomized controlled clinical trial. Drugs2009;69(5):549‐65. ">Rennard 2009</a> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>12</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>1483</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>AZ</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>320, 640</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>63</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>63</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>NR</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>39</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><a href="./references#CD010115-bbs2-0037" title="SharafkhanehA , SouthardJG , GoldmanM , UryniakT , MartinUJ . Effect of budesonide/formoterol pMDI on COPD exacerbations: a double‐blind, randomized study. Respiratory Medicine2012;106(2):257‐68. SharafkhanehA , UryniakT , MartinU . Long‐term effects of budesonide/formoterol pressurized metered‐dose inhaler on Chronic Obstructive Pulmonary Disease (COPD) symptoms and health status in patients with COPD [Abstract]. Chest2011;140(4):528A. ">Sharafkhaneh 2012</a> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>12</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>1219</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>AZ</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>320, 640</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>62</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>63</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>44</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>38</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><a href="./references#CD010115-bbs2-0038" title="AndersonP . Budesonide/formoterol in a single inhaler (Symbicort) provides early and sustained improvement in lung function in moderate to severe COPD. Thorax2002;57 Suppl 3:iii43. BorgstromL , AskingL , OlssonH , PetersonS . Lack of interaction between disease severity and therapeutic response with budesonide/formoterol in a single inhaler [Abstract].. American Thoracic Society 100th International Conference; May 21‐26; Orlando. 2004:C22 [Poster 505]. CalverleyP , Pauwels DaggerR , LöfdahlCG , SvenssonK , HigenbottamT , CarlssonLG , et al. Relationship between respiratory symptoms and medical treatment in exacerbations of COPD. European Respiratory Journal2005;26(3):406‐13. CalverleyPMA . Effect of budesonide/formoterol on severe exacerbations and lung function in moderate to severe COPD. Thorax2002;BTS Winter Meeting 2002:S145. CalverleyPMA , SzafranskiW , AnderssonA . Budesonide/formoterol is a well‐tolerated long term maintenance therapy for COPD. European Respiratory Journal2005;26 Suppl 49:Poster 1917. CalverleyPMA , ThompsonNC , OlssonH . Budesonide/formoterol in a single inhaler sustains lung function improvements in COPD [Abstract]. European Respiratory Journal2003;22 Suppl 45:P435. CampbellLM , SzafranskiW . Budesonide/formoterol in a single inhaler (Symbicort) provides sustained relief from symptoms in moderate to severe COPD. Thorax. 2002; Vol. BTS Winter Meeting 2002:S143. CampbellLW , SzafranskiW . Budesonide/formoterol in a single inhaler (Symbicort) reduces severe exacerbations in patients with moderate‐severe COPD. Thorax. 2002; Vol. BTS Winter Meeting 2002:S141. DahlR , CukierA , OlssonH . Budesonide/formoterol in a single inhaler reduces severe and mild exacerbations in patients with moderate to severe COPD. European Respiratory Journal2002;20 Suppl 38:242 [P1575]. EgedeF , MengaG . Budesonide/formoterol in a single inhaler provides sustained relief from symptoms and night‐time awakenings in moderate‐severe COPD: results from symptoms and night‐time awakenings in moderate to severe COPD: results from a 1‐year study. European Respiratory Journal2002;20 Suppl 38:242 [P1574]. HalpinD , StahlE , LundbackB , AndersonF , PetersonS . Treatment costs and number needed to treat (NNT) with budesonide/formoterol to avoid one exacerbation of COPD [Abstract]. American Thoracic Society 100th International Conference; May 21‐26; Orlando. 2004:D22 Poster 525. JonesPW , StahlE , SvenssonK . Improvement in health status in patients with moderate to severe COPD after treatment with budesonide/formoterol in a single inhaler. European Respiratory Journal2002;20 Suppl 38:250 [P1613]. KorsgaardJ , SansoresR . Budesonide/formoterol (single inhaler) provides sustained relief from shortness of breath and chest tightness in a 1‐year study of patients with moderate to severe COPD. European Respiratory Journal2002;20 Suppl 38:242 [P1577]. LangeP , SaenzC . Budesonide/formoterol in a single inhaler is well tolerated in patients with moderate to severe COPD: results of a 1 year study. European Respiratory Journal2002;20 Suppl 38:242 [P1573]. LofdahlCG . Reducing the impact of COPD exacerbations: clinical efficacy of budesonide/formoterol. European Respiratory Review2004;13(88):14‐21. MilanowskiJ , NahabedianS . Budesonide/formoterol in a single inhaler acts rapidly to improve lung function and relieve symptoms in patients with moderate to severe COPD. European Respiratory Journal2002;20 Suppl 38:242 [P1576]. SzafranskiW , CukierA , RamirezA , MengaG , SansoresR , NahabedianS , et al. Efficacy and safety of budesonide/formoterol in the management of chronic obstructive pulmonary disease. European Respiratory Journal2003;21:74‐81. SzfranskiW , RamirezA , PetersonS . Budesonide/formoterol in single inhaler provides sustained improvements in lung function in patients with moderate to severe COPD [Abstract]. European Respiratory Society Annual Congress; Sep 14‐18; Stockholm. 2002. ">Szafranski 2003</a><sup>a</sup> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>12</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>409</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>AZ</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>640</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>79</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>64</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>45</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>36</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><a href="./references#CD010115-bbs2-0039" title="AstraZeneca . A 6‐month double‐blind, double‐dummy, randomized, parallel group, multicenter efficacy &amp; safety study of SYMBICORT® pMDI 2 x 160/4.5 μg &amp; 80/4.5 μg bid compared to formoterol TBH, budesonide pMDI (&amp; the combination) &amp; placebo in COPD Patients (SHINE) (study number D589900002). www.astrazenecaclinicaltrials.com (accessed 18 April 2012). BleeckerER , MeyersDA , BaileyWC , SimsAM , BujacSR , GoldmanM , et al. Effect of ß2‐Adrenergic Receptor Gene Polymorphism Gly16Arg on Response to Budesonide/Formoterol Pressurized Metered‐Dose Inhaler in Chronic Obstructive Pulmonary Disease [Abstract]. American Journal of Respiratory and Critical Care Medicine2011;183:A4086. TashkinDP , RennardSI , MartinP , RamachandranS , MartinUJ , SilkoffPE . Efficacy and safety of budesonide and formoterol in one pressurized metered‐dose inhaler in patients with moderate to very severe chronic obstructive pulmonary disease: results of a 6‐month randomized clinical trial. Drugs2008;68(14):1975‐2000. ">Tashkin 2008 SHINE</a><sup>a</sup> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>6</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>1129</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>AZ</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>320, 640</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>68</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>63</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>41</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>40</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""></td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><b>WM 9 m</b> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><b>932</b> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><b>‐</b> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><b>‐</b> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><b>75</b> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><b>64</b> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><b>41</b> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><b>39</b> </p> </td> </tr> </tbody> </table> <div class="table-footnote"> <p><sup>a</sup>Multi‐arm studies making both comparisons of interest (ICS vs placebo and ICS/LABA vs LABA). </p> <p>Dose is given as the total received per day (i.e. 640 signifies 320 morning and evening).</p> <p>WM = weighted mean.</p> </div> </div> </section> <section id="CD010115-sec-0067"> <h5 class="title">Participant inclusion and exclusion criteria</h5> <p>Full details of the inclusion and exclusion criteria for each trial can be found in <a href="http://onlinelibrary.wiley.com/doi/10.1002/14651858.CD010177.pub2/tables#CD010177-sec2-0020" target="_blank">Characteristics of included studies</a>. Inclusion and exclusion criteria were largely similar across trials, with the exception of which medications participants were allowed to continue taking during the study period. In most studies, participants were required to be over the age of 40 and to have a smoking history of at least 10 pack‐years. In terms of lung function, most studies required values consistent with a GOLD diagnosis of COPD. Studies excluded participants if they had asthma or any other respiratory disorder. Other common exclusion criteria included recent lower respiratory tract infection, the need for long‐term or nocturnal oxygen therapy and recent use of antibiotics or oral corticosteroids (usually within four to six weeks of screening). </p> </section> <section id="CD010115-sec-0068"> <h5 class="title">Baseline characteristics of participants</h5> <p>Baseline data are given for individual trial arms in <a href="./references#CD010115-sec-0139" title="">Characteristics of included studies</a> tables and are summarised across fluticasone and budesonide studies in <a href="#CD010115-tbl-0003">Table 1</a> and <a href="#CD010115-tbl-0004">Table 2</a>, respectively. All of the trials recruited more men than women, with a mean of around 70% and 75% in the fluticasone and budesonide studies, respectively (range 52% to 100%). Mean age within the trials ranged from 47 to 67 years, and the overall mean was similar in the fluticasone and budesonide studies (˜63 years). Smoking history as measured by overall pack‐years (one pack‐year = one pack of 20 cigarettes per day for one year) was reported in three‐quarters of the studies, and the mean was higher in the fluticasone combination therapy studies (53 pack‐years) than in the other sets of trials; all were between 41 and 43 pack‐years overall. The range across all trials was 27 to 63 pack‐years. Percentage predicted FEV<sub>1</sub>, an indicator of disease severity, was reported in most trials. Overall means for fluticasone and budesonide were very similar (47% and 48%, respectively). One outlier in the fluticasone monotherapy studies recruited a much less severe population (those showing early signs and symptoms of COPD; <a href="./references#CD010115-bbs2-0040" title="vanGrunsvenP , SchermerT , AkkermansR , AlbersM , van denBoomG , vanSchayckO , et al. Short‐ and long‐term efficacy of fluticasone propionate in subjects with early signs and symptoms of chronic obstructive pulmonary disease. Results of the DIMCA study. Respiratory Medicine2003;97(12):1303‐12. ">van Grunsven 2003</a>), with nine mean pack‐years and percentage predicted FEV<sub>1</sub> of 97. Two budesonide monotherapy studies also recruited less severe populations, with percentage predicted FEV<sub>1</sub> of 77 and 87 (<a href="./references#CD010115-bbs2-0031" title="JohnellO , PauwelsR , LöfdahlC‐G , LaitinenLA , PostmaDS , PrideNB , et al. Bone mineral density in patients with chronic obstructive pulmonary disease treated with budesonide Turbuhaler. European Respiratory Journal2002;19(6):1058‐63. LofdahlCG , PostmaDS , LaitinenLA , OhlssonSV , PauwelsRA , PrideNB . The European Respiratory Society study on chronic obstructive pulmonary disease (EUROSCOP): recruitment methods and strategies. Respiratory Medicine1998;92(3):467‐72. PauwelsRA , LofdahlCG , LaitinenLA , SchoutenJP , PostmaDS , PrideNB , et al. Long‐term treatment with inhaled budesonide in persons with mild chronic obstructive pulmonary disease who continue smoking. European Respiratory Society Study on Chronic Obstructive Pulmonary Disease. New England Journal of Medicine1999;340(25):1948‐53. PauwelsRA , LofdahlCG , PrideNB , PostmaDS , LaitinenLA , OhlssonSV . European Respiratory Society study on chronic obstructive pulmonary disease (EUROSCOP): hypothesis and design. European Respiratory Journal1992;5(10):1254‐61. ">Pauwels 1999</a>; <a href="./references#CD010115-bbs2-0042" title="VestboJ , SorensenT , LangeP , BrixA , TorreP , ViskumK . Long‐term effect of inhaled budesonide in mild and moderate chronic obstructive pulmonary disease: a randomised controlled trial. Lancet1999;353(9167):1819‐23. [MEDLINE: 99285938] ">Vestbo 1999</a>). None of these three studies reported the primary outcome. </p> </section> <section id="CD010115-sec-0069"> <h5 class="title">Characteristics of the interventions</h5> <p>Of the 26 fluticasone studies, 18 compared fluticasone monotherapy versus placebo, and 15 compared fluticasone/LABA combination versus LABA monotherapy (12 using salmeterol and three using the new LABA, vilanterol). Seven trials used multi‐arm double‐dummy designs that performed both comparisons of interest (<a href="./references#CD010115-bbs2-0006" title="CalverleyP , PauwelsR , VestboJ , JonesP , PrideN , GulsvikA , et al. Combined salmeterol and fluticasone in the treatment of chronic obstructive pulmonary disease: a randomised controlled trial. Lancet2003;361(9356):449‐56. CalverleyPMA , PauwelsR , VestboJ , JonesP , PrideN , GulsvikA , et al. Safety of salmeterol/fluticasone propionate combination in the treatment of chronic obstructive pulmonary disease. European Respiratory Journal2002;20(Suppl 38):242s [P1572]. CalverleyPMA , PauwelsRA , VestboJ , JonesPW , PrideNB , GulsvikA , et al. Clinical improvements with salmeterol / fluticasone propionate combination in differing severities of COPD [A035] [Poster D50]. http://www.abstracts2view.com (accessed 20 April 2012). CalverleyPMA , PauwelsRA , VestboJ , JonesPW , PrideNB , GulsvikA , et al. Salmeterol/fluticasone propionate combination for one year provides greater clinical benefit than its individual components [A98] [Poster 306]. http://www.abstracts‐on‐line.com/abstracts/ATS (accessed 20 April 2012). HunjanMK , ChandlerF . Numbers needed to treat (NNT) to avoid an exacerbation in patients with chronic obstructive pulmonary disease (COPD) using salmeterol/fluticasone propionate combination (SFC) and associated costs [Abstract]. American Thoracic Society 100th International Conference; 2004 May 21‐26; Orlando. 2004:D22 Poster 503. HunjanMK , WilliamsDT . Costs of avoiding exacerbations in patients with chronic obstructive pulmonary disease (COPD) treated with salmeterol/fluticasone propionate combination (Seretide) and salmeterol. European Respiratory Journal2004;24 Suppl 48:291s. HunjanMK , WilliamsDT . Salmeterol/fluticasone propionate combination is clinically effective in avoiding exacerbations in patients with moderate/severe COPD. European Respiratory Journal2004;24 Suppl 48:513s. JonesPW , EdinHM , AndersonJ . Salmeterol/fluticasone propionate combination improves health status in COPD patients.. http://www.abstracts‐on‐line.com/abstracts/ATS (accessed 21 April 2012). JonesPW , StåhlE . Budesonide/formoterol sustains clinically relevant improvements in health status in COPD [Abstract]. European Respiratory Journal2005;26 Suppl 49:Abstract No. 1352. JonesPW , VestboJ , PauwelsRA , CalverleyPMA , AndersonJA , SpencerMD . Informative drop out in COPD studies. Investigation of health status of withdrawals in the TRISTAN study. European Respiratory Society 13th Annual Congress; 2003 Sep 28‐29; Vienna. 2003:P1593. NitschmannS . Inhalational combination therapy in chronic obstructive lung disease. TRISTAN study. German Internist2004;45(6):727‐8. PauwelsRA , CalverlyPMA , VestboJ , JonesPW , PrideN , GulsvikA , et al. Reduction of exacerbations with salmeterol/fluticasone combination 50/500 mcg bd in the treatment of chronic obstructive pulmonary disease. European Respiratory Journal2002;20 Suppl 38:240 [P1569]. PauwelsRA , VestboJ , CalverleyPMA , JonesPW , PrideNB , GulsvikA . Characterization of exacerbations in the TRISTAN study of salmeterol / fluticasone propionate (SFC) combination in moderate to severe COPD. http://www.abstracts2view.com (accessed 20 April 2012). SFCB3024 . A multi‐centre, randomised, double‐blind, parallel group, placebo‐controlled study to compare the efficacy and safety of the salmeterol/FP combination product at a strength of 50/500mcg bd with salmeterol 50mcg bd alone and FP 500mcg bd alone, delivered via the DISKUS™/ACCUHALER™, in the treatment of subjects with chronic obstructive pulmonary disease (COPD) for 12 months. http://ctr.gsk.co.uk (accessed 21 April 2012). SpencerM , BriggsAH , GrossmanRF , RanceL . Development of an economic model to assess the cost effectiveness of treatment interventions for chronic obstructive pulmonary disease. Pharmacoeconomics2005;23(6):619‐37. SpencerMD , KariaN , AndersonJ . The clinical significance of treatment benefits with the salmeterol/fluticasone propionate 50/500mcg combination in COPD. European Respiratory Journal2004;24 Suppl 48:290s. VestboJ , CalverleyPMA , PauwelsR , JonesP , PrideN , GulsvikA , et al. Absence of gender susceptibility to the combination of salmeterol and fluticasone in the treatment of chronic obstructive pulmonary disease. European Respiratory Journal2002;20 Suppl 38:240 [P1570]. VestboJ , PauwelsR , AndersonJA , JonesP , CalverleyP . Early onset of effect of salmeterol and fluticasone propionate in chronic obstructive pulmonary disease. Thorax2005;60(4):301‐4. VestboJ , PauwelsRA , CalverleyPMA , JonesPW , PrideNB , GulsvikA . Salmeterol/fluticasone propionate combination produces improvement in lung function detectable within 24 hours in moderate to severe COPD. http://www.abstracts2view.com (accessed 20 April 2012). VestboJ , SorianoJB , AndersonJA , CalverleyP , PauwelsR , JonesP . Gender does not influence the response to the combination of salmeterol and fluticasone propionate in COPD. Respiratory Medicine2004;98(11):1045‐50. ">Calverley 2003 TRISTAN</a>; <a href="./references#CD010115-bbs2-0007" title="AllegraL . TORCH study: An invitation to clinical considerations. GIMT ‐ Giornale Italiano delle Malattie del Torace2007;61(1):15‐23. BriggsAH , GlickHA , Lozano‐OrtegaG , SpencerM , CalverleyPM , JonesPW , et al. Is treatment with ICS and LABA cost‐effective for COPD? Multinational economic analysis of the TORCH study. European Respiratory Journal2010;35(3):532‐9. BriggsAH , Lozano‐OrtegaG , SpencerS , BaleG , SpencerMD , BurgePS . Estimating the cost‐effectiveness of fluticasone propionate for treating chronic obstructive pulmonary disease in the presence of missing data. Value in Health2006;9(4):227‐35. CalverleyP , CelliB , AndersonJ , FergusonG , JenkinsC , JonesP , et al. Salmeterol/fluticasone propionate combination (SFC) improves survival in COPD over three years: on‐treatment analysis from the TORCH study [Abstract]. American Thoracic Society International Conference; 2009 May 15‐20; San Diego. 2009:A6191[Poster #219]. CalverleyP , CelliB , AndersonJA , FergusonGT , JenkinsC , JonesPW , et al. The TOwards a Revolution in COPD Health (TORCH) study: salmeterol/fluticasone propionate improves survival in COPD over three years [Abstract]. Respirology2006;11 Suppl 5:A149 [PS‐3‐8]. CalverleyPM , AndersonJA , CelliB , FergusonGT , JenkinsC , JonesPW , et al. Salmeterol and fluticasone propionate and survival in chronic obstructive pulmonary disease. New England Journal of Medicine2007;356(8):775‐89. CalverleyPM , AndersonJA , CelliB , FergusonGT , JenkinsC , Jones PW et al and TORCH Investigators. Cardiovascular events in patients with COPD: TORCH study results. Thorax2010;65(8):719‐25. CalverleyPM , CelliB , AndersonJA , FergusonGT , JenkinsC , JonesPW , et al. The TOwards a Revolution in COPD Health (TORCH) study: fluticasone propionate /salmeterol improves survival in COPD over three years. Chest2006;130(4):122s. CalverleyPMA , CelliB , AndersenJA , FergusonGT , JenkinsC , JonesPW , et al. The TORCH (TOwards a Revolution in COPD Health) study salmeterol/fluticasone propionate (SFC) improves survival in COPD over three years. European Respiratory Journal2006;28 Suppl 50:34. CelliB , CalverleyPM , AndersonJA , FergusonGT , JenkinsC , JonesP , et al. The TOwards a Revolution in COPD HEalth (TORCH) Study: salmeterol/fluticasone propionate reduces the rate of exacerbations over three years. Respirology2006;11 Suppl 5:A140. CelliB , CalverleyPM , AndersonJA , FergusonGT , JenkinsC , JonesPW , et al. The TOwards a Revolution in COPD Health (TORCH) study: fluticasone propionate/salmeterol reduces the rate of exacerbations over 3 years [Abstract]. Chest2006;130(4):177s. CelliB , CalverleyPMA , AndersonJA , FergusonGT , JenkinsC , JonesPW , et al. The TORCH (TOwards a Revolution in COPD Health) study salmeterol/fluticasone propionate (SFC) improves health status reduces exacerbations and improves lung function over three years [Abstract]. European Respiratory Journal2006;28 Suppl 50:34s [E312]. CelliB , EmmettA , CraterG , KalbergC . Fluticasone propionate/salmeterol (FSC) improves the inspiratory to total lung capacity ratio (IC/TLC) and exercise endurance time in patients with COPD. European Respiratory Society 16th Annual Congress; 2006 Sep 2‐6; Munich. 2006:A320 (Poster 323). CelliB , FergusonGT , AndersonJA , JenkinsCR , JonesPW , VestboJ , et al. Salmeterol/fluticasone propionate (SFC) improves lung function and reduces the rate of decline over three years in the TORCH survival study [Abstract]. American Thoracic Society International Conference; 2007 May 18‐23; San Francisco. 2007:A763. CelliB , VestboJ , JenkinsCR , JonesPW , FergusonGT , CalverleyPMA , et al. Sex differences in mortality and clinical expressions of patients with chronic obstructive pulmonary disease: the TORCH experience. American Journal of Respiratory and Critical Care Medicine2011;183(3):317‐22. CelliBR , ThomasNE , AndersonJA , FergusonGT , JenkinsCR , JonesPW , et al. Effect of pharmacotherapy on rate of decline of lung function in chronic obstructive pulmonary disease: results from the TORCH study. American Journal of Respiratory and Critical Care Medicine2008;178(4):332‐8. CelliD , EmmettA , CraterG , KalbergC . Salmeterol/fluticasone propionate (SFC) improves the inspiratory to total lung capacity ratio (IC/TLC) and exercise endurance time in patients with COPD. European Respiratory Journal2006;28 Suppl 50:764 [4395]. CorhayJL , LouisR . Clinical study of the month: the TORCH study (TOwards a Revolution in COPD Health) [L'étude clinique du mois. L'étude TORCH (TOwards a Revolution in COPD Health): vers une revolution de la santé des patients souffrant de BPCO]. Revue Medicale de Liege2007;62(4):230‐4. FergusonGT , CalverleyPM , AndersonJA , CelliB , JenkinsC , JonesPW , et al. The TOwards a Revolution in COPD Health (TORCH) study: fluticasone propionate/salmeterol is well tolerated in patients with COPD over 3 years [Abstract]. Chest2006;130(4):178s. FergusonGT , CalverleyPM , AndersonJA , CelliB , JenkinsCR , JonesPW , et al. Effect of salmeterol/fluticasone propionate (SFC) on bone mineral density (BMD) and eye disorders over three years in the TORCH trial [Abstract]. American Thoracic Society International Conference; 2007 May 18‐23; San Francisco. 2007:A763. FergusonGT , CalverleyPM , AndersonJA , JenkinsCR , CelliB , et al. Prevalence and progression of osteoporosis in patients with COPD results from the towards a revolution in COPD health study. Chest2009;136(6):1456‐65. FergusonGT , CalverleyPMA , AndersonJA , et al. The TORCH (TOwards a Revolution in COPD Health) study: salmeterol/fluticasone propionate (SFC) improves survival in COPD over three years. European Respiratory Journal2006;28 Suppl 50:34s. GlickH , BriggsA , Lozano‐OrtegaG , SpencerM , VestboJ , CalverleyP . Is treatment with ICS/LABA combination good value for money in COPD? Evidence from the TORCH study [Abstract]. American Thoracic Society International Conference; 2007 May 18‐23; San Francisco. 2007:[C97]. JenkinsC , CelliB , AndersonJ , FergusonG , CalverleyP , JonesP , et al. Salmeterol/fluticasone propionate (SFC) is efficacious in GOLD stage II COPD patients: analysis from the TORCH study [Abstract]. American Thoracic Society International Conference; May 15‐20; San Diego. 2009:A6186 [Poster #213]. JenkinsCR , CelliB , AndersonJA , FergusonGT , JonesPW , VestboJ , et al. Seasonality and determinants of moderate and severe COPD exacerbations in the TORCH study. European Respiratory Journal2012;39:38‐45. JenkinsCR , CelliB , AndersonJA , FergusonGT , JonesPW , VestboJ , et al. The TORCH survival study: consistent efficacy results seen in geographic regions in a multi‐national study [Abstract]. American Thoracic Society International Conference; May 18‐23; San Francisco. 2007:[C97]. JenkinsCR , JonesPW , CalverleyPM , CelliB , AndersonJA , FergusonGT , et al. Efficacy of salmeterol/fluticasone propionate by GOLD stage of chronic obstructive pulmonary disease: analysis from the randomised, placebo‐controlled TORCH study. Respiratory Research2009;10:59. JonesPW , AndersonJA , CalverleyPM , CelliBR , FergusonGT , JenkinsC , et al. Health status in the TORCH study of COPD: treatment efficacy and other determinants of change. Respiratory Research2011;12:71. JonesPW , CalverleyPM , CelliB , AndersonJA , FergusonGT , JenkinsC , et al. The TOwards a Revolution in COPD Health (TORCH) study: fluticasone propionate/salmeterol improves and sustains health status in COPD over 3 years. Chest2006;130(4):177s. JonesPW , VestboJ , AndersonJA , CelliB , FergusonGT , JenkinsCR , et al. Informative withdrawal in a COPD study. An example from the TORCH Study [Abstract]. American Thoracic Society International Conference; 2007 May 18‐23; San Francisco. 2007:[C97]. KeeneON , VestboJ , AndersonJA , CalverleyPM , CelliB , FergusonGT , et al. Methods for therapeutic trials in COPD: Lessons from the TORCH trial. European Respiratory Journal2009;34(5):1018‐23. McDonoughC , BlanchardAR . TORCH study results: pharmacotherapy reduces lung function decline in patients with chronic obstructive pulmonary disease. Hospital Practice2010;38(2):92‐3. McGarveyLP , JohnM , AndersonJA , ZvarichM , WiseRA , Committee TCE et al. Ascertainment of cause‐specific mortality in COPD: operations of the TORCH Clinical Endpoint Committee. Thorax2007;62(5):411‐5. MehtaRS , KathmanSJ , Daley‐YatesPT , CahnT , BeeraheeM , KunkaRL , et al. Pharmacokinetics and pharmacodynamics in COPD patients following long‐term twice‐daily treatment with salmeterol/fluticasone propionate (SFC) 50/500mg and the individual components [Abstract]. American Thoracic Society International Conference; 2007 May 18‐23; San Francisco. 2007:Poster #A41. SCO30003 . A multi‐centre, randomised, double‐blind, parallel group, placebo‐controlled study to investigate the long‐term effects of salmeterol/fluticasone propionate (SERETIDE®/VIANI®/ADVAIR®) 50/500mcg bd, salmeterol 50mcg bd and fluticasone propionate 500mcg bd, all delivered via the DISKUS®/ACCUHALER® inhaler, on the survival of subjects with chronic obstructive pulmonary disease (COPD) over 3 years of treatment. www.ctr.gsk.co.uk (accessed 21 April 2012). SacchettaA . Long term therapy and outcome of chronic obstructive pulmonary disease with or without co‐morbidity: The TORCH Study. Italian Journal of Medicine2008;2(3):11‐5. VestboJ , AndersonJA , CalverleyPM , CelliB , FergusonGT , JenkinsC , et al. Bias due to withdrawal in long‐term randomised trials in COPD: Evidence from the TORCH study. Clinical Respiratory Journal2011;5(1):44‐9. VestboJ , TORCH Study Group. The TORCH (TOwards a Revolution in COPD Health) survival study protocol. European Respiratory Journal2004;24(2):206‐10. ">Calverley 2007 TORCH</a>; <a href="./references#CD010115-bbs2-0017" title="Evaluation of Novel Endpoints in Subjects with Chronic Obstructive Pulmonary Disease(COPD) in a Randomized, Double‐Blind, Placebo‐Controlled Study of Treatment with FluticasonePropionate/Salmeterol 500/50mcg combination and its individual components, FluticasonePropionate 500mcg and Salmeterol 50mcg. http://www.gsk‐clinicalstudyregister.com/ 2008 (accessed 19 April 2012). SCO104925 . Evaluation of Novel Endpoints in Subjects with Chronic Obstructive Pulmonary Disease(COPD) in a Randomized, Double‐Blind, Placebo‐Controlled Study of Treatment with FluticasonePropionate/Salmeterol 500/50mcg combination and its individual components, FluticasonePropionate 500mcg and Salmeterol 50mcg. http:ctr.gsk.co.uk (accessed 19 April 2012). ">GSK SCO104925 2008</a>; <a href="./references#CD010115-bbs2-0020" title="HananiaNA , DarkenP , HorstmanD , ReisnerC , LeeB , DavisS , et al. The efficacy and safety of fluticasone propionate (250 mcg)/salmeterol (50 mcg) combined in the Diskus inhaler for the treatment of COPD. Chest2003;124(3):834‐43. HananiaNA , KnobilK , WatkinsM , WireP , YatesJ , DarkenP . Salmeterol and fluticasone propionate therapy administered by a single Diskus in patients with COPD. Chest2002:S129. HananiaNA , RamsdellJ , PayneK , DavisS , HorstmanD , LeeB , et al. Improvements in airflow and dyspnoea in COPD patients following 24 weeks treatment with salmeterol 50mcg and fluticasone propionate 250mcg alone or in combination via the Diskus. American Journal of Respiratory and Critical Care Medicine2001;163 Suppl 5:A279. HorstmanD , DarkenP , DavisS , LeeB . Improvements in FEV1 and symptoms in poorly reversible COPD patients following treatment with salmeterol 50mcg/fluticasone propionate 250mcg combination [Abstract]. European Respiratory Journal2003;22 Suppl 45:P434. MahlerDA , DarkenP , BrownCP , KnobilK . Predicting lung function responses to combination therapy in chronic obstructive pulmonary disease (COPD) [Abstract]. National COPD Conference; 2003 Nov 14‐15; Arlington. 2003:1081. MahlerDA , DarkenP , BrownCP , KnobilK . Predicting lung function responses to salmeterol/fluticasone propionate combination therapy in COPD [Abstract]. European Respiratory Journal2003;22 Suppl 45:P429. SFCA3007 . A randomized, double‐blind, placebo‐controlled, parallel‐group trial evaluating the safety and efficacy of the DISKUS formulations of salmeterol (SAL) 50mcg BID and fluticasone propionate (FP) 250mcg BID individually and in combination as salmeterol 50mcg/fluticasone propionate 250mcg BID (SFC 50/250) compared to placebo in COPD subjects. http://ctr.gsk.co.uk (accessed 20 April 2012). SpencerM , WireP , LeeB , ChangCN , DarkenP , HorstmanD . Patients with COPD using salmeterol/fluticasone propionate combination therapy experience improved quality of life. European Respiratory Journal2003;22 Suppl 45:51s. SpencerMD , KariaN , AndersonJ . The clinical significance of treatment benefits with the salmeterol/fluticasone propionate 50/500mcg combination in COPD. European Respiratory Journal2004;24 Suppl 48:290s. ">Hanania 2003</a>; <a href="./references#CD010115-bbs2-0026" title="MahlerDA , DarkenP , BrownCP , KnobilK . Predicting lung function responses to combination therapy in chronic obstructive pulmonary disease (COPD). http://www.abstracts2view.com (accessed 15 April 2012). MahlerDA , WireP , HorstmanD , ChangCN , YatesJ , FischerT , et al. Effectiveness of fluticasone propionate and salmeterol combination delivered via the Diskus device in the treatment of chronic obstructive pulmonary disease. American Journal of Respiratory and Critical Care Medicine2002;166(8):1084‐91. SFCA3006 . A randomized, double‐blind, placebo‐controlled, parallel‐group trial evaluating the safety and efficacy of the DISKUS formulations of salmeterol (SAL) 50mcg BID and fluticasone propionate (FP) 500mcg BID individually and in combination as salmeterol 50mcg/fluticasone propionate 500mcg BID (SFC 50/500) compared to placebo in COPD subjects. http://ctr.gsk.co.uk (accessed 17 April 2012). SpencerM , WireP , LeeB , ChangCN , DarkenP , HorstmanD . Patients with COPD using salmeterol/fluticasone propionate combination therapy experience improved quality of life. European Respiratory Journal2003;22 Suppl 45:51. SpencerMD , AndersonJA . Salmeterol/fluticasone combination produces clinically important benefits in dyspnoea and fatigue [Abstract]. American Thoracic Society 2005 International Conference; 2005 May 20‐25; San Diego. 2005:B93 [Poster 308]. SpencerMD , KariaN , AndersonJ . The clinical significance of treatment benefits with the salmeterol/fluticasone propionate 50/500mcg combination in COPD. European Respiratory Journal2004;24 Suppl 48:290. ">Mahler 2002</a>), including two newly published trials using vilanterol and fluticasone furoate (<a href="./references#CD010115-bbs2-0023" title="KerwinEM , Scott‐WilsonC , SanfordL , RennardS , AgustiA , BarnesN , et al. A randomised trial of fluticasone furoate/vilanterol (50/25 mug; 100/25 mug) on lung function in COPD. Respiratory Medicine2013; Vol. 107, issue 4:560‐9. [0954‐6111] KerwinEM , Scott‐WilsonC , SanfordL , RennardSI , AgustiA , BarnesN , et al. Lung function effects and safety of fluticasone furoate (FF)/vilanterol (VI) in patients with COPD: Low‐mid dose assessment [Abstract]. European Respiratory Society Annual Congress; Sep 1‐5; Vienna. 2012; Vol. 40, issue Suppl 56:545s [3082]. ">Kerwin 2013</a>; <a href="./references#CD010115-bbs2-0027" title="MartinezF , BosciaJ , FeldmanG , Scott‐WilsonC , KilbrideS , FabbriL , et al. Lung function effects and safety of fluticasone furoate (FF)/vilanterol (VI) in patients with COPD: mid‐high dose assessment [Abstract]. European Respiratory Society Annual Congress, Vienna, Austria, September 1‐5. 2012; Vol. 40, issue Suppl 56:527s [P2887]. MartinezFJ , BosciaJ , FeldmanG , Scott‐WilsonC , KilbrideS , FabbriL , et al. Fluticasone furoate/vilanterol (100/25; 200/25 mug) improves lung function in COPD: a randomised trial. Respiratory Medicine2013;107(4):550‐9. [0954‐6111] ">Martinez 2013</a>). Fifteen fluticasone studies used fluticasone propionate at a total daily dose of 1000 mcg, and seven used 500 mcg. One further study, <a href="./references#CD010115-bbs2-0015" title="FLTA3025 . A randomized, double‐blind, parallel‐group, comparative trial of inhaled fluticasone propionate 250mcg BID, 500mcg BID, and placebo BID via the DISKUS in subjects with chronic obstructive pulmonary disease (COPD). GlaxoSmithKline Clinical Trial Register (accessed 18 April 2012). ">GSK FLTA3025 2005</a>, included both doses. The three vilanterol studies used fluticasone furoate at total daily doses of 50, 100 and 200 mcg, and 25 mcg of vilanterol. </p> <p>Of the 17 budesonide studies, 13 compared budesonide monotherapy versus placebo, and seven compared budesonide/formoterol combination versus formoterol monotherapy. Three studies had four or more arms and performed both comparisons of interest (<a href="./references#CD010115-bbs2-0005" title="BorgstromL , AskingL , OlssonH , PetersonS . Lack of interaction between disease severity and therapeutic response with budesonide/formoterol in a single inhaler [Abstract]. American Thoracic Society 100th International Conference; 2004 May 21‐26; Orlando. 2004:C22 Poster 505. CalverleyPM , BonsawatW , CsekeZ , ZhongN , PetersonS , OlssonH . Maintenance therapy with budesonide and formoterol in chronic obstructive pulmonary disease. European Respiratory Journal2003;22(6):912‐9. CalverleyPMA . Effect of budesonide/formoterol on severe exacerbations and lung function in moderate to severe COPD. Thorax2002;57 Suppl III:iii44. CalverleyPMA , CsekeZ , PetersonS . Budesonide/formoterol reduces the use of oral corticosteroids in the treatment of COPD [Abstract]. European Respiratory Journal2003;22 Suppl 45:P436. CalverleyPMA , KunaP , OlssonH . COPD exacerbations are reduced by budesonide/formoterol in a single inhaler [Abstract]. European Respiratory Journal2003;22 Suppl 45:P1587. CalverleyPMA , OlssonH , Symbicort International COPD Study Group. Budesonide/formoterol in a single inhaler sustains improvements in lung function over 12 months compared with mono‐components and placebo in patients with COPD [abstract]. American Thoracic Society 99th International Conference; 2003 May 16‐21; Seattle. 2003:B024 Poster 418. CalverleyPMA , PetersonS . Combining budesonide/formoterol in a single inhaler reduces exacerbation frequency in COPD [abstract]. American Thoracic Society 99th International Conference; 2003 May 16‐21; Seattle. 2003:D092 Poster 211. CalverleyPMA , StahlE , JonesPW . Budesonide/formoterol improves the general health status of patients with COPD [Abstract]. American Thoracic Society International Conference; 2005 May 20‐25; San Diego. 2005:B93 Poster 303. CalverleyPMA , SzafranskiW , AnderssonA . Budesonide/formoterol is a well‐tolerated long term maintenance therapy for COPD. European Respiratory Journal2005;26 Suppl 49:Poster 1917. CalverleyPMA , ThompsonNC , OlssonH . Budesonide/formoterol in a single inhaler sustains lung function improvements in COPD [Abstract]. European Respiratory Journal2003;22 Suppl 45:P435. HalpinD , StåhlE , LundbackB , AndersonF , PetersonS . Treatment costs and number needed to treat (NNT) with budesonide/formoterol to avoid one exacerbation of COPD [Abstract]. American Thoracic Society 100th International Conference; 2004 May 21‐26; Orlando. 2004:D22 Poster 525. HalpinDMG , LarssonT , CalverleyPMA . How many patients with COPD must be treated with budesonide/formoterol compared with formoterol alone to avoid 1 day of oral steroid use? [Abstract]. American Thoracic Society International Conference; 2005 May 20‐25; San Diego. 2005:B93 Poster 314. JonesPW , StåhlE . Budesonide/formoterol in a single inhaler improves health status in patients with COPD [abstract]. American Thoracic Society 99th International Conference; 2003 May 16‐21; Seattle. 2003:B024 Poster 419. JonesPW , StåhlE . Budesonide/formoterol sustains clinically relevant improvements in health status in COPD [Abstract]. European Respiratory Journal2005;26(Suppl 49):Abstract No. 1352. JonesPW , StåhlE . Reducing exacerbations leads to a better health‐related quality of life in patients with COPD. European Respiratory Society 13th Annual Congress; 2003 Sep 28‐29; Vienna. 2003:P1586. LofdahlCG . Reducing the impact of COPD exacerbations: clinical efficacy of budesonide/formoterol. European Respiratory Review2004;13(88):14‐21. LofdahlCG , AndreassonE , SvenssonK , EricssonA . Budesonide/formoterol in a single inhaler improves health status in patients with COPD without increasing healthcare costs [Abstract]. European Respiratory Journal2003;22(Suppl 45):P433. LofdahlCG , EricssonA , SvenssonK , AndreassonE . Cost effectiveness of budesonide/formoterol in a single inhaler for COPD compared with each mono‐component used alone. Pharmacoeconomics2005;23(4):365‐75. ">Calverley 2003b</a>; <a href="./references#CD010115-bbs2-0038" title="AndersonP . Budesonide/formoterol in a single inhaler (Symbicort) provides early and sustained improvement in lung function in moderate to severe COPD. Thorax2002;57 Suppl 3:iii43. BorgstromL , AskingL , OlssonH , PetersonS . Lack of interaction between disease severity and therapeutic response with budesonide/formoterol in a single inhaler [Abstract].. American Thoracic Society 100th International Conference; May 21‐26; Orlando. 2004:C22 [Poster 505]. CalverleyP , Pauwels DaggerR , LöfdahlCG , SvenssonK , HigenbottamT , CarlssonLG , et al. Relationship between respiratory symptoms and medical treatment in exacerbations of COPD. European Respiratory Journal2005;26(3):406‐13. CalverleyPMA . Effect of budesonide/formoterol on severe exacerbations and lung function in moderate to severe COPD. Thorax2002;BTS Winter Meeting 2002:S145. CalverleyPMA , SzafranskiW , AnderssonA . Budesonide/formoterol is a well‐tolerated long term maintenance therapy for COPD. European Respiratory Journal2005;26 Suppl 49:Poster 1917. CalverleyPMA , ThompsonNC , OlssonH . Budesonide/formoterol in a single inhaler sustains lung function improvements in COPD [Abstract]. European Respiratory Journal2003;22 Suppl 45:P435. CampbellLM , SzafranskiW . Budesonide/formoterol in a single inhaler (Symbicort) provides sustained relief from symptoms in moderate to severe COPD. Thorax. 2002; Vol. BTS Winter Meeting 2002:S143. CampbellLW , SzafranskiW . Budesonide/formoterol in a single inhaler (Symbicort) reduces severe exacerbations in patients with moderate‐severe COPD. Thorax. 2002; Vol. BTS Winter Meeting 2002:S141. DahlR , CukierA , OlssonH . Budesonide/formoterol in a single inhaler reduces severe and mild exacerbations in patients with moderate to severe COPD. European Respiratory Journal2002;20 Suppl 38:242 [P1575]. EgedeF , MengaG . Budesonide/formoterol in a single inhaler provides sustained relief from symptoms and night‐time awakenings in moderate‐severe COPD: results from symptoms and night‐time awakenings in moderate to severe COPD: results from a 1‐year study. European Respiratory Journal2002;20 Suppl 38:242 [P1574]. HalpinD , StahlE , LundbackB , AndersonF , PetersonS . Treatment costs and number needed to treat (NNT) with budesonide/formoterol to avoid one exacerbation of COPD [Abstract]. American Thoracic Society 100th International Conference; May 21‐26; Orlando. 2004:D22 Poster 525. JonesPW , StahlE , SvenssonK . Improvement in health status in patients with moderate to severe COPD after treatment with budesonide/formoterol in a single inhaler. European Respiratory Journal2002;20 Suppl 38:250 [P1613]. KorsgaardJ , SansoresR . Budesonide/formoterol (single inhaler) provides sustained relief from shortness of breath and chest tightness in a 1‐year study of patients with moderate to severe COPD. European Respiratory Journal2002;20 Suppl 38:242 [P1577]. LangeP , SaenzC . Budesonide/formoterol in a single inhaler is well tolerated in patients with moderate to severe COPD: results of a 1 year study. European Respiratory Journal2002;20 Suppl 38:242 [P1573]. LofdahlCG . Reducing the impact of COPD exacerbations: clinical efficacy of budesonide/formoterol. European Respiratory Review2004;13(88):14‐21. MilanowskiJ , NahabedianS . Budesonide/formoterol in a single inhaler acts rapidly to improve lung function and relieve symptoms in patients with moderate to severe COPD. European Respiratory Journal2002;20 Suppl 38:242 [P1576]. SzafranskiW , CukierA , RamirezA , MengaG , SansoresR , NahabedianS , et al. Efficacy and safety of budesonide/formoterol in the management of chronic obstructive pulmonary disease. European Respiratory Journal2003;21:74‐81. SzfranskiW , RamirezA , PetersonS . Budesonide/formoterol in single inhaler provides sustained improvements in lung function in patients with moderate to severe COPD [Abstract]. European Respiratory Society Annual Congress; Sep 14‐18; Stockholm. 2002. ">Szafranski 2003</a>; <a href="./references#CD010115-bbs2-0039" title="AstraZeneca . A 6‐month double‐blind, double‐dummy, randomized, parallel group, multicenter efficacy &amp; safety study of SYMBICORT® pMDI 2 x 160/4.5 μg &amp; 80/4.5 μg bid compared to formoterol TBH, budesonide pMDI (&amp; the combination) &amp; placebo in COPD Patients (SHINE) (study number D589900002). www.astrazenecaclinicaltrials.com (accessed 18 April 2012). BleeckerER , MeyersDA , BaileyWC , SimsAM , BujacSR , GoldmanM , et al. Effect of ß2‐Adrenergic Receptor Gene Polymorphism Gly16Arg on Response to Budesonide/Formoterol Pressurized Metered‐Dose Inhaler in Chronic Obstructive Pulmonary Disease [Abstract]. American Journal of Respiratory and Critical Care Medicine2011;183:A4086. TashkinDP , RennardSI , MartinP , RamachandranS , MartinUJ , SilkoffPE . Efficacy and safety of budesonide and formoterol in one pressurized metered‐dose inhaler in patients with moderate to very severe chronic obstructive pulmonary disease: results of a 6‐month randomized clinical trial. Drugs2008;68(14):1975‐2000. ">Tashkin 2008 SHINE</a>). Twelve studies used a total daily budesonide dose of 640 mcg, and two studies used a daily dose of 1280 mcg (<a href="./references#CD010115-bbs2-0032" title="RenkemaTE , SchoutenJP , KoeterGH , PostmaDS . Effects of long‐term treatment with corticosteroids in COPD. Chest1996;109(5):1156‐62. vanGrunsvenPM , vanSchayckCP , DerenneJP , KerstjensHA , RenkemaTE , PostmaDS , et al. Long term effects of inhaled corticosteroids in chronic obstructive pulmonary disease: a meta‐analysis. Thorax1999;54(1):7‐14. ">Renkema 1996</a>; <a href="./references#CD010115-bbs2-0043" title="YildizF , BasyigitI , YildirimE , BoyaciH , IlgazliA . Does addition of inhaled steroids to combined bronchodilator therapy affect health status in patients with COPD?. Respirology2004;9(3):352‐5. ">Yildiz 2004</a>). Three studies used more than one dose (<a href="./references#CD010115-bbs2-0033" title="BleeckerER , MeyersDA , BaileyWC , SimsAM , BujacSR , GoldmanM , et al. ADRB2 polymorphisms and budesonide/formoterol responses in COPD. Chest2012; Vol. 142, issue 2:320‐8. RennardSI , TashkinDP , McElhattanJ , GoldmanM , RamachandranS , MartinUJ , et al. Efficacy and tolerability of budesonide/formoterol in one hydrofluoroalkane pressurized metered‐dose inhaler in patients with chronic obstructive pulmonary disease. Results from a 1‐year randomized controlled clinical trial. Drugs2009;69(5):549‐65. ">Rennard 2009</a>; <a href="./references#CD010115-bbs2-0037" title="SharafkhanehA , SouthardJG , GoldmanM , UryniakT , MartinUJ . Effect of budesonide/formoterol pMDI on COPD exacerbations: a double‐blind, randomized study. Respiratory Medicine2012;106(2):257‐68. SharafkhanehA , UryniakT , MartinU . Long‐term effects of budesonide/formoterol pressurized metered‐dose inhaler on Chronic Obstructive Pulmonary Disease (COPD) symptoms and health status in patients with COPD [Abstract]. Chest2011;140(4):528A. ">Sharafkhaneh 2012</a>), including one that had a total of six arms (<a href="./references#CD010115-bbs2-0039" title="AstraZeneca . A 6‐month double‐blind, double‐dummy, randomized, parallel group, multicenter efficacy &amp; safety study of SYMBICORT® pMDI 2 x 160/4.5 μg &amp; 80/4.5 μg bid compared to formoterol TBH, budesonide pMDI (&amp; the combination) &amp; placebo in COPD Patients (SHINE) (study number D589900002). www.astrazenecaclinicaltrials.com (accessed 18 April 2012). BleeckerER , MeyersDA , BaileyWC , SimsAM , BujacSR , GoldmanM , et al. Effect of ß2‐Adrenergic Receptor Gene Polymorphism Gly16Arg on Response to Budesonide/Formoterol Pressurized Metered‐Dose Inhaler in Chronic Obstructive Pulmonary Disease [Abstract]. American Journal of Respiratory and Critical Care Medicine2011;183:A4086. TashkinDP , RennardSI , MartinP , RamachandranS , MartinUJ , SilkoffPE . Efficacy and safety of budesonide and formoterol in one pressurized metered‐dose inhaler in patients with moderate to very severe chronic obstructive pulmonary disease: results of a 6‐month randomized clinical trial. Drugs2008;68(14):1975‐2000. ">Tashkin 2008 SHINE</a>): three combination arms, budesonide 640 mcg, formoterol 18 mcg and placebo. Formoterol as monotherapy control or in combination with budesonide was given at a total daily dose of 18 mcg in all studies. </p> <p><a href="#CD010115-tbl-0005">Table 3</a> presents the beclomethasone dipropionate (BDP) equivalent doses for the included treatments. As shown, higher‐dose budesonide (1280 mcg/d = 1280 BDP) is more similar to the lower dose of fluticasone (500 mcg/d = 1000 BDP). Fluticasone furoate doses of 100 mcg and 200 mcg daily are equivalent to fluticasone propionate 250 mcg twice daily (1000 BDP) and 500 mcg twice daily (2000 BDP) respectively, and the lowest dose of fluticasone furoate is equivalent to 500 BDP. Only the 100 mcg dose of fluticasone furoate is currently licensed for use in COPD </p> <div class="table" id="CD010115-tbl-0005"> <table><a class="open-table-viewer open-in-figure-viewer" href="#0">Open in table viewer</a><div class="table-heading"><span class="table-label">Table 3.</span> <span class="table-title">BDP equivalent doses</span></div> <tbody> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><b>Drug</b> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><b>Daily dose (mcg)</b> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><b>BDP equivalent (mcg)</b> </p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="3" valign=""> <p>Budesonide</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>320</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>320</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>640</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>640</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>1280</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>1280</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="5" valign=""> <p>Fluticasone</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>500 (propionate)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>1000</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>1000 (propionate)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>2000</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>50 (furoate)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>500</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>100 (furoate)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>1000</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>200 (furoate)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>2000</p> </td> </tr> </tbody> </table> </div> <p>In most studies, participants were allowed short‐acting bronchodilators and treatment for acute exacerbations. Most studies also allowed people to continue on some long‐acting treatments that were not the treatments under study (usually theophylline, mucolytics, anticholinergics). Run‐in periods varied somewhat in length and nature. Most ranged from two to eight weeks; some required all bronchodilator treatment, ICS alone or ICS and LABA treatment to be tapered off; others used placebo and oral corticosteroids; and a subset did not describe the procedures used. </p> </section> <section id="CD010115-sec-0070"> <h5 class="title">Transitivity and similarity</h5> <p> <ol id="CD010115-list-0013"> <li> <p>Inclusion and exclusion criteria: Inclusion and exclusion criteria, as described above, were considered comparable between the two sets of trials; although variation was noted in the allowed co‐medications between individual trials, this was not systematically different between the fluticasone and budesonide studies. </p> </li> <li> <p>Baseline characteristics: Although variation between trials was seen, we did not consider that baseline characteristics systematically differed between budesonide monotherapy and fluticasone monotherapy trials, or between budesonide combination therapy and fluticasone combination therapy trials (see above and <a href="#CD010115-tbl-0003">Table 1</a>; <a href="#CD010115-tbl-0004">Table 2</a>). </p> </li> <li> <p>Intervention characteristics: Budesonide and fluticasone studies most often used the respective commonly used twice‐daily dose, although the once‐daily fluticasone furoate studies introduced a potential source of heterogeneity. More important, the fluticasone studies generally used the Diskus or Accuhaler, and the budesonide studies used the Turbuhaler device; this may have confounded the common placebo comparator. </p> </li> <li> <p>Methodology: We were concerned that funding for the fluticasone and budesonide trials was systematically different, but in light of similar inclusion criteria, baseline characteristics and study designs, we believed that funding alone was not a reason to believe that the transitivity assumption did not hold. However, although the monotherapy trials were of a comparable duration (weighted means of 22 and 23 months), the fluticasone combination therapy trials were a lot longer than the budesonide combination therapy trials (16 and nine months, respectively). Risk of bias was similar across all studies and did not differ systematically between those funded by the two main drug companies. Similarly, although fluticasone monotherapy trials had somewhat larger sample sizes than budesonide monotherapy trials, this finding was not deemed significant. The two sets of combination therapy trials had very similar mean sample sizes. </p> </li> <li> <p>Control group event rates: Event rates for placebo monotherapy comparisons and for LABA combination therapy comparisons are presented in <a href="#CD010115-tbl-0006">Table 4</a>. Differences were noted between fluticasone and placebo for both monotherapy and combination therapy comparisons, with fluticasone studies consistently showing higher control group event rates. Inspection of control events showed that <a href="./references#CD010115-bbs2-0007" title="AllegraL . TORCH study: An invitation to clinical considerations. GIMT ‐ Giornale Italiano delle Malattie del Torace2007;61(1):15‐23. BriggsAH , GlickHA , Lozano‐OrtegaG , SpencerM , CalverleyPM , JonesPW , et al. Is treatment with ICS and LABA cost‐effective for COPD? Multinational economic analysis of the TORCH study. European Respiratory Journal2010;35(3):532‐9. BriggsAH , Lozano‐OrtegaG , SpencerS , BaleG , SpencerMD , BurgePS . Estimating the cost‐effectiveness of fluticasone propionate for treating chronic obstructive pulmonary disease in the presence of missing data. Value in Health2006;9(4):227‐35. CalverleyP , CelliB , AndersonJ , FergusonG , JenkinsC , JonesP , et al. Salmeterol/fluticasone propionate combination (SFC) improves survival in COPD over three years: on‐treatment analysis from the TORCH study [Abstract]. American Thoracic Society International Conference; 2009 May 15‐20; San Diego. 2009:A6191[Poster #219]. CalverleyP , CelliB , AndersonJA , FergusonGT , JenkinsC , JonesPW , et al. The TOwards a Revolution in COPD Health (TORCH) study: salmeterol/fluticasone propionate improves survival in COPD over three years [Abstract]. Respirology2006;11 Suppl 5:A149 [PS‐3‐8]. CalverleyPM , AndersonJA , CelliB , FergusonGT , JenkinsC , JonesPW , et al. Salmeterol and fluticasone propionate and survival in chronic obstructive pulmonary disease. New England Journal of Medicine2007;356(8):775‐89. CalverleyPM , AndersonJA , CelliB , FergusonGT , JenkinsC , Jones PW et al and TORCH Investigators. Cardiovascular events in patients with COPD: TORCH study results. Thorax2010;65(8):719‐25. CalverleyPM , CelliB , AndersonJA , FergusonGT , JenkinsC , JonesPW , et al. The TOwards a Revolution in COPD Health (TORCH) study: fluticasone propionate /salmeterol improves survival in COPD over three years. Chest2006;130(4):122s. CalverleyPMA , CelliB , AndersenJA , FergusonGT , JenkinsC , JonesPW , et al. The TORCH (TOwards a Revolution in COPD Health) study salmeterol/fluticasone propionate (SFC) improves survival in COPD over three years. European Respiratory Journal2006;28 Suppl 50:34. CelliB , CalverleyPM , AndersonJA , FergusonGT , JenkinsC , JonesP , et al. The TOwards a Revolution in COPD HEalth (TORCH) Study: salmeterol/fluticasone propionate reduces the rate of exacerbations over three years. Respirology2006;11 Suppl 5:A140. CelliB , CalverleyPM , AndersonJA , FergusonGT , JenkinsC , JonesPW , et al. The TOwards a Revolution in COPD Health (TORCH) study: fluticasone propionate/salmeterol reduces the rate of exacerbations over 3 years [Abstract]. Chest2006;130(4):177s. CelliB , CalverleyPMA , AndersonJA , FergusonGT , JenkinsC , JonesPW , et al. The TORCH (TOwards a Revolution in COPD Health) study salmeterol/fluticasone propionate (SFC) improves health status reduces exacerbations and improves lung function over three years [Abstract]. European Respiratory Journal2006;28 Suppl 50:34s [E312]. CelliB , EmmettA , CraterG , KalbergC . Fluticasone propionate/salmeterol (FSC) improves the inspiratory to total lung capacity ratio (IC/TLC) and exercise endurance time in patients with COPD. European Respiratory Society 16th Annual Congress; 2006 Sep 2‐6; Munich. 2006:A320 (Poster 323). CelliB , FergusonGT , AndersonJA , JenkinsCR , JonesPW , VestboJ , et al. Salmeterol/fluticasone propionate (SFC) improves lung function and reduces the rate of decline over three years in the TORCH survival study [Abstract]. American Thoracic Society International Conference; 2007 May 18‐23; San Francisco. 2007:A763. CelliB , VestboJ , JenkinsCR , JonesPW , FergusonGT , CalverleyPMA , et al. Sex differences in mortality and clinical expressions of patients with chronic obstructive pulmonary disease: the TORCH experience. American Journal of Respiratory and Critical Care Medicine2011;183(3):317‐22. CelliBR , ThomasNE , AndersonJA , FergusonGT , JenkinsCR , JonesPW , et al. Effect of pharmacotherapy on rate of decline of lung function in chronic obstructive pulmonary disease: results from the TORCH study. American Journal of Respiratory and Critical Care Medicine2008;178(4):332‐8. CelliD , EmmettA , CraterG , KalbergC . Salmeterol/fluticasone propionate (SFC) improves the inspiratory to total lung capacity ratio (IC/TLC) and exercise endurance time in patients with COPD. European Respiratory Journal2006;28 Suppl 50:764 [4395]. CorhayJL , LouisR . Clinical study of the month: the TORCH study (TOwards a Revolution in COPD Health) [L'étude clinique du mois. L'étude TORCH (TOwards a Revolution in COPD Health): vers une revolution de la santé des patients souffrant de BPCO]. Revue Medicale de Liege2007;62(4):230‐4. FergusonGT , CalverleyPM , AndersonJA , CelliB , JenkinsC , JonesPW , et al. The TOwards a Revolution in COPD Health (TORCH) study: fluticasone propionate/salmeterol is well tolerated in patients with COPD over 3 years [Abstract]. Chest2006;130(4):178s. FergusonGT , CalverleyPM , AndersonJA , CelliB , JenkinsCR , JonesPW , et al. Effect of salmeterol/fluticasone propionate (SFC) on bone mineral density (BMD) and eye disorders over three years in the TORCH trial [Abstract]. American Thoracic Society International Conference; 2007 May 18‐23; San Francisco. 2007:A763. FergusonGT , CalverleyPM , AndersonJA , JenkinsCR , CelliB , et al. Prevalence and progression of osteoporosis in patients with COPD results from the towards a revolution in COPD health study. Chest2009;136(6):1456‐65. FergusonGT , CalverleyPMA , AndersonJA , et al. The TORCH (TOwards a Revolution in COPD Health) study: salmeterol/fluticasone propionate (SFC) improves survival in COPD over three years. European Respiratory Journal2006;28 Suppl 50:34s. GlickH , BriggsA , Lozano‐OrtegaG , SpencerM , VestboJ , CalverleyP . Is treatment with ICS/LABA combination good value for money in COPD? Evidence from the TORCH study [Abstract]. American Thoracic Society International Conference; 2007 May 18‐23; San Francisco. 2007:[C97]. JenkinsC , CelliB , AndersonJ , FergusonG , CalverleyP , JonesP , et al. Salmeterol/fluticasone propionate (SFC) is efficacious in GOLD stage II COPD patients: analysis from the TORCH study [Abstract]. American Thoracic Society International Conference; May 15‐20; San Diego. 2009:A6186 [Poster #213]. JenkinsCR , CelliB , AndersonJA , FergusonGT , JonesPW , VestboJ , et al. Seasonality and determinants of moderate and severe COPD exacerbations in the TORCH study. European Respiratory Journal2012;39:38‐45. JenkinsCR , CelliB , AndersonJA , FergusonGT , JonesPW , VestboJ , et al. The TORCH survival study: consistent efficacy results seen in geographic regions in a multi‐national study [Abstract]. American Thoracic Society International Conference; May 18‐23; San Francisco. 2007:[C97]. JenkinsCR , JonesPW , CalverleyPM , CelliB , AndersonJA , FergusonGT , et al. Efficacy of salmeterol/fluticasone propionate by GOLD stage of chronic obstructive pulmonary disease: analysis from the randomised, placebo‐controlled TORCH study. Respiratory Research2009;10:59. JonesPW , AndersonJA , CalverleyPM , CelliBR , FergusonGT , JenkinsC , et al. Health status in the TORCH study of COPD: treatment efficacy and other determinants of change. Respiratory Research2011;12:71. JonesPW , CalverleyPM , CelliB , AndersonJA , FergusonGT , JenkinsC , et al. The TOwards a Revolution in COPD Health (TORCH) study: fluticasone propionate/salmeterol improves and sustains health status in COPD over 3 years. Chest2006;130(4):177s. JonesPW , VestboJ , AndersonJA , CelliB , FergusonGT , JenkinsCR , et al. Informative withdrawal in a COPD study. An example from the TORCH Study [Abstract]. American Thoracic Society International Conference; 2007 May 18‐23; San Francisco. 2007:[C97]. KeeneON , VestboJ , AndersonJA , CalverleyPM , CelliB , FergusonGT , et al. Methods for therapeutic trials in COPD: Lessons from the TORCH trial. European Respiratory Journal2009;34(5):1018‐23. McDonoughC , BlanchardAR . TORCH study results: pharmacotherapy reduces lung function decline in patients with chronic obstructive pulmonary disease. Hospital Practice2010;38(2):92‐3. McGarveyLP , JohnM , AndersonJA , ZvarichM , WiseRA , Committee TCE et al. Ascertainment of cause‐specific mortality in COPD: operations of the TORCH Clinical Endpoint Committee. Thorax2007;62(5):411‐5. MehtaRS , KathmanSJ , Daley‐YatesPT , CahnT , BeeraheeM , KunkaRL , et al. Pharmacokinetics and pharmacodynamics in COPD patients following long‐term twice‐daily treatment with salmeterol/fluticasone propionate (SFC) 50/500mg and the individual components [Abstract]. American Thoracic Society International Conference; 2007 May 18‐23; San Francisco. 2007:Poster #A41. SCO30003 . A multi‐centre, randomised, double‐blind, parallel group, placebo‐controlled study to investigate the long‐term effects of salmeterol/fluticasone propionate (SERETIDE®/VIANI®/ADVAIR®) 50/500mcg bd, salmeterol 50mcg bd and fluticasone propionate 500mcg bd, all delivered via the DISKUS®/ACCUHALER® inhaler, on the survival of subjects with chronic obstructive pulmonary disease (COPD) over 3 years of treatment. www.ctr.gsk.co.uk (accessed 21 April 2012). SacchettaA . Long term therapy and outcome of chronic obstructive pulmonary disease with or without co‐morbidity: The TORCH Study. Italian Journal of Medicine2008;2(3):11‐5. VestboJ , AndersonJA , CalverleyPM , CelliB , FergusonGT , JenkinsC , et al. Bias due to withdrawal in long‐term randomised trials in COPD: Evidence from the TORCH study. Clinical Respiratory Journal2011;5(1):44‐9. VestboJ , TORCH Study Group. The TORCH (TOwards a Revolution in COPD Health) survival study protocol. European Respiratory Journal2004;24(2):206‐10. ">Calverley 2007 TORCH</a>, which observed a large population over a longer time scale than most other studies (three years), was skewing the event rates. Although four other long‐term fluticasone monotherapy studies (two to three years) were identified, they had smaller populations, did not contribute to all of the outcomes and did not observe the same magnitude of event rates. With this study removed, control group events were much more similar between the two drugs (presented in brackets). Overall, considered in light of similar baselines and inclusion criteria, it is unlikely that the figures represent true differences in baseline event rates of the two populations. </p> </li> </ol> </p> <div class="table" id="CD010115-tbl-0006"> <table><a class="open-table-viewer open-in-figure-viewer" href="#0">Open in table viewer</a><div class="table-heading"><span class="table-label">Table 4.</span> <span class="table-title">Control group event rates</span></div> <tbody> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="2" valign=""></td> <td align="" bgcolor="#ffffff" colspan="2" rowspan="1" valign=""> <p><b>Monotherapy comparison—Placebo control events</b> </p> </td> <td align="" bgcolor="#ffffff" colspan="2" rowspan="1" valign=""> <p><b>Combination comparison—LABA control events</b> </p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><b>Fluticasone</b> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><b>Budesonide</b> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><b>Fluticasone</b> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><b>Budesonide</b> </p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="2" valign=""> <p>Pneumonia‐related serious adverse events</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>2.5%, 77/310</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="2" valign=""> <p>0.9%, 4/445</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>2.5%, 134/5420</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="2" valign=""> <p>0.9%, 19/2079</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>0.5% without TORCH</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>0.7% without TORCH</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="2" valign=""> <p>All‐cause mortality</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>7.6%, 282/3713</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="2" valign=""> <p>2.1%, 37/1763</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>5.1%, 254/5489</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="2" valign=""> <p>1.5%, 37/2534</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>2.4% without TORCH</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>1.2% without TORCH</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="2" valign=""> <p>All‐cause serious adverse events</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>25%, 882/3471</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="2" valign=""> <p>15%, 268/1763</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>21%, 1152/5489</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="2" valign=""> <p>14%, 356/2534</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>14% without TORCH</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>14% without TORCH</p> </td> </tr> </tbody> </table> <div class="table-footnote"> <p>For the fluticasone control groups with and without the large 3‐year TORCH study.</p> </div> </div> <p>In light of all of the information collected, we decided to calculate the indirect comparison of fluticasone and budesonide monotherapy via placebo because the only potential confound was the inhaler device used, and all other moderating factors were considered comparable. For the reasons outlined regarding control group event rates, we conducted a sensitivity analysis excluding <a href="./references#CD010115-bbs2-0007" title="AllegraL . TORCH study: An invitation to clinical considerations. GIMT ‐ Giornale Italiano delle Malattie del Torace2007;61(1):15‐23. BriggsAH , GlickHA , Lozano‐OrtegaG , SpencerM , CalverleyPM , JonesPW , et al. Is treatment with ICS and LABA cost‐effective for COPD? Multinational economic analysis of the TORCH study. European Respiratory Journal2010;35(3):532‐9. BriggsAH , Lozano‐OrtegaG , SpencerS , BaleG , SpencerMD , BurgePS . Estimating the cost‐effectiveness of fluticasone propionate for treating chronic obstructive pulmonary disease in the presence of missing data. Value in Health2006;9(4):227‐35. CalverleyP , CelliB , AndersonJ , FergusonG , JenkinsC , JonesP , et al. Salmeterol/fluticasone propionate combination (SFC) improves survival in COPD over three years: on‐treatment analysis from the TORCH study [Abstract]. American Thoracic Society International Conference; 2009 May 15‐20; San Diego. 2009:A6191[Poster #219]. CalverleyP , CelliB , AndersonJA , FergusonGT , JenkinsC , JonesPW , et al. The TOwards a Revolution in COPD Health (TORCH) study: salmeterol/fluticasone propionate improves survival in COPD over three years [Abstract]. Respirology2006;11 Suppl 5:A149 [PS‐3‐8]. CalverleyPM , AndersonJA , CelliB , FergusonGT , JenkinsC , JonesPW , et al. Salmeterol and fluticasone propionate and survival in chronic obstructive pulmonary disease. New England Journal of Medicine2007;356(8):775‐89. CalverleyPM , AndersonJA , CelliB , FergusonGT , JenkinsC , Jones PW et al and TORCH Investigators. Cardiovascular events in patients with COPD: TORCH study results. Thorax2010;65(8):719‐25. CalverleyPM , CelliB , AndersonJA , FergusonGT , JenkinsC , JonesPW , et al. The TOwards a Revolution in COPD Health (TORCH) study: fluticasone propionate /salmeterol improves survival in COPD over three years. Chest2006;130(4):122s. CalverleyPMA , CelliB , AndersenJA , FergusonGT , JenkinsC , JonesPW , et al. The TORCH (TOwards a Revolution in COPD Health) study salmeterol/fluticasone propionate (SFC) improves survival in COPD over three years. European Respiratory Journal2006;28 Suppl 50:34. CelliB , CalverleyPM , AndersonJA , FergusonGT , JenkinsC , JonesP , et al. The TOwards a Revolution in COPD HEalth (TORCH) Study: salmeterol/fluticasone propionate reduces the rate of exacerbations over three years. Respirology2006;11 Suppl 5:A140. CelliB , CalverleyPM , AndersonJA , FergusonGT , JenkinsC , JonesPW , et al. The TOwards a Revolution in COPD Health (TORCH) study: fluticasone propionate/salmeterol reduces the rate of exacerbations over 3 years [Abstract]. Chest2006;130(4):177s. CelliB , CalverleyPMA , AndersonJA , FergusonGT , JenkinsC , JonesPW , et al. The TORCH (TOwards a Revolution in COPD Health) study salmeterol/fluticasone propionate (SFC) improves health status reduces exacerbations and improves lung function over three years [Abstract]. European Respiratory Journal2006;28 Suppl 50:34s [E312]. CelliB , EmmettA , CraterG , KalbergC . Fluticasone propionate/salmeterol (FSC) improves the inspiratory to total lung capacity ratio (IC/TLC) and exercise endurance time in patients with COPD. European Respiratory Society 16th Annual Congress; 2006 Sep 2‐6; Munich. 2006:A320 (Poster 323). CelliB , FergusonGT , AndersonJA , JenkinsCR , JonesPW , VestboJ , et al. Salmeterol/fluticasone propionate (SFC) improves lung function and reduces the rate of decline over three years in the TORCH survival study [Abstract]. American Thoracic Society International Conference; 2007 May 18‐23; San Francisco. 2007:A763. CelliB , VestboJ , JenkinsCR , JonesPW , FergusonGT , CalverleyPMA , et al. Sex differences in mortality and clinical expressions of patients with chronic obstructive pulmonary disease: the TORCH experience. American Journal of Respiratory and Critical Care Medicine2011;183(3):317‐22. CelliBR , ThomasNE , AndersonJA , FergusonGT , JenkinsCR , JonesPW , et al. Effect of pharmacotherapy on rate of decline of lung function in chronic obstructive pulmonary disease: results from the TORCH study. American Journal of Respiratory and Critical Care Medicine2008;178(4):332‐8. CelliD , EmmettA , CraterG , KalbergC . Salmeterol/fluticasone propionate (SFC) improves the inspiratory to total lung capacity ratio (IC/TLC) and exercise endurance time in patients with COPD. European Respiratory Journal2006;28 Suppl 50:764 [4395]. CorhayJL , LouisR . Clinical study of the month: the TORCH study (TOwards a Revolution in COPD Health) [L'étude clinique du mois. L'étude TORCH (TOwards a Revolution in COPD Health): vers une revolution de la santé des patients souffrant de BPCO]. Revue Medicale de Liege2007;62(4):230‐4. FergusonGT , CalverleyPM , AndersonJA , CelliB , JenkinsC , JonesPW , et al. The TOwards a Revolution in COPD Health (TORCH) study: fluticasone propionate/salmeterol is well tolerated in patients with COPD over 3 years [Abstract]. Chest2006;130(4):178s. FergusonGT , CalverleyPM , AndersonJA , CelliB , JenkinsCR , JonesPW , et al. Effect of salmeterol/fluticasone propionate (SFC) on bone mineral density (BMD) and eye disorders over three years in the TORCH trial [Abstract]. American Thoracic Society International Conference; 2007 May 18‐23; San Francisco. 2007:A763. FergusonGT , CalverleyPM , AndersonJA , JenkinsCR , CelliB , et al. Prevalence and progression of osteoporosis in patients with COPD results from the towards a revolution in COPD health study. Chest2009;136(6):1456‐65. FergusonGT , CalverleyPMA , AndersonJA , et al. The TORCH (TOwards a Revolution in COPD Health) study: salmeterol/fluticasone propionate (SFC) improves survival in COPD over three years. European Respiratory Journal2006;28 Suppl 50:34s. GlickH , BriggsA , Lozano‐OrtegaG , SpencerM , VestboJ , CalverleyP . Is treatment with ICS/LABA combination good value for money in COPD? Evidence from the TORCH study [Abstract]. American Thoracic Society International Conference; 2007 May 18‐23; San Francisco. 2007:[C97]. JenkinsC , CelliB , AndersonJ , FergusonG , CalverleyP , JonesP , et al. Salmeterol/fluticasone propionate (SFC) is efficacious in GOLD stage II COPD patients: analysis from the TORCH study [Abstract]. American Thoracic Society International Conference; May 15‐20; San Diego. 2009:A6186 [Poster #213]. JenkinsCR , CelliB , AndersonJA , FergusonGT , JonesPW , VestboJ , et al. Seasonality and determinants of moderate and severe COPD exacerbations in the TORCH study. European Respiratory Journal2012;39:38‐45. JenkinsCR , CelliB , AndersonJA , FergusonGT , JonesPW , VestboJ , et al. The TORCH survival study: consistent efficacy results seen in geographic regions in a multi‐national study [Abstract]. American Thoracic Society International Conference; May 18‐23; San Francisco. 2007:[C97]. JenkinsCR , JonesPW , CalverleyPM , CelliB , AndersonJA , FergusonGT , et al. Efficacy of salmeterol/fluticasone propionate by GOLD stage of chronic obstructive pulmonary disease: analysis from the randomised, placebo‐controlled TORCH study. Respiratory Research2009;10:59. JonesPW , AndersonJA , CalverleyPM , CelliBR , FergusonGT , JenkinsC , et al. Health status in the TORCH study of COPD: treatment efficacy and other determinants of change. Respiratory Research2011;12:71. JonesPW , CalverleyPM , CelliB , AndersonJA , FergusonGT , JenkinsC , et al. The TOwards a Revolution in COPD Health (TORCH) study: fluticasone propionate/salmeterol improves and sustains health status in COPD over 3 years. Chest2006;130(4):177s. JonesPW , VestboJ , AndersonJA , CelliB , FergusonGT , JenkinsCR , et al. Informative withdrawal in a COPD study. An example from the TORCH Study [Abstract]. American Thoracic Society International Conference; 2007 May 18‐23; San Francisco. 2007:[C97]. KeeneON , VestboJ , AndersonJA , CalverleyPM , CelliB , FergusonGT , et al. Methods for therapeutic trials in COPD: Lessons from the TORCH trial. European Respiratory Journal2009;34(5):1018‐23. McDonoughC , BlanchardAR . TORCH study results: pharmacotherapy reduces lung function decline in patients with chronic obstructive pulmonary disease. Hospital Practice2010;38(2):92‐3. McGarveyLP , JohnM , AndersonJA , ZvarichM , WiseRA , Committee TCE et al. Ascertainment of cause‐specific mortality in COPD: operations of the TORCH Clinical Endpoint Committee. Thorax2007;62(5):411‐5. MehtaRS , KathmanSJ , Daley‐YatesPT , CahnT , BeeraheeM , KunkaRL , et al. Pharmacokinetics and pharmacodynamics in COPD patients following long‐term twice‐daily treatment with salmeterol/fluticasone propionate (SFC) 50/500mg and the individual components [Abstract]. American Thoracic Society International Conference; 2007 May 18‐23; San Francisco. 2007:Poster #A41. SCO30003 . A multi‐centre, randomised, double‐blind, parallel group, placebo‐controlled study to investigate the long‐term effects of salmeterol/fluticasone propionate (SERETIDE®/VIANI®/ADVAIR®) 50/500mcg bd, salmeterol 50mcg bd and fluticasone propionate 500mcg bd, all delivered via the DISKUS®/ACCUHALER® inhaler, on the survival of subjects with chronic obstructive pulmonary disease (COPD) over 3 years of treatment. www.ctr.gsk.co.uk (accessed 21 April 2012). SacchettaA . Long term therapy and outcome of chronic obstructive pulmonary disease with or without co‐morbidity: The TORCH Study. Italian Journal of Medicine2008;2(3):11‐5. VestboJ , AndersonJA , CalverleyPM , CelliB , FergusonGT , JenkinsC , et al. Bias due to withdrawal in long‐term randomised trials in COPD: Evidence from the TORCH study. Clinical Respiratory Journal2011;5(1):44‐9. VestboJ , TORCH Study Group. The TORCH (TOwards a Revolution in COPD Health) survival study protocol. European Respiratory Journal2004;24(2):206‐10. ">Calverley 2007 TORCH</a>. </p> <p>For the combination therapy comparison, we considered the common LABA comparison to systematically differ between the two sets of combination studies; fluticasone studies used either salmeterol or vilanterol, which differed in their delivery and dosing schedules, and budesonide was always compared with formoterol. In addition, the fluticasone studies were much longer, and the same funding and device issues existed as for the monotherapy studies. As such, we did not perform an indirect comparison to compare fluticasone/LABA versus budesonide/LABA. </p> </section> <section id="CD010115-sec-0071"> <h5 class="title">Outcomes and analysis structure</h5> <p>Unless otherwise stated, all of the analyses were conducted as proposed with fixed‐effect models using Mantel‐Haenszel methods. Several outcomes included some zero cells, but estimates were barely affected in sensitivity analyses using the Peto method. Therefore, Peto odds ratios were used only for 'mortality due to pneumonia', because events for this outcome were very rare. The quality of evidence for each outcome was rated using GRADEPro software, and this information is presented in <a href="./full#CD010115-tbl-0001">summary of findings Table for the main comparison</a> (fluticasone) and <a href="./full#CD010115-tbl-0002">summary of findings Table 2</a> (budesonide). </p> <p>Indirect comparisons performed to compare fluticasone with budesonide monotherapy are presented for the primary outcome and for three secondary outcomes (all‐cause mortality, all non‐fatal serious adverse events and all pneumonia events). Although we did not foresee the inclusion of fluticasone furoate when we conceived of the protocol, we decided to combine these data with the fluticasone propionate data on the basis of consistency observed in the monotherapy subgroup of each of the relevant direct analyses (<a href="./references#CD010115-fig-0007" title="">Analysis 1.1</a>; <a href="./references#CD010115-fig-0008" title="">Analysis 1.2</a>; <a href="./references#CD010115-fig-0010" title="">Analysis 1.4</a>). </p> <p>For the primary outcome, 'non‐fatal serious adverse pneumonia events', data were organised into three sets of subgroups to explore the effects of three prespecified potential moderators. Subgroup analyses for daily dose, duration of ICS therapy (≤ one year and &gt; one year) and baseline severity (&lt; 50% FEV<sub>1</sub> predicted and ≥ 50% FEV<sub>1</sub> predicted) are presented separately for fluticasone and budesonide in comparisons three and four, respectively. </p> <p>We also conducted a sensitivity analysis while removing studies judged to be at high risk of bias because of high or uneven levels of dropout. Of the 17 studies that fell into this category, eight reported the primary outcome and were removed from the analysis (fluticasone: <a href="./references#CD010115-bbs2-0006" title="CalverleyP , PauwelsR , VestboJ , JonesP , PrideN , GulsvikA , et al. Combined salmeterol and fluticasone in the treatment of chronic obstructive pulmonary disease: a randomised controlled trial. Lancet2003;361(9356):449‐56. CalverleyPMA , PauwelsR , VestboJ , JonesP , PrideN , GulsvikA , et al. Safety of salmeterol/fluticasone propionate combination in the treatment of chronic obstructive pulmonary disease. European Respiratory Journal2002;20(Suppl 38):242s [P1572]. CalverleyPMA , PauwelsRA , VestboJ , JonesPW , PrideNB , GulsvikA , et al. Clinical improvements with salmeterol / fluticasone propionate combination in differing severities of COPD [A035] [Poster D50]. http://www.abstracts2view.com (accessed 20 April 2012). CalverleyPMA , PauwelsRA , VestboJ , JonesPW , PrideNB , GulsvikA , et al. Salmeterol/fluticasone propionate combination for one year provides greater clinical benefit than its individual components [A98] [Poster 306]. http://www.abstracts‐on‐line.com/abstracts/ATS (accessed 20 April 2012). HunjanMK , ChandlerF . Numbers needed to treat (NNT) to avoid an exacerbation in patients with chronic obstructive pulmonary disease (COPD) using salmeterol/fluticasone propionate combination (SFC) and associated costs [Abstract]. American Thoracic Society 100th International Conference; 2004 May 21‐26; Orlando. 2004:D22 Poster 503. HunjanMK , WilliamsDT . Costs of avoiding exacerbations in patients with chronic obstructive pulmonary disease (COPD) treated with salmeterol/fluticasone propionate combination (Seretide) and salmeterol. European Respiratory Journal2004;24 Suppl 48:291s. HunjanMK , WilliamsDT . Salmeterol/fluticasone propionate combination is clinically effective in avoiding exacerbations in patients with moderate/severe COPD. European Respiratory Journal2004;24 Suppl 48:513s. JonesPW , EdinHM , AndersonJ . Salmeterol/fluticasone propionate combination improves health status in COPD patients.. http://www.abstracts‐on‐line.com/abstracts/ATS (accessed 21 April 2012). JonesPW , StåhlE . Budesonide/formoterol sustains clinically relevant improvements in health status in COPD [Abstract]. European Respiratory Journal2005;26 Suppl 49:Abstract No. 1352. JonesPW , VestboJ , PauwelsRA , CalverleyPMA , AndersonJA , SpencerMD . Informative drop out in COPD studies. Investigation of health status of withdrawals in the TRISTAN study. European Respiratory Society 13th Annual Congress; 2003 Sep 28‐29; Vienna. 2003:P1593. NitschmannS . Inhalational combination therapy in chronic obstructive lung disease. TRISTAN study. German Internist2004;45(6):727‐8. PauwelsRA , CalverlyPMA , VestboJ , JonesPW , PrideN , GulsvikA , et al. Reduction of exacerbations with salmeterol/fluticasone combination 50/500 mcg bd in the treatment of chronic obstructive pulmonary disease. European Respiratory Journal2002;20 Suppl 38:240 [P1569]. PauwelsRA , VestboJ , CalverleyPMA , JonesPW , PrideNB , GulsvikA . Characterization of exacerbations in the TRISTAN study of salmeterol / fluticasone propionate (SFC) combination in moderate to severe COPD. http://www.abstracts2view.com (accessed 20 April 2012). SFCB3024 . A multi‐centre, randomised, double‐blind, parallel group, placebo‐controlled study to compare the efficacy and safety of the salmeterol/FP combination product at a strength of 50/500mcg bd with salmeterol 50mcg bd alone and FP 500mcg bd alone, delivered via the DISKUS™/ACCUHALER™, in the treatment of subjects with chronic obstructive pulmonary disease (COPD) for 12 months. http://ctr.gsk.co.uk (accessed 21 April 2012). SpencerM , BriggsAH , GrossmanRF , RanceL . Development of an economic model to assess the cost effectiveness of treatment interventions for chronic obstructive pulmonary disease. Pharmacoeconomics2005;23(6):619‐37. SpencerMD , KariaN , AndersonJ . The clinical significance of treatment benefits with the salmeterol/fluticasone propionate 50/500mcg combination in COPD. European Respiratory Journal2004;24 Suppl 48:290s. VestboJ , CalverleyPMA , PauwelsR , JonesP , PrideN , GulsvikA , et al. Absence of gender susceptibility to the combination of salmeterol and fluticasone in the treatment of chronic obstructive pulmonary disease. European Respiratory Journal2002;20 Suppl 38:240 [P1570]. VestboJ , PauwelsR , AndersonJA , JonesP , CalverleyP . Early onset of effect of salmeterol and fluticasone propionate in chronic obstructive pulmonary disease. Thorax2005;60(4):301‐4. VestboJ , PauwelsRA , CalverleyPMA , JonesPW , PrideNB , GulsvikA . Salmeterol/fluticasone propionate combination produces improvement in lung function detectable within 24 hours in moderate to severe COPD. http://www.abstracts2view.com (accessed 20 April 2012). VestboJ , SorianoJB , AndersonJA , CalverleyP , PauwelsR , JonesP . Gender does not influence the response to the combination of salmeterol and fluticasone propionate in COPD. Respiratory Medicine2004;98(11):1045‐50. ">Calverley 2003 TRISTAN</a>; <a href="./references#CD010115-bbs2-0012" title="DalalAA , BlanchetteCM , PetersenH , ManaviK , St. CharlesM . Cost‐effectiveness of fluticasone propionate/salmeterol (250/50 mcg) compared to salmeterol (50 mcg) in patients with COPD: economic evaluation of a randomized, double‐blind, parallel‐group, multi‐centre trial (Study SCO40043) [Abstract]. Chest2008;134(4):106003s. FergusonG , AnzuetoA , FeiR , EmmettA , CraterG , KnobilK , et al. A randomized, double‐blind trial comparing the effect of fluticasone/salmeterol 250/50 to salmeterol on COPD exacerbations in patients with COPD. Chest2007;132(4):530b‐531. FergusonGT , AnzuetoA , FeiR , EmmettA , KnobilK , KalbergC . Effect of fluticasone propionate/salmeterol (250/50 mcg) or salmeterol (50 mcg) on COPD exacerbations. Respiratory Medicine2008;102:1099‐108. SCO40043 . A randomized, double‐blind, parallel‐group, 52‐week study to compare the effect of fluticasone propionate/salmeterol DISKUS® 250/50mcg bid with salmeterol DISKUS® 50mcg bid on the annual rate of moderate/severe exacerbations in subjects with chronic obstructive pulmonary disease (COPD). http://ctr.gsk.co.uk (accessed 8 April 2008). ">Ferguson 2008</a>; <a href="./references#CD010115-bbs2-0019" title="NCT00355342 . A Randomized, Double‐Blind, Parallel‐Group Clinical Trial Evaluating the Effect of the Fluticasone Propionate/Salmeterol Combination Product 250/50mcg BID Via DISKUS Versus Salmeterol 50mcg BID Via DISKUS on Bone Mineral Density in Subjects With Chronic Obstructive Pulmonary Disease (COPD). http://clinicaltrials.gov/show/NCT00355342 (accessed 19 April 2012). ">GSK SCO40041 2008</a>; <a href="./references#CD010115-bbs2-0024" title="KunzLIZ , StrebusJ , BudulacSE , LapperreTS , SterkPJ , PostmaDS , et al. Inhaled Steroids Modulate Extracellular Matrix Composition in Bronchial Biopsies of COPD Patients: A Randomized, Controlled Trial. PloS one2013; Vol. 8, issue 5:e63430. LapperreTS , Snoeck‐StrobandJB , GosmanMM , JansenDF , vanSchadewijkA , ThiadensHA , et al. Effect of fluticasone with and without salmeterol on pulmonary outcomes in chronic obstructive pulmonary disease: a randomized trial. Annals of Internal Medicine2009;151(8):517‐27. ">Lapperre 2009</a>; <a href="./references#CD010115-bbs2-0026" title="MahlerDA , DarkenP , BrownCP , KnobilK . Predicting lung function responses to combination therapy in chronic obstructive pulmonary disease (COPD). http://www.abstracts2view.com (accessed 15 April 2012). MahlerDA , WireP , HorstmanD , ChangCN , YatesJ , FischerT , et al. Effectiveness of fluticasone propionate and salmeterol combination delivered via the Diskus device in the treatment of chronic obstructive pulmonary disease. American Journal of Respiratory and Critical Care Medicine2002;166(8):1084‐91. SFCA3006 . A randomized, double‐blind, placebo‐controlled, parallel‐group trial evaluating the safety and efficacy of the DISKUS formulations of salmeterol (SAL) 50mcg BID and fluticasone propionate (FP) 500mcg BID individually and in combination as salmeterol 50mcg/fluticasone propionate 500mcg BID (SFC 50/500) compared to placebo in COPD subjects. http://ctr.gsk.co.uk (accessed 17 April 2012). SpencerM , WireP , LeeB , ChangCN , DarkenP , HorstmanD . Patients with COPD using salmeterol/fluticasone propionate combination therapy experience improved quality of life. European Respiratory Journal2003;22 Suppl 45:51. SpencerMD , AndersonJA . Salmeterol/fluticasone combination produces clinically important benefits in dyspnoea and fatigue [Abstract]. American Thoracic Society 2005 International Conference; 2005 May 20‐25; San Diego. 2005:B93 [Poster 308]. SpencerMD , KariaN , AndersonJ . The clinical significance of treatment benefits with the salmeterol/fluticasone propionate 50/500mcg combination in COPD. European Respiratory Journal2004;24 Suppl 48:290. ">Mahler 2002</a>; budesonide: <a href="./references#CD010115-bbs2-0033" title="BleeckerER , MeyersDA , BaileyWC , SimsAM , BujacSR , GoldmanM , et al. ADRB2 polymorphisms and budesonide/formoterol responses in COPD. Chest2012; Vol. 142, issue 2:320‐8. RennardSI , TashkinDP , McElhattanJ , GoldmanM , RamachandranS , MartinUJ , et al. Efficacy and tolerability of budesonide/formoterol in one hydrofluoroalkane pressurized metered‐dose inhaler in patients with chronic obstructive pulmonary disease. Results from a 1‐year randomized controlled clinical trial. Drugs2009;69(5):549‐65. ">Rennard 2009</a>; <a href="./references#CD010115-bbs2-0036" title="ShakerSB , DirksenA , UlrikCS , HestadM , StavngaardT , LaursenLC , et al. The effect of inhaled corticosteroids on the development of emphysema in smokers assessed by annual computed tomography. COPD: Journal of Chronic Obstructive Pulmonary Disease2009;6(2):104‐11. ShakerSB , StavngaardT , LaursenLC , StoelBC , DirksenA . Rapid fall in lung density following smoking cessation in COPD. COPD: Journal of Chronic Obstructive Pulmonary Disease2011;8(1):2‐7. ">Shaker 2009</a>; <a href="./references#CD010115-bbs2-0037" title="SharafkhanehA , SouthardJG , GoldmanM , UryniakT , MartinUJ . Effect of budesonide/formoterol pMDI on COPD exacerbations: a double‐blind, randomized study. Respiratory Medicine2012;106(2):257‐68. SharafkhanehA , UryniakT , MartinU . Long‐term effects of budesonide/formoterol pressurized metered‐dose inhaler on Chronic Obstructive Pulmonary Disease (COPD) symptoms and health status in patients with COPD [Abstract]. Chest2011;140(4):528A. ">Sharafkhaneh 2012</a>). </p> </section> </section> <section id="CD010115-sec-0072"> <h4 class="title">Excluded studies</h4> <p>Thirty‐one references were excluded after full texts were consulted. Reasons for exclusion were 'wrong comparison' (n = 19), discontinuation of study (n = 6), 'asthma diagnosis' (n = 2) and 'treatment period less than 12 weeks (n = 2). One study is awaiting classification (only abstract is available), and recruitment for one study was ongoing in March 2014. Full details are listed in <a href="./references#CD010115-sec-0140" title="">Characteristics of excluded studies</a>. </p> </section> </section> <section id="CD010115-sec-0073"> <h3 class="title">Risk of bias in included studies</h3> <p>Studies generally were well conducted and were rated as low or unclear risk of bias for all four of the allocation and blinding parameters. However, in almost half of the studies, potential for bias was due to attrition and selective outcome reporting. Full details of our judgements for each study, as well as supporting information for each judgement, can be found in <a href="./references#CD010115-sec-0139" title="">Characteristics of included studies</a>. A summary of risk of bias across all studies is shown in <a href="#CD010115-fig-0003">Figure 3</a>. </p> <div class="figure" id="CD010115-fig-0003"> <div class="figure-caption-wrapper-top"> <nav class="inline-nav-list has-dividers"> <ul> <li><a class="open-in-figure-viewer" href="#0">Open in figure viewer</a></li> </ul> </nav> <div class="figure-label">Figure 3</div> </div> <hr class="top"/><img alt="Risk of bias summary: review authors' judgements about each risk of bias item for each included study." data-id="CD010115-fig-0003" src="/cdsr/doi/10.1002/14651858.CD010115.pub2/media/CDSR/CD010115/image_n/nCD010115-AFig-FIG03.png"/><hr class="bottom"/> <div class="figure-caption-wrapper-bottom"> <div class="figure-caption"> <p>Risk of bias summary: review authors' judgements about each risk of bias item for each included study. </p> </div> </div> </div> <section id="CD010115-sec-0074"> <h4 class="title">Allocation</h4> <p>Studies were rated for potential biases introduced by the method of sequence generation (e.g. computerised random number generator) and by the methods used to conceal the allocation sequence from those recruiting people into the studies. </p> <p>Most studies were judged to be at low risk of bias for sequence generation (n = 39). Although not all of these studies adequately described sequence generation methods, all were funded by pharmaceutical companies that had previously confirmed their methods. The remaining four studies were rated 'unclear' because they did not describe their methods in detail and did not appear to be funded by a pharmaceutical company (<a href="./references#CD010115-bbs2-0010" title="Dal NegroR , MichelettoC , TrevsianF , TognellaS . Salmeterol and fluticasone 50ug/250ug BiD versus salmeterol 50ug bid and versus placebo in the long term treatment of COPD. American Thoracic Society 98th International Conference; May 17‐22; Georgia. 2002. Dal NegroRW , PomariC , TognellaS , MichelettoC . Salmeterol &amp; fluticasone 50 mcg/250 mcg bid in combination provides a better long‐term control than salmeterol 50 microg bid alone and placebo in COPD patients already treated with theophylline. Pulmonary Pharmacology and Therapeutics2003;16(4):241‐6. ">Dal Negro 2003</a>; <a href="./references#CD010115-bbs2-0035" title="SenderovitzT , VestboJ , FrandsenJ , MaltbaekN , NorgaardM , NielsenC , et al. Steroid reversibility test followed by inhaled budesonide or placebo in outpatients with stable chronic obstructive pulmonary disease. Respiratory Medicine1999;93(10):715‐8. ">Senderovitz 1999</a>; <a href="./references#CD010115-bbs2-0043" title="YildizF , BasyigitI , YildirimE , BoyaciH , IlgazliA . Does addition of inhaled steroids to combined bronchodilator therapy affect health status in patients with COPD?. Respirology2004;9(3):352‐5. ">Yildiz 2004</a>). </p> <p>Allocation concealment was not well reported, and only 17 studies were given a rating of low risk of bias because they adequately described the methods used. However, no studies were considered to be at high risk of bias, and the remaining 26 studies were given an 'unclear' rating. </p> </section> <section id="CD010115-sec-0075"> <h4 class="title">Blinding</h4> <p>The risk of bias introduced by methods of blinding was rated separately for blinding of participants and personnel and for blinding of the people assessing outcomes. </p> <p>Most studies stated that double‐blind procedures were used, and trial reports or registrations usually confirmed that this approach included both participants and investigators. For this reason, most studies were rated as low risk of bias (n = 39), and the remaining four were rated as 'unclear'. No studies were open‐label or used inadequate blinding procedures, so none were judged to be at high risk of bias. </p> <p>Quite often, it was difficult to ascertain from the study reports who the outcome assessors were and for which outcomes the blinding applied. Only 10 studies gave enough information to allow a judgement of low risk of bias to be made, and the remaining 33 were rated as 'unclear'. </p> </section> <section id="CD010115-sec-0076"> <h4 class="title">Incomplete outcome data</h4> <p>Around half of the studies were rated as low risk of bias because of incomplete outcome data (n = 21), either because the number of dropouts per group was low and even, or because the quantity and distribution of missing data were deemed acceptable given the method of imputation (e.g. intention‐to‐treat analysis using last observation carried forward). Sixteen studies were rated as high risk of bias, usually because dropout was very high in both groups, or because dropout was much higher in one group than in another. In the remaining six studies, authors considered that the information regarding attrition was not sufficient to permit judgement of whether dropout and methods of data imputation were likely to have affected the results. </p> </section> <section id="CD010115-sec-0077"> <h4 class="title">Selective reporting</h4> <p>More than half of the studies were rated as low risk of bias for selective outcome reporting (n = 24), either because reported outcomes could be checked against the outcomes stated in a prospectively registered protocol, or because study authors provided additional data through personal communication. Five studies were rated as unclear, usually because no clear evidence on missing outcomes was available, but no trial registration could be found to confirm that all prespecified outcomes were properly reported. In all cases, attempts were made to contact trial authors for clarification; this is detailed in each study's risk of bias table in <a href="./references#CD010115-sec-0139" title="">Characteristics of included studies</a>. The remaining 14 studies were judged to be at high risk of bias, either because outcomes stated in the trial registration were missing or poorly reported in the published report, or because several key outcomes analysed in this review were not reported. </p> </section> <section id="CD010115-sec-0078"> <h4 class="title">Other potential sources of bias</h4> <p>No additional sources of bias were identified.</p> </section> </section> <section id="CD010115-sec-0079"> <h3 class="title" id="CD010115-sec-0079">Effects of interventions</h3> <p>See: <a href="./full#CD010115-tbl-0001"><b>Summary of findings for the main comparison</b> Fluticasone for chronic obstructive pulmonary disease</a>; <a href="./full#CD010115-tbl-0002"><b>Summary of findings 2</b> Budesonide for chronic obstructive pulmonary disease</a> </p> <p>In comparisons one and three, studies are pooled for fluticasone and budesonide, respectively, and are subgrouped in each case in terms of whether each randomly assigned group also received a long‐acting beta‐agonist. Comparisons two and four show additional subgroup analyses for the primary outcome of non‐fatal serious adverse events for fluticasone and budesonide, respectively. </p> <p>Comparison five presents results for the indirect comparison of fluticasone and budesonide via the common placebo comparator (<a href="#CD010115-fig-0001">Figure 1</a>). Comparison six refers to the equivalent comparison of fluticasone with budesonide given as combination therapy with a long‐acting beta‐agonist. As described above, no indirect comparison was undertaken for combination therapy because of violations of transitivity and similarity. </p> <p>For illustration and visual comparison of the two drugs, effects of all fluticasone studies (comparison one) and all budesonide studies (comparison three) are presented together for each outcome in <a href="#CD010115-fig-0004">Figure 4</a>. No statistical heterogeneity was noted between the pooled effect for budesonide and that of fluticasone for all outcomes except 'all pneumonia events'; for this reason the effects are not pooled for this outcome. </p> <div class="figure" id="CD010115-fig-0004"> <div class="figure-caption-wrapper-top"> <nav class="inline-nav-list has-dividers"> <ul> <li><a class="open-in-figure-viewer" href="#0">Open in figure viewer</a></li> </ul> </nav> <div class="figure-label">Figure 4</div> </div> <hr class="top"/><img alt="Summary of pooled effects of trials comparing ICS versus placebo and combination versus LABA.  Non‐fatal serious adverse pneumonia events were those requiring hospital admission. Data for all pneumonia events were not pooled because of heterogeneity." data-id="CD010115-fig-0004" src="/cdsr/doi/10.1002/14651858.CD010115.pub2/media/CDSR/CD010115/image_n/nCD010115-AFig-FIG04.png"/><hr class="bottom"/> <div class="figure-caption-wrapper-bottom"> <div class="figure-caption"> <p>Summary of pooled effects of trials comparing ICS versus placebo and combination versus LABA.<br/> Non‐fatal serious adverse pneumonia events were those requiring hospital admission. Data for all pneumonia events were not pooled because of heterogeneity. </p> </div> </div> </div> <section id="CD010115-sec-0080"> <h4 class="title">Comparison one: fluticasone versus controls (all outcomes subgrouped to compare ICS vs placebo with ICS/LABA vs LABA) </h4> <section id="CD010115-sec-0081"> <h5 class="title">1.1 Primary outcome: non‐fatal, serious adverse pneumonia events (requiring hospital admission) </h5> <p>Twenty‐four comparisons in 17 studies were analysed (n = 19,504), with seven studies contributing data to both the 'fluticasone versus placebo' and 'fluticasone/LABA versus LABA' subgroups. Fluticasone increased the incidence of non‐fatal serious adverse pneumonia events (OR 1.78, 95% CI 1.50 to 2.12; I<sup>2</sup> = 0%, P value 0.65), with no significant heterogeneity noted between studies. No significant evidence indicated that the odds of having a serious adverse pneumonia event were differentially affected by fluticasone alone (against placebo) compared with fluticasone/LABA combination (against LABA alone) (I<sup>2</sup> = 0%, P value 0.77). The outcome was rated of high quality. </p> </section> <section id="CD010115-sec-0082"> <h5 class="title">1.2 Mortality, all‐cause</h5> <p>Twenty‐nine comparisons in 22 fluticasone studies were included in the analysis (n = 20,861), although seven comparisons did not contribute to the pooled estimate because no events were reported in either group. No evidence suggested a difference between fluticasone and controls (OR 0.99, 95% CI 0.87 to 1.13; I<sup>2</sup> = 0%, P value 0.73), and a test for subgroup differences between 'fluticasone versus placebo' and 'fluticasone/LABA versus LABA' comparisons was not significant (I<sup>2</sup> = 0%, P value 0.39). Evidence was rated of high quality. </p> </section> <section id="CD010115-sec-0083"> <h5 class="title">1.3 Mortality, due to pneumonia</h5> <p>Data for pneumonia‐related deaths were available for 25 comparisons in 18 studies (n = 19,532). However, all but five comparisons observed no events, and <a href="./references#CD010115-bbs2-0007" title="AllegraL . TORCH study: An invitation to clinical considerations. GIMT ‐ Giornale Italiano delle Malattie del Torace2007;61(1):15‐23. BriggsAH , GlickHA , Lozano‐OrtegaG , SpencerM , CalverleyPM , JonesPW , et al. Is treatment with ICS and LABA cost‐effective for COPD? Multinational economic analysis of the TORCH study. European Respiratory Journal2010;35(3):532‐9. BriggsAH , Lozano‐OrtegaG , SpencerS , BaleG , SpencerMD , BurgePS . Estimating the cost‐effectiveness of fluticasone propionate for treating chronic obstructive pulmonary disease in the presence of missing data. Value in Health2006;9(4):227‐35. CalverleyP , CelliB , AndersonJ , FergusonG , JenkinsC , JonesP , et al. Salmeterol/fluticasone propionate combination (SFC) improves survival in COPD over three years: on‐treatment analysis from the TORCH study [Abstract]. American Thoracic Society International Conference; 2009 May 15‐20; San Diego. 2009:A6191[Poster #219]. CalverleyP , CelliB , AndersonJA , FergusonGT , JenkinsC , JonesPW , et al. The TOwards a Revolution in COPD Health (TORCH) study: salmeterol/fluticasone propionate improves survival in COPD over three years [Abstract]. Respirology2006;11 Suppl 5:A149 [PS‐3‐8]. CalverleyPM , AndersonJA , CelliB , FergusonGT , JenkinsC , JonesPW , et al. Salmeterol and fluticasone propionate and survival in chronic obstructive pulmonary disease. New England Journal of Medicine2007;356(8):775‐89. CalverleyPM , AndersonJA , CelliB , FergusonGT , JenkinsC , Jones PW et al and TORCH Investigators. Cardiovascular events in patients with COPD: TORCH study results. Thorax2010;65(8):719‐25. CalverleyPM , CelliB , AndersonJA , FergusonGT , JenkinsC , JonesPW , et al. The TOwards a Revolution in COPD Health (TORCH) study: fluticasone propionate /salmeterol improves survival in COPD over three years. Chest2006;130(4):122s. CalverleyPMA , CelliB , AndersenJA , FergusonGT , JenkinsC , JonesPW , et al. The TORCH (TOwards a Revolution in COPD Health) study salmeterol/fluticasone propionate (SFC) improves survival in COPD over three years. European Respiratory Journal2006;28 Suppl 50:34. CelliB , CalverleyPM , AndersonJA , FergusonGT , JenkinsC , JonesP , et al. The TOwards a Revolution in COPD HEalth (TORCH) Study: salmeterol/fluticasone propionate reduces the rate of exacerbations over three years. Respirology2006;11 Suppl 5:A140. CelliB , CalverleyPM , AndersonJA , FergusonGT , JenkinsC , JonesPW , et al. The TOwards a Revolution in COPD Health (TORCH) study: fluticasone propionate/salmeterol reduces the rate of exacerbations over 3 years [Abstract]. Chest2006;130(4):177s. CelliB , CalverleyPMA , AndersonJA , FergusonGT , JenkinsC , JonesPW , et al. The TORCH (TOwards a Revolution in COPD Health) study salmeterol/fluticasone propionate (SFC) improves health status reduces exacerbations and improves lung function over three years [Abstract]. European Respiratory Journal2006;28 Suppl 50:34s [E312]. CelliB , EmmettA , CraterG , KalbergC . Fluticasone propionate/salmeterol (FSC) improves the inspiratory to total lung capacity ratio (IC/TLC) and exercise endurance time in patients with COPD. European Respiratory Society 16th Annual Congress; 2006 Sep 2‐6; Munich. 2006:A320 (Poster 323). CelliB , FergusonGT , AndersonJA , JenkinsCR , JonesPW , VestboJ , et al. Salmeterol/fluticasone propionate (SFC) improves lung function and reduces the rate of decline over three years in the TORCH survival study [Abstract]. American Thoracic Society International Conference; 2007 May 18‐23; San Francisco. 2007:A763. CelliB , VestboJ , JenkinsCR , JonesPW , FergusonGT , CalverleyPMA , et al. Sex differences in mortality and clinical expressions of patients with chronic obstructive pulmonary disease: the TORCH experience. American Journal of Respiratory and Critical Care Medicine2011;183(3):317‐22. CelliBR , ThomasNE , AndersonJA , FergusonGT , JenkinsCR , JonesPW , et al. Effect of pharmacotherapy on rate of decline of lung function in chronic obstructive pulmonary disease: results from the TORCH study. American Journal of Respiratory and Critical Care Medicine2008;178(4):332‐8. CelliD , EmmettA , CraterG , KalbergC . Salmeterol/fluticasone propionate (SFC) improves the inspiratory to total lung capacity ratio (IC/TLC) and exercise endurance time in patients with COPD. European Respiratory Journal2006;28 Suppl 50:764 [4395]. CorhayJL , LouisR . Clinical study of the month: the TORCH study (TOwards a Revolution in COPD Health) [L'étude clinique du mois. L'étude TORCH (TOwards a Revolution in COPD Health): vers une revolution de la santé des patients souffrant de BPCO]. Revue Medicale de Liege2007;62(4):230‐4. FergusonGT , CalverleyPM , AndersonJA , CelliB , JenkinsC , JonesPW , et al. The TOwards a Revolution in COPD Health (TORCH) study: fluticasone propionate/salmeterol is well tolerated in patients with COPD over 3 years [Abstract]. Chest2006;130(4):178s. FergusonGT , CalverleyPM , AndersonJA , CelliB , JenkinsCR , JonesPW , et al. Effect of salmeterol/fluticasone propionate (SFC) on bone mineral density (BMD) and eye disorders over three years in the TORCH trial [Abstract]. American Thoracic Society International Conference; 2007 May 18‐23; San Francisco. 2007:A763. FergusonGT , CalverleyPM , AndersonJA , JenkinsCR , CelliB , et al. Prevalence and progression of osteoporosis in patients with COPD results from the towards a revolution in COPD health study. Chest2009;136(6):1456‐65. FergusonGT , CalverleyPMA , AndersonJA , et al. The TORCH (TOwards a Revolution in COPD Health) study: salmeterol/fluticasone propionate (SFC) improves survival in COPD over three years. European Respiratory Journal2006;28 Suppl 50:34s. GlickH , BriggsA , Lozano‐OrtegaG , SpencerM , VestboJ , CalverleyP . Is treatment with ICS/LABA combination good value for money in COPD? Evidence from the TORCH study [Abstract]. American Thoracic Society International Conference; 2007 May 18‐23; San Francisco. 2007:[C97]. JenkinsC , CelliB , AndersonJ , FergusonG , CalverleyP , JonesP , et al. Salmeterol/fluticasone propionate (SFC) is efficacious in GOLD stage II COPD patients: analysis from the TORCH study [Abstract]. American Thoracic Society International Conference; May 15‐20; San Diego. 2009:A6186 [Poster #213]. JenkinsCR , CelliB , AndersonJA , FergusonGT , JonesPW , VestboJ , et al. Seasonality and determinants of moderate and severe COPD exacerbations in the TORCH study. European Respiratory Journal2012;39:38‐45. JenkinsCR , CelliB , AndersonJA , FergusonGT , JonesPW , VestboJ , et al. The TORCH survival study: consistent efficacy results seen in geographic regions in a multi‐national study [Abstract]. American Thoracic Society International Conference; May 18‐23; San Francisco. 2007:[C97]. JenkinsCR , JonesPW , CalverleyPM , CelliB , AndersonJA , FergusonGT , et al. Efficacy of salmeterol/fluticasone propionate by GOLD stage of chronic obstructive pulmonary disease: analysis from the randomised, placebo‐controlled TORCH study. Respiratory Research2009;10:59. JonesPW , AndersonJA , CalverleyPM , CelliBR , FergusonGT , JenkinsC , et al. Health status in the TORCH study of COPD: treatment efficacy and other determinants of change. Respiratory Research2011;12:71. JonesPW , CalverleyPM , CelliB , AndersonJA , FergusonGT , JenkinsC , et al. The TOwards a Revolution in COPD Health (TORCH) study: fluticasone propionate/salmeterol improves and sustains health status in COPD over 3 years. Chest2006;130(4):177s. JonesPW , VestboJ , AndersonJA , CelliB , FergusonGT , JenkinsCR , et al. Informative withdrawal in a COPD study. An example from the TORCH Study [Abstract]. American Thoracic Society International Conference; 2007 May 18‐23; San Francisco. 2007:[C97]. KeeneON , VestboJ , AndersonJA , CalverleyPM , CelliB , FergusonGT , et al. Methods for therapeutic trials in COPD: Lessons from the TORCH trial. European Respiratory Journal2009;34(5):1018‐23. McDonoughC , BlanchardAR . TORCH study results: pharmacotherapy reduces lung function decline in patients with chronic obstructive pulmonary disease. Hospital Practice2010;38(2):92‐3. McGarveyLP , JohnM , AndersonJA , ZvarichM , WiseRA , Committee TCE et al. Ascertainment of cause‐specific mortality in COPD: operations of the TORCH Clinical Endpoint Committee. Thorax2007;62(5):411‐5. MehtaRS , KathmanSJ , Daley‐YatesPT , CahnT , BeeraheeM , KunkaRL , et al. Pharmacokinetics and pharmacodynamics in COPD patients following long‐term twice‐daily treatment with salmeterol/fluticasone propionate (SFC) 50/500mg and the individual components [Abstract]. American Thoracic Society International Conference; 2007 May 18‐23; San Francisco. 2007:Poster #A41. SCO30003 . A multi‐centre, randomised, double‐blind, parallel group, placebo‐controlled study to investigate the long‐term effects of salmeterol/fluticasone propionate (SERETIDE®/VIANI®/ADVAIR®) 50/500mcg bd, salmeterol 50mcg bd and fluticasone propionate 500mcg bd, all delivered via the DISKUS®/ACCUHALER® inhaler, on the survival of subjects with chronic obstructive pulmonary disease (COPD) over 3 years of treatment. www.ctr.gsk.co.uk (accessed 21 April 2012). SacchettaA . Long term therapy and outcome of chronic obstructive pulmonary disease with or without co‐morbidity: The TORCH Study. Italian Journal of Medicine2008;2(3):11‐5. VestboJ , AndersonJA , CalverleyPM , CelliB , FergusonGT , JenkinsC , et al. Bias due to withdrawal in long‐term randomised trials in COPD: Evidence from the TORCH study. Clinical Respiratory Journal2011;5(1):44‐9. VestboJ , TORCH Study Group. The TORCH (TOwards a Revolution in COPD Health) survival study protocol. European Respiratory Journal2004;24(2):206‐10. ">Calverley 2007 TORCH</a> accounted for 80% of the analysis weight across its two comparisons. No difference was detected between fluticasone and control overall (Peto OR 1.23, 95% CI 0.70 to 2.15; I<sup>2</sup> = 0%, P value 0.95), and no observable subgroup differences were reported between the monotherapy and combination therapy subgroups (I<sup>2</sup> = 0%, P value 0.44). Evidence was rated of moderate quality, being downgraded once for imprecision because so few events were reported. </p> </section> <section id="CD010115-sec-0084"> <h5 class="title">1.4. Non‐fatal serious adverse events, all‐cause</h5> <p>Nineteen studies across 26 comparisons reported all‐cause serious adverse events (n = 20,381). The odds of a serious adverse event were higher with fluticasone than with control (OR 1.06, 95% CI 0.99 to 1.16; I<sup>2</sup> = 0%, P value 0.66). The lower confidence just crossed the line of no effect, but no significant heterogeneity was noted between studies. No evidence suggested a difference between monotherapy and combination therapy subgroups (I<sup>2</sup> = 0%, P value 0.58). Evidence was rated of high quality. </p> </section> <section id="CD010115-sec-0085"> <h5 class="title">1.5. All pneumonia events</h5> <p>Fifteen studies making 11 comparisons reported the outcome (n = 15,377), and <a href="./references#CD010115-bbs2-0007" title="AllegraL . TORCH study: An invitation to clinical considerations. GIMT ‐ Giornale Italiano delle Malattie del Torace2007;61(1):15‐23. BriggsAH , GlickHA , Lozano‐OrtegaG , SpencerM , CalverleyPM , JonesPW , et al. Is treatment with ICS and LABA cost‐effective for COPD? Multinational economic analysis of the TORCH study. European Respiratory Journal2010;35(3):532‐9. BriggsAH , Lozano‐OrtegaG , SpencerS , BaleG , SpencerMD , BurgePS . Estimating the cost‐effectiveness of fluticasone propionate for treating chronic obstructive pulmonary disease in the presence of missing data. Value in Health2006;9(4):227‐35. CalverleyP , CelliB , AndersonJ , FergusonG , JenkinsC , JonesP , et al. Salmeterol/fluticasone propionate combination (SFC) improves survival in COPD over three years: on‐treatment analysis from the TORCH study [Abstract]. American Thoracic Society International Conference; 2009 May 15‐20; San Diego. 2009:A6191[Poster #219]. CalverleyP , CelliB , AndersonJA , FergusonGT , JenkinsC , JonesPW , et al. The TOwards a Revolution in COPD Health (TORCH) study: salmeterol/fluticasone propionate improves survival in COPD over three years [Abstract]. Respirology2006;11 Suppl 5:A149 [PS‐3‐8]. CalverleyPM , AndersonJA , CelliB , FergusonGT , JenkinsC , JonesPW , et al. Salmeterol and fluticasone propionate and survival in chronic obstructive pulmonary disease. New England Journal of Medicine2007;356(8):775‐89. CalverleyPM , AndersonJA , CelliB , FergusonGT , JenkinsC , Jones PW et al and TORCH Investigators. Cardiovascular events in patients with COPD: TORCH study results. Thorax2010;65(8):719‐25. CalverleyPM , CelliB , AndersonJA , FergusonGT , JenkinsC , JonesPW , et al. The TOwards a Revolution in COPD Health (TORCH) study: fluticasone propionate /salmeterol improves survival in COPD over three years. Chest2006;130(4):122s. CalverleyPMA , CelliB , AndersenJA , FergusonGT , JenkinsC , JonesPW , et al. The TORCH (TOwards a Revolution in COPD Health) study salmeterol/fluticasone propionate (SFC) improves survival in COPD over three years. European Respiratory Journal2006;28 Suppl 50:34. CelliB , CalverleyPM , AndersonJA , FergusonGT , JenkinsC , JonesP , et al. The TOwards a Revolution in COPD HEalth (TORCH) Study: salmeterol/fluticasone propionate reduces the rate of exacerbations over three years. Respirology2006;11 Suppl 5:A140. CelliB , CalverleyPM , AndersonJA , FergusonGT , JenkinsC , JonesPW , et al. The TOwards a Revolution in COPD Health (TORCH) study: fluticasone propionate/salmeterol reduces the rate of exacerbations over 3 years [Abstract]. Chest2006;130(4):177s. CelliB , CalverleyPMA , AndersonJA , FergusonGT , JenkinsC , JonesPW , et al. The TORCH (TOwards a Revolution in COPD Health) study salmeterol/fluticasone propionate (SFC) improves health status reduces exacerbations and improves lung function over three years [Abstract]. European Respiratory Journal2006;28 Suppl 50:34s [E312]. CelliB , EmmettA , CraterG , KalbergC . Fluticasone propionate/salmeterol (FSC) improves the inspiratory to total lung capacity ratio (IC/TLC) and exercise endurance time in patients with COPD. European Respiratory Society 16th Annual Congress; 2006 Sep 2‐6; Munich. 2006:A320 (Poster 323). CelliB , FergusonGT , AndersonJA , JenkinsCR , JonesPW , VestboJ , et al. Salmeterol/fluticasone propionate (SFC) improves lung function and reduces the rate of decline over three years in the TORCH survival study [Abstract]. American Thoracic Society International Conference; 2007 May 18‐23; San Francisco. 2007:A763. CelliB , VestboJ , JenkinsCR , JonesPW , FergusonGT , CalverleyPMA , et al. Sex differences in mortality and clinical expressions of patients with chronic obstructive pulmonary disease: the TORCH experience. American Journal of Respiratory and Critical Care Medicine2011;183(3):317‐22. CelliBR , ThomasNE , AndersonJA , FergusonGT , JenkinsCR , JonesPW , et al. Effect of pharmacotherapy on rate of decline of lung function in chronic obstructive pulmonary disease: results from the TORCH study. American Journal of Respiratory and Critical Care Medicine2008;178(4):332‐8. CelliD , EmmettA , CraterG , KalbergC . Salmeterol/fluticasone propionate (SFC) improves the inspiratory to total lung capacity ratio (IC/TLC) and exercise endurance time in patients with COPD. European Respiratory Journal2006;28 Suppl 50:764 [4395]. CorhayJL , LouisR . Clinical study of the month: the TORCH study (TOwards a Revolution in COPD Health) [L'étude clinique du mois. L'étude TORCH (TOwards a Revolution in COPD Health): vers une revolution de la santé des patients souffrant de BPCO]. Revue Medicale de Liege2007;62(4):230‐4. FergusonGT , CalverleyPM , AndersonJA , CelliB , JenkinsC , JonesPW , et al. The TOwards a Revolution in COPD Health (TORCH) study: fluticasone propionate/salmeterol is well tolerated in patients with COPD over 3 years [Abstract]. Chest2006;130(4):178s. FergusonGT , CalverleyPM , AndersonJA , CelliB , JenkinsCR , JonesPW , et al. Effect of salmeterol/fluticasone propionate (SFC) on bone mineral density (BMD) and eye disorders over three years in the TORCH trial [Abstract]. American Thoracic Society International Conference; 2007 May 18‐23; San Francisco. 2007:A763. FergusonGT , CalverleyPM , AndersonJA , JenkinsCR , CelliB , et al. Prevalence and progression of osteoporosis in patients with COPD results from the towards a revolution in COPD health study. Chest2009;136(6):1456‐65. FergusonGT , CalverleyPMA , AndersonJA , et al. The TORCH (TOwards a Revolution in COPD Health) study: salmeterol/fluticasone propionate (SFC) improves survival in COPD over three years. European Respiratory Journal2006;28 Suppl 50:34s. GlickH , BriggsA , Lozano‐OrtegaG , SpencerM , VestboJ , CalverleyP . Is treatment with ICS/LABA combination good value for money in COPD? Evidence from the TORCH study [Abstract]. American Thoracic Society International Conference; 2007 May 18‐23; San Francisco. 2007:[C97]. JenkinsC , CelliB , AndersonJ , FergusonG , CalverleyP , JonesP , et al. Salmeterol/fluticasone propionate (SFC) is efficacious in GOLD stage II COPD patients: analysis from the TORCH study [Abstract]. American Thoracic Society International Conference; May 15‐20; San Diego. 2009:A6186 [Poster #213]. JenkinsCR , CelliB , AndersonJA , FergusonGT , JonesPW , VestboJ , et al. Seasonality and determinants of moderate and severe COPD exacerbations in the TORCH study. European Respiratory Journal2012;39:38‐45. JenkinsCR , CelliB , AndersonJA , FergusonGT , JonesPW , VestboJ , et al. The TORCH survival study: consistent efficacy results seen in geographic regions in a multi‐national study [Abstract]. American Thoracic Society International Conference; May 18‐23; San Francisco. 2007:[C97]. JenkinsCR , JonesPW , CalverleyPM , CelliB , AndersonJA , FergusonGT , et al. Efficacy of salmeterol/fluticasone propionate by GOLD stage of chronic obstructive pulmonary disease: analysis from the randomised, placebo‐controlled TORCH study. Respiratory Research2009;10:59. JonesPW , AndersonJA , CalverleyPM , CelliBR , FergusonGT , JenkinsC , et al. Health status in the TORCH study of COPD: treatment efficacy and other determinants of change. Respiratory Research2011;12:71. JonesPW , CalverleyPM , CelliB , AndersonJA , FergusonGT , JenkinsC , et al. The TOwards a Revolution in COPD Health (TORCH) study: fluticasone propionate/salmeterol improves and sustains health status in COPD over 3 years. Chest2006;130(4):177s. JonesPW , VestboJ , AndersonJA , CelliB , FergusonGT , JenkinsCR , et al. Informative withdrawal in a COPD study. An example from the TORCH Study [Abstract]. American Thoracic Society International Conference; 2007 May 18‐23; San Francisco. 2007:[C97]. KeeneON , VestboJ , AndersonJA , CalverleyPM , CelliB , FergusonGT , et al. Methods for therapeutic trials in COPD: Lessons from the TORCH trial. European Respiratory Journal2009;34(5):1018‐23. McDonoughC , BlanchardAR . TORCH study results: pharmacotherapy reduces lung function decline in patients with chronic obstructive pulmonary disease. Hospital Practice2010;38(2):92‐3. McGarveyLP , JohnM , AndersonJA , ZvarichM , WiseRA , Committee TCE et al. Ascertainment of cause‐specific mortality in COPD: operations of the TORCH Clinical Endpoint Committee. Thorax2007;62(5):411‐5. MehtaRS , KathmanSJ , Daley‐YatesPT , CahnT , BeeraheeM , KunkaRL , et al. Pharmacokinetics and pharmacodynamics in COPD patients following long‐term twice‐daily treatment with salmeterol/fluticasone propionate (SFC) 50/500mg and the individual components [Abstract]. American Thoracic Society International Conference; 2007 May 18‐23; San Francisco. 2007:Poster #A41. SCO30003 . A multi‐centre, randomised, double‐blind, parallel group, placebo‐controlled study to investigate the long‐term effects of salmeterol/fluticasone propionate (SERETIDE®/VIANI®/ADVAIR®) 50/500mcg bd, salmeterol 50mcg bd and fluticasone propionate 500mcg bd, all delivered via the DISKUS®/ACCUHALER® inhaler, on the survival of subjects with chronic obstructive pulmonary disease (COPD) over 3 years of treatment. www.ctr.gsk.co.uk (accessed 21 April 2012). SacchettaA . Long term therapy and outcome of chronic obstructive pulmonary disease with or without co‐morbidity: The TORCH Study. Italian Journal of Medicine2008;2(3):11‐5. VestboJ , AndersonJA , CalverleyPM , CelliB , FergusonGT , JenkinsC , et al. Bias due to withdrawal in long‐term randomised trials in COPD: Evidence from the TORCH study. Clinical Respiratory Journal2011;5(1):44‐9. VestboJ , TORCH Study Group. The TORCH (TOwards a Revolution in COPD Health) survival study protocol. European Respiratory Journal2004;24(2):206‐10. ">Calverley 2007 TORCH</a> carried almost 80% of the weight across the analysis. The odds of any pneumonia event were significantly greater with fluticasone than with control (OR 1.68, 95% CI 1.49 to 1.90), with no important heterogeneity observed between studies (I<sup>2</sup> = 0%, P value 0.76) or subgroups (I<sup>2</sup> = 0%, P value 0.64). The outcome was underreported across the studies, so evidence was downgraded for publication bias, and was rated of moderate quality. </p> </section> <section id="CD010115-sec-0086"> <h5 class="title">1.6. Withdrawals</h5> <p>Data from 26 studies (33 comparisons, n = 21,243) show that withdrawals were much less common on fluticasone than on control, with no significant heterogeneity noted (OR 0.81, 95% CI 0.77 to 0.86; I<sup>2</sup> = 3%, P value 0.43). The effect was larger for fluticasone monotherapy, but the difference between subgroups was not statistically significant (I<sup>2</sup> = 66%, P value 0.09). No reasons suggested the need to downgrade the evidence from high quality. </p> </section> </section> <section id="CD010115-sec-0087"> <h4 class="title">Comparison two: subgroup analyses—fluticasone versus controls</h4> <p><i>Dose:</i> Combining all studies and organising by fluticasone dose did not reveal significant subgroup differences between doses (I<sup>2</sup> = 0%, P value 0.90; <a href="./references#CD010115-fig-0013" title="">Analysis 2.1</a>). Pooled effects for the three furoate dose subgroups (50 mcg, 100 mcg and 200 mcg once a day) contained fewer data and therefore had much wider confidence intervals than the more widely used propionate preparation doses. Higher‐dose fluticasone propionate was the most widely studied and hence has the most precise estimate, but the pooled effect was not statistically different from the other dose subgroups. </p> <p><i>Trial duration:</i> No evidence shows significant differences between the trials with duration of one year or less and the three trials (four comparisons) that followed participants for three years (I<sup>2</sup> = 0%, P value 0.61; <a href="./references#CD010115-fig-0014" title="">Analysis 2.2</a>). No significant heterogeneity between individual studies was noted within either subgroup (I<sup>2</sup> = 0% in both cases). </p> <p><i>Baseline percentage predicted FEV<sub>1</sub> </i> : Studies with a mean baseline percentage predicted FEV<sub>1</sub> of less than 50% accounted for 99% of the analysis weight (<a href="./references#CD010115-fig-0015" title="">Analysis 2.3</a>), so no conclusions could be drawn regarding the moderating effect of baseline severity. </p> </section> <section id="CD010115-sec-0088"> <h4 class="title">Comparison three: budesonide versus controls (all outcomes subgrouped to compare ICS vs placebo with ICS/LABA vs LABA) </h4> <section id="CD010115-sec-0089"> <h5 class="title">3.1 Primary outcome: non‐fatal, serious adverse pneumonia events (requiring hospital admission) </h5> <p>Data for eight comparisons in seven studies were analysed (n = 6472), with <a href="./references#CD010115-bbs2-0039" title="AstraZeneca . A 6‐month double‐blind, double‐dummy, randomized, parallel group, multicenter efficacy &amp; safety study of SYMBICORT® pMDI 2 x 160/4.5 μg &amp; 80/4.5 μg bid compared to formoterol TBH, budesonide pMDI (&amp; the combination) &amp; placebo in COPD Patients (SHINE) (study number D589900002). www.astrazenecaclinicaltrials.com (accessed 18 April 2012). BleeckerER , MeyersDA , BaileyWC , SimsAM , BujacSR , GoldmanM , et al. Effect of ß2‐Adrenergic Receptor Gene Polymorphism Gly16Arg on Response to Budesonide/Formoterol Pressurized Metered‐Dose Inhaler in Chronic Obstructive Pulmonary Disease [Abstract]. American Journal of Respiratory and Critical Care Medicine2011;183:A4086. TashkinDP , RennardSI , MartinP , RamachandranS , MartinUJ , SilkoffPE . Efficacy and safety of budesonide and formoterol in one pressurized metered‐dose inhaler in patients with moderate to very severe chronic obstructive pulmonary disease: results of a 6‐month randomized clinical trial. Drugs2008;68(14):1975‐2000. ">Tashkin 2008 SHINE</a> contributing data to both 'budesonide versus placebo' and 'budesonide/LABA versus LABA' subgroups. Budesonide increased non‐fatal serious adverse pneumonia events (OR 1.62, 95% CI 1.00 to 2.62), and, although a degree of variation was noted between study results, it was not significant (I<sup>2</sup> = 28%, P value 0.21). Heterogeneity was evident between the monotherapy and combination subgroups, but the test for differences was not statistically significant (I<sup>2</sup> = 55%, P value 0.14). The confidence intervals around the pooled estimate were quite wide but were not considered serious enough to warrant downgrading. However, because two‐thirds of the budesonide studies did not appear in the analysis, the outcome was downgraded once for publication bias and was rated of moderate quality. </p> </section> <section id="CD010115-sec-0090"> <h5 class="title">3.2. Mortality, all‐cause</h5> <p>Budesonide did not significantly affect all‐cause mortality relative to control interventions (OR 0.90, 95% CI 0.65 to 1.24), based on 15 comparisons in 12 studies (n = 10,009). Heterogeneity was not significant across studies (I<sup>2</sup> = 0%, P value 0.76), and no statistically significant difference was noted between the monotherapy and combination therapy subgroups (I<sup>2</sup> = 0%, P value 0.75). Evidence was rated of moderate quality after being downgraded once for imprecision because the confidence intervals included significant benefit and harm. </p> </section> <section id="CD010115-sec-0091"> <h5 class="title">3.3. Mortality, due to pneumonia</h5> <p>Only three budesonide studies reported the outcome (n = 1511), of which two studies observed no events in either group. No conclusions could be made from <a href="./references#CD010115-bbs2-0037" title="SharafkhanehA , SouthardJG , GoldmanM , UryniakT , MartinUJ . Effect of budesonide/formoterol pMDI on COPD exacerbations: a double‐blind, randomized study. Respiratory Medicine2012;106(2):257‐68. SharafkhanehA , UryniakT , MartinU . Long‐term effects of budesonide/formoterol pressurized metered‐dose inhaler on Chronic Obstructive Pulmonary Disease (COPD) symptoms and health status in patients with COPD [Abstract]. Chest2011;140(4):528A. ">Sharafkhaneh 2012</a>, which observed one event in the budesonide/LABA group. Evidence was rated of very low quality, being downgraded twice for imprecision and once for publication bias. </p> </section> <section id="CD010115-sec-0092"> <h5 class="title">3.4. Non‐fatal serious adverse events, all‐cause</h5> <p>Fifteen comparisons in 12 studies were analysed (n = 10,009). Budesonide was not found to increase the odds of a serious adverse event (OR 1.01, 95% CI 0.83 to 1.22), although significant heterogeneity was noted between studies (I<sup>2</sup> = 59%, P value 0.002), so a random‐effects analysis was used and the outcome was downgraded for inconsistency to moderate quality. No heterogeneity was observed between the subgroups (I<sup>2</sup> = 0%, P value 0.68). </p> <p>An outlier in the budesonide versus placebo subgroup was removed in a post hoc sensitivity analysis (<a href="./references#CD010115-bbs2-0042" title="VestboJ , SorensenT , LangeP , BrixA , TorreP , ViskumK . Long‐term effect of inhaled budesonide in mild and moderate chronic obstructive pulmonary disease: a randomised controlled trial. Lancet1999;353(9167):1819‐23. [MEDLINE: 99285938] ">Vestbo 1999</a>), which changed the effect for the subgroup to favour the control (OR 1.27, 95% CI 1.04 to 1.55) with no within‐subgroup heterogeneity (previously I<sup>2</sup> = 72%). The study recruited a less severe population, which might explain the difference in effect. </p> </section> <section id="CD010115-sec-0093"> <h5 class="title">3.5. All pneumonia events</h5> <p>Not enough evidence was obtained to rule out a significant increase or a potential reduction in pneumonia events on budesonide compared with controls (OR 1.12, 95% CI 0.83 to 1.51; eight comparisons in six studies; n = 7011). A degree of unexplained heterogeneity was observed between studies (I<sup>2</sup> = 13%, P value 0.33) and between treatment subgroups (I<sup>2</sup> = 14%, P value 0.28), neither of which was significant. Although confidence intervals were quite wide, findings were not deemed serious enough to warrant downgrading of the evidence. However, because most of the budesonide studies did not appear in the analysis, the outcome was downgraded for publication bias and was rated of moderate quality. </p> </section> <section id="CD010115-sec-0094"> <h5 class="title">3.6. Withdrawals</h5> <p>When 18 comparisons in 15 studies were combined (n = 10,150), withdrawals were seen to be less common in the budesonide groups than in the control groups (OR 0.78, 95% CI 0.71 to 0.85). No important heterogeneity was noted between individual studies (I<sup>2</sup> = 12%, P value 0.31) or between monotherapy and combination therapy subgroups (I<sup>2</sup> = 0%, P value 0.57). Evidence was rated of high quality. </p> </section> </section> <section id="CD010115-sec-0095"> <h4 class="title">Comparison four: subgroup analyses—budesonide versus controls</h4> <p><i>Dose:</i> When all budesonide studies were subgrouped according to daily dose, the difference between 320 mcg and 640 mcg was significant (I<sup>2</sup> = 74%, P value 0.05; <a href="./references#CD010115-fig-0022" title="">Analysis 4.1</a>); the higher dose increased non‐fatal serious adverse pneumonia events (OR 2.02, 95% CI 1.15 to 3.57), and no significant difference was observed for the lower dose (OR 0.68, 95% CI 0.27 to 1.71). The only study using the highest dose of 1280 mcg, <a href="./references#CD010115-bbs2-0043" title="YildizF , BasyigitI , YildirimE , BoyaciH , IlgazliA . Does addition of inhaled steroids to combined bronchodilator therapy affect health status in patients with COPD?. Respirology2004;9(3):352‐5. ">Yildiz 2004</a>, did not contribute data to the analysis because no events occurred in either group. </p> <p><i>Trial duration:</i> The difference between five studies lasting a year or less and <a href="./references#CD010115-bbs2-0036" title="ShakerSB , DirksenA , UlrikCS , HestadM , StavngaardT , LaursenLC , et al. The effect of inhaled corticosteroids on the development of emphysema in smokers assessed by annual computed tomography. COPD: Journal of Chronic Obstructive Pulmonary Disease2009;6(2):104‐11. ShakerSB , StavngaardT , LaursenLC , StoelBC , DirksenA . Rapid fall in lung density following smoking cessation in COPD. COPD: Journal of Chronic Obstructive Pulmonary Disease2011;8(1):2‐7. ">Shaker 2009</a> (which followed participants for a minimum of two years) was not significant (I<sup>2</sup> = 39%, P value 0.20; <a href="./references#CD010115-fig-0023" title="">Analysis 4.2</a>). </p> <p><i>Baseline percentage predicted FEV<sub>1</sub>:</i> When studies were subgrouped according to baseline severity, differences were not significant (I<sup>2</sup> = 40%, P value 0.20; <a href="./references#CD010115-fig-0024" title="">Analysis 4.3</a>), and only one study reported a baseline mean FEV<sub>1</sub> above 50% predicted (<a href="./references#CD010115-bbs2-0036" title="ShakerSB , DirksenA , UlrikCS , HestadM , StavngaardT , LaursenLC , et al. The effect of inhaled corticosteroids on the development of emphysema in smokers assessed by annual computed tomography. COPD: Journal of Chronic Obstructive Pulmonary Disease2009;6(2):104‐11. ShakerSB , StavngaardT , LaursenLC , StoelBC , DirksenA . Rapid fall in lung density following smoking cessation in COPD. COPD: Journal of Chronic Obstructive Pulmonary Disease2011;8(1):2‐7. ">Shaker 2009</a>). </p> </section> <section id="CD010115-sec-0096"> <h4 class="title">Comparison five: sensitivity analysis—risk of bias</h4> <section id="CD010115-sec-0097"> <h5 class="title">5.1 Non‐fatal serious adverse pneumonia events</h5> <section id="CD010115-sec-0098"> <h6 class="title">5.1.1 Fluticasone versus controls</h6> <p>Four fluticasone studies representing six comparisons rated at high risk for attrition were removed from the primary outcome in a sensitivity analysis. The estimate gave a slightly larger effect of fluticasone on pneumonia than the main analysis (15 RCTs; n = 16,338; OR 1.82, 95% CI 1.52 to 2.19). </p> </section> <section id="CD010115-sec-0099"> <h6 class="title">5.1.2 Budesonide versus controls</h6> <p>Three studies judged to be at high risk of bias due to high or uneven levels of attrition were removed from the primary outcome in a sensitivity analysis. The effect from the remaining four studies was larger but more imprecise because far fewer events were included in the analysis (5 RCTs; n = 3515; OR 3.28, 95% CI 1.22 to 8.81). </p> </section> </section> </section> <section id="CD010115-sec-0100"> <h4 class="title">Comparison six: indirect comparison of fluticasone and budesonide monotherapy</h4> <p>We calculated the relative effects of fluticasone and budesonide for four outcomes by comparing their effects against placebo (see <a href="#CD010115-fig-0001">Figure 1</a>). No studies directly comparing the two drugs met this review's inclusion criteria, but cohort data are summarised in <a href="#CD010115-sec-0111">Agreements and disagreements with other studies or reviews</a>. </p> <p>All four outcomes were downgraded for indirectness because no direct evidence was found and the estimate was obtained purely from indirect comparisons. None of the outcomes were downgraded for risk of bias or inconsistency. The indirect comparisons are presented in <a href="#CD010115-fig-0005">Figure 5</a> and are summarised below, and the sensitivity analysis removing <a href="./references#CD010115-bbs2-0007" title="AllegraL . TORCH study: An invitation to clinical considerations. GIMT ‐ Giornale Italiano delle Malattie del Torace2007;61(1):15‐23. BriggsAH , GlickHA , Lozano‐OrtegaG , SpencerM , CalverleyPM , JonesPW , et al. Is treatment with ICS and LABA cost‐effective for COPD? Multinational economic analysis of the TORCH study. European Respiratory Journal2010;35(3):532‐9. BriggsAH , Lozano‐OrtegaG , SpencerS , BaleG , SpencerMD , BurgePS . Estimating the cost‐effectiveness of fluticasone propionate for treating chronic obstructive pulmonary disease in the presence of missing data. Value in Health2006;9(4):227‐35. CalverleyP , CelliB , AndersonJ , FergusonG , JenkinsC , JonesP , et al. Salmeterol/fluticasone propionate combination (SFC) improves survival in COPD over three years: on‐treatment analysis from the TORCH study [Abstract]. American Thoracic Society International Conference; 2009 May 15‐20; San Diego. 2009:A6191[Poster #219]. CalverleyP , CelliB , AndersonJA , FergusonGT , JenkinsC , JonesPW , et al. The TOwards a Revolution in COPD Health (TORCH) study: salmeterol/fluticasone propionate improves survival in COPD over three years [Abstract]. Respirology2006;11 Suppl 5:A149 [PS‐3‐8]. CalverleyPM , AndersonJA , CelliB , FergusonGT , JenkinsC , JonesPW , et al. Salmeterol and fluticasone propionate and survival in chronic obstructive pulmonary disease. New England Journal of Medicine2007;356(8):775‐89. CalverleyPM , AndersonJA , CelliB , FergusonGT , JenkinsC , Jones PW et al and TORCH Investigators. Cardiovascular events in patients with COPD: TORCH study results. Thorax2010;65(8):719‐25. CalverleyPM , CelliB , AndersonJA , FergusonGT , JenkinsC , JonesPW , et al. The TOwards a Revolution in COPD Health (TORCH) study: fluticasone propionate /salmeterol improves survival in COPD over three years. Chest2006;130(4):122s. CalverleyPMA , CelliB , AndersenJA , FergusonGT , JenkinsC , JonesPW , et al. The TORCH (TOwards a Revolution in COPD Health) study salmeterol/fluticasone propionate (SFC) improves survival in COPD over three years. European Respiratory Journal2006;28 Suppl 50:34. CelliB , CalverleyPM , AndersonJA , FergusonGT , JenkinsC , JonesP , et al. The TOwards a Revolution in COPD HEalth (TORCH) Study: salmeterol/fluticasone propionate reduces the rate of exacerbations over three years. Respirology2006;11 Suppl 5:A140. CelliB , CalverleyPM , AndersonJA , FergusonGT , JenkinsC , JonesPW , et al. The TOwards a Revolution in COPD Health (TORCH) study: fluticasone propionate/salmeterol reduces the rate of exacerbations over 3 years [Abstract]. Chest2006;130(4):177s. CelliB , CalverleyPMA , AndersonJA , FergusonGT , JenkinsC , JonesPW , et al. The TORCH (TOwards a Revolution in COPD Health) study salmeterol/fluticasone propionate (SFC) improves health status reduces exacerbations and improves lung function over three years [Abstract]. European Respiratory Journal2006;28 Suppl 50:34s [E312]. CelliB , EmmettA , CraterG , KalbergC . Fluticasone propionate/salmeterol (FSC) improves the inspiratory to total lung capacity ratio (IC/TLC) and exercise endurance time in patients with COPD. European Respiratory Society 16th Annual Congress; 2006 Sep 2‐6; Munich. 2006:A320 (Poster 323). CelliB , FergusonGT , AndersonJA , JenkinsCR , JonesPW , VestboJ , et al. Salmeterol/fluticasone propionate (SFC) improves lung function and reduces the rate of decline over three years in the TORCH survival study [Abstract]. American Thoracic Society International Conference; 2007 May 18‐23; San Francisco. 2007:A763. CelliB , VestboJ , JenkinsCR , JonesPW , FergusonGT , CalverleyPMA , et al. Sex differences in mortality and clinical expressions of patients with chronic obstructive pulmonary disease: the TORCH experience. American Journal of Respiratory and Critical Care Medicine2011;183(3):317‐22. CelliBR , ThomasNE , AndersonJA , FergusonGT , JenkinsCR , JonesPW , et al. Effect of pharmacotherapy on rate of decline of lung function in chronic obstructive pulmonary disease: results from the TORCH study. American Journal of Respiratory and Critical Care Medicine2008;178(4):332‐8. CelliD , EmmettA , CraterG , KalbergC . Salmeterol/fluticasone propionate (SFC) improves the inspiratory to total lung capacity ratio (IC/TLC) and exercise endurance time in patients with COPD. European Respiratory Journal2006;28 Suppl 50:764 [4395]. CorhayJL , LouisR . Clinical study of the month: the TORCH study (TOwards a Revolution in COPD Health) [L'étude clinique du mois. L'étude TORCH (TOwards a Revolution in COPD Health): vers une revolution de la santé des patients souffrant de BPCO]. Revue Medicale de Liege2007;62(4):230‐4. FergusonGT , CalverleyPM , AndersonJA , CelliB , JenkinsC , JonesPW , et al. The TOwards a Revolution in COPD Health (TORCH) study: fluticasone propionate/salmeterol is well tolerated in patients with COPD over 3 years [Abstract]. Chest2006;130(4):178s. FergusonGT , CalverleyPM , AndersonJA , CelliB , JenkinsCR , JonesPW , et al. Effect of salmeterol/fluticasone propionate (SFC) on bone mineral density (BMD) and eye disorders over three years in the TORCH trial [Abstract]. American Thoracic Society International Conference; 2007 May 18‐23; San Francisco. 2007:A763. FergusonGT , CalverleyPM , AndersonJA , JenkinsCR , CelliB , et al. Prevalence and progression of osteoporosis in patients with COPD results from the towards a revolution in COPD health study. Chest2009;136(6):1456‐65. FergusonGT , CalverleyPMA , AndersonJA , et al. The TORCH (TOwards a Revolution in COPD Health) study: salmeterol/fluticasone propionate (SFC) improves survival in COPD over three years. European Respiratory Journal2006;28 Suppl 50:34s. GlickH , BriggsA , Lozano‐OrtegaG , SpencerM , VestboJ , CalverleyP . Is treatment with ICS/LABA combination good value for money in COPD? Evidence from the TORCH study [Abstract]. American Thoracic Society International Conference; 2007 May 18‐23; San Francisco. 2007:[C97]. JenkinsC , CelliB , AndersonJ , FergusonG , CalverleyP , JonesP , et al. Salmeterol/fluticasone propionate (SFC) is efficacious in GOLD stage II COPD patients: analysis from the TORCH study [Abstract]. American Thoracic Society International Conference; May 15‐20; San Diego. 2009:A6186 [Poster #213]. JenkinsCR , CelliB , AndersonJA , FergusonGT , JonesPW , VestboJ , et al. Seasonality and determinants of moderate and severe COPD exacerbations in the TORCH study. European Respiratory Journal2012;39:38‐45. JenkinsCR , CelliB , AndersonJA , FergusonGT , JonesPW , VestboJ , et al. The TORCH survival study: consistent efficacy results seen in geographic regions in a multi‐national study [Abstract]. American Thoracic Society International Conference; May 18‐23; San Francisco. 2007:[C97]. JenkinsCR , JonesPW , CalverleyPM , CelliB , AndersonJA , FergusonGT , et al. Efficacy of salmeterol/fluticasone propionate by GOLD stage of chronic obstructive pulmonary disease: analysis from the randomised, placebo‐controlled TORCH study. Respiratory Research2009;10:59. JonesPW , AndersonJA , CalverleyPM , CelliBR , FergusonGT , JenkinsC , et al. Health status in the TORCH study of COPD: treatment efficacy and other determinants of change. Respiratory Research2011;12:71. JonesPW , CalverleyPM , CelliB , AndersonJA , FergusonGT , JenkinsC , et al. The TOwards a Revolution in COPD Health (TORCH) study: fluticasone propionate/salmeterol improves and sustains health status in COPD over 3 years. Chest2006;130(4):177s. JonesPW , VestboJ , AndersonJA , CelliB , FergusonGT , JenkinsCR , et al. Informative withdrawal in a COPD study. An example from the TORCH Study [Abstract]. American Thoracic Society International Conference; 2007 May 18‐23; San Francisco. 2007:[C97]. KeeneON , VestboJ , AndersonJA , CalverleyPM , CelliB , FergusonGT , et al. Methods for therapeutic trials in COPD: Lessons from the TORCH trial. European Respiratory Journal2009;34(5):1018‐23. McDonoughC , BlanchardAR . TORCH study results: pharmacotherapy reduces lung function decline in patients with chronic obstructive pulmonary disease. Hospital Practice2010;38(2):92‐3. McGarveyLP , JohnM , AndersonJA , ZvarichM , WiseRA , Committee TCE et al. Ascertainment of cause‐specific mortality in COPD: operations of the TORCH Clinical Endpoint Committee. Thorax2007;62(5):411‐5. MehtaRS , KathmanSJ , Daley‐YatesPT , CahnT , BeeraheeM , KunkaRL , et al. Pharmacokinetics and pharmacodynamics in COPD patients following long‐term twice‐daily treatment with salmeterol/fluticasone propionate (SFC) 50/500mg and the individual components [Abstract]. American Thoracic Society International Conference; 2007 May 18‐23; San Francisco. 2007:Poster #A41. SCO30003 . A multi‐centre, randomised, double‐blind, parallel group, placebo‐controlled study to investigate the long‐term effects of salmeterol/fluticasone propionate (SERETIDE®/VIANI®/ADVAIR®) 50/500mcg bd, salmeterol 50mcg bd and fluticasone propionate 500mcg bd, all delivered via the DISKUS®/ACCUHALER® inhaler, on the survival of subjects with chronic obstructive pulmonary disease (COPD) over 3 years of treatment. www.ctr.gsk.co.uk (accessed 21 April 2012). SacchettaA . Long term therapy and outcome of chronic obstructive pulmonary disease with or without co‐morbidity: The TORCH Study. Italian Journal of Medicine2008;2(3):11‐5. VestboJ , AndersonJA , CalverleyPM , CelliB , FergusonGT , JenkinsC , et al. Bias due to withdrawal in long‐term randomised trials in COPD: Evidence from the TORCH study. Clinical Respiratory Journal2011;5(1):44‐9. VestboJ , TORCH Study Group. The TORCH (TOwards a Revolution in COPD Health) survival study protocol. European Respiratory Journal2004;24(2):206‐10. ">Calverley 2007 TORCH</a> is shown in <a href="#CD010115-fig-0006">Figure 6</a>. </p> <div class="figure" id="CD010115-fig-0005"> <div class="figure-caption-wrapper-top"> <nav class="inline-nav-list has-dividers"> <ul> <li><a class="open-in-figure-viewer" href="#0">Open in figure viewer</a></li> </ul> </nav> <div class="figure-label">Figure 5</div> </div> <hr class="top"/><img alt="Indirect comparisons of fluticasone and budesonide monotherapy.Non‐fatal serious adverse pneumonia events were defined as those requiring hospital admission." data-id="CD010115-fig-0005" src="/cdsr/doi/10.1002/14651858.CD010115.pub2/media/CDSR/CD010115/image_n/nCD010115-AFig-FIG05.png"/><hr class="bottom"/> <div class="figure-caption-wrapper-bottom"> <div class="figure-caption"> <p>Indirect comparisons of fluticasone and budesonide monotherapy.</p> <p>Non‐fatal serious adverse pneumonia events were defined as those requiring hospital admission. </p> </div> </div> </div> <div class="figure" id="CD010115-fig-0006"> <div class="figure-caption-wrapper-top"> <nav class="inline-nav-list has-dividers"> <ul> <li><a class="open-in-figure-viewer" href="#0">Open in figure viewer</a></li> </ul> </nav> <div class="figure-label">Figure 6</div> </div> <hr class="top"/><img alt="Indirect comparisons of fluticasone and budesonide monotherapy—Sensitivity analysis removing (Calverley 2007 TORCH)." data-id="CD010115-fig-0006" src="/cdsr/doi/10.1002/14651858.CD010115.pub2/media/CDSR/CD010115/image_n/nCD010115-AFig-FIG06.png"/><hr class="bottom"/> <div class="figure-caption-wrapper-bottom"> <div class="figure-caption"> <p>Indirect comparisons of fluticasone and budesonide monotherapy—Sensitivity analysis removing (<a href="./references#CD010115-bbs2-0007" title="AllegraL . TORCH study: An invitation to clinical considerations. GIMT ‐ Giornale Italiano delle Malattie del Torace2007;61(1):15‐23. BriggsAH , GlickHA , Lozano‐OrtegaG , SpencerM , CalverleyPM , JonesPW , et al. Is treatment with ICS and LABA cost‐effective for COPD? Multinational economic analysis of the TORCH study. European Respiratory Journal2010;35(3):532‐9. BriggsAH , Lozano‐OrtegaG , SpencerS , BaleG , SpencerMD , BurgePS . Estimating the cost‐effectiveness of fluticasone propionate for treating chronic obstructive pulmonary disease in the presence of missing data. Value in Health2006;9(4):227‐35. CalverleyP , CelliB , AndersonJ , FergusonG , JenkinsC , JonesP , et al. Salmeterol/fluticasone propionate combination (SFC) improves survival in COPD over three years: on‐treatment analysis from the TORCH study [Abstract]. American Thoracic Society International Conference; 2009 May 15‐20; San Diego. 2009:A6191[Poster #219]. CalverleyP , CelliB , AndersonJA , FergusonGT , JenkinsC , JonesPW , et al. The TOwards a Revolution in COPD Health (TORCH) study: salmeterol/fluticasone propionate improves survival in COPD over three years [Abstract]. Respirology2006;11 Suppl 5:A149 [PS‐3‐8]. CalverleyPM , AndersonJA , CelliB , FergusonGT , JenkinsC , JonesPW , et al. Salmeterol and fluticasone propionate and survival in chronic obstructive pulmonary disease. New England Journal of Medicine2007;356(8):775‐89. CalverleyPM , AndersonJA , CelliB , FergusonGT , JenkinsC , Jones PW et al and TORCH Investigators. Cardiovascular events in patients with COPD: TORCH study results. Thorax2010;65(8):719‐25. CalverleyPM , CelliB , AndersonJA , FergusonGT , JenkinsC , JonesPW , et al. The TOwards a Revolution in COPD Health (TORCH) study: fluticasone propionate /salmeterol improves survival in COPD over three years. Chest2006;130(4):122s. CalverleyPMA , CelliB , AndersenJA , FergusonGT , JenkinsC , JonesPW , et al. The TORCH (TOwards a Revolution in COPD Health) study salmeterol/fluticasone propionate (SFC) improves survival in COPD over three years. European Respiratory Journal2006;28 Suppl 50:34. CelliB , CalverleyPM , AndersonJA , FergusonGT , JenkinsC , JonesP , et al. The TOwards a Revolution in COPD HEalth (TORCH) Study: salmeterol/fluticasone propionate reduces the rate of exacerbations over three years. Respirology2006;11 Suppl 5:A140. CelliB , CalverleyPM , AndersonJA , FergusonGT , JenkinsC , JonesPW , et al. The TOwards a Revolution in COPD Health (TORCH) study: fluticasone propionate/salmeterol reduces the rate of exacerbations over 3 years [Abstract]. Chest2006;130(4):177s. CelliB , CalverleyPMA , AndersonJA , FergusonGT , JenkinsC , JonesPW , et al. The TORCH (TOwards a Revolution in COPD Health) study salmeterol/fluticasone propionate (SFC) improves health status reduces exacerbations and improves lung function over three years [Abstract]. European Respiratory Journal2006;28 Suppl 50:34s [E312]. CelliB , EmmettA , CraterG , KalbergC . Fluticasone propionate/salmeterol (FSC) improves the inspiratory to total lung capacity ratio (IC/TLC) and exercise endurance time in patients with COPD. European Respiratory Society 16th Annual Congress; 2006 Sep 2‐6; Munich. 2006:A320 (Poster 323). CelliB , FergusonGT , AndersonJA , JenkinsCR , JonesPW , VestboJ , et al. Salmeterol/fluticasone propionate (SFC) improves lung function and reduces the rate of decline over three years in the TORCH survival study [Abstract]. American Thoracic Society International Conference; 2007 May 18‐23; San Francisco. 2007:A763. CelliB , VestboJ , JenkinsCR , JonesPW , FergusonGT , CalverleyPMA , et al. Sex differences in mortality and clinical expressions of patients with chronic obstructive pulmonary disease: the TORCH experience. American Journal of Respiratory and Critical Care Medicine2011;183(3):317‐22. CelliBR , ThomasNE , AndersonJA , FergusonGT , JenkinsCR , JonesPW , et al. Effect of pharmacotherapy on rate of decline of lung function in chronic obstructive pulmonary disease: results from the TORCH study. American Journal of Respiratory and Critical Care Medicine2008;178(4):332‐8. CelliD , EmmettA , CraterG , KalbergC . Salmeterol/fluticasone propionate (SFC) improves the inspiratory to total lung capacity ratio (IC/TLC) and exercise endurance time in patients with COPD. European Respiratory Journal2006;28 Suppl 50:764 [4395]. CorhayJL , LouisR . Clinical study of the month: the TORCH study (TOwards a Revolution in COPD Health) [L'étude clinique du mois. L'étude TORCH (TOwards a Revolution in COPD Health): vers une revolution de la santé des patients souffrant de BPCO]. Revue Medicale de Liege2007;62(4):230‐4. FergusonGT , CalverleyPM , AndersonJA , CelliB , JenkinsC , JonesPW , et al. The TOwards a Revolution in COPD Health (TORCH) study: fluticasone propionate/salmeterol is well tolerated in patients with COPD over 3 years [Abstract]. Chest2006;130(4):178s. FergusonGT , CalverleyPM , AndersonJA , CelliB , JenkinsCR , JonesPW , et al. Effect of salmeterol/fluticasone propionate (SFC) on bone mineral density (BMD) and eye disorders over three years in the TORCH trial [Abstract]. American Thoracic Society International Conference; 2007 May 18‐23; San Francisco. 2007:A763. FergusonGT , CalverleyPM , AndersonJA , JenkinsCR , CelliB , et al. Prevalence and progression of osteoporosis in patients with COPD results from the towards a revolution in COPD health study. Chest2009;136(6):1456‐65. FergusonGT , CalverleyPMA , AndersonJA , et al. The TORCH (TOwards a Revolution in COPD Health) study: salmeterol/fluticasone propionate (SFC) improves survival in COPD over three years. European Respiratory Journal2006;28 Suppl 50:34s. GlickH , BriggsA , Lozano‐OrtegaG , SpencerM , VestboJ , CalverleyP . Is treatment with ICS/LABA combination good value for money in COPD? Evidence from the TORCH study [Abstract]. American Thoracic Society International Conference; 2007 May 18‐23; San Francisco. 2007:[C97]. JenkinsC , CelliB , AndersonJ , FergusonG , CalverleyP , JonesP , et al. Salmeterol/fluticasone propionate (SFC) is efficacious in GOLD stage II COPD patients: analysis from the TORCH study [Abstract]. American Thoracic Society International Conference; May 15‐20; San Diego. 2009:A6186 [Poster #213]. JenkinsCR , CelliB , AndersonJA , FergusonGT , JonesPW , VestboJ , et al. Seasonality and determinants of moderate and severe COPD exacerbations in the TORCH study. European Respiratory Journal2012;39:38‐45. JenkinsCR , CelliB , AndersonJA , FergusonGT , JonesPW , VestboJ , et al. The TORCH survival study: consistent efficacy results seen in geographic regions in a multi‐national study [Abstract]. American Thoracic Society International Conference; May 18‐23; San Francisco. 2007:[C97]. JenkinsCR , JonesPW , CalverleyPM , CelliB , AndersonJA , FergusonGT , et al. Efficacy of salmeterol/fluticasone propionate by GOLD stage of chronic obstructive pulmonary disease: analysis from the randomised, placebo‐controlled TORCH study. Respiratory Research2009;10:59. JonesPW , AndersonJA , CalverleyPM , CelliBR , FergusonGT , JenkinsC , et al. Health status in the TORCH study of COPD: treatment efficacy and other determinants of change. Respiratory Research2011;12:71. JonesPW , CalverleyPM , CelliB , AndersonJA , FergusonGT , JenkinsC , et al. The TOwards a Revolution in COPD Health (TORCH) study: fluticasone propionate/salmeterol improves and sustains health status in COPD over 3 years. Chest2006;130(4):177s. JonesPW , VestboJ , AndersonJA , CelliB , FergusonGT , JenkinsCR , et al. Informative withdrawal in a COPD study. An example from the TORCH Study [Abstract]. American Thoracic Society International Conference; 2007 May 18‐23; San Francisco. 2007:[C97]. KeeneON , VestboJ , AndersonJA , CalverleyPM , CelliB , FergusonGT , et al. Methods for therapeutic trials in COPD: Lessons from the TORCH trial. European Respiratory Journal2009;34(5):1018‐23. McDonoughC , BlanchardAR . TORCH study results: pharmacotherapy reduces lung function decline in patients with chronic obstructive pulmonary disease. Hospital Practice2010;38(2):92‐3. McGarveyLP , JohnM , AndersonJA , ZvarichM , WiseRA , Committee TCE et al. Ascertainment of cause‐specific mortality in COPD: operations of the TORCH Clinical Endpoint Committee. Thorax2007;62(5):411‐5. MehtaRS , KathmanSJ , Daley‐YatesPT , CahnT , BeeraheeM , KunkaRL , et al. Pharmacokinetics and pharmacodynamics in COPD patients following long‐term twice‐daily treatment with salmeterol/fluticasone propionate (SFC) 50/500mg and the individual components [Abstract]. American Thoracic Society International Conference; 2007 May 18‐23; San Francisco. 2007:Poster #A41. SCO30003 . A multi‐centre, randomised, double‐blind, parallel group, placebo‐controlled study to investigate the long‐term effects of salmeterol/fluticasone propionate (SERETIDE®/VIANI®/ADVAIR®) 50/500mcg bd, salmeterol 50mcg bd and fluticasone propionate 500mcg bd, all delivered via the DISKUS®/ACCUHALER® inhaler, on the survival of subjects with chronic obstructive pulmonary disease (COPD) over 3 years of treatment. www.ctr.gsk.co.uk (accessed 21 April 2012). SacchettaA . Long term therapy and outcome of chronic obstructive pulmonary disease with or without co‐morbidity: The TORCH Study. Italian Journal of Medicine2008;2(3):11‐5. VestboJ , AndersonJA , CalverleyPM , CelliB , FergusonGT , JenkinsC , et al. Bias due to withdrawal in long‐term randomised trials in COPD: Evidence from the TORCH study. Clinical Respiratory Journal2011;5(1):44‐9. VestboJ , TORCH Study Group. The TORCH (TOwards a Revolution in COPD Health) survival study protocol. European Respiratory Journal2004;24(2):206‐10. ">Calverley 2007 TORCH</a>). </p> </div> </div> </div> <section id="CD010115-sec-0101"> <h5 class="title">6.1 Non‐fatal serious adverse pneumonia events</h5> <p>The point estimate favoured fluticasone, but the difference was not significant and the confidence intervals were very wide (OR 0.53, 95% CI 0.16 to 1.71). In addition to being downgraded for indirectness, the outcome was downgraded twice for imprecision and was rated as very low quality. </p> </section> <section id="CD010115-sec-0102"> <h5 class="title">6.2 Mortality, all‐cause</h5> <p>The point estimate favoured budesonide, but the difference was not significant and the confidence intervals were wide (OR 1.24, 95% CI 0.74 to 2.07). Evidence was also downgraded once for imprecision and was rated of low quality. </p> </section> <section id="CD010115-sec-0103"> <h5 class="title">6.3 All non‐fatal serious adverse events</h5> <p>The difference between fluticasone and budesonide was not significant, and the confidence intervals were much tighter than for the other two indirect comparisons (OR 0.96, 95% CI 0.77 to 1.20). The evidence was not downgraded for any other reason and was rated of moderate quality. </p> </section> <section id="CD010115-sec-0104"> <h5 class="title">6.4 All pneumonia events</h5> <p>A significant difference was noted between fluticasone and budesonide, although the confidence interval was quite wide (OR 1.86, 95% CI 1.04 to 3.34). The evidence was not downgraded for any other reason and was rated of moderate quality. When <a href="./references#CD010115-bbs2-0007" title="AllegraL . TORCH study: An invitation to clinical considerations. GIMT ‐ Giornale Italiano delle Malattie del Torace2007;61(1):15‐23. BriggsAH , GlickHA , Lozano‐OrtegaG , SpencerM , CalverleyPM , JonesPW , et al. Is treatment with ICS and LABA cost‐effective for COPD? Multinational economic analysis of the TORCH study. European Respiratory Journal2010;35(3):532‐9. BriggsAH , Lozano‐OrtegaG , SpencerS , BaleG , SpencerMD , BurgePS . Estimating the cost‐effectiveness of fluticasone propionate for treating chronic obstructive pulmonary disease in the presence of missing data. Value in Health2006;9(4):227‐35. CalverleyP , CelliB , AndersonJ , FergusonG , JenkinsC , JonesP , et al. Salmeterol/fluticasone propionate combination (SFC) improves survival in COPD over three years: on‐treatment analysis from the TORCH study [Abstract]. American Thoracic Society International Conference; 2009 May 15‐20; San Diego. 2009:A6191[Poster #219]. CalverleyP , CelliB , AndersonJA , FergusonGT , JenkinsC , JonesPW , et al. The TOwards a Revolution in COPD Health (TORCH) study: salmeterol/fluticasone propionate improves survival in COPD over three years [Abstract]. Respirology2006;11 Suppl 5:A149 [PS‐3‐8]. CalverleyPM , AndersonJA , CelliB , FergusonGT , JenkinsC , JonesPW , et al. Salmeterol and fluticasone propionate and survival in chronic obstructive pulmonary disease. New England Journal of Medicine2007;356(8):775‐89. CalverleyPM , AndersonJA , CelliB , FergusonGT , JenkinsC , Jones PW et al and TORCH Investigators. Cardiovascular events in patients with COPD: TORCH study results. Thorax2010;65(8):719‐25. CalverleyPM , CelliB , AndersonJA , FergusonGT , JenkinsC , JonesPW , et al. The TOwards a Revolution in COPD Health (TORCH) study: fluticasone propionate /salmeterol improves survival in COPD over three years. Chest2006;130(4):122s. CalverleyPMA , CelliB , AndersenJA , FergusonGT , JenkinsC , JonesPW , et al. The TORCH (TOwards a Revolution in COPD Health) study salmeterol/fluticasone propionate (SFC) improves survival in COPD over three years. European Respiratory Journal2006;28 Suppl 50:34. CelliB , CalverleyPM , AndersonJA , FergusonGT , JenkinsC , JonesP , et al. The TOwards a Revolution in COPD HEalth (TORCH) Study: salmeterol/fluticasone propionate reduces the rate of exacerbations over three years. Respirology2006;11 Suppl 5:A140. CelliB , CalverleyPM , AndersonJA , FergusonGT , JenkinsC , JonesPW , et al. The TOwards a Revolution in COPD Health (TORCH) study: fluticasone propionate/salmeterol reduces the rate of exacerbations over 3 years [Abstract]. Chest2006;130(4):177s. CelliB , CalverleyPMA , AndersonJA , FergusonGT , JenkinsC , JonesPW , et al. The TORCH (TOwards a Revolution in COPD Health) study salmeterol/fluticasone propionate (SFC) improves health status reduces exacerbations and improves lung function over three years [Abstract]. European Respiratory Journal2006;28 Suppl 50:34s [E312]. CelliB , EmmettA , CraterG , KalbergC . Fluticasone propionate/salmeterol (FSC) improves the inspiratory to total lung capacity ratio (IC/TLC) and exercise endurance time in patients with COPD. European Respiratory Society 16th Annual Congress; 2006 Sep 2‐6; Munich. 2006:A320 (Poster 323). CelliB , FergusonGT , AndersonJA , JenkinsCR , JonesPW , VestboJ , et al. Salmeterol/fluticasone propionate (SFC) improves lung function and reduces the rate of decline over three years in the TORCH survival study [Abstract]. American Thoracic Society International Conference; 2007 May 18‐23; San Francisco. 2007:A763. CelliB , VestboJ , JenkinsCR , JonesPW , FergusonGT , CalverleyPMA , et al. Sex differences in mortality and clinical expressions of patients with chronic obstructive pulmonary disease: the TORCH experience. American Journal of Respiratory and Critical Care Medicine2011;183(3):317‐22. CelliBR , ThomasNE , AndersonJA , FergusonGT , JenkinsCR , JonesPW , et al. Effect of pharmacotherapy on rate of decline of lung function in chronic obstructive pulmonary disease: results from the TORCH study. American Journal of Respiratory and Critical Care Medicine2008;178(4):332‐8. CelliD , EmmettA , CraterG , KalbergC . Salmeterol/fluticasone propionate (SFC) improves the inspiratory to total lung capacity ratio (IC/TLC) and exercise endurance time in patients with COPD. European Respiratory Journal2006;28 Suppl 50:764 [4395]. CorhayJL , LouisR . Clinical study of the month: the TORCH study (TOwards a Revolution in COPD Health) [L'étude clinique du mois. L'étude TORCH (TOwards a Revolution in COPD Health): vers une revolution de la santé des patients souffrant de BPCO]. Revue Medicale de Liege2007;62(4):230‐4. FergusonGT , CalverleyPM , AndersonJA , CelliB , JenkinsC , JonesPW , et al. The TOwards a Revolution in COPD Health (TORCH) study: fluticasone propionate/salmeterol is well tolerated in patients with COPD over 3 years [Abstract]. Chest2006;130(4):178s. FergusonGT , CalverleyPM , AndersonJA , CelliB , JenkinsCR , JonesPW , et al. Effect of salmeterol/fluticasone propionate (SFC) on bone mineral density (BMD) and eye disorders over three years in the TORCH trial [Abstract]. American Thoracic Society International Conference; 2007 May 18‐23; San Francisco. 2007:A763. FergusonGT , CalverleyPM , AndersonJA , JenkinsCR , CelliB , et al. Prevalence and progression of osteoporosis in patients with COPD results from the towards a revolution in COPD health study. Chest2009;136(6):1456‐65. FergusonGT , CalverleyPMA , AndersonJA , et al. The TORCH (TOwards a Revolution in COPD Health) study: salmeterol/fluticasone propionate (SFC) improves survival in COPD over three years. European Respiratory Journal2006;28 Suppl 50:34s. GlickH , BriggsA , Lozano‐OrtegaG , SpencerM , VestboJ , CalverleyP . Is treatment with ICS/LABA combination good value for money in COPD? Evidence from the TORCH study [Abstract]. American Thoracic Society International Conference; 2007 May 18‐23; San Francisco. 2007:[C97]. JenkinsC , CelliB , AndersonJ , FergusonG , CalverleyP , JonesP , et al. Salmeterol/fluticasone propionate (SFC) is efficacious in GOLD stage II COPD patients: analysis from the TORCH study [Abstract]. American Thoracic Society International Conference; May 15‐20; San Diego. 2009:A6186 [Poster #213]. JenkinsCR , CelliB , AndersonJA , FergusonGT , JonesPW , VestboJ , et al. Seasonality and determinants of moderate and severe COPD exacerbations in the TORCH study. European Respiratory Journal2012;39:38‐45. JenkinsCR , CelliB , AndersonJA , FergusonGT , JonesPW , VestboJ , et al. The TORCH survival study: consistent efficacy results seen in geographic regions in a multi‐national study [Abstract]. American Thoracic Society International Conference; May 18‐23; San Francisco. 2007:[C97]. JenkinsCR , JonesPW , CalverleyPM , CelliB , AndersonJA , FergusonGT , et al. Efficacy of salmeterol/fluticasone propionate by GOLD stage of chronic obstructive pulmonary disease: analysis from the randomised, placebo‐controlled TORCH study. Respiratory Research2009;10:59. JonesPW , AndersonJA , CalverleyPM , CelliBR , FergusonGT , JenkinsC , et al. Health status in the TORCH study of COPD: treatment efficacy and other determinants of change. Respiratory Research2011;12:71. JonesPW , CalverleyPM , CelliB , AndersonJA , FergusonGT , JenkinsC , et al. The TOwards a Revolution in COPD Health (TORCH) study: fluticasone propionate/salmeterol improves and sustains health status in COPD over 3 years. Chest2006;130(4):177s. JonesPW , VestboJ , AndersonJA , CelliB , FergusonGT , JenkinsCR , et al. Informative withdrawal in a COPD study. An example from the TORCH Study [Abstract]. American Thoracic Society International Conference; 2007 May 18‐23; San Francisco. 2007:[C97]. KeeneON , VestboJ , AndersonJA , CalverleyPM , CelliB , FergusonGT , et al. Methods for therapeutic trials in COPD: Lessons from the TORCH trial. European Respiratory Journal2009;34(5):1018‐23. McDonoughC , BlanchardAR . TORCH study results: pharmacotherapy reduces lung function decline in patients with chronic obstructive pulmonary disease. Hospital Practice2010;38(2):92‐3. McGarveyLP , JohnM , AndersonJA , ZvarichM , WiseRA , Committee TCE et al. Ascertainment of cause‐specific mortality in COPD: operations of the TORCH Clinical Endpoint Committee. Thorax2007;62(5):411‐5. MehtaRS , KathmanSJ , Daley‐YatesPT , CahnT , BeeraheeM , KunkaRL , et al. Pharmacokinetics and pharmacodynamics in COPD patients following long‐term twice‐daily treatment with salmeterol/fluticasone propionate (SFC) 50/500mg and the individual components [Abstract]. American Thoracic Society International Conference; 2007 May 18‐23; San Francisco. 2007:Poster #A41. SCO30003 . A multi‐centre, randomised, double‐blind, parallel group, placebo‐controlled study to investigate the long‐term effects of salmeterol/fluticasone propionate (SERETIDE®/VIANI®/ADVAIR®) 50/500mcg bd, salmeterol 50mcg bd and fluticasone propionate 500mcg bd, all delivered via the DISKUS®/ACCUHALER® inhaler, on the survival of subjects with chronic obstructive pulmonary disease (COPD) over 3 years of treatment. www.ctr.gsk.co.uk (accessed 21 April 2012). SacchettaA . Long term therapy and outcome of chronic obstructive pulmonary disease with or without co‐morbidity: The TORCH Study. Italian Journal of Medicine2008;2(3):11‐5. VestboJ , AndersonJA , CalverleyPM , CelliB , FergusonGT , JenkinsC , et al. Bias due to withdrawal in long‐term randomised trials in COPD: Evidence from the TORCH study. Clinical Respiratory Journal2011;5(1):44‐9. VestboJ , TORCH Study Group. The TORCH (TOwards a Revolution in COPD Health) survival study protocol. European Respiratory Journal2004;24(2):206‐10. ">Calverley 2007 TORCH</a> was removed from the sensitivity analysis, the difference was larger in magnitude but was much less precise and was not statistically significant (OR 2.30, 95% CI 0.79 to 6.67). </p> </section> </section> <section id="CD010115-sec-0105"> <h4 class="title">Comparison seven: indirect comparison of fluticasone/LABA and budesonide/LABA combination therapy </h4> <p>For the reasons described in 'Transitivity and similarity', we chose not to calculate an indirect comparison for combination therapy. Recent studies directly comparing fluticasone/salmeterol with budesonide/formoterol were not comparable with the design or time scales used in the rest of this review (<a href="./references#CD010115-bbs2-0064" title="BlaisL , ForgetA , RamachandranS . Relative effectiveness of budesonide/formoterol and fluticasone propionate/salmeterol in a 1‐year, population‐based, matched cohort study of patients with chronic obstructive pulmonary disease (COPD): effect on COPD‐related exacerbations, emergency department visits and hospitalizations, medication utilization, and treatment adherence. Clinical Therapeutics2010;32(7):1320‐8. ">Blais 2010</a>; <a href="./references#CD010115-bbs2-0076" title="JansonC , LarssonK , LisspersKH , StallbergB , StratelisG , GoikeH , et al. Pneumonia and pneumonia related mortality in patients with COPD treated with fixed combinations of inhaled corticosteroid and long acting beta2 agonist: observational matched cohort study (PATHOS). BMJ. 2013/05/31 2013; Vol. 346:f3306. [1756‐1833: (Electronic)] ">Janson 2013 [PATHOS]</a>; <a href="./references#CD010115-bbs2-0083" title="PartridgeMR , SchuermannW , BeckmanO , PerssonT , PolanowskiT . Effect on lung function and morning activities of budesonide/formoterol versus salmeterol/fluticasone in patients with COPD. Therapeutic Advances in Respiratory Disease2009;3(4):147‐57. ">Partridge 2009</a>; <a href="./references#CD010115-bbs2-0085" title="RobertsM , MapelD , PetersenH , BlanchetteC , RamachandranS . Comparative effectiveness of budesonide/formoterol and fluticasone/salmeterol for COPD management. Journal of Medical Economics2011;14(6):769‐76. ">Roberts 2011</a>), but their findings are discussed in <a href="#CD010115-sec-0111">Agreements and disagreements with other studies or reviews</a>. </p> </section> </section> </section> </section> <section class="discussion"> <div class="section-header section-collapse-header" id="CD010115-sec-0106" lang="en"> <h2 class="title section-collapse-title"> Discussion <i aria-hidden="true" class="fa fa-caret-up section-collapse-icon"></i> </h2> </div> <section class="discussion" lang="en"> <div class="section-header" id="CD010115-sec-0106"></div> <section id="CD010115-sec-0107"> <h3 class="title" id="CD010115-sec-0107">Summary of main results</h3> <p>We found a total of 43 studies that met the inclusion criteria for this review, with more evidence for fluticasone (26 studies, n = 21,247) than budesonide (17 studies, n = 10,150). Evidence from the budesonide studies was more inconsistent and less precise, and the mean duration of trials was shorter. </p> <p>Fluticasone increased non‐fatal serious adverse pneumonia events (i.e. those requiring a hospital admission) (OR 1.78, 95% CI 1.50 to 2.12; high‐quality evidence), and no significant evidence suggested that this was different when fluticasone was delivered in combination with salmeterol or vilanterol (subgroup differences, I<sup>2</sup> = 0%, P value 0.51). We did not find that different doses, trial duration or baseline severity significantly affected this estimate. Budesonide also increased non‐fatal serious adverse pneumonia events, but the effect was less precise (OR 1.62, 95% CI 1.00 to 2.62; moderate‐quality evidence). Some of the variation in the budesonide data could be explained by a significant difference between the two commonly used doses: 640 mcg showed a larger increase than 320 mcg (subgroup differences, I<sup>2</sup> = 74%, P value 0.05). An indirect comparison of budesonide and fluticasone using placebo as a common comparator showed no significant differences with respect to serious adverse events (pneumonia‐related or all‐cause) or mortality. </p> <p>No difference in overall mortality rates was noted between either of the inhaled steroids and the control interventions (both high‐quality evidence), but no conclusions could be drawn regarding deaths that were pneumonia‐related, as so few events were reported. Evidence of total pneumonia events on fluticasone was dominated by the three‐year <a href="./references#CD010115-bbs2-0007" title="AllegraL . TORCH study: An invitation to clinical considerations. GIMT ‐ Giornale Italiano delle Malattie del Torace2007;61(1):15‐23. BriggsAH , GlickHA , Lozano‐OrtegaG , SpencerM , CalverleyPM , JonesPW , et al. Is treatment with ICS and LABA cost‐effective for COPD? Multinational economic analysis of the TORCH study. European Respiratory Journal2010;35(3):532‐9. BriggsAH , Lozano‐OrtegaG , SpencerS , BaleG , SpencerMD , BurgePS . Estimating the cost‐effectiveness of fluticasone propionate for treating chronic obstructive pulmonary disease in the presence of missing data. Value in Health2006;9(4):227‐35. CalverleyP , CelliB , AndersonJ , FergusonG , JenkinsC , JonesP , et al. Salmeterol/fluticasone propionate combination (SFC) improves survival in COPD over three years: on‐treatment analysis from the TORCH study [Abstract]. American Thoracic Society International Conference; 2009 May 15‐20; San Diego. 2009:A6191[Poster #219]. CalverleyP , CelliB , AndersonJA , FergusonGT , JenkinsC , JonesPW , et al. The TOwards a Revolution in COPD Health (TORCH) study: salmeterol/fluticasone propionate improves survival in COPD over three years [Abstract]. Respirology2006;11 Suppl 5:A149 [PS‐3‐8]. CalverleyPM , AndersonJA , CelliB , FergusonGT , JenkinsC , JonesPW , et al. Salmeterol and fluticasone propionate and survival in chronic obstructive pulmonary disease. New England Journal of Medicine2007;356(8):775‐89. CalverleyPM , AndersonJA , CelliB , FergusonGT , JenkinsC , Jones PW et al and TORCH Investigators. Cardiovascular events in patients with COPD: TORCH study results. Thorax2010;65(8):719‐25. CalverleyPM , CelliB , AndersonJA , FergusonGT , JenkinsC , JonesPW , et al. The TOwards a Revolution in COPD Health (TORCH) study: fluticasone propionate /salmeterol improves survival in COPD over three years. Chest2006;130(4):122s. CalverleyPMA , CelliB , AndersenJA , FergusonGT , JenkinsC , JonesPW , et al. The TORCH (TOwards a Revolution in COPD Health) study salmeterol/fluticasone propionate (SFC) improves survival in COPD over three years. European Respiratory Journal2006;28 Suppl 50:34. CelliB , CalverleyPM , AndersonJA , FergusonGT , JenkinsC , JonesP , et al. The TOwards a Revolution in COPD HEalth (TORCH) Study: salmeterol/fluticasone propionate reduces the rate of exacerbations over three years. Respirology2006;11 Suppl 5:A140. CelliB , CalverleyPM , AndersonJA , FergusonGT , JenkinsC , JonesPW , et al. The TOwards a Revolution in COPD Health (TORCH) study: fluticasone propionate/salmeterol reduces the rate of exacerbations over 3 years [Abstract]. Chest2006;130(4):177s. CelliB , CalverleyPMA , AndersonJA , FergusonGT , JenkinsC , JonesPW , et al. The TORCH (TOwards a Revolution in COPD Health) study salmeterol/fluticasone propionate (SFC) improves health status reduces exacerbations and improves lung function over three years [Abstract]. European Respiratory Journal2006;28 Suppl 50:34s [E312]. CelliB , EmmettA , CraterG , KalbergC . Fluticasone propionate/salmeterol (FSC) improves the inspiratory to total lung capacity ratio (IC/TLC) and exercise endurance time in patients with COPD. European Respiratory Society 16th Annual Congress; 2006 Sep 2‐6; Munich. 2006:A320 (Poster 323). CelliB , FergusonGT , AndersonJA , JenkinsCR , JonesPW , VestboJ , et al. Salmeterol/fluticasone propionate (SFC) improves lung function and reduces the rate of decline over three years in the TORCH survival study [Abstract]. American Thoracic Society International Conference; 2007 May 18‐23; San Francisco. 2007:A763. CelliB , VestboJ , JenkinsCR , JonesPW , FergusonGT , CalverleyPMA , et al. Sex differences in mortality and clinical expressions of patients with chronic obstructive pulmonary disease: the TORCH experience. American Journal of Respiratory and Critical Care Medicine2011;183(3):317‐22. CelliBR , ThomasNE , AndersonJA , FergusonGT , JenkinsCR , JonesPW , et al. Effect of pharmacotherapy on rate of decline of lung function in chronic obstructive pulmonary disease: results from the TORCH study. American Journal of Respiratory and Critical Care Medicine2008;178(4):332‐8. CelliD , EmmettA , CraterG , KalbergC . Salmeterol/fluticasone propionate (SFC) improves the inspiratory to total lung capacity ratio (IC/TLC) and exercise endurance time in patients with COPD. European Respiratory Journal2006;28 Suppl 50:764 [4395]. CorhayJL , LouisR . Clinical study of the month: the TORCH study (TOwards a Revolution in COPD Health) [L'étude clinique du mois. L'étude TORCH (TOwards a Revolution in COPD Health): vers une revolution de la santé des patients souffrant de BPCO]. Revue Medicale de Liege2007;62(4):230‐4. FergusonGT , CalverleyPM , AndersonJA , CelliB , JenkinsC , JonesPW , et al. The TOwards a Revolution in COPD Health (TORCH) study: fluticasone propionate/salmeterol is well tolerated in patients with COPD over 3 years [Abstract]. Chest2006;130(4):178s. FergusonGT , CalverleyPM , AndersonJA , CelliB , JenkinsCR , JonesPW , et al. Effect of salmeterol/fluticasone propionate (SFC) on bone mineral density (BMD) and eye disorders over three years in the TORCH trial [Abstract]. American Thoracic Society International Conference; 2007 May 18‐23; San Francisco. 2007:A763. FergusonGT , CalverleyPM , AndersonJA , JenkinsCR , CelliB , et al. Prevalence and progression of osteoporosis in patients with COPD results from the towards a revolution in COPD health study. Chest2009;136(6):1456‐65. FergusonGT , CalverleyPMA , AndersonJA , et al. The TORCH (TOwards a Revolution in COPD Health) study: salmeterol/fluticasone propionate (SFC) improves survival in COPD over three years. European Respiratory Journal2006;28 Suppl 50:34s. GlickH , BriggsA , Lozano‐OrtegaG , SpencerM , VestboJ , CalverleyP . Is treatment with ICS/LABA combination good value for money in COPD? Evidence from the TORCH study [Abstract]. American Thoracic Society International Conference; 2007 May 18‐23; San Francisco. 2007:[C97]. JenkinsC , CelliB , AndersonJ , FergusonG , CalverleyP , JonesP , et al. Salmeterol/fluticasone propionate (SFC) is efficacious in GOLD stage II COPD patients: analysis from the TORCH study [Abstract]. American Thoracic Society International Conference; May 15‐20; San Diego. 2009:A6186 [Poster #213]. JenkinsCR , CelliB , AndersonJA , FergusonGT , JonesPW , VestboJ , et al. Seasonality and determinants of moderate and severe COPD exacerbations in the TORCH study. European Respiratory Journal2012;39:38‐45. JenkinsCR , CelliB , AndersonJA , FergusonGT , JonesPW , VestboJ , et al. The TORCH survival study: consistent efficacy results seen in geographic regions in a multi‐national study [Abstract]. American Thoracic Society International Conference; May 18‐23; San Francisco. 2007:[C97]. JenkinsCR , JonesPW , CalverleyPM , CelliB , AndersonJA , FergusonGT , et al. Efficacy of salmeterol/fluticasone propionate by GOLD stage of chronic obstructive pulmonary disease: analysis from the randomised, placebo‐controlled TORCH study. Respiratory Research2009;10:59. JonesPW , AndersonJA , CalverleyPM , CelliBR , FergusonGT , JenkinsC , et al. Health status in the TORCH study of COPD: treatment efficacy and other determinants of change. Respiratory Research2011;12:71. JonesPW , CalverleyPM , CelliB , AndersonJA , FergusonGT , JenkinsC , et al. The TOwards a Revolution in COPD Health (TORCH) study: fluticasone propionate/salmeterol improves and sustains health status in COPD over 3 years. Chest2006;130(4):177s. JonesPW , VestboJ , AndersonJA , CelliB , FergusonGT , JenkinsCR , et al. Informative withdrawal in a COPD study. An example from the TORCH Study [Abstract]. American Thoracic Society International Conference; 2007 May 18‐23; San Francisco. 2007:[C97]. KeeneON , VestboJ , AndersonJA , CalverleyPM , CelliB , FergusonGT , et al. Methods for therapeutic trials in COPD: Lessons from the TORCH trial. European Respiratory Journal2009;34(5):1018‐23. McDonoughC , BlanchardAR . TORCH study results: pharmacotherapy reduces lung function decline in patients with chronic obstructive pulmonary disease. Hospital Practice2010;38(2):92‐3. McGarveyLP , JohnM , AndersonJA , ZvarichM , WiseRA , Committee TCE et al. Ascertainment of cause‐specific mortality in COPD: operations of the TORCH Clinical Endpoint Committee. Thorax2007;62(5):411‐5. MehtaRS , KathmanSJ , Daley‐YatesPT , CahnT , BeeraheeM , KunkaRL , et al. Pharmacokinetics and pharmacodynamics in COPD patients following long‐term twice‐daily treatment with salmeterol/fluticasone propionate (SFC) 50/500mg and the individual components [Abstract]. American Thoracic Society International Conference; 2007 May 18‐23; San Francisco. 2007:Poster #A41. SCO30003 . A multi‐centre, randomised, double‐blind, parallel group, placebo‐controlled study to investigate the long‐term effects of salmeterol/fluticasone propionate (SERETIDE®/VIANI®/ADVAIR®) 50/500mcg bd, salmeterol 50mcg bd and fluticasone propionate 500mcg bd, all delivered via the DISKUS®/ACCUHALER® inhaler, on the survival of subjects with chronic obstructive pulmonary disease (COPD) over 3 years of treatment. www.ctr.gsk.co.uk (accessed 21 April 2012). SacchettaA . Long term therapy and outcome of chronic obstructive pulmonary disease with or without co‐morbidity: The TORCH Study. Italian Journal of Medicine2008;2(3):11‐5. VestboJ , AndersonJA , CalverleyPM , CelliB , FergusonGT , JenkinsC , et al. Bias due to withdrawal in long‐term randomised trials in COPD: Evidence from the TORCH study. Clinical Respiratory Journal2011;5(1):44‐9. VestboJ , TORCH Study Group. The TORCH (TOwards a Revolution in COPD Health) survival study protocol. European Respiratory Journal2004;24(2):206‐10. ">Calverley 2007 TORCH</a> study, and far fewer budesonide studies reported the outcome. </p> <p>Indirect comparisons of budesonide and fluticasone monotherapy showed no significant differences with respect to serious adverse events (pneumonia‐related or all‐cause) or mortality. The risk of any pneumonia event (i.e. less serious cases treated in the community) was higher with fluticasone than with budesonide (OR 1.86, 95% CI 1.04 to 3.34); this was the only significant difference found between the two drugs. However, this finding should be interpreted with caution because of possible differences in assignment of a diagnosis of pneumonia, and because no trials directly compared the two drugs. </p> <p>Fewer people in the inhaled steroid groups withdrew from study medication; this was true for both monotherapy versus placebo and combination therapy versus LABA trials. It is possible that this was a result of lack of efficacy in the control groups, but it was not formally evaluated. High or uneven dropout was considered to show a high risk of bias in almost 40% of the trials, but conclusions for the primary outcome did not change when the trials at high risk of bias were removed in a sensitivity analysis. </p> </section> <section id="CD010115-sec-0108"> <h3 class="title" id="CD010115-sec-0108">Overall completeness and applicability of evidence</h3> <p>Efforts were made to contact all trial authors to obtain additional data when outcomes did not appear in the available reports. Although this resulted in some additional data being provided—both numerical and related to study conduct—most studies do not appear in every analysis; only around a third of the studies contribute data to the primary outcome. </p> <p>We chose to look at fluticasone and budesonide as the two most widely used inhaled steroids that are also commonly prescribed in combination with the long‐acting beta<sub>2</sub>‐agonists salmeterol and formoterol, respectively, and we did not include trials studying other available inhaled steroids (e.g. mometasone, triamcinolone, ciclesonide, beclomethasone, flunisolide). As such, the study results can be applied only to the inhaled steroids in question, not to the class in general. </p> <p>The plan to indirectly compare budesonide/formoterol and fluticasone/salmeterol combination therapies was more complicated than it was for monotherapy, and by choosing not to conduct the indirect comparison, we were unable to draw conclusions about the relative safety of budesonide and fluticasone when used in combination with a LABA. Even without the addition of the fluticasone furoate/vilanterol studies, we considered the LABA comparator to differ systematically between fluticasone and budesonide combination therapy studies, hence violating the transitivity assumption. Variation in the LABA used <i>within</i> the fluticasone trials further reduced our confidence in the indirect comparison. </p> <p>Inhaled corticosteroids are not equal in strength, and their doses are normally expressed as equivalents to budesonide dipropionate (BDP) doses (<a href="#CD010115-tbl-0005">Table 3</a>). By pooling data for all doses of fluticasone for comparison with all doses of budesonide, the indirect comparison could not account for the dose‐related effects that we found with budesonide, or for differences in dose equivalence between the two sets of data. </p> </section> <section id="CD010115-sec-0109"> <h3 class="title" id="CD010115-sec-0109">Quality of the evidence</h3> <p>We wrote to all study authors when numerical outcome data or details related to risk of bias could not be obtained from available reports. Of all the studies, nine reported all information and did not need to be contacted; we failed to find contact details for a further six. Of the remaining 28 studies, 13 study authors did not reply, six provided additional data or confirmed that all measured outcomes were reported in the original reports, four forwarded the request to the drug company that held the data, four were requests sent directly to GlaxoSmithKline and one could not provide data. No drug company data were provided by the time the review was published, and the application for data is ongoing and may be incorporated in future updates. In addition, nearly half of the studies were conducted 10 or more years ago; this made it difficult for review authors to locate contact details and for study authors to locate the data requested. </p> <p>The definition of pneumonia and the method of diagnosis were routinely missing from trial reports, and this information could not be obtained to conduct a subgroup analysis on this basis. We were unsure whether pneumonia was radiographically confirmed in most cases, and the trials were not designed for the purpose of measuring the incidence of pneumonia. In addition, the extent to which pneumonia events are misclassified as acute exacerbations of COPD (and vice versa) is somewhat unclear (<a href="./references#CD010115-bbs2-0079" title="MarzorattiL , IannellaHA , WatererGW . Inhaled corticosteroids and the increased risk of pneumonia. Therapeutic Advances in Respiratory Disease. 2013/03/01 2013; Vol. 7, issue 4:225‐34. [1753‐4666: (Electronic)] ">Marzoratti 2013</a>). We could not obtain information to judge whether ascertainment of pneumonia was systematically different between funding drug companies or between healthcare systems in which studies were conducted; this is a potential source of bias. </p> <p>Despite a relatively low rate of response from trial authors, all outcomes based on direct evidence were rated as high or moderate quality with GRADE. All trials were generally of good methodological quality, having been conducted by large pharmaceutical companies. In addition, more than 40 studies were found that contributed data to at least one analysis. Some imprecision was noted for rare events such as mortality due to pneumonia; we were unable to draw conclusions in these cases, especially for budesonide, for which less evidence was available. For this reason, we were generally less confident in the budesonide outcomes. </p> <p>We identified two potential confounds, which we did not consider to be sufficient to downgrade the quality of the evidence. First, most of the budesonide studies were funded by AstraZeneca, and most of the fluticasone studies by GlaxoSmithKline. However, systematic differences in study conduct were not identified in the assessments of bias. Second, budesonide monotherapy and combination therapy are delivered via a Turbuhaler, and fluticasone is given via a Diskus or Accuhaler device. We assumed that participants in the trials were given adequate training for the device used, and that this did not systematically affect the amount of drug delivered or the likelihood of compliance between the two drugs. For this reason, and because in each double‐blind trial the placebo device matched that of the active drug, we did not consider different drug devices a reason not to conduct the indirect comparison of budesonide versus fluticasone. </p> <p>When the protocol for this review was written, we did not anticipate the inclusion of a new preparation of fluticasone furoate in combination with the long‐acting beta<sub>2</sub>‐agonist vilanterol. Including these studies may have introduced heterogeneity into the direct fluticasone versus placebo comparison, and into the fluticasone/LABA versus LABA comparison, although a recent randomised trial comparing fluticasone/vilanterol with fluticasone/salmeterol found no significant differences in their efficacy or safety profiles (<a href="./references#CD010115-bbs2-0062" title="AgustiA , deTeresaL , DeBackerW , ZvarichMT , LocantoreN , BarnesN , et al. A comparison of the efficacy and safety of once‐daily fluticasone furoate/vilanterol with twice‐daily fluticasone propionate/salmeterol in moderate to very severe COPD. The European Respiratory Journal. 2013/10/12 2013 Oct 10 [Epub ahead of print]. [1399‐3003: (Electronic)] ">Agusti 2013</a>). Inclusion of these studies may also have reduced the reliability of the indirect comparisons by increasing variation within the fluticasone monotherapy node and the fluticasone/salmeterol node (by including fluticasone/vilanterol studies in a combined fluticasone/LABA node), but the absence of statistical heterogeneity in the analyses did not suggest that this was the case. The expected publication of further RCTs of fluticasone furoate and other new preparations will increase the likelihood of detecting any differences which may exist between their safety profiles and more established corticosteroids. This may warrant dealing with different preparations separately in future updates of this review, which was not possible with the current evidence base. </p> <p>Our decision to conduct the monotherapy indirect comparison was based on statistical consistency within the two sets of monotherapy trials (budesonide vs placebo and fluticasone vs placebo) and on a comprehensive assessment of transitivity across these two sets of trials. As such, we considered the indirect comparison to be valid, but the quality of the evidence remains limited by the observational nature of indirect comparisons, and by the lack of head‐to‐head trials comparing fluticasone and budesonide. </p> </section> <section id="CD010115-sec-0110"> <h3 class="title" id="CD010115-sec-0110">Potential biases in the review process</h3> <p>We made every effort to adhere to Cochrane methods during the review process. As stated in the protocol, all numerical data were extracted by two review authors, and discrepancies were resolved through discussion. The same was true for the risk of bias ratings. Neither of the review authors have conflicting interests. </p> <p>It is unlikely that the review is biased as a result of published studies missed during study selection. The electronic searches were relatively broad, and review authors searched additional resources to locate any studies that might have been missed (e.g. trial registration websites, drug company databases, reference lists of included studies). In addition, review authors attempted to contact all study authors when data or details of study methodology were not reported in the published reports. </p> </section> <section id="CD010115-sec-0111"> <h3 class="title" id="CD010115-sec-0111">Agreements and disagreements with other studies or reviews</h3> <p>Two Cochrane reviews that are related to this safety review have recently been updated: <a href="./references#CD010115-bbs2-0096" title="YangIA , ClarkeMS , SimEH , FongKM . Inhaled corticosteroids for stable chronic obstructive pulmonary disease. The Cochrane Database of Systematic Reviews. 2012/07/13 2012; Vol. 7:CD002991. [1469‐493X: (Electronic)] ">Yang 2012</a>, looking at the safety and efficacy of any inhaled corticosteroid versus placebo, and <a href="./references#CD010115-bbs2-0080" title="NanniniLJ , LassersonTJ , PooleP . Combined corticosteroid and long‐acting beta2‐agonist in one inhaler versus long‐acting beta2‐agonists for chronic obstructive pulmonary disease. Cochrane Database of Systematic Reviews2012, Issue 9. [DOI: 10.1002/14651858.CD006829.pub2] ">Nannini 2012</a>, focusing on ICS/LABA combination therapy versus LABA alone. Both reviews are consistent with the findings and conclusions of this review; no effect was observed for mortality, and increased rates of pneumonia seen with inhaled steroids were not significantly different between types of inhaled steroids. <a href="./references#CD010115-bbs2-0080" title="NanniniLJ , LassersonTJ , PooleP . Combined corticosteroid and long‐acting beta2‐agonist in one inhaler versus long‐acting beta2‐agonists for chronic obstructive pulmonary disease. Cochrane Database of Systematic Reviews2012, Issue 9. [DOI: 10.1002/14651858.CD006829.pub2] ">Nannini 2012</a> called for more evidence regarding differential safety of different doses of inhaled steroids, which this review has helped to clarify. Both author teams correctly point out in their reviews that evidence for harms associated with these medications needs to be assessed in conjunction with good evidence of the clinical benefit of inhaled steroids (notably, fewer exacerbations and improved quality of life). In contrast to other previous meta‐analyses (<a href="./references#CD010115-bbs2-0087" title="Ruiz GarciaV , Compte TorreroL . [Risk of pneumonia with inhaled corticosteroids for stable chronic obstructive pulmonary disease patients]. Medicina Clinica. 2011/03/15 2011; Vol. 137, issue 7:302‐4. [0025‐7753: (Print)] ">Ruiz 2011</a>; <a href="./references#CD010115-bbs2-0088" title="SinDD , TashkinD , ZhangX , RadnerF , SjobringU , ThorenA , et al. Budesonide and the risk of pneumonia: a meta‐analysis of individual patient data. Lancet2009;374(9691):712‐9. [1474‐547X: (Electronic)] ">Sin 2009</a>), this review found evidence for an association between budesonide and serious adverse pneumonia events, and indirect comparison with fluticasone yielded little evidence for differential safety between the two drugs. It is problematic to incorporate evidence for dose‐related safety with efficacy data to assess whether a particular dose of a drug is preferable to another; evidence from <a href="./references#CD010115-bbs2-0007" title="AllegraL . TORCH study: An invitation to clinical considerations. GIMT ‐ Giornale Italiano delle Malattie del Torace2007;61(1):15‐23. BriggsAH , GlickHA , Lozano‐OrtegaG , SpencerM , CalverleyPM , JonesPW , et al. Is treatment with ICS and LABA cost‐effective for COPD? Multinational economic analysis of the TORCH study. European Respiratory Journal2010;35(3):532‐9. BriggsAH , Lozano‐OrtegaG , SpencerS , BaleG , SpencerMD , BurgePS . Estimating the cost‐effectiveness of fluticasone propionate for treating chronic obstructive pulmonary disease in the presence of missing data. Value in Health2006;9(4):227‐35. CalverleyP , CelliB , AndersonJ , FergusonG , JenkinsC , JonesP , et al. Salmeterol/fluticasone propionate combination (SFC) improves survival in COPD over three years: on‐treatment analysis from the TORCH study [Abstract]. American Thoracic Society International Conference; 2009 May 15‐20; San Diego. 2009:A6191[Poster #219]. CalverleyP , CelliB , AndersonJA , FergusonGT , JenkinsC , JonesPW , et al. The TOwards a Revolution in COPD Health (TORCH) study: salmeterol/fluticasone propionate improves survival in COPD over three years [Abstract]. Respirology2006;11 Suppl 5:A149 [PS‐3‐8]. CalverleyPM , AndersonJA , CelliB , FergusonGT , JenkinsC , JonesPW , et al. Salmeterol and fluticasone propionate and survival in chronic obstructive pulmonary disease. New England Journal of Medicine2007;356(8):775‐89. CalverleyPM , AndersonJA , CelliB , FergusonGT , JenkinsC , Jones PW et al and TORCH Investigators. Cardiovascular events in patients with COPD: TORCH study results. Thorax2010;65(8):719‐25. CalverleyPM , CelliB , AndersonJA , FergusonGT , JenkinsC , JonesPW , et al. The TOwards a Revolution in COPD Health (TORCH) study: fluticasone propionate /salmeterol improves survival in COPD over three years. Chest2006;130(4):122s. CalverleyPMA , CelliB , AndersenJA , FergusonGT , JenkinsC , JonesPW , et al. The TORCH (TOwards a Revolution in COPD Health) study salmeterol/fluticasone propionate (SFC) improves survival in COPD over three years. European Respiratory Journal2006;28 Suppl 50:34. CelliB , CalverleyPM , AndersonJA , FergusonGT , JenkinsC , JonesP , et al. The TOwards a Revolution in COPD HEalth (TORCH) Study: salmeterol/fluticasone propionate reduces the rate of exacerbations over three years. Respirology2006;11 Suppl 5:A140. CelliB , CalverleyPM , AndersonJA , FergusonGT , JenkinsC , JonesPW , et al. The TOwards a Revolution in COPD Health (TORCH) study: fluticasone propionate/salmeterol reduces the rate of exacerbations over 3 years [Abstract]. Chest2006;130(4):177s. CelliB , CalverleyPMA , AndersonJA , FergusonGT , JenkinsC , JonesPW , et al. The TORCH (TOwards a Revolution in COPD Health) study salmeterol/fluticasone propionate (SFC) improves health status reduces exacerbations and improves lung function over three years [Abstract]. European Respiratory Journal2006;28 Suppl 50:34s [E312]. CelliB , EmmettA , CraterG , KalbergC . Fluticasone propionate/salmeterol (FSC) improves the inspiratory to total lung capacity ratio (IC/TLC) and exercise endurance time in patients with COPD. European Respiratory Society 16th Annual Congress; 2006 Sep 2‐6; Munich. 2006:A320 (Poster 323). CelliB , FergusonGT , AndersonJA , JenkinsCR , JonesPW , VestboJ , et al. Salmeterol/fluticasone propionate (SFC) improves lung function and reduces the rate of decline over three years in the TORCH survival study [Abstract]. American Thoracic Society International Conference; 2007 May 18‐23; San Francisco. 2007:A763. CelliB , VestboJ , JenkinsCR , JonesPW , FergusonGT , CalverleyPMA , et al. Sex differences in mortality and clinical expressions of patients with chronic obstructive pulmonary disease: the TORCH experience. American Journal of Respiratory and Critical Care Medicine2011;183(3):317‐22. CelliBR , ThomasNE , AndersonJA , FergusonGT , JenkinsCR , JonesPW , et al. Effect of pharmacotherapy on rate of decline of lung function in chronic obstructive pulmonary disease: results from the TORCH study. American Journal of Respiratory and Critical Care Medicine2008;178(4):332‐8. CelliD , EmmettA , CraterG , KalbergC . Salmeterol/fluticasone propionate (SFC) improves the inspiratory to total lung capacity ratio (IC/TLC) and exercise endurance time in patients with COPD. European Respiratory Journal2006;28 Suppl 50:764 [4395]. CorhayJL , LouisR . Clinical study of the month: the TORCH study (TOwards a Revolution in COPD Health) [L'étude clinique du mois. L'étude TORCH (TOwards a Revolution in COPD Health): vers une revolution de la santé des patients souffrant de BPCO]. Revue Medicale de Liege2007;62(4):230‐4. FergusonGT , CalverleyPM , AndersonJA , CelliB , JenkinsC , JonesPW , et al. The TOwards a Revolution in COPD Health (TORCH) study: fluticasone propionate/salmeterol is well tolerated in patients with COPD over 3 years [Abstract]. Chest2006;130(4):178s. FergusonGT , CalverleyPM , AndersonJA , CelliB , JenkinsCR , JonesPW , et al. Effect of salmeterol/fluticasone propionate (SFC) on bone mineral density (BMD) and eye disorders over three years in the TORCH trial [Abstract]. American Thoracic Society International Conference; 2007 May 18‐23; San Francisco. 2007:A763. FergusonGT , CalverleyPM , AndersonJA , JenkinsCR , CelliB , et al. Prevalence and progression of osteoporosis in patients with COPD results from the towards a revolution in COPD health study. Chest2009;136(6):1456‐65. FergusonGT , CalverleyPMA , AndersonJA , et al. The TORCH (TOwards a Revolution in COPD Health) study: salmeterol/fluticasone propionate (SFC) improves survival in COPD over three years. European Respiratory Journal2006;28 Suppl 50:34s. GlickH , BriggsA , Lozano‐OrtegaG , SpencerM , VestboJ , CalverleyP . Is treatment with ICS/LABA combination good value for money in COPD? Evidence from the TORCH study [Abstract]. American Thoracic Society International Conference; 2007 May 18‐23; San Francisco. 2007:[C97]. JenkinsC , CelliB , AndersonJ , FergusonG , CalverleyP , JonesP , et al. Salmeterol/fluticasone propionate (SFC) is efficacious in GOLD stage II COPD patients: analysis from the TORCH study [Abstract]. American Thoracic Society International Conference; May 15‐20; San Diego. 2009:A6186 [Poster #213]. JenkinsCR , CelliB , AndersonJA , FergusonGT , JonesPW , VestboJ , et al. Seasonality and determinants of moderate and severe COPD exacerbations in the TORCH study. European Respiratory Journal2012;39:38‐45. JenkinsCR , CelliB , AndersonJA , FergusonGT , JonesPW , VestboJ , et al. The TORCH survival study: consistent efficacy results seen in geographic regions in a multi‐national study [Abstract]. American Thoracic Society International Conference; May 18‐23; San Francisco. 2007:[C97]. JenkinsCR , JonesPW , CalverleyPM , CelliB , AndersonJA , FergusonGT , et al. Efficacy of salmeterol/fluticasone propionate by GOLD stage of chronic obstructive pulmonary disease: analysis from the randomised, placebo‐controlled TORCH study. Respiratory Research2009;10:59. JonesPW , AndersonJA , CalverleyPM , CelliBR , FergusonGT , JenkinsC , et al. Health status in the TORCH study of COPD: treatment efficacy and other determinants of change. Respiratory Research2011;12:71. JonesPW , CalverleyPM , CelliB , AndersonJA , FergusonGT , JenkinsC , et al. The TOwards a Revolution in COPD Health (TORCH) study: fluticasone propionate/salmeterol improves and sustains health status in COPD over 3 years. Chest2006;130(4):177s. JonesPW , VestboJ , AndersonJA , CelliB , FergusonGT , JenkinsCR , et al. Informative withdrawal in a COPD study. An example from the TORCH Study [Abstract]. American Thoracic Society International Conference; 2007 May 18‐23; San Francisco. 2007:[C97]. KeeneON , VestboJ , AndersonJA , CalverleyPM , CelliB , FergusonGT , et al. Methods for therapeutic trials in COPD: Lessons from the TORCH trial. European Respiratory Journal2009;34(5):1018‐23. McDonoughC , BlanchardAR . TORCH study results: pharmacotherapy reduces lung function decline in patients with chronic obstructive pulmonary disease. Hospital Practice2010;38(2):92‐3. McGarveyLP , JohnM , AndersonJA , ZvarichM , WiseRA , Committee TCE et al. Ascertainment of cause‐specific mortality in COPD: operations of the TORCH Clinical Endpoint Committee. Thorax2007;62(5):411‐5. MehtaRS , KathmanSJ , Daley‐YatesPT , CahnT , BeeraheeM , KunkaRL , et al. Pharmacokinetics and pharmacodynamics in COPD patients following long‐term twice‐daily treatment with salmeterol/fluticasone propionate (SFC) 50/500mg and the individual components [Abstract]. American Thoracic Society International Conference; 2007 May 18‐23; San Francisco. 2007:Poster #A41. SCO30003 . A multi‐centre, randomised, double‐blind, parallel group, placebo‐controlled study to investigate the long‐term effects of salmeterol/fluticasone propionate (SERETIDE®/VIANI®/ADVAIR®) 50/500mcg bd, salmeterol 50mcg bd and fluticasone propionate 500mcg bd, all delivered via the DISKUS®/ACCUHALER® inhaler, on the survival of subjects with chronic obstructive pulmonary disease (COPD) over 3 years of treatment. www.ctr.gsk.co.uk (accessed 21 April 2012). SacchettaA . Long term therapy and outcome of chronic obstructive pulmonary disease with or without co‐morbidity: The TORCH Study. Italian Journal of Medicine2008;2(3):11‐5. VestboJ , AndersonJA , CalverleyPM , CelliB , FergusonGT , JenkinsC , et al. Bias due to withdrawal in long‐term randomised trials in COPD: Evidence from the TORCH study. Clinical Respiratory Journal2011;5(1):44‐9. VestboJ , TORCH Study Group. The TORCH (TOwards a Revolution in COPD Health) survival study protocol. European Respiratory Journal2004;24(2):206‐10. ">Calverley 2007 TORCH</a> suggests that the trade‐off between reducing exacerbations and increasing pneumonia changes over time for fluticasone, but it is not yet clear whether this is true for different doses and products (<a href="./references#CD010115-bbs2-0067" title="CatesC . Inhaled corticosteroids in COPD: quantifying risks and benefits. Thorax2013;68(6):499‐500. ">Cates 2013</a>). </p> <p>Evidence from cohorts corroborates the data from randomised trials, showing increased rates of pneumonia in those treated with inhaled steroids and more clearly demonstrating a dose‐related effect (<a href="./references#CD010115-bbs2-0071" title="ErnstP , GonzalezAV , BrassardP , SuissaS . Inhaled corticosteroid use in chronic obstructive pulmonary disease and the risk of hospitalization for pneumonia. American Journal of Respiratory and Critical Care Medicine2007;176:162‐6. ">Ernst 2007</a>; <a href="./references#CD010115-bbs2-0076" title="JansonC , LarssonK , LisspersKH , StallbergB , StratelisG , GoikeH , et al. Pneumonia and pneumonia related mortality in patients with COPD treated with fixed combinations of inhaled corticosteroid and long acting beta2 agonist: observational matched cohort study (PATHOS). BMJ. 2013/05/31 2013; Vol. 346:f3306. [1756‐1833: (Electronic)] ">Janson 2013 [PATHOS]</a>; <a href="./references#CD010115-bbs2-0092" title="SuissaS , PatenaudeV , LapiF , ErnstP . Inhaled corticosteroids in COPD and the risk of serious pneumonia. Thorax2013;68:1029‐36. ">Suissa 2013</a>; <a href="./references#CD010115-bbs2-0097" title="YawnBP , LiY , TianH , ZhangJ , ArconaS , KahlerKH . Inhaled corticosteroid use in patients with chronic obstructive pulmonary disease and the risk of pneumonia: a retrospective claims data analysis. International Journal of Chronic Obstructive Pulmonary Disease. 2013/07/10 2013; Vol. 8:295‐304. [1178‐2005: (Electronic)] ">Yawn 2013</a>). Evidence from one of the cohorts, which observed more than 20,000 serious pneumonias, revealed increased risk with fluticasone (RR 2.01, 95% CI 1.93 to 2.10) compared with budesonide (RR 1.17, 95% CI 1.09 to 1.26) (<a href="./references#CD010115-bbs2-0092" title="SuissaS , PatenaudeV , LapiF , ErnstP . Inhaled corticosteroids in COPD and the risk of serious pneumonia. Thorax2013;68:1029‐36. ">Suissa 2013</a>); this conclusion could not be drawn from the randomised trial evidence. Although we believe that it was not viable to make an indirect comparison of budesonide combination therapy versus fluticasone combination therapy, cohort data suggest that the fluticasone combination is associated with higher rates of pneumonia, deaths related to pneumonia and admissions to hospital than budesonide/formoterol, but the duration of admissions for pneumonia and overall mortality were similar (<a href="./references#CD010115-bbs2-0076" title="JansonC , LarssonK , LisspersKH , StallbergB , StratelisG , GoikeH , et al. Pneumonia and pneumonia related mortality in patients with COPD treated with fixed combinations of inhaled corticosteroid and long acting beta2 agonist: observational matched cohort study (PATHOS). BMJ. 2013/05/31 2013; Vol. 346:f3306. [1756‐1833: (Electronic)] ">Janson 2013 [PATHOS]</a>). We found no indirect comparisons of budesonide/formoterol and fluticasone/salmeterol using a LABA control group, but indirect evidence based on randomised trials using placebo as the common comparator supported the cohort findings (<a href="./references#CD010115-bbs2-0074" title="HalpinDM , GrayJ , EdwardsSJ , MoraisJ , SinghD . Budesonide/formoterol vs. salmeterol/fluticasone in COPD: a systematic review and adjusted indirect comparison of pneumonia in randomised controlled trials. International Journal of Clinical Practice2011;65(7):764‐74. [1742‐1241: (Electronic)] ">Halpin 2011</a>). </p> </section> </section> </section> <div class="figures-list"> <div class="figure" id="CD010115-fig-0001"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD010115.pub2/media/CDSR/CD010115/urn:x-wiley:14651858:media:CD010115:CD010115-AFig-FIG01" target="_blank"><b></b></a></p> </div> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD010115.pub2/media/CDSR/CD010115/image_t/tCD010115-AFig-FIG01.png" target="_blank"><b></b></a></p> </div><img alt="Direct and indirect comparisons of fluticasone and budesonide covered in the review." data-id="CD010115-fig-0001" src="/cdsr/doi/10.1002/14651858.CD010115.pub2/media/CDSR/CD010115/image_n/nCD010115-AFig-FIG01.png"/> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Figure 1</div> <div class="figure-caption"> <p>Direct and indirect comparisons of fluticasone and budesonide covered in the review.</p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD010115.pub2/full#CD010115-fig-0001">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD010115.pub2/media/CDSR/CD010115/image_n/nCD010115-AFig-FIG01.png" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD010115-fig-0002"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD010115.pub2/media/CDSR/CD010115/urn:x-wiley:14651858:media:CD010115:CD010115-AFig-FIG02" target="_blank"><b></b></a></p> </div> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD010115.pub2/media/CDSR/CD010115/image_t/tCD010115-AFig-FIG02.png" target="_blank"><b></b></a></p> </div><img alt="Study flow diagram." data-id="CD010115-fig-0002" src="/cdsr/doi/10.1002/14651858.CD010115.pub2/media/CDSR/CD010115/image_n/nCD010115-AFig-FIG02.png"/> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Figure 2</div> <div class="figure-caption"> <p>Study flow diagram.</p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD010115.pub2/full#CD010115-fig-0002">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD010115.pub2/media/CDSR/CD010115/image_n/nCD010115-AFig-FIG02.png" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD010115-fig-0003"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD010115.pub2/media/CDSR/CD010115/urn:x-wiley:14651858:media:CD010115:CD010115-AFig-FIG03" target="_blank"><b></b></a></p> </div> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD010115.pub2/media/CDSR/CD010115/image_t/tCD010115-AFig-FIG03.png" target="_blank"><b></b></a></p> </div><img alt="Risk of bias summary: review authors' judgements about each risk of bias item for each included study." data-id="CD010115-fig-0003" src="/cdsr/doi/10.1002/14651858.CD010115.pub2/media/CDSR/CD010115/image_n/nCD010115-AFig-FIG03.png"/> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Figure 3</div> <div class="figure-caption"> <p>Risk of bias summary: review authors' judgements about each risk of bias item for each included study. </p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD010115.pub2/full#CD010115-fig-0003">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD010115.pub2/media/CDSR/CD010115/image_n/nCD010115-AFig-FIG03.png" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD010115-fig-0004"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD010115.pub2/media/CDSR/CD010115/urn:x-wiley:14651858:media:CD010115:CD010115-AFig-FIG04" target="_blank"><b></b></a></p> </div> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD010115.pub2/media/CDSR/CD010115/image_t/tCD010115-AFig-FIG04.png" target="_blank"><b></b></a></p> </div><img alt="Summary of pooled effects of trials comparing ICS versus placebo and combination versus LABA.  Non‐fatal serious adverse pneumonia events were those requiring hospital admission. Data for all pneumonia events were not pooled because of heterogeneity." data-id="CD010115-fig-0004" src="/cdsr/doi/10.1002/14651858.CD010115.pub2/media/CDSR/CD010115/image_n/nCD010115-AFig-FIG04.png"/> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Figure 4</div> <div class="figure-caption"> <p>Summary of pooled effects of trials comparing ICS versus placebo and combination versus LABA.<br/> Non‐fatal serious adverse pneumonia events were those requiring hospital admission. Data for all pneumonia events were not pooled because of heterogeneity. </p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD010115.pub2/full#CD010115-fig-0004">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD010115.pub2/media/CDSR/CD010115/image_n/nCD010115-AFig-FIG04.png" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD010115-fig-0005"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD010115.pub2/media/CDSR/CD010115/urn:x-wiley:14651858:media:CD010115:CD010115-AFig-FIG05" target="_blank"><b></b></a></p> </div> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD010115.pub2/media/CDSR/CD010115/image_t/tCD010115-AFig-FIG05.png" target="_blank"><b></b></a></p> </div><img alt="Indirect comparisons of fluticasone and budesonide monotherapy.Non‐fatal serious adverse pneumonia events were defined as those requiring hospital admission." data-id="CD010115-fig-0005" src="/cdsr/doi/10.1002/14651858.CD010115.pub2/media/CDSR/CD010115/image_n/nCD010115-AFig-FIG05.png"/> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Figure 5</div> <div class="figure-caption"> <p>Indirect comparisons of fluticasone and budesonide monotherapy.</p> <p>Non‐fatal serious adverse pneumonia events were defined as those requiring hospital admission. </p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD010115.pub2/full#CD010115-fig-0005">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD010115.pub2/media/CDSR/CD010115/image_n/nCD010115-AFig-FIG05.png" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD010115-fig-0006"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD010115.pub2/media/CDSR/CD010115/urn:x-wiley:14651858:media:CD010115:CD010115-AFig-FIG06" target="_blank"><b></b></a></p> </div> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD010115.pub2/media/CDSR/CD010115/image_t/tCD010115-AFig-FIG06.png" target="_blank"><b></b></a></p> </div><img alt="Indirect comparisons of fluticasone and budesonide monotherapy—Sensitivity analysis removing (Calverley 2007 TORCH)." data-id="CD010115-fig-0006" src="/cdsr/doi/10.1002/14651858.CD010115.pub2/media/CDSR/CD010115/image_n/nCD010115-AFig-FIG06.png"/> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Figure 6</div> <div class="figure-caption"> <p>Indirect comparisons of fluticasone and budesonide monotherapy—Sensitivity analysis removing (<a href="./references#CD010115-bbs2-0007" title="AllegraL . TORCH study: An invitation to clinical considerations. GIMT ‐ Giornale Italiano delle Malattie del Torace2007;61(1):15‐23. BriggsAH , GlickHA , Lozano‐OrtegaG , SpencerM , CalverleyPM , JonesPW , et al. Is treatment with ICS and LABA cost‐effective for COPD? Multinational economic analysis of the TORCH study. European Respiratory Journal2010;35(3):532‐9. BriggsAH , Lozano‐OrtegaG , SpencerS , BaleG , SpencerMD , BurgePS . Estimating the cost‐effectiveness of fluticasone propionate for treating chronic obstructive pulmonary disease in the presence of missing data. Value in Health2006;9(4):227‐35. CalverleyP , CelliB , AndersonJ , FergusonG , JenkinsC , JonesP , et al. Salmeterol/fluticasone propionate combination (SFC) improves survival in COPD over three years: on‐treatment analysis from the TORCH study [Abstract]. American Thoracic Society International Conference; 2009 May 15‐20; San Diego. 2009:A6191[Poster #219]. CalverleyP , CelliB , AndersonJA , FergusonGT , JenkinsC , JonesPW , et al. The TOwards a Revolution in COPD Health (TORCH) study: salmeterol/fluticasone propionate improves survival in COPD over three years [Abstract]. Respirology2006;11 Suppl 5:A149 [PS‐3‐8]. CalverleyPM , AndersonJA , CelliB , FergusonGT , JenkinsC , JonesPW , et al. Salmeterol and fluticasone propionate and survival in chronic obstructive pulmonary disease. New England Journal of Medicine2007;356(8):775‐89. CalverleyPM , AndersonJA , CelliB , FergusonGT , JenkinsC , Jones PW et al and TORCH Investigators. Cardiovascular events in patients with COPD: TORCH study results. Thorax2010;65(8):719‐25. CalverleyPM , CelliB , AndersonJA , FergusonGT , JenkinsC , JonesPW , et al. The TOwards a Revolution in COPD Health (TORCH) study: fluticasone propionate /salmeterol improves survival in COPD over three years. Chest2006;130(4):122s. CalverleyPMA , CelliB , AndersenJA , FergusonGT , JenkinsC , JonesPW , et al. The TORCH (TOwards a Revolution in COPD Health) study salmeterol/fluticasone propionate (SFC) improves survival in COPD over three years. European Respiratory Journal2006;28 Suppl 50:34. CelliB , CalverleyPM , AndersonJA , FergusonGT , JenkinsC , JonesP , et al. The TOwards a Revolution in COPD HEalth (TORCH) Study: salmeterol/fluticasone propionate reduces the rate of exacerbations over three years. Respirology2006;11 Suppl 5:A140. CelliB , CalverleyPM , AndersonJA , FergusonGT , JenkinsC , JonesPW , et al. The TOwards a Revolution in COPD Health (TORCH) study: fluticasone propionate/salmeterol reduces the rate of exacerbations over 3 years [Abstract]. Chest2006;130(4):177s. CelliB , CalverleyPMA , AndersonJA , FergusonGT , JenkinsC , JonesPW , et al. The TORCH (TOwards a Revolution in COPD Health) study salmeterol/fluticasone propionate (SFC) improves health status reduces exacerbations and improves lung function over three years [Abstract]. European Respiratory Journal2006;28 Suppl 50:34s [E312]. CelliB , EmmettA , CraterG , KalbergC . Fluticasone propionate/salmeterol (FSC) improves the inspiratory to total lung capacity ratio (IC/TLC) and exercise endurance time in patients with COPD. European Respiratory Society 16th Annual Congress; 2006 Sep 2‐6; Munich. 2006:A320 (Poster 323). CelliB , FergusonGT , AndersonJA , JenkinsCR , JonesPW , VestboJ , et al. Salmeterol/fluticasone propionate (SFC) improves lung function and reduces the rate of decline over three years in the TORCH survival study [Abstract]. American Thoracic Society International Conference; 2007 May 18‐23; San Francisco. 2007:A763. CelliB , VestboJ , JenkinsCR , JonesPW , FergusonGT , CalverleyPMA , et al. Sex differences in mortality and clinical expressions of patients with chronic obstructive pulmonary disease: the TORCH experience. American Journal of Respiratory and Critical Care Medicine2011;183(3):317‐22. CelliBR , ThomasNE , AndersonJA , FergusonGT , JenkinsCR , JonesPW , et al. Effect of pharmacotherapy on rate of decline of lung function in chronic obstructive pulmonary disease: results from the TORCH study. American Journal of Respiratory and Critical Care Medicine2008;178(4):332‐8. CelliD , EmmettA , CraterG , KalbergC . Salmeterol/fluticasone propionate (SFC) improves the inspiratory to total lung capacity ratio (IC/TLC) and exercise endurance time in patients with COPD. European Respiratory Journal2006;28 Suppl 50:764 [4395]. CorhayJL , LouisR . Clinical study of the month: the TORCH study (TOwards a Revolution in COPD Health) [L'étude clinique du mois. L'étude TORCH (TOwards a Revolution in COPD Health): vers une revolution de la santé des patients souffrant de BPCO]. Revue Medicale de Liege2007;62(4):230‐4. FergusonGT , CalverleyPM , AndersonJA , CelliB , JenkinsC , JonesPW , et al. The TOwards a Revolution in COPD Health (TORCH) study: fluticasone propionate/salmeterol is well tolerated in patients with COPD over 3 years [Abstract]. Chest2006;130(4):178s. FergusonGT , CalverleyPM , AndersonJA , CelliB , JenkinsCR , JonesPW , et al. Effect of salmeterol/fluticasone propionate (SFC) on bone mineral density (BMD) and eye disorders over three years in the TORCH trial [Abstract]. American Thoracic Society International Conference; 2007 May 18‐23; San Francisco. 2007:A763. FergusonGT , CalverleyPM , AndersonJA , JenkinsCR , CelliB , et al. Prevalence and progression of osteoporosis in patients with COPD results from the towards a revolution in COPD health study. Chest2009;136(6):1456‐65. FergusonGT , CalverleyPMA , AndersonJA , et al. The TORCH (TOwards a Revolution in COPD Health) study: salmeterol/fluticasone propionate (SFC) improves survival in COPD over three years. European Respiratory Journal2006;28 Suppl 50:34s. GlickH , BriggsA , Lozano‐OrtegaG , SpencerM , VestboJ , CalverleyP . Is treatment with ICS/LABA combination good value for money in COPD? Evidence from the TORCH study [Abstract]. American Thoracic Society International Conference; 2007 May 18‐23; San Francisco. 2007:[C97]. JenkinsC , CelliB , AndersonJ , FergusonG , CalverleyP , JonesP , et al. Salmeterol/fluticasone propionate (SFC) is efficacious in GOLD stage II COPD patients: analysis from the TORCH study [Abstract]. American Thoracic Society International Conference; May 15‐20; San Diego. 2009:A6186 [Poster #213]. JenkinsCR , CelliB , AndersonJA , FergusonGT , JonesPW , VestboJ , et al. Seasonality and determinants of moderate and severe COPD exacerbations in the TORCH study. European Respiratory Journal2012;39:38‐45. JenkinsCR , CelliB , AndersonJA , FergusonGT , JonesPW , VestboJ , et al. The TORCH survival study: consistent efficacy results seen in geographic regions in a multi‐national study [Abstract]. American Thoracic Society International Conference; May 18‐23; San Francisco. 2007:[C97]. JenkinsCR , JonesPW , CalverleyPM , CelliB , AndersonJA , FergusonGT , et al. Efficacy of salmeterol/fluticasone propionate by GOLD stage of chronic obstructive pulmonary disease: analysis from the randomised, placebo‐controlled TORCH study. Respiratory Research2009;10:59. JonesPW , AndersonJA , CalverleyPM , CelliBR , FergusonGT , JenkinsC , et al. Health status in the TORCH study of COPD: treatment efficacy and other determinants of change. Respiratory Research2011;12:71. JonesPW , CalverleyPM , CelliB , AndersonJA , FergusonGT , JenkinsC , et al. The TOwards a Revolution in COPD Health (TORCH) study: fluticasone propionate/salmeterol improves and sustains health status in COPD over 3 years. Chest2006;130(4):177s. JonesPW , VestboJ , AndersonJA , CelliB , FergusonGT , JenkinsCR , et al. Informative withdrawal in a COPD study. An example from the TORCH Study [Abstract]. American Thoracic Society International Conference; 2007 May 18‐23; San Francisco. 2007:[C97]. KeeneON , VestboJ , AndersonJA , CalverleyPM , CelliB , FergusonGT , et al. Methods for therapeutic trials in COPD: Lessons from the TORCH trial. European Respiratory Journal2009;34(5):1018‐23. McDonoughC , BlanchardAR . TORCH study results: pharmacotherapy reduces lung function decline in patients with chronic obstructive pulmonary disease. Hospital Practice2010;38(2):92‐3. McGarveyLP , JohnM , AndersonJA , ZvarichM , WiseRA , Committee TCE et al. Ascertainment of cause‐specific mortality in COPD: operations of the TORCH Clinical Endpoint Committee. Thorax2007;62(5):411‐5. MehtaRS , KathmanSJ , Daley‐YatesPT , CahnT , BeeraheeM , KunkaRL , et al. Pharmacokinetics and pharmacodynamics in COPD patients following long‐term twice‐daily treatment with salmeterol/fluticasone propionate (SFC) 50/500mg and the individual components [Abstract]. American Thoracic Society International Conference; 2007 May 18‐23; San Francisco. 2007:Poster #A41. SCO30003 . A multi‐centre, randomised, double‐blind, parallel group, placebo‐controlled study to investigate the long‐term effects of salmeterol/fluticasone propionate (SERETIDE®/VIANI®/ADVAIR®) 50/500mcg bd, salmeterol 50mcg bd and fluticasone propionate 500mcg bd, all delivered via the DISKUS®/ACCUHALER® inhaler, on the survival of subjects with chronic obstructive pulmonary disease (COPD) over 3 years of treatment. www.ctr.gsk.co.uk (accessed 21 April 2012). SacchettaA . Long term therapy and outcome of chronic obstructive pulmonary disease with or without co‐morbidity: The TORCH Study. Italian Journal of Medicine2008;2(3):11‐5. VestboJ , AndersonJA , CalverleyPM , CelliB , FergusonGT , JenkinsC , et al. Bias due to withdrawal in long‐term randomised trials in COPD: Evidence from the TORCH study. Clinical Respiratory Journal2011;5(1):44‐9. VestboJ , TORCH Study Group. The TORCH (TOwards a Revolution in COPD Health) survival study protocol. European Respiratory Journal2004;24(2):206‐10. ">Calverley 2007 TORCH</a>). </p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD010115.pub2/full#CD010115-fig-0006">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD010115.pub2/media/CDSR/CD010115/image_n/nCD010115-AFig-FIG06.png" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD010115-fig-0007"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD010115.pub2/media/CDSR/CD010115/urn:x-wiley:14651858:media:CD010115:CD010115-CMP-001-01" target="_blank"><b></b></a></p> </div> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD010115.pub2/media/CDSR/CD010115/image_t/tCD010115-CMP-001-01.xxx" target="_blank"><b></b></a></p> </div><img alt="Comparison 1 Fluticasone versus controls (all outcomes by treatment), Outcome 1 Non‐fatal, serious adverse pneumonia events." data-id="CD010115-fig-0007" src="/cdsr/doi/10.1002/14651858.CD010115.pub2/media/CDSR/CD010115/image_n/nCD010115-CMP-001-01.png"/> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Analysis 1.1</div> <div class="figure-caption"> <p>Comparison 1 Fluticasone versus controls (all outcomes by treatment), Outcome 1 Non‐fatal, serious adverse pneumonia events. </p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD010115.pub2/references#CD010115-fig-0007">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD010115.pub2/media/CDSR/CD010115/image_n/nCD010115-CMP-001-01.png" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD010115-fig-0008"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD010115.pub2/media/CDSR/CD010115/urn:x-wiley:14651858:media:CD010115:CD010115-CMP-001-02" target="_blank"><b></b></a></p> </div> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD010115.pub2/media/CDSR/CD010115/image_t/tCD010115-CMP-001-02.xxx" target="_blank"><b></b></a></p> </div><img alt="Comparison 1 Fluticasone versus controls (all outcomes by treatment), Outcome 2 Mortality, all‐cause." data-id="CD010115-fig-0008" src="/cdsr/doi/10.1002/14651858.CD010115.pub2/media/CDSR/CD010115/image_n/nCD010115-CMP-001-02.png"/> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Analysis 1.2</div> <div class="figure-caption"> <p>Comparison 1 Fluticasone versus controls (all outcomes by treatment), Outcome 2 Mortality, all‐cause. </p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD010115.pub2/references#CD010115-fig-0008">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD010115.pub2/media/CDSR/CD010115/image_n/nCD010115-CMP-001-02.png" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD010115-fig-0009"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD010115.pub2/media/CDSR/CD010115/urn:x-wiley:14651858:media:CD010115:CD010115-CMP-001-03" target="_blank"><b></b></a></p> </div> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD010115.pub2/media/CDSR/CD010115/image_t/tCD010115-CMP-001-03.xxx" target="_blank"><b></b></a></p> </div><img alt="Comparison 1 Fluticasone versus controls (all outcomes by treatment), Outcome 3 Mortality, due to pneumonia." data-id="CD010115-fig-0009" src="/cdsr/doi/10.1002/14651858.CD010115.pub2/media/CDSR/CD010115/image_n/nCD010115-CMP-001-03.png"/> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Analysis 1.3</div> <div class="figure-caption"> <p>Comparison 1 Fluticasone versus controls (all outcomes by treatment), Outcome 3 Mortality, due to pneumonia. </p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD010115.pub2/references#CD010115-fig-0009">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD010115.pub2/media/CDSR/CD010115/image_n/nCD010115-CMP-001-03.png" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD010115-fig-0010"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD010115.pub2/media/CDSR/CD010115/urn:x-wiley:14651858:media:CD010115:CD010115-CMP-001-04" target="_blank"><b></b></a></p> </div> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD010115.pub2/media/CDSR/CD010115/image_t/tCD010115-CMP-001-04.xxx" target="_blank"><b></b></a></p> </div><img alt="Comparison 1 Fluticasone versus controls (all outcomes by treatment), Outcome 4 Non‐fatal, serious adverse events (all)." data-id="CD010115-fig-0010" src="/cdsr/doi/10.1002/14651858.CD010115.pub2/media/CDSR/CD010115/image_n/nCD010115-CMP-001-04.png"/> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Analysis 1.4</div> <div class="figure-caption"> <p>Comparison 1 Fluticasone versus controls (all outcomes by treatment), Outcome 4 Non‐fatal, serious adverse events (all). </p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD010115.pub2/references#CD010115-fig-0010">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD010115.pub2/media/CDSR/CD010115/image_n/nCD010115-CMP-001-04.png" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD010115-fig-0011"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD010115.pub2/media/CDSR/CD010115/urn:x-wiley:14651858:media:CD010115:CD010115-CMP-001-05" target="_blank"><b></b></a></p> </div> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD010115.pub2/media/CDSR/CD010115/image_t/tCD010115-CMP-001-05.xxx" target="_blank"><b></b></a></p> </div><img alt="Comparison 1 Fluticasone versus controls (all outcomes by treatment), Outcome 5 All pneumonia events." data-id="CD010115-fig-0011" src="/cdsr/doi/10.1002/14651858.CD010115.pub2/media/CDSR/CD010115/image_n/nCD010115-CMP-001-05.png"/> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Analysis 1.5</div> <div class="figure-caption"> <p>Comparison 1 Fluticasone versus controls (all outcomes by treatment), Outcome 5 All pneumonia events. </p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD010115.pub2/references#CD010115-fig-0011">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD010115.pub2/media/CDSR/CD010115/image_n/nCD010115-CMP-001-05.png" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD010115-fig-0012"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD010115.pub2/media/CDSR/CD010115/urn:x-wiley:14651858:media:CD010115:CD010115-CMP-001-06" target="_blank"><b></b></a></p> </div> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD010115.pub2/media/CDSR/CD010115/image_t/tCD010115-CMP-001-06.xxx" target="_blank"><b></b></a></p> </div><img alt="Comparison 1 Fluticasone versus controls (all outcomes by treatment), Outcome 6 Withdrawals." data-id="CD010115-fig-0012" src="/cdsr/doi/10.1002/14651858.CD010115.pub2/media/CDSR/CD010115/image_n/nCD010115-CMP-001-06.png"/> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Analysis 1.6</div> <div class="figure-caption"> <p>Comparison 1 Fluticasone versus controls (all outcomes by treatment), Outcome 6 Withdrawals.</p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD010115.pub2/references#CD010115-fig-0012">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD010115.pub2/media/CDSR/CD010115/image_n/nCD010115-CMP-001-06.png" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD010115-fig-0013"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD010115.pub2/media/CDSR/CD010115/urn:x-wiley:14651858:media:CD010115:CD010115-CMP-002-01" target="_blank"><b></b></a></p> </div> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD010115.pub2/media/CDSR/CD010115/image_t/tCD010115-CMP-002-01.xxx" target="_blank"><b></b></a></p> </div><img alt="Comparison 2 Subgroup analyses—fluticasone versus controls, Outcome 1 Dose—Non‐fatal, serious adverse pneumonia events." data-id="CD010115-fig-0013" src="/cdsr/doi/10.1002/14651858.CD010115.pub2/media/CDSR/CD010115/image_n/nCD010115-CMP-002-01.png"/> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Analysis 2.1</div> <div class="figure-caption"> <p>Comparison 2 Subgroup analyses—fluticasone versus controls, Outcome 1 Dose—Non‐fatal, serious adverse pneumonia events. </p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD010115.pub2/references#CD010115-fig-0013">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD010115.pub2/media/CDSR/CD010115/image_n/nCD010115-CMP-002-01.png" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD010115-fig-0014"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD010115.pub2/media/CDSR/CD010115/urn:x-wiley:14651858:media:CD010115:CD010115-CMP-002-02" target="_blank"><b></b></a></p> </div> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD010115.pub2/media/CDSR/CD010115/image_t/tCD010115-CMP-002-02.xxx" target="_blank"><b></b></a></p> </div><img alt="Comparison 2 Subgroup analyses—fluticasone versus controls, Outcome 2 Duration—Non‐fatal, serious adverse pneumonia events." data-id="CD010115-fig-0014" src="/cdsr/doi/10.1002/14651858.CD010115.pub2/media/CDSR/CD010115/image_n/nCD010115-CMP-002-02.png"/> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Analysis 2.2</div> <div class="figure-caption"> <p>Comparison 2 Subgroup analyses—fluticasone versus controls, Outcome 2 Duration—Non‐fatal, serious adverse pneumonia events. </p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD010115.pub2/references#CD010115-fig-0014">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD010115.pub2/media/CDSR/CD010115/image_n/nCD010115-CMP-002-02.png" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD010115-fig-0015"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD010115.pub2/media/CDSR/CD010115/urn:x-wiley:14651858:media:CD010115:CD010115-CMP-002-03" target="_blank"><b></b></a></p> </div> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD010115.pub2/media/CDSR/CD010115/image_t/tCD010115-CMP-002-03.xxx" target="_blank"><b></b></a></p> </div><img alt="Comparison 2 Subgroup analyses—fluticasone versus controls, Outcome 3 % FEV1 predicted normal—Non‐fatal, serious adverse pneumonia events." data-id="CD010115-fig-0015" src="/cdsr/doi/10.1002/14651858.CD010115.pub2/media/CDSR/CD010115/image_n/nCD010115-CMP-002-03.png"/> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Analysis 2.3</div> <div class="figure-caption"> <p>Comparison 2 Subgroup analyses—fluticasone versus controls, Outcome 3 % FEV<sub>1</sub> predicted normal—Non‐fatal, serious adverse pneumonia events. </p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD010115.pub2/references#CD010115-fig-0015">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD010115.pub2/media/CDSR/CD010115/image_n/nCD010115-CMP-002-03.png" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD010115-fig-0016"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD010115.pub2/media/CDSR/CD010115/urn:x-wiley:14651858:media:CD010115:CD010115-CMP-003-01" target="_blank"><b></b></a></p> </div> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD010115.pub2/media/CDSR/CD010115/image_t/tCD010115-CMP-003-01.xxx" target="_blank"><b></b></a></p> </div><img alt="Comparison 3 Budesonide versus controls (all outcomes by treatment), Outcome 1 Non‐fatal, serious adverse pneumonia events." data-id="CD010115-fig-0016" src="/cdsr/doi/10.1002/14651858.CD010115.pub2/media/CDSR/CD010115/image_n/nCD010115-CMP-003-01.png"/> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Analysis 3.1</div> <div class="figure-caption"> <p>Comparison 3 Budesonide versus controls (all outcomes by treatment), Outcome 1 Non‐fatal, serious adverse pneumonia events. </p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD010115.pub2/references#CD010115-fig-0016">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD010115.pub2/media/CDSR/CD010115/image_n/nCD010115-CMP-003-01.png" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD010115-fig-0017"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD010115.pub2/media/CDSR/CD010115/urn:x-wiley:14651858:media:CD010115:CD010115-CMP-003-02" target="_blank"><b></b></a></p> </div> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD010115.pub2/media/CDSR/CD010115/image_t/tCD010115-CMP-003-02.xxx" target="_blank"><b></b></a></p> </div><img alt="Comparison 3 Budesonide versus controls (all outcomes by treatment), Outcome 2 Mortality, all‐cause." data-id="CD010115-fig-0017" src="/cdsr/doi/10.1002/14651858.CD010115.pub2/media/CDSR/CD010115/image_n/nCD010115-CMP-003-02.png"/> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Analysis 3.2</div> <div class="figure-caption"> <p>Comparison 3 Budesonide versus controls (all outcomes by treatment), Outcome 2 Mortality, all‐cause. </p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD010115.pub2/references#CD010115-fig-0017">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD010115.pub2/media/CDSR/CD010115/image_n/nCD010115-CMP-003-02.png" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD010115-fig-0018"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD010115.pub2/media/CDSR/CD010115/urn:x-wiley:14651858:media:CD010115:CD010115-CMP-003-03" target="_blank"><b></b></a></p> </div> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD010115.pub2/media/CDSR/CD010115/image_t/tCD010115-CMP-003-03.xxx" target="_blank"><b></b></a></p> </div><img alt="Comparison 3 Budesonide versus controls (all outcomes by treatment), Outcome 3 Mortality, due to pneumonia." data-id="CD010115-fig-0018" src="/cdsr/doi/10.1002/14651858.CD010115.pub2/media/CDSR/CD010115/image_n/nCD010115-CMP-003-03.png"/> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Analysis 3.3</div> <div class="figure-caption"> <p>Comparison 3 Budesonide versus controls (all outcomes by treatment), Outcome 3 Mortality, due to pneumonia. </p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD010115.pub2/references#CD010115-fig-0018">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD010115.pub2/media/CDSR/CD010115/image_n/nCD010115-CMP-003-03.png" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD010115-fig-0019"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD010115.pub2/media/CDSR/CD010115/urn:x-wiley:14651858:media:CD010115:CD010115-CMP-003-04" target="_blank"><b></b></a></p> </div> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD010115.pub2/media/CDSR/CD010115/image_t/tCD010115-CMP-003-04.xxx" target="_blank"><b></b></a></p> </div><img alt="Comparison 3 Budesonide versus controls (all outcomes by treatment), Outcome 4 Non‐fatal, serious adverse events (all)." data-id="CD010115-fig-0019" src="/cdsr/doi/10.1002/14651858.CD010115.pub2/media/CDSR/CD010115/image_n/nCD010115-CMP-003-04.png"/> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Analysis 3.4</div> <div class="figure-caption"> <p>Comparison 3 Budesonide versus controls (all outcomes by treatment), Outcome 4 Non‐fatal, serious adverse events (all). </p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD010115.pub2/references#CD010115-fig-0019">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD010115.pub2/media/CDSR/CD010115/image_n/nCD010115-CMP-003-04.png" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD010115-fig-0020"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD010115.pub2/media/CDSR/CD010115/urn:x-wiley:14651858:media:CD010115:CD010115-CMP-003-05" target="_blank"><b></b></a></p> </div> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD010115.pub2/media/CDSR/CD010115/image_t/tCD010115-CMP-003-05.xxx" target="_blank"><b></b></a></p> </div><img alt="Comparison 3 Budesonide versus controls (all outcomes by treatment), Outcome 5 All pneumonia events." data-id="CD010115-fig-0020" src="/cdsr/doi/10.1002/14651858.CD010115.pub2/media/CDSR/CD010115/image_n/nCD010115-CMP-003-05.png"/> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Analysis 3.5</div> <div class="figure-caption"> <p>Comparison 3 Budesonide versus controls (all outcomes by treatment), Outcome 5 All pneumonia events. </p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD010115.pub2/references#CD010115-fig-0020">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD010115.pub2/media/CDSR/CD010115/image_n/nCD010115-CMP-003-05.png" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD010115-fig-0021"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD010115.pub2/media/CDSR/CD010115/urn:x-wiley:14651858:media:CD010115:CD010115-CMP-003-06" target="_blank"><b></b></a></p> </div> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD010115.pub2/media/CDSR/CD010115/image_t/tCD010115-CMP-003-06.xxx" target="_blank"><b></b></a></p> </div><img alt="Comparison 3 Budesonide versus controls (all outcomes by treatment), Outcome 6 Withdrawals." data-id="CD010115-fig-0021" src="/cdsr/doi/10.1002/14651858.CD010115.pub2/media/CDSR/CD010115/image_n/nCD010115-CMP-003-06.png"/> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Analysis 3.6</div> <div class="figure-caption"> <p>Comparison 3 Budesonide versus controls (all outcomes by treatment), Outcome 6 Withdrawals.</p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD010115.pub2/references#CD010115-fig-0021">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD010115.pub2/media/CDSR/CD010115/image_n/nCD010115-CMP-003-06.png" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD010115-fig-0022"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD010115.pub2/media/CDSR/CD010115/urn:x-wiley:14651858:media:CD010115:CD010115-CMP-004-01" target="_blank"><b></b></a></p> </div> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD010115.pub2/media/CDSR/CD010115/image_t/tCD010115-CMP-004-01.xxx" target="_blank"><b></b></a></p> </div><img alt="Comparison 4 Subgroup analyses—budesonide versus controls, Outcome 1 Dose ‐ Non‐fatal, serious adverse pneumonia events." data-id="CD010115-fig-0022" src="/cdsr/doi/10.1002/14651858.CD010115.pub2/media/CDSR/CD010115/image_n/nCD010115-CMP-004-01.png"/> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Analysis 4.1</div> <div class="figure-caption"> <p>Comparison 4 Subgroup analyses—budesonide versus controls, Outcome 1 Dose ‐ Non‐fatal, serious adverse pneumonia events. </p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD010115.pub2/references#CD010115-fig-0022">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD010115.pub2/media/CDSR/CD010115/image_n/nCD010115-CMP-004-01.png" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD010115-fig-0023"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD010115.pub2/media/CDSR/CD010115/urn:x-wiley:14651858:media:CD010115:CD010115-CMP-004-02" target="_blank"><b></b></a></p> </div> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD010115.pub2/media/CDSR/CD010115/image_t/tCD010115-CMP-004-02.xxx" target="_blank"><b></b></a></p> </div><img alt="Comparison 4 Subgroup analyses—budesonide versus controls, Outcome 2 Duration ‐ Non‐fatal, serious adverse pneumonia events." data-id="CD010115-fig-0023" src="/cdsr/doi/10.1002/14651858.CD010115.pub2/media/CDSR/CD010115/image_n/nCD010115-CMP-004-02.png"/> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Analysis 4.2</div> <div class="figure-caption"> <p>Comparison 4 Subgroup analyses—budesonide versus controls, Outcome 2 Duration ‐ Non‐fatal, serious adverse pneumonia events. </p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD010115.pub2/references#CD010115-fig-0023">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD010115.pub2/media/CDSR/CD010115/image_n/nCD010115-CMP-004-02.png" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD010115-fig-0024"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD010115.pub2/media/CDSR/CD010115/urn:x-wiley:14651858:media:CD010115:CD010115-CMP-004-03" target="_blank"><b></b></a></p> </div> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD010115.pub2/media/CDSR/CD010115/image_t/tCD010115-CMP-004-03.xxx" target="_blank"><b></b></a></p> </div><img alt="Comparison 4 Subgroup analyses—budesonide versus controls, Outcome 3 % FEV1 predicted normal ‐ Non‐fatal, serious adverse pneumonia events." data-id="CD010115-fig-0024" src="/cdsr/doi/10.1002/14651858.CD010115.pub2/media/CDSR/CD010115/image_n/nCD010115-CMP-004-03.png"/> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Analysis 4.3</div> <div class="figure-caption"> <p>Comparison 4 Subgroup analyses—budesonide versus controls, Outcome 3 % FEV<sub>1</sub> predicted normal ‐ Non‐fatal, serious adverse pneumonia events. </p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD010115.pub2/references#CD010115-fig-0024">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD010115.pub2/media/CDSR/CD010115/image_n/nCD010115-CMP-004-03.png" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD010115-fig-0025"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD010115.pub2/media/CDSR/CD010115/urn:x-wiley:14651858:media:CD010115:CD010115-CMP-005-01" target="_blank"><b></b></a></p> </div> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD010115.pub2/media/CDSR/CD010115/image_t/tCD010115-CMP-005-01.xxx" target="_blank"><b></b></a></p> </div><img alt="Comparison 5 Sensitivity analysis—risk of bias, Outcome 1 Non‐fatal serious adverse pneumonia events." data-id="CD010115-fig-0025" src="/cdsr/doi/10.1002/14651858.CD010115.pub2/media/CDSR/CD010115/image_n/nCD010115-CMP-005-01.png"/> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Analysis 5.1</div> <div class="figure-caption"> <p>Comparison 5 Sensitivity analysis—risk of bias, Outcome 1 Non‐fatal serious adverse pneumonia events. </p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD010115.pub2/references#CD010115-fig-0025">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD010115.pub2/media/CDSR/CD010115/image_n/nCD010115-CMP-005-01.png" target="_blank">Open in new tab</a></div> </div> </div> <div class="tables-list"> <div class="table"> <table class="summary-of-findings framed" data-id="CD010115-tbl-0001"> <div class="table-heading"><span class="table-label">Summary of findings for the main comparison.</span> <span class="table-title">Fluticasone for chronic obstructive pulmonary disease</span></div> <tbody> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="6" rowspan="1" valign=""> <p><b>Fluticasone for chronic obstructive pulmonary disease</b> </p> </td> </tr> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="6" rowspan="1" valign=""> <p><b>Patient or population:</b> patients with chronic obstructive pulmonary disease<br/> <b>Intervention:</b> fluticasone (alone or with LABA co‐intervention) </p> <p><b>Comparison:</b> placebo or LABA monotherapy (dependent upon whether fluticasone was given with LABA in the intervention group) </p> <p><b>Setting:</b> community </p> </td> </tr> <tr class="table-header separated"> <td align="left" class="table-header" colspan="1" rowspan="3" valign="top"> <p><b>Outcomes</b> </p> <p><b> Follow‐ups presented as weighted means</b> </p> </td> <td align="left" class="table-tint table-highlight" colspan="2" rowspan="1" valign="top"> <p><b>Illustrative comparative risks* (95% CI)</b> </p> </td> <td align="left" class="table-header" colspan="1" rowspan="3" valign="top"> <p><b>Relative effect<br/> (95% CI)</b> </p> </td> <td align="left" class="table-header" colspan="1" rowspan="3" valign="top"> <p><b>No. of participants<br/> (studies)</b> </p> </td> <td align="left" class="table-header" colspan="1" rowspan="3" valign="top"> <p><b>Quality of the evidence<br/> (GRADE)</b> </p> </td> </tr> <tr class="table-header separated"> <td align="left" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p><b>Assumed risk</b> </p> </td> <td align="left" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p><b>Corresponding risk</b> </p> </td> </tr> <tr class="table-header separated"> <td align="left" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p><b> Control</b> </p> </td> <td align="left" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p><b> Fluticasone</b> </p> </td> </tr> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><b>Non‐fatal, serious adverse pneumonia events (requiring hospital admission)</b> <br/> Follow‐up: 18 months </p> </td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign=""> <p><b>25 per 1000</b> </p> </td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign=""> <p><b>43 per 1000</b> <br/> (37 to 51) </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><b>OR 1.78</b> <br/> (1.50 to 2.12) </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>19,504<br/> (17 studies) </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>⊕⊕⊕⊕<br/> <b>high</b> </p> </td> </tr> <tr class="separated"> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>Mortality, all‐cause</b> <br/> Follow‐up: 19 months </p> </td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p><b>58 per 1000</b> </p> </td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p><b>58 per 1000</b> <br/> (51 to 65) </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>OR 0.99</b> <br/> (0.87 to 1.13) </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>20,861<br/> (22 studies) </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>⊕⊕⊕⊕<br/> <b>high</b> </p> </td> </tr> <tr class="separated"> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>Mortality, due to pneumonia</b> <br/> Follow‐up: 18 months </p> </td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p><b>2 per 1000</b> </p> </td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p><b>3 per 1000</b> <br/> (2 to 5) </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>OR 1.23</b> <br/> (0.70 to 2.15) </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>19,532<br/> (18 studies) </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>⊕⊕⊕⊝<br/> <b>moderate</b><sup>1</sup> </p> </td> </tr> <tr class="separated"> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>Non‐fatal, serious adverse events (all)</b> <br/> Follow‐up: 19 months </p> </td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p><b>227 per 1000</b> </p> </td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p><b>237 per 1000</b> <br/> (225 to 251) </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>OR 1.06</b> <br/> (0.99 to 1.14) </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>20,381<br/> (19 studies) </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>⊕⊕⊕⊕<br/> <b>high</b> </p> </td> </tr> <tr class="separated"> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>All pneumonia events</b> <br/> Follow‐up: 22 months </p> </td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p><b>72 per 1000</b> </p> </td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p><b>116 per 1000</b> <br/> (104 to 129) </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>OR 1.68</b> <br/> (1.49 to 1.90) </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>15,377<br/> (11 studies) </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>⊕⊕⊕⊝<br/> <b>moderate</b><sup>2</sup> </p> </td> </tr> <tr class="separated"> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>Withdrawals</b> <br/> Follow‐up: 18 months </p> </td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p><b>343 per 1000</b> </p> </td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p><b>297 per 1000</b> <br/> (286 to 310) </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>OR 0.81</b> <br/> (0.77 to 0.86) </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>21,243<br/> (26 studies) </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>⊕⊕⊕⊕<br/> <b>high</b> </p> </td> </tr> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="6" rowspan="1" valign=""> <p>*The basis for the <b>assumed risk</b> (e.g. the median control group risk across studies) is provided in footnotes. The <b>corresponding risk</b> (and its 95% confidence interval) is based on the assumed risk in the comparison group and the <b>relative effect</b> of the intervention (and its 95% CI).<br/> <b>CI:</b> Confidence interval; <b>OR:</b> Odds ratio. </p> <p>Unless otherwise stated, subgroup differences between monotherapy studies (fluticasone versus placebo) and combination therapy studies (fluticasone/LABA versus LABA) were not significant. </p> </td> </tr> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="6" rowspan="1" valign=""> <p>GRADE Working Group grades of evidence.<br/> <b>High quality:</b> Further research is very unlikely to change our confidence in the estimate of effect.<br/> <b>Moderate quality:</b> Further research is likely to have an important impact on our confidence in the estimate of effect and may change the estimate.<br/> <b>Low quality:</b> Further research is very likely to have an important impact on our confidence in the estimate of effect and is likely to change the estimate.<br/> <b>Very low quality:</b> We are very uncertain about the estimate. </p> </td> </tr> </tbody> <tfoot> <tr> <td colspan="6"> <div class="table-footnote"> <p><sup>1</sup>Wide confidence intervals include significant benefit and harm, based on very few events (‐1 for imprecision).<br/> <sup>2</sup>More than half the studies did not report the outcome (‐1 for publication bias). </p> </div> </td> </tr> </tfoot> </table> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="table-viewer-caption"> <div class="table-heading"><span class="table-label">Summary of findings for the main comparison.</span> <span class="table-title">Fluticasone for chronic obstructive pulmonary disease</span></div> </div> <div class="tools"><a class="tableList" href="/cdsr/doi/10.1002/14651858.CD010115.pub2/full#CD010115-tbl-0001">Navigate to table in review</a></div> </div> <div class="table"> <table class="summary-of-findings framed" data-id="CD010115-tbl-0002"> <div class="table-heading"><span class="table-label">Summary of findings 2.</span> <span class="table-title">Budesonide for chronic obstructive pulmonary disease</span></div> <tbody> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="6" rowspan="1" valign=""> <p><b>Budesonide for chronic obstructive pulmonary disease</b> </p> </td> </tr> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="6" rowspan="1" valign=""> <p><b>Patient or population:</b> patients with chronic obstructive pulmonary disease<br/> <b>Intervention:</b> budesonide (alone or with LABA co‐intervention) </p> <p><b>Comparison:</b> placebo or LABA monotherapy (dependent upon whether fluticasone was given with LABA in the intervention group) </p> <p><b>Setting:</b> community </p> </td> </tr> <tr class="table-header separated"> <td align="left" class="table-header" colspan="1" rowspan="3" valign="top"> <p><b>Outcomes</b> </p> <p><b> Follow‐ups presented as weighted means</b> </p> </td> <td align="left" class="table-tint table-highlight" colspan="2" rowspan="1" valign="top"> <p><b>Illustrative comparative risks* (95% CI)</b> </p> </td> <td align="left" class="table-header" colspan="1" rowspan="3" valign="top"> <p><b>Relative effect<br/> (95% CI)</b> </p> </td> <td align="left" class="table-header" colspan="1" rowspan="3" valign="top"> <p><b>No of Participants<br/> (studies)</b> </p> </td> <td align="left" class="table-header" colspan="1" rowspan="3" valign="top"> <p><b>Quality of the evidence<br/> (GRADE)</b> </p> </td> </tr> <tr class="table-header separated"> <td align="left" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p><b>Assumed risk</b> </p> </td> <td align="left" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p><b>Corresponding risk</b> </p> </td> </tr> <tr class="table-header separated"> <td align="left" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p><b> Control</b> </p> </td> <td align="left" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p><b> Budesonide</b> </p> </td> </tr> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><b>Non‐fatal, serious adverse pneumonia events (requiring hospital admission)</b> <br/> Follow‐up: 9 months </p> </td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign=""> <p><b>9 per 1000</b> </p> </td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign=""> <p><b>15 per 1000</b> <br/> (9 to 24) </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><b>OR 1.62</b> <br/> (1.00 to 2.62) </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>6472<br/> (7 studies) </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>⊕⊕⊕⊝<br/> <b>moderate</b><sup>1,2</sup> </p> </td> </tr> <tr class="separated"> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>Mortality, all‐cause</b> <br/> Follow‐up: 14 months </p> </td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p><b>17 per 1000</b> </p> </td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p><b>16 per 1000</b> <br/> (11 to 21) </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>OR 0.90</b> <br/> (0.65 to 1.24) </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>10,009<br/> (12 studies) </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>⊕⊕⊕⊝<br/> <b>moderate</b><sup>3</sup> </p> </td> </tr> <tr class="separated"> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>Mortality, due to pneumonia</b> <br/> Follow‐up: 12 months </p> </td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p><b>0 per 1000</b> </p> </td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p><b>0 per 1000</b> <br/> (0 to 0) </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>OR 4.46</b> <br/> (0.07 to 286.99) </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>1511<br/> (3 studies) </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>⊕⊝⊝⊝<br/> <b>very low<sup>2,</sup> </b><sup>4</sup> </p> </td> </tr> <tr class="separated"> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>Non‐fatal, serious adverse events (all)</b> <br/> Follow‐up: 14 months </p> </td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p><b>145 per 1000</b> </p> </td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p><b>146 per 1000</b> <br/> (124 to 172) </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>OR 1.01</b> <br/> (0.83 to 1.22) </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>10,009<br/> (12 studies) </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>⊕⊕⊕⊝<br/> <b>moderate</b><sup>5</sup> </p> </td> </tr> <tr class="separated"> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>All pneumonia events</b> <br/> Follow‐up: 10 months </p> </td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p><b>28 per 1000</b> </p> </td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p><b>31 per 1000</b> <br/> (23 to 41) </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>OR 1.12</b> <br/> (0.83 to 1.51) </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>7011<br/> (6 studies) </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>⊕⊕⊕⊝<br/> <b>moderate</b><sup>1,2</sup> </p> </td> </tr> <tr class="separated"> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>Withdrawals</b> <br/> Follow‐up: 14 months </p> </td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p><b>280 per 1000</b> </p> </td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p><b>232 per 1000</b> <br/> (216 to 248) </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>OR 0.78</b> <br/> (0.71 to 0.85) </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>10150<br/> (15 studies) </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>⊕⊕⊕⊕<br/> <b>high</b> </p> </td> </tr> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="6" rowspan="1" valign=""> <p>*The basis for the <b>assumed risk</b> (e.g. the median control group risk across studies) is provided in footnotes. The <b>corresponding risk</b> (and its 95% confidence interval) is based on the assumed risk in the comparison group and the <b>relative effect</b> of the intervention (and its 95% CI).<br/> <b>CI:</b> Confidence interval; <b>OR:</b> Odds ratio. </p> <p>Unless otherwise stated, subgroup differences between monotherapy studies (budesonide versus placebo) and combination therapy studies (budesonide/LABA versus LABA) were not significant. </p> </td> </tr> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="6" rowspan="1" valign=""> <p>GRADE Working Group grades of evidence.<br/> <b>High quality:</b> Further research is very unlikely to change our confidence in the estimate of effect.<br/> <b>Moderate quality:</b> Further research is likely to have an important impact on our confidence in the estimate of effect and may change the estimate.<br/> <b>Low quality:</b> Further research is very likely to have an important impact on our confidence in the estimate of effect and is likely to change the estimate.<br/> <b>Very low quality:</b> We are very uncertain about the estimate. </p> </td> </tr> </tbody> <tfoot> <tr> <td colspan="6"> <div class="table-footnote"> <p><sup>1</sup>Confidence intervals are quite wide but are not considered serious enough to downgrade.<br/> <sup>2</sup>More than half the studies did not report the outcome (‐1 for publication bias).<br/> <sup>3</sup>Confidence interval includes significant benefit and potential harm.<br/> <sup>4</sup>Very wide confidence intervals. Only one death observed over the three studies (‐2 for imprecision).<br/> <sup>5</sup>I<sup>2</sup> = 59%, P value 0.002 (‐1 for inconsistency). </p> </div> </td> </tr> </tfoot> </table> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="table-viewer-caption"> <div class="table-heading"><span class="table-label">Summary of findings 2.</span> <span class="table-title">Budesonide for chronic obstructive pulmonary disease</span></div> </div> <div class="tools"><a class="tableList" href="/cdsr/doi/10.1002/14651858.CD010115.pub2/full#CD010115-tbl-0002">Navigate to table in review</a></div> </div> <div class="table"> <table data-id="CD010115-tbl-0003"> <div class="table-heading"><span class="table-label">Table 1.</span> <span class="table-title">Fluticasone—summary of studies and baseline characteristics</span></div> <tbody> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><b>Study ID</b> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><b>Duration (m)</b> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><b>N Rand</b> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><b>Funder</b> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><b>ICS dose (mcg)</b> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><b>% Male</b> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><b>Mean age</b> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><b>Pack‐years</b> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><b>% pred FEV<sub>1</sub> </b> </p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="9" rowspan="1" valign=""> <p><b>Fluticasone versus placebo (n = 18)</b> </p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><a href="./references#CD010115-bbs2-0003" title="BourbeauJ , ChristodoulopoulosP , MaltaisF , YamauchiY , OlivensteinR , HamidQ . Effect of salmeterol/fluticasone propionate on airway inflammation in COPD: a randomised controlled trial. Thorax2007;62(11):938‐43. ">Bourbeau 2007</a> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>3</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>41</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>GSK</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>1000</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>78</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>65</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>53</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>57</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><a href="./references#CD010115-bbs2-0004" title="BaleG , Martinez‐CamblorP , BurgePS , SorianoJB . Long‐term mortality follow‐up of the ISOLDE participants: causes of death during 13 years after trial completion. Respiratory Medicine2008;102(10):1468‐72. BaleGA , BurgePS , BurgeC , MooreVC . The ISOLDE Study 11‐13 years on: what were the causes of death? [Abstract]. American Thoracic Society International Conference; 2007 May 18‐23; San Francisco. 2007:Poster H42. BriggsAH , Lozano‐OrtegaG , SpencerS , BaleG , SpencerMD , BurgePS . Estimating the cost‐effectiveness of fluticasone propionate for treating chronic obstructive pulmonary disease in the presence of missing data. Value In Health2006;9(4):227‐35. BurgePS , CalverleyPM , JonesPW , SpencerS , AndersonJA . Prednisolone response in patients with chronic obstructive pulmonary disease: results from the ISOLDE study. Thorax2003;58(8):654‐8. BurgePS , CalverleyPM , JonesPW , SpencerS , AndersonJA , MaslenTK . Randomised, double blind, placebo controlled study of fluticasone propionate in patients with moderate to severe chronic obstructive pulmonary disease: the ISOLDE trial. British Medical Journal2000;320(7245):1297‐303. BurgeS , SondhiS , WilliamsMK , WilsonK , EfthimiouJ . An economic evaluation of fluticasone propionate in patients with moderate to severe chronic obstructive pulmonary disease (COPD) from the isolde trial. American Journal of Respiratory and Critical Care Medicine2000;161 Suppl 3:A491. CalverleyPM , BurgePS , SpencerS , AndersonJA , JonesPW . Bronchodilator reversibility testing in chronic obstructive pulmonary disease. Thorax2003;58(8):659‐64. CalverleyPM , SpencerS , WillitsL , BurgePS , JonesPW . Withdrawal from treatment as an outcome in the ISOLDE study of COPD. Chest2003;124(4):1350. D'UrzoAD , CalverleyPMA . Withdrawal of treatment in the ISOLDE study [letter]. Chest2004;125(6):2368. GlaxoSmithKlineF . A multi‐centre, double‐blind, placebo‐controlled, parallel group study of the efficacy and tolerability of long‐term inhaled fluticasone propionate 500 mcg twice daily via a Volumatic Spacer device in patients with non‐asthmatic chronic obstructive pulmonary disease, including an acute oral corticosteroid trial. FLTB3054. www.gsk‐clinicalstudyregister.com/ (accessed 20 May 2013). JaradNA , WedzichaJA , BurgePS , CalverleyPM . An observational study of inhaled corticosteroid withdrawal in stable chronic obstructive pulmonary disease. ISOLDE Study Group. Respiratory Medicine1999;93(3):161‐6. JebrakG . Corticosteroid therapy and chronic obstructive broncho‐pneumopathies: the ISOLDE study. Presse Medicale2000;29(16):1461‐2. JonesPW , WillitsLR , BurgePS , CalverleyPMA . Disease severity and the effect of fluticasone propionate on chronic obstructive pulmonary disease exacerbations. European Respiratory Journal2003;21(1):68‐73. MarchandE . Withdrawal from and study design of the ISOLDE trial [comment]. Chest2004;126(0012‐3692):659. SpencerS , CalverleyPM , BurgePS , JonesPW . Health status deterioration in patients with chronic obstructive pulmonary disease. American Journal of Respiratory and Critical Care Medicine2001;163(1):122‐8. SpencerS , CalverleyPM , BurgePS , JonesPW . Impact of preventing exacerbations on deterioration of health status in COPD. European Respiratory Journal2004;23(5):698‐702. ">Burge 2000</a> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>36</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>740</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>GSK</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>1000</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>75</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>64</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>44</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>50</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><a href="./references#CD010115-bbs2-0006" title="CalverleyP , PauwelsR , VestboJ , JonesP , PrideN , GulsvikA , et al. Combined salmeterol and fluticasone in the treatment of chronic obstructive pulmonary disease: a randomised controlled trial. Lancet2003;361(9356):449‐56. CalverleyPMA , PauwelsR , VestboJ , JonesP , PrideN , GulsvikA , et al. Safety of salmeterol/fluticasone propionate combination in the treatment of chronic obstructive pulmonary disease. European Respiratory Journal2002;20(Suppl 38):242s [P1572]. CalverleyPMA , PauwelsRA , VestboJ , JonesPW , PrideNB , GulsvikA , et al. Clinical improvements with salmeterol / fluticasone propionate combination in differing severities of COPD [A035] [Poster D50]. http://www.abstracts2view.com (accessed 20 April 2012). CalverleyPMA , PauwelsRA , VestboJ , JonesPW , PrideNB , GulsvikA , et al. Salmeterol/fluticasone propionate combination for one year provides greater clinical benefit than its individual components [A98] [Poster 306]. http://www.abstracts‐on‐line.com/abstracts/ATS (accessed 20 April 2012). HunjanMK , ChandlerF . Numbers needed to treat (NNT) to avoid an exacerbation in patients with chronic obstructive pulmonary disease (COPD) using salmeterol/fluticasone propionate combination (SFC) and associated costs [Abstract]. American Thoracic Society 100th International Conference; 2004 May 21‐26; Orlando. 2004:D22 Poster 503. HunjanMK , WilliamsDT . Costs of avoiding exacerbations in patients with chronic obstructive pulmonary disease (COPD) treated with salmeterol/fluticasone propionate combination (Seretide) and salmeterol. European Respiratory Journal2004;24 Suppl 48:291s. HunjanMK , WilliamsDT . Salmeterol/fluticasone propionate combination is clinically effective in avoiding exacerbations in patients with moderate/severe COPD. European Respiratory Journal2004;24 Suppl 48:513s. JonesPW , EdinHM , AndersonJ . Salmeterol/fluticasone propionate combination improves health status in COPD patients.. http://www.abstracts‐on‐line.com/abstracts/ATS (accessed 21 April 2012). JonesPW , StåhlE . Budesonide/formoterol sustains clinically relevant improvements in health status in COPD [Abstract]. European Respiratory Journal2005;26 Suppl 49:Abstract No. 1352. JonesPW , VestboJ , PauwelsRA , CalverleyPMA , AndersonJA , SpencerMD . Informative drop out in COPD studies. Investigation of health status of withdrawals in the TRISTAN study. European Respiratory Society 13th Annual Congress; 2003 Sep 28‐29; Vienna. 2003:P1593. NitschmannS . Inhalational combination therapy in chronic obstructive lung disease. TRISTAN study. German Internist2004;45(6):727‐8. PauwelsRA , CalverlyPMA , VestboJ , JonesPW , PrideN , GulsvikA , et al. Reduction of exacerbations with salmeterol/fluticasone combination 50/500 mcg bd in the treatment of chronic obstructive pulmonary disease. European Respiratory Journal2002;20 Suppl 38:240 [P1569]. PauwelsRA , VestboJ , CalverleyPMA , JonesPW , PrideNB , GulsvikA . Characterization of exacerbations in the TRISTAN study of salmeterol / fluticasone propionate (SFC) combination in moderate to severe COPD. http://www.abstracts2view.com (accessed 20 April 2012). SFCB3024 . A multi‐centre, randomised, double‐blind, parallel group, placebo‐controlled study to compare the efficacy and safety of the salmeterol/FP combination product at a strength of 50/500mcg bd with salmeterol 50mcg bd alone and FP 500mcg bd alone, delivered via the DISKUS™/ACCUHALER™, in the treatment of subjects with chronic obstructive pulmonary disease (COPD) for 12 months. http://ctr.gsk.co.uk (accessed 21 April 2012). SpencerM , BriggsAH , GrossmanRF , RanceL . Development of an economic model to assess the cost effectiveness of treatment interventions for chronic obstructive pulmonary disease. Pharmacoeconomics2005;23(6):619‐37. SpencerMD , KariaN , AndersonJ . The clinical significance of treatment benefits with the salmeterol/fluticasone propionate 50/500mcg combination in COPD. European Respiratory Journal2004;24 Suppl 48:290s. VestboJ , CalverleyPMA , PauwelsR , JonesP , PrideN , GulsvikA , et al. Absence of gender susceptibility to the combination of salmeterol and fluticasone in the treatment of chronic obstructive pulmonary disease. European Respiratory Journal2002;20 Suppl 38:240 [P1570]. VestboJ , PauwelsR , AndersonJA , JonesP , CalverleyP . Early onset of effect of salmeterol and fluticasone propionate in chronic obstructive pulmonary disease. Thorax2005;60(4):301‐4. VestboJ , PauwelsRA , CalverleyPMA , JonesPW , PrideNB , GulsvikA . Salmeterol/fluticasone propionate combination produces improvement in lung function detectable within 24 hours in moderate to severe COPD. http://www.abstracts2view.com (accessed 20 April 2012). VestboJ , SorianoJB , AndersonJA , CalverleyP , PauwelsR , JonesP . Gender does not influence the response to the combination of salmeterol and fluticasone propionate in COPD. Respiratory Medicine2004;98(11):1045‐50. ">Calverley 2003 TRISTAN</a><sup>a</sup> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>12</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>763</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>GSK</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>1000</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>73</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>63</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>43</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>45</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><a href="./references#CD010115-bbs2-0007" title="AllegraL . TORCH study: An invitation to clinical considerations. GIMT ‐ Giornale Italiano delle Malattie del Torace2007;61(1):15‐23. BriggsAH , GlickHA , Lozano‐OrtegaG , SpencerM , CalverleyPM , JonesPW , et al. Is treatment with ICS and LABA cost‐effective for COPD? Multinational economic analysis of the TORCH study. European Respiratory Journal2010;35(3):532‐9. BriggsAH , Lozano‐OrtegaG , SpencerS , BaleG , SpencerMD , BurgePS . Estimating the cost‐effectiveness of fluticasone propionate for treating chronic obstructive pulmonary disease in the presence of missing data. Value in Health2006;9(4):227‐35. CalverleyP , CelliB , AndersonJ , FergusonG , JenkinsC , JonesP , et al. Salmeterol/fluticasone propionate combination (SFC) improves survival in COPD over three years: on‐treatment analysis from the TORCH study [Abstract]. American Thoracic Society International Conference; 2009 May 15‐20; San Diego. 2009:A6191[Poster #219]. CalverleyP , CelliB , AndersonJA , FergusonGT , JenkinsC , JonesPW , et al. The TOwards a Revolution in COPD Health (TORCH) study: salmeterol/fluticasone propionate improves survival in COPD over three years [Abstract]. Respirology2006;11 Suppl 5:A149 [PS‐3‐8]. CalverleyPM , AndersonJA , CelliB , FergusonGT , JenkinsC , JonesPW , et al. Salmeterol and fluticasone propionate and survival in chronic obstructive pulmonary disease. New England Journal of Medicine2007;356(8):775‐89. CalverleyPM , AndersonJA , CelliB , FergusonGT , JenkinsC , Jones PW et al and TORCH Investigators. Cardiovascular events in patients with COPD: TORCH study results. Thorax2010;65(8):719‐25. CalverleyPM , CelliB , AndersonJA , FergusonGT , JenkinsC , JonesPW , et al. The TOwards a Revolution in COPD Health (TORCH) study: fluticasone propionate /salmeterol improves survival in COPD over three years. Chest2006;130(4):122s. CalverleyPMA , CelliB , AndersenJA , FergusonGT , JenkinsC , JonesPW , et al. The TORCH (TOwards a Revolution in COPD Health) study salmeterol/fluticasone propionate (SFC) improves survival in COPD over three years. European Respiratory Journal2006;28 Suppl 50:34. CelliB , CalverleyPM , AndersonJA , FergusonGT , JenkinsC , JonesP , et al. The TOwards a Revolution in COPD HEalth (TORCH) Study: salmeterol/fluticasone propionate reduces the rate of exacerbations over three years. Respirology2006;11 Suppl 5:A140. CelliB , CalverleyPM , AndersonJA , FergusonGT , JenkinsC , JonesPW , et al. The TOwards a Revolution in COPD Health (TORCH) study: fluticasone propionate/salmeterol reduces the rate of exacerbations over 3 years [Abstract]. Chest2006;130(4):177s. CelliB , CalverleyPMA , AndersonJA , FergusonGT , JenkinsC , JonesPW , et al. The TORCH (TOwards a Revolution in COPD Health) study salmeterol/fluticasone propionate (SFC) improves health status reduces exacerbations and improves lung function over three years [Abstract]. European Respiratory Journal2006;28 Suppl 50:34s [E312]. CelliB , EmmettA , CraterG , KalbergC . Fluticasone propionate/salmeterol (FSC) improves the inspiratory to total lung capacity ratio (IC/TLC) and exercise endurance time in patients with COPD. European Respiratory Society 16th Annual Congress; 2006 Sep 2‐6; Munich. 2006:A320 (Poster 323). CelliB , FergusonGT , AndersonJA , JenkinsCR , JonesPW , VestboJ , et al. Salmeterol/fluticasone propionate (SFC) improves lung function and reduces the rate of decline over three years in the TORCH survival study [Abstract]. American Thoracic Society International Conference; 2007 May 18‐23; San Francisco. 2007:A763. CelliB , VestboJ , JenkinsCR , JonesPW , FergusonGT , CalverleyPMA , et al. Sex differences in mortality and clinical expressions of patients with chronic obstructive pulmonary disease: the TORCH experience. American Journal of Respiratory and Critical Care Medicine2011;183(3):317‐22. CelliBR , ThomasNE , AndersonJA , FergusonGT , JenkinsCR , JonesPW , et al. Effect of pharmacotherapy on rate of decline of lung function in chronic obstructive pulmonary disease: results from the TORCH study. American Journal of Respiratory and Critical Care Medicine2008;178(4):332‐8. CelliD , EmmettA , CraterG , KalbergC . Salmeterol/fluticasone propionate (SFC) improves the inspiratory to total lung capacity ratio (IC/TLC) and exercise endurance time in patients with COPD. European Respiratory Journal2006;28 Suppl 50:764 [4395]. CorhayJL , LouisR . Clinical study of the month: the TORCH study (TOwards a Revolution in COPD Health) [L'étude clinique du mois. L'étude TORCH (TOwards a Revolution in COPD Health): vers une revolution de la santé des patients souffrant de BPCO]. Revue Medicale de Liege2007;62(4):230‐4. FergusonGT , CalverleyPM , AndersonJA , CelliB , JenkinsC , JonesPW , et al. The TOwards a Revolution in COPD Health (TORCH) study: fluticasone propionate/salmeterol is well tolerated in patients with COPD over 3 years [Abstract]. Chest2006;130(4):178s. FergusonGT , CalverleyPM , AndersonJA , CelliB , JenkinsCR , JonesPW , et al. Effect of salmeterol/fluticasone propionate (SFC) on bone mineral density (BMD) and eye disorders over three years in the TORCH trial [Abstract]. American Thoracic Society International Conference; 2007 May 18‐23; San Francisco. 2007:A763. FergusonGT , CalverleyPM , AndersonJA , JenkinsCR , CelliB , et al. Prevalence and progression of osteoporosis in patients with COPD results from the towards a revolution in COPD health study. Chest2009;136(6):1456‐65. FergusonGT , CalverleyPMA , AndersonJA , et al. The TORCH (TOwards a Revolution in COPD Health) study: salmeterol/fluticasone propionate (SFC) improves survival in COPD over three years. European Respiratory Journal2006;28 Suppl 50:34s. GlickH , BriggsA , Lozano‐OrtegaG , SpencerM , VestboJ , CalverleyP . Is treatment with ICS/LABA combination good value for money in COPD? Evidence from the TORCH study [Abstract]. American Thoracic Society International Conference; 2007 May 18‐23; San Francisco. 2007:[C97]. JenkinsC , CelliB , AndersonJ , FergusonG , CalverleyP , JonesP , et al. Salmeterol/fluticasone propionate (SFC) is efficacious in GOLD stage II COPD patients: analysis from the TORCH study [Abstract]. American Thoracic Society International Conference; May 15‐20; San Diego. 2009:A6186 [Poster #213]. JenkinsCR , CelliB , AndersonJA , FergusonGT , JonesPW , VestboJ , et al. Seasonality and determinants of moderate and severe COPD exacerbations in the TORCH study. European Respiratory Journal2012;39:38‐45. JenkinsCR , CelliB , AndersonJA , FergusonGT , JonesPW , VestboJ , et al. The TORCH survival study: consistent efficacy results seen in geographic regions in a multi‐national study [Abstract]. American Thoracic Society International Conference; May 18‐23; San Francisco. 2007:[C97]. JenkinsCR , JonesPW , CalverleyPM , CelliB , AndersonJA , FergusonGT , et al. Efficacy of salmeterol/fluticasone propionate by GOLD stage of chronic obstructive pulmonary disease: analysis from the randomised, placebo‐controlled TORCH study. Respiratory Research2009;10:59. JonesPW , AndersonJA , CalverleyPM , CelliBR , FergusonGT , JenkinsC , et al. Health status in the TORCH study of COPD: treatment efficacy and other determinants of change. Respiratory Research2011;12:71. JonesPW , CalverleyPM , CelliB , AndersonJA , FergusonGT , JenkinsC , et al. The TOwards a Revolution in COPD Health (TORCH) study: fluticasone propionate/salmeterol improves and sustains health status in COPD over 3 years. Chest2006;130(4):177s. JonesPW , VestboJ , AndersonJA , CelliB , FergusonGT , JenkinsCR , et al. Informative withdrawal in a COPD study. An example from the TORCH Study [Abstract]. American Thoracic Society International Conference; 2007 May 18‐23; San Francisco. 2007:[C97]. KeeneON , VestboJ , AndersonJA , CalverleyPM , CelliB , FergusonGT , et al. Methods for therapeutic trials in COPD: Lessons from the TORCH trial. European Respiratory Journal2009;34(5):1018‐23. McDonoughC , BlanchardAR . TORCH study results: pharmacotherapy reduces lung function decline in patients with chronic obstructive pulmonary disease. Hospital Practice2010;38(2):92‐3. McGarveyLP , JohnM , AndersonJA , ZvarichM , WiseRA , Committee TCE et al. Ascertainment of cause‐specific mortality in COPD: operations of the TORCH Clinical Endpoint Committee. Thorax2007;62(5):411‐5. MehtaRS , KathmanSJ , Daley‐YatesPT , CahnT , BeeraheeM , KunkaRL , et al. Pharmacokinetics and pharmacodynamics in COPD patients following long‐term twice‐daily treatment with salmeterol/fluticasone propionate (SFC) 50/500mg and the individual components [Abstract]. American Thoracic Society International Conference; 2007 May 18‐23; San Francisco. 2007:Poster #A41. SCO30003 . A multi‐centre, randomised, double‐blind, parallel group, placebo‐controlled study to investigate the long‐term effects of salmeterol/fluticasone propionate (SERETIDE®/VIANI®/ADVAIR®) 50/500mcg bd, salmeterol 50mcg bd and fluticasone propionate 500mcg bd, all delivered via the DISKUS®/ACCUHALER® inhaler, on the survival of subjects with chronic obstructive pulmonary disease (COPD) over 3 years of treatment. www.ctr.gsk.co.uk (accessed 21 April 2012). SacchettaA . Long term therapy and outcome of chronic obstructive pulmonary disease with or without co‐morbidity: The TORCH Study. Italian Journal of Medicine2008;2(3):11‐5. VestboJ , AndersonJA , CalverleyPM , CelliB , FergusonGT , JenkinsC , et al. Bias due to withdrawal in long‐term randomised trials in COPD: Evidence from the TORCH study. Clinical Respiratory Journal2011;5(1):44‐9. VestboJ , TORCH Study Group. The TORCH (TOwards a Revolution in COPD Health) survival study protocol. European Respiratory Journal2004;24(2):206‐10. ">Calverley 2007 TORCH</a><sup>a</sup> </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>36</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>3097</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>GSK</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>1000</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>76</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>65</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>49</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>44</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><a href="./references#CD010115-bbs2-0009" title="ChoudhuryAB , DawsonCM , KilvingtonHE , EldridgeHE , JamesWY , WedzichaJA , et al. Withdrawal of inhaled corticosteroids in people with chronic obstructive pulmonary disease (COPD) in primary care ‐ a randomised controlled trial [Abstract]. European Respiratory Journal2005;26 Suppl 49:Abstract No. 1328. ChoudhuryAB , DawsonCM , KilvingtonHE , EldridgeS , JamesWY , WedzichaJA , et al. Withdrawal of inhaled corticosteroids in people with COPD in primary care: a randomised controlled trial. Respiratory Research2007;8:93. ">Choudhury 2005</a> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>12</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>260</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Indep.</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>1000</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>52</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>67</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>39</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>54</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><a href="./references#CD010115-bbs2-0015" title="FLTA3025 . A randomized, double‐blind, parallel‐group, comparative trial of inhaled fluticasone propionate 250mcg BID, 500mcg BID, and placebo BID via the DISKUS in subjects with chronic obstructive pulmonary disease (COPD). GlaxoSmithKline Clinical Trial Register (accessed 18 April 2012). ">GSK FLTA3025 2005</a> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>6</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>640</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>GSK</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>500, 1000</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>69</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>64</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>‐</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>‐</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><a href="./references#CD010115-bbs2-0017" title="Evaluation of Novel Endpoints in Subjects with Chronic Obstructive Pulmonary Disease(COPD) in a Randomized, Double‐Blind, Placebo‐Controlled Study of Treatment with FluticasonePropionate/Salmeterol 500/50mcg combination and its individual components, FluticasonePropionate 500mcg and Salmeterol 50mcg. http://www.gsk‐clinicalstudyregister.com/ 2008 (accessed 19 April 2012). SCO104925 . Evaluation of Novel Endpoints in Subjects with Chronic Obstructive Pulmonary Disease(COPD) in a Randomized, Double‐Blind, Placebo‐Controlled Study of Treatment with FluticasonePropionate/Salmeterol 500/50mcg combination and its individual components, FluticasonePropionate 500mcg and Salmeterol 50mcg. http:ctr.gsk.co.uk (accessed 19 April 2012). ">GSK SCO104925 2008</a><sup>a</sup> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>3</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>84</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>GSK</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>1000</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>77</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>64</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>‐</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>‐</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><a href="./references#CD010115-bbs2-0018" title="SCO30002 . A multi‐centre, randomised, double‐blind, parallel group, placebo‐controlled study to compare the efficacy and safety of inhaled salmeterol/fluticasone propionate combination product 25/250 µg two puffs bd and fluticasone propionate 250µg two puffs bd alone, all administered via metered dose inhalers (MDI), in the treatment of subjects with chronic obstructive pulmonary disease (COPD) for 52 weeks. GlaxoSmithKline Clinical Trial Register (accessed 21 April 2012). ">GSK SCO30002 2005</a> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>12</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>256</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>GSK</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>1000</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>82</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>65</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>‐</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>‐</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><a href="./references#CD010115-bbs2-0020" title="HananiaNA , DarkenP , HorstmanD , ReisnerC , LeeB , DavisS , et al. The efficacy and safety of fluticasone propionate (250 mcg)/salmeterol (50 mcg) combined in the Diskus inhaler for the treatment of COPD. Chest2003;124(3):834‐43. HananiaNA , KnobilK , WatkinsM , WireP , YatesJ , DarkenP . Salmeterol and fluticasone propionate therapy administered by a single Diskus in patients with COPD. Chest2002:S129. HananiaNA , RamsdellJ , PayneK , DavisS , HorstmanD , LeeB , et al. Improvements in airflow and dyspnoea in COPD patients following 24 weeks treatment with salmeterol 50mcg and fluticasone propionate 250mcg alone or in combination via the Diskus. American Journal of Respiratory and Critical Care Medicine2001;163 Suppl 5:A279. HorstmanD , DarkenP , DavisS , LeeB . Improvements in FEV1 and symptoms in poorly reversible COPD patients following treatment with salmeterol 50mcg/fluticasone propionate 250mcg combination [Abstract]. European Respiratory Journal2003;22 Suppl 45:P434. MahlerDA , DarkenP , BrownCP , KnobilK . Predicting lung function responses to combination therapy in chronic obstructive pulmonary disease (COPD) [Abstract]. National COPD Conference; 2003 Nov 14‐15; Arlington. 2003:1081. MahlerDA , DarkenP , BrownCP , KnobilK . Predicting lung function responses to salmeterol/fluticasone propionate combination therapy in COPD [Abstract]. European Respiratory Journal2003;22 Suppl 45:P429. SFCA3007 . A randomized, double‐blind, placebo‐controlled, parallel‐group trial evaluating the safety and efficacy of the DISKUS formulations of salmeterol (SAL) 50mcg BID and fluticasone propionate (FP) 250mcg BID individually and in combination as salmeterol 50mcg/fluticasone propionate 250mcg BID (SFC 50/250) compared to placebo in COPD subjects. http://ctr.gsk.co.uk (accessed 20 April 2012). SpencerM , WireP , LeeB , ChangCN , DarkenP , HorstmanD . Patients with COPD using salmeterol/fluticasone propionate combination therapy experience improved quality of life. European Respiratory Journal2003;22 Suppl 45:51s. SpencerMD , KariaN , AndersonJ . The clinical significance of treatment benefits with the salmeterol/fluticasone propionate 50/500mcg combination in COPD. European Respiratory Journal2004;24 Suppl 48:290s. ">Hanania 2003</a><sup>a</sup> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>6</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>368</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>GSK</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>500</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>63</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>64</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>57</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>42</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><a href="./references#CD010115-bbs2-0021" title="GizyckiMJ , HattotuwaKL , BarnesN , JefferyPK . Effects of fluticasone propionate on inflammatory cells in COPD: an ultrastructural examination of endobronchial biopsy tissue. Thorax2002;57(9):799‐803. HattotuwaKL , GizyckiMJ , AnsariTW , JefferyPK , BarnesNC . The effects of inhaled fluticasone on airway inflammation in chronic obstructive pulmonary disease. American Journal of Respiratory and Critical Care Medicine2002;165(12):1592‐9. ">Hattotuwa 2002</a> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>3</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>36</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>GSK</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>1000</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>87</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>65</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>63</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>46</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><a href="./references#CD010115-bbs2-0023" title="KerwinEM , Scott‐WilsonC , SanfordL , RennardS , AgustiA , BarnesN , et al. A randomised trial of fluticasone furoate/vilanterol (50/25 mug; 100/25 mug) on lung function in COPD. Respiratory Medicine2013; Vol. 107, issue 4:560‐9. [0954‐6111] KerwinEM , Scott‐WilsonC , SanfordL , RennardSI , AgustiA , BarnesN , et al. Lung function effects and safety of fluticasone furoate (FF)/vilanterol (VI) in patients with COPD: Low‐mid dose assessment [Abstract]. European Respiratory Society Annual Congress; Sep 1‐5; Vienna. 2012; Vol. 40, issue Suppl 56:545s [3082]. ">Kerwin 2013</a><sup>a,b</sup> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>6</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>413</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>GSK</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>100</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>66</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>62</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>46</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>42</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><a href="./references#CD010115-bbs2-0024" title="KunzLIZ , StrebusJ , BudulacSE , LapperreTS , SterkPJ , PostmaDS , et al. Inhaled Steroids Modulate Extracellular Matrix Composition in Bronchial Biopsies of COPD Patients: A Randomized, Controlled Trial. PloS one2013; Vol. 8, issue 5:e63430. LapperreTS , Snoeck‐StrobandJB , GosmanMM , JansenDF , vanSchadewijkA , ThiadensHA , et al. Effect of fluticasone with and without salmeterol on pulmonary outcomes in chronic obstructive pulmonary disease: a randomized trial. Annals of Internal Medicine2009;151(8):517‐27. ">Lapperre 2009</a> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>30</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>55</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>GSK</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>1000</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>86</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>60</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>43</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>55</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><a href="./references#CD010115-bbs2-0026" title="MahlerDA , DarkenP , BrownCP , KnobilK . Predicting lung function responses to combination therapy in chronic obstructive pulmonary disease (COPD). http://www.abstracts2view.com (accessed 15 April 2012). MahlerDA , WireP , HorstmanD , ChangCN , YatesJ , FischerT , et al. Effectiveness of fluticasone propionate and salmeterol combination delivered via the Diskus device in the treatment of chronic obstructive pulmonary disease. American Journal of Respiratory and Critical Care Medicine2002;166(8):1084‐91. SFCA3006 . A randomized, double‐blind, placebo‐controlled, parallel‐group trial evaluating the safety and efficacy of the DISKUS formulations of salmeterol (SAL) 50mcg BID and fluticasone propionate (FP) 500mcg BID individually and in combination as salmeterol 50mcg/fluticasone propionate 500mcg BID (SFC 50/500) compared to placebo in COPD subjects. http://ctr.gsk.co.uk (accessed 17 April 2012). SpencerM , WireP , LeeB , ChangCN , DarkenP , HorstmanD . Patients with COPD using salmeterol/fluticasone propionate combination therapy experience improved quality of life. European Respiratory Journal2003;22 Suppl 45:51. SpencerMD , AndersonJA . Salmeterol/fluticasone combination produces clinically important benefits in dyspnoea and fatigue [Abstract]. American Thoracic Society 2005 International Conference; 2005 May 20‐25; San Diego. 2005:B93 [Poster 308]. SpencerMD , KariaN , AndersonJ . The clinical significance of treatment benefits with the salmeterol/fluticasone propionate 50/500mcg combination in COPD. European Respiratory Journal2004;24 Suppl 48:290. ">Mahler 2002</a><sup>a</sup> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>6</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>349</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>GSK</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>1000</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>66</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>65</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>55</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>41</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><a href="./references#CD010115-bbs2-0027" title="MartinezF , BosciaJ , FeldmanG , Scott‐WilsonC , KilbrideS , FabbriL , et al. Lung function effects and safety of fluticasone furoate (FF)/vilanterol (VI) in patients with COPD: mid‐high dose assessment [Abstract]. European Respiratory Society Annual Congress, Vienna, Austria, September 1‐5. 2012; Vol. 40, issue Suppl 56:527s [P2887]. MartinezFJ , BosciaJ , FeldmanG , Scott‐WilsonC , KilbrideS , FabbriL , et al. Fluticasone furoate/vilanterol (100/25; 200/25 mug) improves lung function in COPD: a randomised trial. Respiratory Medicine2013;107(4):550‐9. [0954‐6111] ">Martinez 2013</a><sup>a,b</sup> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>6</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>612</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>GSK</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>100, 200</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>72</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>62</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>43</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>48</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><a href="./references#CD010115-bbs2-0030" title="FLIT97 . A multi‐centre, randomised, double‐blind, parallel group study of the efficacy and safety of inhaled fluticasone propionate 1000 µg daily with placebo in chronic obstructive pulmonary disease. http://ctr.gsk.co.uk (accessed 20 April 2012). PaggiaroPL , DahleR , BakranI , FrithL , HollingworthK , EfthimiouJ . Multicentre randomised placebo‐controlled trial of inhaled fluticasone propionate in patients with chronic obstructive pulmonary disease. International COPD Study Group. Lancet1998;351(9105):773‐80. ">Paggiaro 1998</a> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>6</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>281</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>‐</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>1000</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>74</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>63</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>‐</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>57</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><a href="./references#CD010115-bbs2-0034" title="ChavannesNH , SchermerTR , WoutersEF , AkkermansRP , DekhuijzenRP , MurisJW , et al. Predictive value and utility of oral steroid testing for treatment of COPD in primary care: the COOPT study. International Journal of COPD2009;4:431‐6. SchermerT , ChavannesN , DekhuijzenR , WoutersE , MurisJ , AkkermansR , et al. Fluticasone and N‐acetylcysteine in primary care patients with COPD or chronic bronchitis. Respiratory Medicine2009;103(4):542‐51. ">Schermer 2009</a> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>36</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>190</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Indep.</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>1000</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>71</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>59</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>28</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>64</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><a href="./references#CD010115-bbs2-0040" title="vanGrunsvenP , SchermerT , AkkermansR , AlbersM , van denBoomG , vanSchayckO , et al. Short‐ and long‐term efficacy of fluticasone propionate in subjects with early signs and symptoms of chronic obstructive pulmonary disease. Results of the DIMCA study. Respiratory Medicine2003;97(12):1303‐12. ">van Grunsven 2003</a> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>24</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>48</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>GSK</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>500</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>52</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>47</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>9</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>97</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><a href="./references#CD010115-bbs2-0041" title="VerhoevenGT , GarreldsIM , HoogstedenHC , ZijlstraFJ . Effects of fluticasone propionate inhalation on levels of arachidonic acid metabolites in patients with chronic obstructive pulmonary disease. Mediators of Inflammation2001;10(1):21‐6. VerhoevenGT , HegmansJP , MulderPG , BogaardJM , HoogstedenHC , PrinsJB . Effects of fluticasone propionate in COPD patients with bronchial hyper‐responsiveness. Thorax2002;57(8):694‐700. VerhoevenGT , WijkhuijsAJ , HooijkaasH , HoogstedenHC , SluiterW . Effect of an inhaled glucocorticoid on reactive oxygen species production by bronchoalveolar lavage cells from smoking COPD patients. Mediators of Inflammation2000;9(2):109‐13. ">Verhoeven 2002</a> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>6</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>23</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>GSK</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>1000</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>82</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>55</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>26</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>63</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""></td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><b>WM 22 m</b> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><b>459</b> </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><b>‐</b> </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><b>‐</b> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><b>72</b> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><b>62</b> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><b>43</b> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><b>54</b> </p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="9" rowspan="1" valign=""> <p><b>Fluticasone/LABA combination versus LABA monotherapy (n = 15)</b> </p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><a href="./references#CD010115-bbs2-0001" title="AnzuetoA , FergusonGT , FeldmanG , ChinskyK , SeibertA , EmmettA , et al. Effect of fluticasone propionate/salmeterol (250/50) on COPD exacerbations and impact on patient outcomes. Journal of Chronic Obstructive Pulmonary Disease2009;6(5):320‐9. DalalAA , BlanchetteCM , PetersenH , St. CharlesM . Cost‐effectiveness of fluticasone propionate/salmeterol (250/50mcg) compared to salmeterol (50mcg) in patients with chronic obstructive pulmonary disease: economic evaluation of study SCO100250 [Abstract]. American Thoracic Society International Conference; 2009 May 15‐20; San Diego. 2009:A1502 [Poster K54]. DiSantostefanoRL , LiH , RubinDB , StempelDA . Which patients with chronic obstructive pulmonary disease benefit from the addition of an inhaled corticosteroid to their bronchodilator? A cluster analysis. BMJ Open2013;3(4):e001838. [DOI: 10.1136/bmjopen‐2012‐001838] GlaxoSmithKline . A Randomized, Double‐Blind, Parallel‐Group, 52‐Week Study to Compare the Effect of Fluticasone Propionate/Salmeterol DISKUS 250/50mcg BID with Salmeterol DISKUS 50mcg BID on the Annual Rate of Moderate/Severe Exacerbations in Subjects with Chronic Obstructive Pulmonary Disease (COPD). SCO100250. www.gsk‐clinicalstudyregister.com/ (accessed 25 May 2013). GlaxoSmithKline . A randomized, double‐blind, parallel‐group, 52‐week study to compare the effect of fluticasone propionate/salmeterol DISKUS 250/50mcg bid with salmeterol DISKUS 50mcg bid on the annual rate of moderate/severe exacerbations in subjects with chronic obstructive pulmonary disease (COPD). www.gsk‐clinicalstudyregister.com/ (accessed 8 April 2013). ">Anzueto 2009</a> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>12</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>797</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>GSK</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>500</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>54</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>65</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>57</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>34</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><a href="./references#CD010115-bbs2-0006" title="CalverleyP , PauwelsR , VestboJ , JonesP , PrideN , GulsvikA , et al. Combined salmeterol and fluticasone in the treatment of chronic obstructive pulmonary disease: a randomised controlled trial. Lancet2003;361(9356):449‐56. CalverleyPMA , PauwelsR , VestboJ , JonesP , PrideN , GulsvikA , et al. Safety of salmeterol/fluticasone propionate combination in the treatment of chronic obstructive pulmonary disease. European Respiratory Journal2002;20(Suppl 38):242s [P1572]. CalverleyPMA , PauwelsRA , VestboJ , JonesPW , PrideNB , GulsvikA , et al. Clinical improvements with salmeterol / fluticasone propionate combination in differing severities of COPD [A035] [Poster D50]. http://www.abstracts2view.com (accessed 20 April 2012). CalverleyPMA , PauwelsRA , VestboJ , JonesPW , PrideNB , GulsvikA , et al. Salmeterol/fluticasone propionate combination for one year provides greater clinical benefit than its individual components [A98] [Poster 306]. http://www.abstracts‐on‐line.com/abstracts/ATS (accessed 20 April 2012). HunjanMK , ChandlerF . Numbers needed to treat (NNT) to avoid an exacerbation in patients with chronic obstructive pulmonary disease (COPD) using salmeterol/fluticasone propionate combination (SFC) and associated costs [Abstract]. American Thoracic Society 100th International Conference; 2004 May 21‐26; Orlando. 2004:D22 Poster 503. HunjanMK , WilliamsDT . Costs of avoiding exacerbations in patients with chronic obstructive pulmonary disease (COPD) treated with salmeterol/fluticasone propionate combination (Seretide) and salmeterol. European Respiratory Journal2004;24 Suppl 48:291s. HunjanMK , WilliamsDT . Salmeterol/fluticasone propionate combination is clinically effective in avoiding exacerbations in patients with moderate/severe COPD. European Respiratory Journal2004;24 Suppl 48:513s. JonesPW , EdinHM , AndersonJ . Salmeterol/fluticasone propionate combination improves health status in COPD patients.. http://www.abstracts‐on‐line.com/abstracts/ATS (accessed 21 April 2012). JonesPW , StåhlE . Budesonide/formoterol sustains clinically relevant improvements in health status in COPD [Abstract]. European Respiratory Journal2005;26 Suppl 49:Abstract No. 1352. JonesPW , VestboJ , PauwelsRA , CalverleyPMA , AndersonJA , SpencerMD . Informative drop out in COPD studies. Investigation of health status of withdrawals in the TRISTAN study. European Respiratory Society 13th Annual Congress; 2003 Sep 28‐29; Vienna. 2003:P1593. NitschmannS . Inhalational combination therapy in chronic obstructive lung disease. TRISTAN study. German Internist2004;45(6):727‐8. PauwelsRA , CalverlyPMA , VestboJ , JonesPW , PrideN , GulsvikA , et al. Reduction of exacerbations with salmeterol/fluticasone combination 50/500 mcg bd in the treatment of chronic obstructive pulmonary disease. European Respiratory Journal2002;20 Suppl 38:240 [P1569]. PauwelsRA , VestboJ , CalverleyPMA , JonesPW , PrideNB , GulsvikA . Characterization of exacerbations in the TRISTAN study of salmeterol / fluticasone propionate (SFC) combination in moderate to severe COPD. http://www.abstracts2view.com (accessed 20 April 2012). SFCB3024 . A multi‐centre, randomised, double‐blind, parallel group, placebo‐controlled study to compare the efficacy and safety of the salmeterol/FP combination product at a strength of 50/500mcg bd with salmeterol 50mcg bd alone and FP 500mcg bd alone, delivered via the DISKUS™/ACCUHALER™, in the treatment of subjects with chronic obstructive pulmonary disease (COPD) for 12 months. http://ctr.gsk.co.uk (accessed 21 April 2012). SpencerM , BriggsAH , GrossmanRF , RanceL . Development of an economic model to assess the cost effectiveness of treatment interventions for chronic obstructive pulmonary disease. Pharmacoeconomics2005;23(6):619‐37. SpencerMD , KariaN , AndersonJ . The clinical significance of treatment benefits with the salmeterol/fluticasone propionate 50/500mcg combination in COPD. European Respiratory Journal2004;24 Suppl 48:290s. VestboJ , CalverleyPMA , PauwelsR , JonesP , PrideN , GulsvikA , et al. Absence of gender susceptibility to the combination of salmeterol and fluticasone in the treatment of chronic obstructive pulmonary disease. European Respiratory Journal2002;20 Suppl 38:240 [P1570]. VestboJ , PauwelsR , AndersonJA , JonesP , CalverleyP . Early onset of effect of salmeterol and fluticasone propionate in chronic obstructive pulmonary disease. Thorax2005;60(4):301‐4. VestboJ , PauwelsRA , CalverleyPMA , JonesPW , PrideNB , GulsvikA . Salmeterol/fluticasone propionate combination produces improvement in lung function detectable within 24 hours in moderate to severe COPD. http://www.abstracts2view.com (accessed 20 April 2012). VestboJ , SorianoJB , AndersonJA , CalverleyP , PauwelsR , JonesP . Gender does not influence the response to the combination of salmeterol and fluticasone propionate in COPD. Respiratory Medicine2004;98(11):1045‐50. ">Calverley 2003 TRISTAN</a><sup>a</sup> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>12</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>731</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>GSK</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>1000</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>73</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>63</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>43</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>45</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><a href="./references#CD010115-bbs2-0007" title="AllegraL . TORCH study: An invitation to clinical considerations. GIMT ‐ Giornale Italiano delle Malattie del Torace2007;61(1):15‐23. BriggsAH , GlickHA , Lozano‐OrtegaG , SpencerM , CalverleyPM , JonesPW , et al. Is treatment with ICS and LABA cost‐effective for COPD? Multinational economic analysis of the TORCH study. European Respiratory Journal2010;35(3):532‐9. BriggsAH , Lozano‐OrtegaG , SpencerS , BaleG , SpencerMD , BurgePS . Estimating the cost‐effectiveness of fluticasone propionate for treating chronic obstructive pulmonary disease in the presence of missing data. Value in Health2006;9(4):227‐35. CalverleyP , CelliB , AndersonJ , FergusonG , JenkinsC , JonesP , et al. Salmeterol/fluticasone propionate combination (SFC) improves survival in COPD over three years: on‐treatment analysis from the TORCH study [Abstract]. American Thoracic Society International Conference; 2009 May 15‐20; San Diego. 2009:A6191[Poster #219]. CalverleyP , CelliB , AndersonJA , FergusonGT , JenkinsC , JonesPW , et al. The TOwards a Revolution in COPD Health (TORCH) study: salmeterol/fluticasone propionate improves survival in COPD over three years [Abstract]. Respirology2006;11 Suppl 5:A149 [PS‐3‐8]. CalverleyPM , AndersonJA , CelliB , FergusonGT , JenkinsC , JonesPW , et al. Salmeterol and fluticasone propionate and survival in chronic obstructive pulmonary disease. New England Journal of Medicine2007;356(8):775‐89. CalverleyPM , AndersonJA , CelliB , FergusonGT , JenkinsC , Jones PW et al and TORCH Investigators. Cardiovascular events in patients with COPD: TORCH study results. Thorax2010;65(8):719‐25. CalverleyPM , CelliB , AndersonJA , FergusonGT , JenkinsC , JonesPW , et al. The TOwards a Revolution in COPD Health (TORCH) study: fluticasone propionate /salmeterol improves survival in COPD over three years. Chest2006;130(4):122s. CalverleyPMA , CelliB , AndersenJA , FergusonGT , JenkinsC , JonesPW , et al. The TORCH (TOwards a Revolution in COPD Health) study salmeterol/fluticasone propionate (SFC) improves survival in COPD over three years. European Respiratory Journal2006;28 Suppl 50:34. CelliB , CalverleyPM , AndersonJA , FergusonGT , JenkinsC , JonesP , et al. The TOwards a Revolution in COPD HEalth (TORCH) Study: salmeterol/fluticasone propionate reduces the rate of exacerbations over three years. Respirology2006;11 Suppl 5:A140. CelliB , CalverleyPM , AndersonJA , FergusonGT , JenkinsC , JonesPW , et al. The TOwards a Revolution in COPD Health (TORCH) study: fluticasone propionate/salmeterol reduces the rate of exacerbations over 3 years [Abstract]. Chest2006;130(4):177s. CelliB , CalverleyPMA , AndersonJA , FergusonGT , JenkinsC , JonesPW , et al. The TORCH (TOwards a Revolution in COPD Health) study salmeterol/fluticasone propionate (SFC) improves health status reduces exacerbations and improves lung function over three years [Abstract]. European Respiratory Journal2006;28 Suppl 50:34s [E312]. CelliB , EmmettA , CraterG , KalbergC . Fluticasone propionate/salmeterol (FSC) improves the inspiratory to total lung capacity ratio (IC/TLC) and exercise endurance time in patients with COPD. European Respiratory Society 16th Annual Congress; 2006 Sep 2‐6; Munich. 2006:A320 (Poster 323). CelliB , FergusonGT , AndersonJA , JenkinsCR , JonesPW , VestboJ , et al. Salmeterol/fluticasone propionate (SFC) improves lung function and reduces the rate of decline over three years in the TORCH survival study [Abstract]. American Thoracic Society International Conference; 2007 May 18‐23; San Francisco. 2007:A763. CelliB , VestboJ , JenkinsCR , JonesPW , FergusonGT , CalverleyPMA , et al. Sex differences in mortality and clinical expressions of patients with chronic obstructive pulmonary disease: the TORCH experience. American Journal of Respiratory and Critical Care Medicine2011;183(3):317‐22. CelliBR , ThomasNE , AndersonJA , FergusonGT , JenkinsCR , JonesPW , et al. Effect of pharmacotherapy on rate of decline of lung function in chronic obstructive pulmonary disease: results from the TORCH study. American Journal of Respiratory and Critical Care Medicine2008;178(4):332‐8. CelliD , EmmettA , CraterG , KalbergC . Salmeterol/fluticasone propionate (SFC) improves the inspiratory to total lung capacity ratio (IC/TLC) and exercise endurance time in patients with COPD. European Respiratory Journal2006;28 Suppl 50:764 [4395]. CorhayJL , LouisR . Clinical study of the month: the TORCH study (TOwards a Revolution in COPD Health) [L'étude clinique du mois. L'étude TORCH (TOwards a Revolution in COPD Health): vers une revolution de la santé des patients souffrant de BPCO]. Revue Medicale de Liege2007;62(4):230‐4. FergusonGT , CalverleyPM , AndersonJA , CelliB , JenkinsC , JonesPW , et al. The TOwards a Revolution in COPD Health (TORCH) study: fluticasone propionate/salmeterol is well tolerated in patients with COPD over 3 years [Abstract]. Chest2006;130(4):178s. FergusonGT , CalverleyPM , AndersonJA , CelliB , JenkinsCR , JonesPW , et al. Effect of salmeterol/fluticasone propionate (SFC) on bone mineral density (BMD) and eye disorders over three years in the TORCH trial [Abstract]. American Thoracic Society International Conference; 2007 May 18‐23; San Francisco. 2007:A763. FergusonGT , CalverleyPM , AndersonJA , JenkinsCR , CelliB , et al. Prevalence and progression of osteoporosis in patients with COPD results from the towards a revolution in COPD health study. Chest2009;136(6):1456‐65. FergusonGT , CalverleyPMA , AndersonJA , et al. The TORCH (TOwards a Revolution in COPD Health) study: salmeterol/fluticasone propionate (SFC) improves survival in COPD over three years. European Respiratory Journal2006;28 Suppl 50:34s. GlickH , BriggsA , Lozano‐OrtegaG , SpencerM , VestboJ , CalverleyP . Is treatment with ICS/LABA combination good value for money in COPD? Evidence from the TORCH study [Abstract]. American Thoracic Society International Conference; 2007 May 18‐23; San Francisco. 2007:[C97]. JenkinsC , CelliB , AndersonJ , FergusonG , CalverleyP , JonesP , et al. Salmeterol/fluticasone propionate (SFC) is efficacious in GOLD stage II COPD patients: analysis from the TORCH study [Abstract]. American Thoracic Society International Conference; May 15‐20; San Diego. 2009:A6186 [Poster #213]. JenkinsCR , CelliB , AndersonJA , FergusonGT , JonesPW , VestboJ , et al. Seasonality and determinants of moderate and severe COPD exacerbations in the TORCH study. European Respiratory Journal2012;39:38‐45. JenkinsCR , CelliB , AndersonJA , FergusonGT , JonesPW , VestboJ , et al. The TORCH survival study: consistent efficacy results seen in geographic regions in a multi‐national study [Abstract]. American Thoracic Society International Conference; May 18‐23; San Francisco. 2007:[C97]. JenkinsCR , JonesPW , CalverleyPM , CelliB , AndersonJA , FergusonGT , et al. Efficacy of salmeterol/fluticasone propionate by GOLD stage of chronic obstructive pulmonary disease: analysis from the randomised, placebo‐controlled TORCH study. Respiratory Research2009;10:59. JonesPW , AndersonJA , CalverleyPM , CelliBR , FergusonGT , JenkinsC , et al. Health status in the TORCH study of COPD: treatment efficacy and other determinants of change. Respiratory Research2011;12:71. JonesPW , CalverleyPM , CelliB , AndersonJA , FergusonGT , JenkinsC , et al. The TOwards a Revolution in COPD Health (TORCH) study: fluticasone propionate/salmeterol improves and sustains health status in COPD over 3 years. Chest2006;130(4):177s. JonesPW , VestboJ , AndersonJA , CelliB , FergusonGT , JenkinsCR , et al. Informative withdrawal in a COPD study. An example from the TORCH Study [Abstract]. American Thoracic Society International Conference; 2007 May 18‐23; San Francisco. 2007:[C97]. KeeneON , VestboJ , AndersonJA , CalverleyPM , CelliB , FergusonGT , et al. Methods for therapeutic trials in COPD: Lessons from the TORCH trial. European Respiratory Journal2009;34(5):1018‐23. McDonoughC , BlanchardAR . TORCH study results: pharmacotherapy reduces lung function decline in patients with chronic obstructive pulmonary disease. Hospital Practice2010;38(2):92‐3. McGarveyLP , JohnM , AndersonJA , ZvarichM , WiseRA , Committee TCE et al. Ascertainment of cause‐specific mortality in COPD: operations of the TORCH Clinical Endpoint Committee. Thorax2007;62(5):411‐5. MehtaRS , KathmanSJ , Daley‐YatesPT , CahnT , BeeraheeM , KunkaRL , et al. Pharmacokinetics and pharmacodynamics in COPD patients following long‐term twice‐daily treatment with salmeterol/fluticasone propionate (SFC) 50/500mg and the individual components [Abstract]. American Thoracic Society International Conference; 2007 May 18‐23; San Francisco. 2007:Poster #A41. SCO30003 . A multi‐centre, randomised, double‐blind, parallel group, placebo‐controlled study to investigate the long‐term effects of salmeterol/fluticasone propionate (SERETIDE®/VIANI®/ADVAIR®) 50/500mcg bd, salmeterol 50mcg bd and fluticasone propionate 500mcg bd, all delivered via the DISKUS®/ACCUHALER® inhaler, on the survival of subjects with chronic obstructive pulmonary disease (COPD) over 3 years of treatment. www.ctr.gsk.co.uk (accessed 21 April 2012). SacchettaA . Long term therapy and outcome of chronic obstructive pulmonary disease with or without co‐morbidity: The TORCH Study. Italian Journal of Medicine2008;2(3):11‐5. VestboJ , AndersonJA , CalverleyPM , CelliB , FergusonGT , JenkinsC , et al. Bias due to withdrawal in long‐term randomised trials in COPD: Evidence from the TORCH study. Clinical Respiratory Journal2011;5(1):44‐9. VestboJ , TORCH Study Group. The TORCH (TOwards a Revolution in COPD Health) survival study protocol. European Respiratory Journal2004;24(2):206‐10. ">Calverley 2007 TORCH</a><sup>a</sup> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>36</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>3088</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>GSK</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>1000</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>76</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>65</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>49</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>44</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><a href="./references#CD010115-bbs2-0010" title="Dal NegroR , MichelettoC , TrevsianF , TognellaS . Salmeterol and fluticasone 50ug/250ug BiD versus salmeterol 50ug bid and versus placebo in the long term treatment of COPD. American Thoracic Society 98th International Conference; May 17‐22; Georgia. 2002. Dal NegroRW , PomariC , TognellaS , MichelettoC . Salmeterol &amp; fluticasone 50 mcg/250 mcg bid in combination provides a better long‐term control than salmeterol 50 microg bid alone and placebo in COPD patients already treated with theophylline. Pulmonary Pharmacology and Therapeutics2003;16(4):241‐6. ">Dal Negro 2003</a> </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>12</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>12</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>‐</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>500</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>92</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>‐</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>42</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>50</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><a href="./references#CD010115-bbs2-0011" title="DransfieldMT , BourbeauJ , JonesPW , HananiaNA , MahlerDA , VestboJ , et al. Once‐daily inhaled fluticasone furoate and vilanterol versus vilanterol only for prevention of exacerbation of COPD: two replicate double‐blind, parallel‐group, randomised controlled trials. The Lancet: Respiratory Medicine2013;1(3):210‐23. ">Dransfield 2013</a><sup>b</sup> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>12</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>3255</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>GSK</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>50, 100, 200</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>57</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>64</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>‐</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>45</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><a href="./references#CD010115-bbs2-0012" title="DalalAA , BlanchetteCM , PetersenH , ManaviK , St. CharlesM . Cost‐effectiveness of fluticasone propionate/salmeterol (250/50 mcg) compared to salmeterol (50 mcg) in patients with COPD: economic evaluation of a randomized, double‐blind, parallel‐group, multi‐centre trial (Study SCO40043) [Abstract]. Chest2008;134(4):106003s. FergusonG , AnzuetoA , FeiR , EmmettA , CraterG , KnobilK , et al. A randomized, double‐blind trial comparing the effect of fluticasone/salmeterol 250/50 to salmeterol on COPD exacerbations in patients with COPD. Chest2007;132(4):530b‐531. FergusonGT , AnzuetoA , FeiR , EmmettA , KnobilK , KalbergC . Effect of fluticasone propionate/salmeterol (250/50 mcg) or salmeterol (50 mcg) on COPD exacerbations. Respiratory Medicine2008;102:1099‐108. SCO40043 . A randomized, double‐blind, parallel‐group, 52‐week study to compare the effect of fluticasone propionate/salmeterol DISKUS® 250/50mcg bid with salmeterol DISKUS® 50mcg bid on the annual rate of moderate/severe exacerbations in subjects with chronic obstructive pulmonary disease (COPD). http://ctr.gsk.co.uk (accessed 8 April 2008). ">Ferguson 2008</a> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>12</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>782</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>GSK</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>500</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>55</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>65</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>56</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>33</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><a href="./references#CD010115-bbs2-0014" title="FCO30002 . A multi‐centre, randomised, placebo‐controlled, double‐blind comparison with 3 parallel groups to investigate the efficacy and safety of inhaled glucocorticoid fluticasone (500 μg bd via Diskus™) vs. oral glucocorticoid therapy vs. placebo in subjects with chronic obstructive airway disease (COPD) under therapy with Salmeterol (50 μg bd). GlaxoSmithKline Clinical Trial Register (accessed 15 April 2012). ">GSK FCO30002 2005</a> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>3</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>140</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>GSK</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>1000</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>66</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>62</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>‐</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>‐</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><a href="./references#CD010115-bbs2-0016" title="SCO100470 . A multi‐centre, randomised, double‐blind, parallel group, 24‐week study to compare the effect of the salmeterol/fluticasone propionate combination product 50/250mcg, with salmeterol 50mcg both delivered twice daily via the DISKUS/ACCUHALER inhaler on lung function and dyspnoea in subjects with Chronic Obstructive Pulmonary Disease (COPD). http:ctr.gsk.co.uk (accessed 20 April 2012). ">GSK SCO100470 2006</a> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>6</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>1050</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>GSK</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>500</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>78</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>64</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>‐</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>‐</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><a href="./references#CD010115-bbs2-0017" title="Evaluation of Novel Endpoints in Subjects with Chronic Obstructive Pulmonary Disease(COPD) in a Randomized, Double‐Blind, Placebo‐Controlled Study of Treatment with FluticasonePropionate/Salmeterol 500/50mcg combination and its individual components, FluticasonePropionate 500mcg and Salmeterol 50mcg. http://www.gsk‐clinicalstudyregister.com/ 2008 (accessed 19 April 2012). SCO104925 . Evaluation of Novel Endpoints in Subjects with Chronic Obstructive Pulmonary Disease(COPD) in a Randomized, Double‐Blind, Placebo‐Controlled Study of Treatment with FluticasonePropionate/Salmeterol 500/50mcg combination and its individual components, FluticasonePropionate 500mcg and Salmeterol 50mcg. http:ctr.gsk.co.uk (accessed 19 April 2012). ">GSK SCO104925 2008</a><sup>a</sup> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>3</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>77</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>GSK</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>1000</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>77</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>64</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>‐</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>‐</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><a href="./references#CD010115-bbs2-0019" title="NCT00355342 . A Randomized, Double‐Blind, Parallel‐Group Clinical Trial Evaluating the Effect of the Fluticasone Propionate/Salmeterol Combination Product 250/50mcg BID Via DISKUS Versus Salmeterol 50mcg BID Via DISKUS on Bone Mineral Density in Subjects With Chronic Obstructive Pulmonary Disease (COPD). http://clinicaltrials.gov/show/NCT00355342 (accessed 19 April 2012). ">GSK SCO40041 2008</a> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>36</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>186</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>GSK</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>500</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>61</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>66</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>‐</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>‐</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><a href="./references#CD010115-bbs2-0020" title="HananiaNA , DarkenP , HorstmanD , ReisnerC , LeeB , DavisS , et al. The efficacy and safety of fluticasone propionate (250 mcg)/salmeterol (50 mcg) combined in the Diskus inhaler for the treatment of COPD. Chest2003;124(3):834‐43. HananiaNA , KnobilK , WatkinsM , WireP , YatesJ , DarkenP . Salmeterol and fluticasone propionate therapy administered by a single Diskus in patients with COPD. Chest2002:S129. HananiaNA , RamsdellJ , PayneK , DavisS , HorstmanD , LeeB , et al. Improvements in airflow and dyspnoea in COPD patients following 24 weeks treatment with salmeterol 50mcg and fluticasone propionate 250mcg alone or in combination via the Diskus. American Journal of Respiratory and Critical Care Medicine2001;163 Suppl 5:A279. HorstmanD , DarkenP , DavisS , LeeB . Improvements in FEV1 and symptoms in poorly reversible COPD patients following treatment with salmeterol 50mcg/fluticasone propionate 250mcg combination [Abstract]. European Respiratory Journal2003;22 Suppl 45:P434. MahlerDA , DarkenP , BrownCP , KnobilK . Predicting lung function responses to combination therapy in chronic obstructive pulmonary disease (COPD) [Abstract]. National COPD Conference; 2003 Nov 14‐15; Arlington. 2003:1081. MahlerDA , DarkenP , BrownCP , KnobilK . Predicting lung function responses to salmeterol/fluticasone propionate combination therapy in COPD [Abstract]. European Respiratory Journal2003;22 Suppl 45:P429. SFCA3007 . A randomized, double‐blind, placebo‐controlled, parallel‐group trial evaluating the safety and efficacy of the DISKUS formulations of salmeterol (SAL) 50mcg BID and fluticasone propionate (FP) 250mcg BID individually and in combination as salmeterol 50mcg/fluticasone propionate 250mcg BID (SFC 50/250) compared to placebo in COPD subjects. http://ctr.gsk.co.uk (accessed 20 April 2012). SpencerM , WireP , LeeB , ChangCN , DarkenP , HorstmanD . Patients with COPD using salmeterol/fluticasone propionate combination therapy experience improved quality of life. European Respiratory Journal2003;22 Suppl 45:51s. SpencerMD , KariaN , AndersonJ . The clinical significance of treatment benefits with the salmeterol/fluticasone propionate 50/500mcg combination in COPD. European Respiratory Journal2004;24 Suppl 48:290s. ">Hanania 2003</a><sup>a</sup> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>6</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>355</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>GSK</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>500</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>63</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>64</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>57</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>42</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><a href="./references#CD010115-bbs2-0022" title="KardosP , WenckerM . Combination therapy with salmeterol and fluticasone propionate (SFC) is more effective than salmeterol (SAL) alone in reducing exacerbations of COPD. European Respiratory Journal2005;26 Suppl 49:Abstract 1944. KardosP , WenckerM , GlaabT , VogelmeierC . Impact of salmeterol/fluticasone propionate versus salmeterol on exacerbations in severe chronic obstructive pulmonary disease. American Journal of Respiratory and Critical Care Medicine2007;175(2):144‐9. SCO30006 . A randomised, double‐blind, parallel‐group study to investigate the protective effect of the combination of fluticasone and salmeterol (500/50 µg bid via the DISKUS) compared with salmeterol (50 µg bid via the DISKUS) on the incidence of moderate to severe exacerbations in patients with severe chronic obstructive pulmonary disease (COPD) (GOLD III/IV). http:ctr.gsk.co.uk (accessed 21 April 2012). VogelmeierC . Combination therapy with salmeterol and fluticasone propionate (SFC) improves quality of life (QoL) more than salmeterol (SAL) alone in COPD. 42nd Nordic Lung Conference; 2005 Jun 9‐11; Trondheim. 2005; Vol. 13 Suppl 22. VogelmeierCF , WenckerM , GlaabTH , KardosP . Number needed to treat (NNT) to reduce exacerbations in severe COPD comparing salmeterol/fluticasone propionate (SFC) with salmeterol (SAL) treatment.. American Thoracic Society International Conference; May 19‐21; San Diego. 2006:A110. ">Kardos 2007</a> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>10</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>994</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>GSK</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>1000</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>76</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>64</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>37</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>40</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><a href="./references#CD010115-bbs2-0023" title="KerwinEM , Scott‐WilsonC , SanfordL , RennardS , AgustiA , BarnesN , et al. A randomised trial of fluticasone furoate/vilanterol (50/25 mug; 100/25 mug) on lung function in COPD. Respiratory Medicine2013; Vol. 107, issue 4:560‐9. [0954‐6111] KerwinEM , Scott‐WilsonC , SanfordL , RennardSI , AgustiA , BarnesN , et al. Lung function effects and safety of fluticasone furoate (FF)/vilanterol (VI) in patients with COPD: Low‐mid dose assessment [Abstract]. European Respiratory Society Annual Congress; Sep 1‐5; Vienna. 2012; Vol. 40, issue Suppl 56:545s [3082]. ">Kerwin 2013</a><sup>a,b</sup> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>6</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>617</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>GSK</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>100</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>67</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>63</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>46</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>43</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><a href="./references#CD010115-bbs2-0026" title="MahlerDA , DarkenP , BrownCP , KnobilK . Predicting lung function responses to combination therapy in chronic obstructive pulmonary disease (COPD). http://www.abstracts2view.com (accessed 15 April 2012). MahlerDA , WireP , HorstmanD , ChangCN , YatesJ , FischerT , et al. Effectiveness of fluticasone propionate and salmeterol combination delivered via the Diskus device in the treatment of chronic obstructive pulmonary disease. American Journal of Respiratory and Critical Care Medicine2002;166(8):1084‐91. SFCA3006 . A randomized, double‐blind, placebo‐controlled, parallel‐group trial evaluating the safety and efficacy of the DISKUS formulations of salmeterol (SAL) 50mcg BID and fluticasone propionate (FP) 500mcg BID individually and in combination as salmeterol 50mcg/fluticasone propionate 500mcg BID (SFC 50/500) compared to placebo in COPD subjects. http://ctr.gsk.co.uk (accessed 17 April 2012). SpencerM , WireP , LeeB , ChangCN , DarkenP , HorstmanD . Patients with COPD using salmeterol/fluticasone propionate combination therapy experience improved quality of life. European Respiratory Journal2003;22 Suppl 45:51. SpencerMD , AndersonJA . Salmeterol/fluticasone combination produces clinically important benefits in dyspnoea and fatigue [Abstract]. American Thoracic Society 2005 International Conference; 2005 May 20‐25; San Diego. 2005:B93 [Poster 308]. SpencerMD , KariaN , AndersonJ . The clinical significance of treatment benefits with the salmeterol/fluticasone propionate 50/500mcg combination in COPD. European Respiratory Journal2004;24 Suppl 48:290. ">Mahler 2002</a><sup>a</sup> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>6</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>325</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>GSK</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>1000</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>66</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>65</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>55</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>41</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><a href="./references#CD010115-bbs2-0027" title="MartinezF , BosciaJ , FeldmanG , Scott‐WilsonC , KilbrideS , FabbriL , et al. Lung function effects and safety of fluticasone furoate (FF)/vilanterol (VI) in patients with COPD: mid‐high dose assessment [Abstract]. European Respiratory Society Annual Congress, Vienna, Austria, September 1‐5. 2012; Vol. 40, issue Suppl 56:527s [P2887]. MartinezFJ , BosciaJ , FeldmanG , Scott‐WilsonC , KilbrideS , FabbriL , et al. Fluticasone furoate/vilanterol (100/25; 200/25 mug) improves lung function in COPD: a randomised trial. Respiratory Medicine2013;107(4):550‐9. [0954‐6111] ">Martinez 2013</a><sup>a,b</sup> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>6</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>610</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>GSK</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>100, 200</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>72</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>62</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>43</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>48</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""></td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><b>WM 16 m</b> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><b>867</b> </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><b>‐</b> </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><b>‐</b> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><b>69</b> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><b>64</b> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><b>53</b> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><b>42</b> </p> </td> </tr> </tbody> <tfoot> <tr> <td colspan="9"> <div class="table-footnote"> <p><sup>a</sup>Multi‐arm studies making both comparisons of interest (ICS vs placebo and ICS/LABA vs LABA). </p> <p><sup>b</sup>Studies using vilanterol as the LABA combination and monotherapy comparator, with fluticasone furoate. </p> <p>Dose is given as the total received per day (i.e. 500 signifies 250 morning and evening).</p> <p>WM = weighted mean.</p> </div> </td> </tr> </tfoot> </table> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="table-viewer-caption"> <div class="table-heading"><span class="table-label">Table 1.</span> <span class="table-title">Fluticasone—summary of studies and baseline characteristics</span></div> </div> <div class="tools"><a class="tableList" href="/cdsr/doi/10.1002/14651858.CD010115.pub2/full#CD010115-tbl-0003">Navigate to table in review</a></div> </div> <div class="table"> <table data-id="CD010115-tbl-0004"> <div class="table-heading"><span class="table-label">Table 2.</span> <span class="table-title">Budesonide—summary of studies and baseline characteristics</span></div> <tbody> <tr> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>Study ID</b> </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>Duration (m)</b> </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>N Rand</b> </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>Funder</b> </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>ICS dose (mcg)</b> </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>% Male</b> </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>Mean age</b> </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>Pack‐years</b> </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>% pred FEV<sub>1</sub> </b> </p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="9" rowspan="1" valign=""> <p><b>Budesonide versus placebo (n = 13)</b> </p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><a href="./references#CD010115-bbs2-0002" title="BourbeauJ , RouleauMY , BoucherS . Randomised controlled trial of inhaled corticosteroids in patients with chronic obstructive pulmonary disease. Thorax1998;53(6):477‐82. ">Bourbeau 1998</a> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>6</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>79</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>AZ</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>640</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>79</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>66</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>51</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>37</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><a href="./references#CD010115-bbs2-0005" title="BorgstromL , AskingL , OlssonH , PetersonS . Lack of interaction between disease severity and therapeutic response with budesonide/formoterol in a single inhaler [Abstract]. American Thoracic Society 100th International Conference; 2004 May 21‐26; Orlando. 2004:C22 Poster 505. CalverleyPM , BonsawatW , CsekeZ , ZhongN , PetersonS , OlssonH . Maintenance therapy with budesonide and formoterol in chronic obstructive pulmonary disease. European Respiratory Journal2003;22(6):912‐9. CalverleyPMA . Effect of budesonide/formoterol on severe exacerbations and lung function in moderate to severe COPD. Thorax2002;57 Suppl III:iii44. CalverleyPMA , CsekeZ , PetersonS . Budesonide/formoterol reduces the use of oral corticosteroids in the treatment of COPD [Abstract]. European Respiratory Journal2003;22 Suppl 45:P436. CalverleyPMA , KunaP , OlssonH . COPD exacerbations are reduced by budesonide/formoterol in a single inhaler [Abstract]. European Respiratory Journal2003;22 Suppl 45:P1587. CalverleyPMA , OlssonH , Symbicort International COPD Study Group. Budesonide/formoterol in a single inhaler sustains improvements in lung function over 12 months compared with mono‐components and placebo in patients with COPD [abstract]. American Thoracic Society 99th International Conference; 2003 May 16‐21; Seattle. 2003:B024 Poster 418. CalverleyPMA , PetersonS . Combining budesonide/formoterol in a single inhaler reduces exacerbation frequency in COPD [abstract]. American Thoracic Society 99th International Conference; 2003 May 16‐21; Seattle. 2003:D092 Poster 211. CalverleyPMA , StahlE , JonesPW . Budesonide/formoterol improves the general health status of patients with COPD [Abstract]. American Thoracic Society International Conference; 2005 May 20‐25; San Diego. 2005:B93 Poster 303. CalverleyPMA , SzafranskiW , AnderssonA . Budesonide/formoterol is a well‐tolerated long term maintenance therapy for COPD. European Respiratory Journal2005;26 Suppl 49:Poster 1917. CalverleyPMA , ThompsonNC , OlssonH . Budesonide/formoterol in a single inhaler sustains lung function improvements in COPD [Abstract]. European Respiratory Journal2003;22 Suppl 45:P435. HalpinD , StåhlE , LundbackB , AndersonF , PetersonS . Treatment costs and number needed to treat (NNT) with budesonide/formoterol to avoid one exacerbation of COPD [Abstract]. American Thoracic Society 100th International Conference; 2004 May 21‐26; Orlando. 2004:D22 Poster 525. HalpinDMG , LarssonT , CalverleyPMA . How many patients with COPD must be treated with budesonide/formoterol compared with formoterol alone to avoid 1 day of oral steroid use? [Abstract]. American Thoracic Society International Conference; 2005 May 20‐25; San Diego. 2005:B93 Poster 314. JonesPW , StåhlE . Budesonide/formoterol in a single inhaler improves health status in patients with COPD [abstract]. American Thoracic Society 99th International Conference; 2003 May 16‐21; Seattle. 2003:B024 Poster 419. JonesPW , StåhlE . Budesonide/formoterol sustains clinically relevant improvements in health status in COPD [Abstract]. European Respiratory Journal2005;26(Suppl 49):Abstract No. 1352. JonesPW , StåhlE . Reducing exacerbations leads to a better health‐related quality of life in patients with COPD. European Respiratory Society 13th Annual Congress; 2003 Sep 28‐29; Vienna. 2003:P1586. LofdahlCG . Reducing the impact of COPD exacerbations: clinical efficacy of budesonide/formoterol. European Respiratory Review2004;13(88):14‐21. LofdahlCG , AndreassonE , SvenssonK , EricssonA . Budesonide/formoterol in a single inhaler improves health status in patients with COPD without increasing healthcare costs [Abstract]. European Respiratory Journal2003;22(Suppl 45):P433. LofdahlCG , EricssonA , SvenssonK , AndreassonE . Cost effectiveness of budesonide/formoterol in a single inhaler for COPD compared with each mono‐component used alone. Pharmacoeconomics2005;23(4):365‐75. ">Calverley 2003b</a><sup>a</sup> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>12</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>513</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>GSK</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>640</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>76</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>64</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>35</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>36</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><a href="./references#CD010115-bbs2-0025" title="LaptsevaIM , LaptsevaEA , BorshchevskyVV , GurevichG , KalechitsO . Inhaled budesonide in the management of chronic obstructive pulmonary disease. European Respiratory Journal2002;20 Suppl 38:244s. ">Laptseva 2002</a> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>6</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>49</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>NR</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>640</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>NR</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>NR</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>NR</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>NR</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><a href="./references#CD010115-bbs2-0028" title="MiriciA , BektasY , OzbakisG , ErmanZ . Effect of inhaled corticosteroids on respiratory function tests and airway inflammation in stable chronic obstructive pulmonary disease. Clinical Drug Investigation2001;21(12):835‐42. ">Mirici 2001</a> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>3</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>50</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>NR</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>640</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>75</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>53</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>27</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>62</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><a href="./references#CD010115-bbs2-0029" title="OzolD , AysanT , SolakZA , MogulkocN , VeralA , SebikF . The effect of inhaled corticosteroids on bronchoalveolar lavage cells and IL‐8 levels in stable COPD patients. Respiratory Medicine2005;99(12):1494‐500. ">Ozol 2005</a> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>6</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>26</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>NR</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>640</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>69</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>65</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>45</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>59</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><a href="./references#CD010115-bbs2-0031" title="JohnellO , PauwelsR , LöfdahlC‐G , LaitinenLA , PostmaDS , PrideNB , et al. Bone mineral density in patients with chronic obstructive pulmonary disease treated with budesonide Turbuhaler. European Respiratory Journal2002;19(6):1058‐63. LofdahlCG , PostmaDS , LaitinenLA , OhlssonSV , PauwelsRA , PrideNB . The European Respiratory Society study on chronic obstructive pulmonary disease (EUROSCOP): recruitment methods and strategies. Respiratory Medicine1998;92(3):467‐72. PauwelsRA , LofdahlCG , LaitinenLA , SchoutenJP , PostmaDS , PrideNB , et al. Long‐term treatment with inhaled budesonide in persons with mild chronic obstructive pulmonary disease who continue smoking. European Respiratory Society Study on Chronic Obstructive Pulmonary Disease. New England Journal of Medicine1999;340(25):1948‐53. PauwelsRA , LofdahlCG , PrideNB , PostmaDS , LaitinenLA , OhlssonSV . European Respiratory Society study on chronic obstructive pulmonary disease (EUROSCOP): hypothesis and design. European Respiratory Journal1992;5(10):1254‐61. ">Pauwels 1999</a> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>36</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>1277</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>AZ</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>640</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>73</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>52</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>39</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>77</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><a href="./references#CD010115-bbs2-0032" title="RenkemaTE , SchoutenJP , KoeterGH , PostmaDS . Effects of long‐term treatment with corticosteroids in COPD. Chest1996;109(5):1156‐62. vanGrunsvenPM , vanSchayckCP , DerenneJP , KerstjensHA , RenkemaTE , PostmaDS , et al. Long term effects of inhaled corticosteroids in chronic obstructive pulmonary disease: a meta‐analysis. Thorax1999;54(1):7‐14. ">Renkema 1996</a> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>24</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>39</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>AZ</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>1280</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>100</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>55</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>NR</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>64</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><a href="./references#CD010115-bbs2-0035" title="SenderovitzT , VestboJ , FrandsenJ , MaltbaekN , NorgaardM , NielsenC , et al. Steroid reversibility test followed by inhaled budesonide or placebo in outpatients with stable chronic obstructive pulmonary disease. Respiratory Medicine1999;93(10):715‐8. ">Senderovitz 1999</a> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>6</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>26</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>NR</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>640</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>54</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>61</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>NR</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>NR</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><a href="./references#CD010115-bbs2-0036" title="ShakerSB , DirksenA , UlrikCS , HestadM , StavngaardT , LaursenLC , et al. The effect of inhaled corticosteroids on the development of emphysema in smokers assessed by annual computed tomography. COPD: Journal of Chronic Obstructive Pulmonary Disease2009;6(2):104‐11. ShakerSB , StavngaardT , LaursenLC , StoelBC , DirksenA . Rapid fall in lung density following smoking cessation in COPD. COPD: Journal of Chronic Obstructive Pulmonary Disease2011;8(1):2‐7. ">Shaker 2009</a> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>36</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>254</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>AZ</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>640</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>58</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>64</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>56</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>52</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><a href="./references#CD010115-bbs2-0038" title="AndersonP . Budesonide/formoterol in a single inhaler (Symbicort) provides early and sustained improvement in lung function in moderate to severe COPD. Thorax2002;57 Suppl 3:iii43. BorgstromL , AskingL , OlssonH , PetersonS . Lack of interaction between disease severity and therapeutic response with budesonide/formoterol in a single inhaler [Abstract].. American Thoracic Society 100th International Conference; May 21‐26; Orlando. 2004:C22 [Poster 505]. CalverleyP , Pauwels DaggerR , LöfdahlCG , SvenssonK , HigenbottamT , CarlssonLG , et al. Relationship between respiratory symptoms and medical treatment in exacerbations of COPD. European Respiratory Journal2005;26(3):406‐13. CalverleyPMA . Effect of budesonide/formoterol on severe exacerbations and lung function in moderate to severe COPD. Thorax2002;BTS Winter Meeting 2002:S145. CalverleyPMA , SzafranskiW , AnderssonA . Budesonide/formoterol is a well‐tolerated long term maintenance therapy for COPD. European Respiratory Journal2005;26 Suppl 49:Poster 1917. CalverleyPMA , ThompsonNC , OlssonH . Budesonide/formoterol in a single inhaler sustains lung function improvements in COPD [Abstract]. European Respiratory Journal2003;22 Suppl 45:P435. CampbellLM , SzafranskiW . Budesonide/formoterol in a single inhaler (Symbicort) provides sustained relief from symptoms in moderate to severe COPD. Thorax. 2002; Vol. BTS Winter Meeting 2002:S143. CampbellLW , SzafranskiW . Budesonide/formoterol in a single inhaler (Symbicort) reduces severe exacerbations in patients with moderate‐severe COPD. Thorax. 2002; Vol. BTS Winter Meeting 2002:S141. DahlR , CukierA , OlssonH . Budesonide/formoterol in a single inhaler reduces severe and mild exacerbations in patients with moderate to severe COPD. European Respiratory Journal2002;20 Suppl 38:242 [P1575]. EgedeF , MengaG . Budesonide/formoterol in a single inhaler provides sustained relief from symptoms and night‐time awakenings in moderate‐severe COPD: results from symptoms and night‐time awakenings in moderate to severe COPD: results from a 1‐year study. European Respiratory Journal2002;20 Suppl 38:242 [P1574]. HalpinD , StahlE , LundbackB , AndersonF , PetersonS . Treatment costs and number needed to treat (NNT) with budesonide/formoterol to avoid one exacerbation of COPD [Abstract]. American Thoracic Society 100th International Conference; May 21‐26; Orlando. 2004:D22 Poster 525. JonesPW , StahlE , SvenssonK . Improvement in health status in patients with moderate to severe COPD after treatment with budesonide/formoterol in a single inhaler. European Respiratory Journal2002;20 Suppl 38:250 [P1613]. KorsgaardJ , SansoresR . Budesonide/formoterol (single inhaler) provides sustained relief from shortness of breath and chest tightness in a 1‐year study of patients with moderate to severe COPD. European Respiratory Journal2002;20 Suppl 38:242 [P1577]. LangeP , SaenzC . Budesonide/formoterol in a single inhaler is well tolerated in patients with moderate to severe COPD: results of a 1 year study. European Respiratory Journal2002;20 Suppl 38:242 [P1573]. LofdahlCG . Reducing the impact of COPD exacerbations: clinical efficacy of budesonide/formoterol. European Respiratory Review2004;13(88):14‐21. MilanowskiJ , NahabedianS . Budesonide/formoterol in a single inhaler acts rapidly to improve lung function and relieve symptoms in patients with moderate to severe COPD. European Respiratory Journal2002;20 Suppl 38:242 [P1576]. SzafranskiW , CukierA , RamirezA , MengaG , SansoresR , NahabedianS , et al. Efficacy and safety of budesonide/formoterol in the management of chronic obstructive pulmonary disease. European Respiratory Journal2003;21:74‐81. SzfranskiW , RamirezA , PetersonS . Budesonide/formoterol in single inhaler provides sustained improvements in lung function in patients with moderate to severe COPD [Abstract]. European Respiratory Society Annual Congress; Sep 14‐18; Stockholm. 2002. ">Szafranski 2003</a><sup>a</sup> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>12</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>403</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>AZ</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>640</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>79</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>64</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>45</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>36</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><a href="./references#CD010115-bbs2-0039" title="AstraZeneca . A 6‐month double‐blind, double‐dummy, randomized, parallel group, multicenter efficacy &amp; safety study of SYMBICORT® pMDI 2 x 160/4.5 μg &amp; 80/4.5 μg bid compared to formoterol TBH, budesonide pMDI (&amp; the combination) &amp; placebo in COPD Patients (SHINE) (study number D589900002). www.astrazenecaclinicaltrials.com (accessed 18 April 2012). BleeckerER , MeyersDA , BaileyWC , SimsAM , BujacSR , GoldmanM , et al. Effect of ß2‐Adrenergic Receptor Gene Polymorphism Gly16Arg on Response to Budesonide/Formoterol Pressurized Metered‐Dose Inhaler in Chronic Obstructive Pulmonary Disease [Abstract]. American Journal of Respiratory and Critical Care Medicine2011;183:A4086. TashkinDP , RennardSI , MartinP , RamachandranS , MartinUJ , SilkoffPE . Efficacy and safety of budesonide and formoterol in one pressurized metered‐dose inhaler in patients with moderate to very severe chronic obstructive pulmonary disease: results of a 6‐month randomized clinical trial. Drugs2008;68(14):1975‐2000. ">Tashkin 2008 SHINE</a><sup>a</sup> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>6</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>575</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>AZ</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>640</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>68</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>63</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>41</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>40</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><a href="./references#CD010115-bbs2-0042" title="VestboJ , SorensenT , LangeP , BrixA , TorreP , ViskumK . Long‐term effect of inhaled budesonide in mild and moderate chronic obstructive pulmonary disease: a randomised controlled trial. Lancet1999;353(9167):1819‐23. [MEDLINE: 99285938] ">Vestbo 1999</a> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>36</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>290</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>AZ</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>640</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>88</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>59</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>NR</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>87</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><a href="./references#CD010115-bbs2-0043" title="YildizF , BasyigitI , YildirimE , BoyaciH , IlgazliA . Does addition of inhaled steroids to combined bronchodilator therapy affect health status in patients with COPD?. Respirology2004;9(3):352‐5. ">Yildiz 2004</a> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>3</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>38</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>?</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>1280</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>100</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>67</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>51</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>46</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""></td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><b>WM 23 m</b> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><b>278</b> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><b>‐</b> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><b>‐</b> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><b>77</b> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><b>61</b> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><b>43</b> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><b>54</b> </p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="9" rowspan="1" valign=""> <p><b>Budesonide/LABA combination versus LABA monotherapy (n = 7)</b> </p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><a href="./references#CD010115-bbs2-0005" title="BorgstromL , AskingL , OlssonH , PetersonS . Lack of interaction between disease severity and therapeutic response with budesonide/formoterol in a single inhaler [Abstract]. American Thoracic Society 100th International Conference; 2004 May 21‐26; Orlando. 2004:C22 Poster 505. CalverleyPM , BonsawatW , CsekeZ , ZhongN , PetersonS , OlssonH . Maintenance therapy with budesonide and formoterol in chronic obstructive pulmonary disease. European Respiratory Journal2003;22(6):912‐9. CalverleyPMA . Effect of budesonide/formoterol on severe exacerbations and lung function in moderate to severe COPD. Thorax2002;57 Suppl III:iii44. CalverleyPMA , CsekeZ , PetersonS . Budesonide/formoterol reduces the use of oral corticosteroids in the treatment of COPD [Abstract]. European Respiratory Journal2003;22 Suppl 45:P436. CalverleyPMA , KunaP , OlssonH . COPD exacerbations are reduced by budesonide/formoterol in a single inhaler [Abstract]. European Respiratory Journal2003;22 Suppl 45:P1587. CalverleyPMA , OlssonH , Symbicort International COPD Study Group. Budesonide/formoterol in a single inhaler sustains improvements in lung function over 12 months compared with mono‐components and placebo in patients with COPD [abstract]. American Thoracic Society 99th International Conference; 2003 May 16‐21; Seattle. 2003:B024 Poster 418. CalverleyPMA , PetersonS . Combining budesonide/formoterol in a single inhaler reduces exacerbation frequency in COPD [abstract]. American Thoracic Society 99th International Conference; 2003 May 16‐21; Seattle. 2003:D092 Poster 211. CalverleyPMA , StahlE , JonesPW . Budesonide/formoterol improves the general health status of patients with COPD [Abstract]. American Thoracic Society International Conference; 2005 May 20‐25; San Diego. 2005:B93 Poster 303. CalverleyPMA , SzafranskiW , AnderssonA . Budesonide/formoterol is a well‐tolerated long term maintenance therapy for COPD. European Respiratory Journal2005;26 Suppl 49:Poster 1917. CalverleyPMA , ThompsonNC , OlssonH . Budesonide/formoterol in a single inhaler sustains lung function improvements in COPD [Abstract]. European Respiratory Journal2003;22 Suppl 45:P435. HalpinD , StåhlE , LundbackB , AndersonF , PetersonS . Treatment costs and number needed to treat (NNT) with budesonide/formoterol to avoid one exacerbation of COPD [Abstract]. American Thoracic Society 100th International Conference; 2004 May 21‐26; Orlando. 2004:D22 Poster 525. HalpinDMG , LarssonT , CalverleyPMA . How many patients with COPD must be treated with budesonide/formoterol compared with formoterol alone to avoid 1 day of oral steroid use? [Abstract]. American Thoracic Society International Conference; 2005 May 20‐25; San Diego. 2005:B93 Poster 314. JonesPW , StåhlE . Budesonide/formoterol in a single inhaler improves health status in patients with COPD [abstract]. American Thoracic Society 99th International Conference; 2003 May 16‐21; Seattle. 2003:B024 Poster 419. JonesPW , StåhlE . Budesonide/formoterol sustains clinically relevant improvements in health status in COPD [Abstract]. European Respiratory Journal2005;26(Suppl 49):Abstract No. 1352. JonesPW , StåhlE . Reducing exacerbations leads to a better health‐related quality of life in patients with COPD. European Respiratory Society 13th Annual Congress; 2003 Sep 28‐29; Vienna. 2003:P1586. LofdahlCG . Reducing the impact of COPD exacerbations: clinical efficacy of budesonide/formoterol. European Respiratory Review2004;13(88):14‐21. LofdahlCG , AndreassonE , SvenssonK , EricssonA . Budesonide/formoterol in a single inhaler improves health status in patients with COPD without increasing healthcare costs [Abstract]. European Respiratory Journal2003;22(Suppl 45):P433. LofdahlCG , EricssonA , SvenssonK , AndreassonE . Cost effectiveness of budesonide/formoterol in a single inhaler for COPD compared with each mono‐component used alone. Pharmacoeconomics2005;23(4):365‐75. ">Calverley 2003b</a><sup>a</sup> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>12</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>509</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>GSK</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>640</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>76</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>64</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>35</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>36</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><a href="./references#CD010115-bbs2-0008" title="CalverleyPMA , KunaP , MonsoE , CostantiniM , PetruzzelliSd , SergioF , et al. Beclomethasone/formoterol in the management of COPD: a randomised controlled trial. Respiratory Medicine2010;104:1858‐68. ">Calverley 2010</a> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>11</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>481</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Chiesi</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>640</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>81</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>64</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>39</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>42</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><a href="./references#CD010115-bbs2-0013" title="FukuchiY , SamoroR , FassakhovR , TaniguchiH , EkelundJ , CarlssonLG , et al. Budesonide/formoterol via Turbuhaler® versus formoterol via Turbuhaler® in patients with moderate to severe chronic obstructive pulmonary disease: Phase III multinational study results. Respirology2013; Vol. 18:866‐73. IchinoseM , SamoroR , FassakhovR , OguriM , EkelundJ , CarlssonLG , et al. Budesonide/formoterol vs formoterol, both via Turbuhaler®, in patients with moderate to severe COPD: Phase III study results [Abstract]. European Respiratory Society Annual Congress; 2012 Sep 1‐5; Vienna. 2012; Vol. 40, issue Suppl 56:374s [P2108]. ">Fukuchi 2013</a> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>3</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>1293</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>AZ</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>640</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>89</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>65</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>44</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>41</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><a href="./references#CD010115-bbs2-0033" title="BleeckerER , MeyersDA , BaileyWC , SimsAM , BujacSR , GoldmanM , et al. ADRB2 polymorphisms and budesonide/formoterol responses in COPD. Chest2012; Vol. 142, issue 2:320‐8. RennardSI , TashkinDP , McElhattanJ , GoldmanM , RamachandranS , MartinUJ , et al. Efficacy and tolerability of budesonide/formoterol in one hydrofluoroalkane pressurized metered‐dose inhaler in patients with chronic obstructive pulmonary disease. Results from a 1‐year randomized controlled clinical trial. Drugs2009;69(5):549‐65. ">Rennard 2009</a> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>12</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>1483</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>AZ</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>320, 640</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>63</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>63</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>NR</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>39</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><a href="./references#CD010115-bbs2-0037" title="SharafkhanehA , SouthardJG , GoldmanM , UryniakT , MartinUJ . Effect of budesonide/formoterol pMDI on COPD exacerbations: a double‐blind, randomized study. Respiratory Medicine2012;106(2):257‐68. SharafkhanehA , UryniakT , MartinU . Long‐term effects of budesonide/formoterol pressurized metered‐dose inhaler on Chronic Obstructive Pulmonary Disease (COPD) symptoms and health status in patients with COPD [Abstract]. Chest2011;140(4):528A. ">Sharafkhaneh 2012</a> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>12</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>1219</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>AZ</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>320, 640</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>62</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>63</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>44</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>38</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><a href="./references#CD010115-bbs2-0038" title="AndersonP . Budesonide/formoterol in a single inhaler (Symbicort) provides early and sustained improvement in lung function in moderate to severe COPD. Thorax2002;57 Suppl 3:iii43. BorgstromL , AskingL , OlssonH , PetersonS . Lack of interaction between disease severity and therapeutic response with budesonide/formoterol in a single inhaler [Abstract].. American Thoracic Society 100th International Conference; May 21‐26; Orlando. 2004:C22 [Poster 505]. CalverleyP , Pauwels DaggerR , LöfdahlCG , SvenssonK , HigenbottamT , CarlssonLG , et al. Relationship between respiratory symptoms and medical treatment in exacerbations of COPD. European Respiratory Journal2005;26(3):406‐13. CalverleyPMA . Effect of budesonide/formoterol on severe exacerbations and lung function in moderate to severe COPD. Thorax2002;BTS Winter Meeting 2002:S145. CalverleyPMA , SzafranskiW , AnderssonA . Budesonide/formoterol is a well‐tolerated long term maintenance therapy for COPD. European Respiratory Journal2005;26 Suppl 49:Poster 1917. CalverleyPMA , ThompsonNC , OlssonH . Budesonide/formoterol in a single inhaler sustains lung function improvements in COPD [Abstract]. European Respiratory Journal2003;22 Suppl 45:P435. CampbellLM , SzafranskiW . Budesonide/formoterol in a single inhaler (Symbicort) provides sustained relief from symptoms in moderate to severe COPD. Thorax. 2002; Vol. BTS Winter Meeting 2002:S143. CampbellLW , SzafranskiW . Budesonide/formoterol in a single inhaler (Symbicort) reduces severe exacerbations in patients with moderate‐severe COPD. Thorax. 2002; Vol. BTS Winter Meeting 2002:S141. DahlR , CukierA , OlssonH . Budesonide/formoterol in a single inhaler reduces severe and mild exacerbations in patients with moderate to severe COPD. European Respiratory Journal2002;20 Suppl 38:242 [P1575]. EgedeF , MengaG . Budesonide/formoterol in a single inhaler provides sustained relief from symptoms and night‐time awakenings in moderate‐severe COPD: results from symptoms and night‐time awakenings in moderate to severe COPD: results from a 1‐year study. European Respiratory Journal2002;20 Suppl 38:242 [P1574]. HalpinD , StahlE , LundbackB , AndersonF , PetersonS . Treatment costs and number needed to treat (NNT) with budesonide/formoterol to avoid one exacerbation of COPD [Abstract]. American Thoracic Society 100th International Conference; May 21‐26; Orlando. 2004:D22 Poster 525. JonesPW , StahlE , SvenssonK . Improvement in health status in patients with moderate to severe COPD after treatment with budesonide/formoterol in a single inhaler. European Respiratory Journal2002;20 Suppl 38:250 [P1613]. KorsgaardJ , SansoresR . Budesonide/formoterol (single inhaler) provides sustained relief from shortness of breath and chest tightness in a 1‐year study of patients with moderate to severe COPD. European Respiratory Journal2002;20 Suppl 38:242 [P1577]. LangeP , SaenzC . Budesonide/formoterol in a single inhaler is well tolerated in patients with moderate to severe COPD: results of a 1 year study. European Respiratory Journal2002;20 Suppl 38:242 [P1573]. LofdahlCG . Reducing the impact of COPD exacerbations: clinical efficacy of budesonide/formoterol. European Respiratory Review2004;13(88):14‐21. MilanowskiJ , NahabedianS . Budesonide/formoterol in a single inhaler acts rapidly to improve lung function and relieve symptoms in patients with moderate to severe COPD. European Respiratory Journal2002;20 Suppl 38:242 [P1576]. SzafranskiW , CukierA , RamirezA , MengaG , SansoresR , NahabedianS , et al. Efficacy and safety of budesonide/formoterol in the management of chronic obstructive pulmonary disease. European Respiratory Journal2003;21:74‐81. SzfranskiW , RamirezA , PetersonS . Budesonide/formoterol in single inhaler provides sustained improvements in lung function in patients with moderate to severe COPD [Abstract]. European Respiratory Society Annual Congress; Sep 14‐18; Stockholm. 2002. ">Szafranski 2003</a><sup>a</sup> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>12</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>409</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>AZ</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>640</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>79</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>64</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>45</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>36</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><a href="./references#CD010115-bbs2-0039" title="AstraZeneca . A 6‐month double‐blind, double‐dummy, randomized, parallel group, multicenter efficacy &amp; safety study of SYMBICORT® pMDI 2 x 160/4.5 μg &amp; 80/4.5 μg bid compared to formoterol TBH, budesonide pMDI (&amp; the combination) &amp; placebo in COPD Patients (SHINE) (study number D589900002). www.astrazenecaclinicaltrials.com (accessed 18 April 2012). BleeckerER , MeyersDA , BaileyWC , SimsAM , BujacSR , GoldmanM , et al. Effect of ß2‐Adrenergic Receptor Gene Polymorphism Gly16Arg on Response to Budesonide/Formoterol Pressurized Metered‐Dose Inhaler in Chronic Obstructive Pulmonary Disease [Abstract]. American Journal of Respiratory and Critical Care Medicine2011;183:A4086. TashkinDP , RennardSI , MartinP , RamachandranS , MartinUJ , SilkoffPE . Efficacy and safety of budesonide and formoterol in one pressurized metered‐dose inhaler in patients with moderate to very severe chronic obstructive pulmonary disease: results of a 6‐month randomized clinical trial. Drugs2008;68(14):1975‐2000. ">Tashkin 2008 SHINE</a><sup>a</sup> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>6</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>1129</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>AZ</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>320, 640</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>68</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>63</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>41</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>40</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""></td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><b>WM 9 m</b> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><b>932</b> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><b>‐</b> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><b>‐</b> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><b>75</b> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><b>64</b> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><b>41</b> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><b>39</b> </p> </td> </tr> </tbody> <tfoot> <tr> <td colspan="9"> <div class="table-footnote"> <p><sup>a</sup>Multi‐arm studies making both comparisons of interest (ICS vs placebo and ICS/LABA vs LABA). </p> <p>Dose is given as the total received per day (i.e. 640 signifies 320 morning and evening).</p> <p>WM = weighted mean.</p> </div> </td> </tr> </tfoot> </table> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="table-viewer-caption"> <div class="table-heading"><span class="table-label">Table 2.</span> <span class="table-title">Budesonide—summary of studies and baseline characteristics</span></div> </div> <div class="tools"><a class="tableList" href="/cdsr/doi/10.1002/14651858.CD010115.pub2/full#CD010115-tbl-0004">Navigate to table in review</a></div> </div> <div class="table"> <table data-id="CD010115-tbl-0005"> <div class="table-heading"><span class="table-label">Table 3.</span> <span class="table-title">BDP equivalent doses</span></div> <tbody> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><b>Drug</b> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><b>Daily dose (mcg)</b> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><b>BDP equivalent (mcg)</b> </p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="3" valign=""> <p>Budesonide</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>320</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>320</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>640</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>640</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>1280</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>1280</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="5" valign=""> <p>Fluticasone</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>500 (propionate)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>1000</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>1000 (propionate)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>2000</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>50 (furoate)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>500</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>100 (furoate)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>1000</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>200 (furoate)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>2000</p> </td> </tr> </tbody> </table> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="table-viewer-caption"> <div class="table-heading"><span class="table-label">Table 3.</span> <span class="table-title">BDP equivalent doses</span></div> </div> <div class="tools"><a class="tableList" href="/cdsr/doi/10.1002/14651858.CD010115.pub2/full#CD010115-tbl-0005">Navigate to table in review</a></div> </div> <div class="table"> <table data-id="CD010115-tbl-0006"> <div class="table-heading"><span class="table-label">Table 4.</span> <span class="table-title">Control group event rates</span></div> <tbody> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="2" valign=""></td> <td align="" bgcolor="#ffffff" colspan="2" rowspan="1" valign=""> <p><b>Monotherapy comparison—Placebo control events</b> </p> </td> <td align="" bgcolor="#ffffff" colspan="2" rowspan="1" valign=""> <p><b>Combination comparison—LABA control events</b> </p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><b>Fluticasone</b> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><b>Budesonide</b> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><b>Fluticasone</b> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><b>Budesonide</b> </p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="2" valign=""> <p>Pneumonia‐related serious adverse events</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>2.5%, 77/310</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="2" valign=""> <p>0.9%, 4/445</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>2.5%, 134/5420</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="2" valign=""> <p>0.9%, 19/2079</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>0.5% without TORCH</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>0.7% without TORCH</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="2" valign=""> <p>All‐cause mortality</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>7.6%, 282/3713</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="2" valign=""> <p>2.1%, 37/1763</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>5.1%, 254/5489</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="2" valign=""> <p>1.5%, 37/2534</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>2.4% without TORCH</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>1.2% without TORCH</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="2" valign=""> <p>All‐cause serious adverse events</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>25%, 882/3471</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="2" valign=""> <p>15%, 268/1763</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>21%, 1152/5489</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="2" valign=""> <p>14%, 356/2534</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>14% without TORCH</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>14% without TORCH</p> </td> </tr> </tbody> <tfoot> <tr> <td colspan="5"> <div class="table-footnote"> <p>For the fluticasone control groups with and without the large 3‐year TORCH study.</p> </div> </td> </tr> </tfoot> </table> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="table-viewer-caption"> <div class="table-heading"><span class="table-label">Table 4.</span> <span class="table-title">Control group event rates</span></div> </div> <div class="tools"><a class="tableList" href="/cdsr/doi/10.1002/14651858.CD010115.pub2/full#CD010115-tbl-0006">Navigate to table in review</a></div> </div> <div class="table"> <table class="comparison" data-id="CD010115-tbl-0007"> <div class="table-heading"><span class="table-label">Comparison 1.</span> <span class="table-title">Fluticasone versus controls (all outcomes by treatment)</span></div> <thead> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>Outcome or subgroup title</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>No. of studies</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>No. of participants</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Statistical method</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>Effect size</p> </td> </tr> </thead> <tbody> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p class="subgroupTitle">1 Non‐fatal, serious adverse pneumonia events <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i aria-hidden="true" class="fa fa-caret-down"></i></span></p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>17</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>19504</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Odds Ratio (M‐H, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>1.78 [1.50, 2.12]</p> </td> </tr> <tr class="figure-image"> <td colspan="5"></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>1.1 Fluticasone versus placebo</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>11</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>6635</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Odds Ratio (M‐H, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>1.84 [1.39, 2.44]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>1.2 Fluticasone/LABA versus LABA</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>13</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>12869</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Odds Ratio (M‐H, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>1.75 [1.41, 2.17]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p class="subgroupTitle">2 Mortality, all‐cause <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i aria-hidden="true" class="fa fa-caret-down"></i></span></p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>22</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>20861</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Odds Ratio (M‐H, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>0.99 [0.87, 1.13]</p> </td> </tr> <tr class="figure-image"> <td colspan="5"></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>2.1 Fluticasone versus placebo</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>15</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>7857</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Odds Ratio (M‐H, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>1.05 [0.88, 1.25]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>2.2 Fluticasone/LABA versus LABA</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>14</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>13004</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Odds Ratio (M‐H, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>0.94 [0.78, 1.12]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p class="subgroupTitle">3 Mortality, due to pneumonia <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i aria-hidden="true" class="fa fa-caret-down"></i></span></p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>18</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>19532</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Peto Odds Ratio (Peto, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>1.23 [0.70, 2.15]</p> </td> </tr> <tr class="figure-image"> <td colspan="5"></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>3.1 Fluticasone versus placebo</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>12</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>6665</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Peto Odds Ratio (Peto, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>1.20 [0.52, 2.77]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>3.2 Fluticasone/LABA versus LABA</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>13</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>12867</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Peto Odds Ratio (Peto, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>1.25 [0.59, 2.65]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p class="subgroupTitle">4 Non‐fatal, serious adverse events (all) <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i aria-hidden="true" class="fa fa-caret-down"></i></span></p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>19</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>20381</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Odds Ratio (M‐H, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>1.06 [0.99, 1.14]</p> </td> </tr> <tr class="figure-image"> <td colspan="5"></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>4.1 Fluticasone versus placebo</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>12</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>7377</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Odds Ratio (M‐H, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>1.07 [0.95, 1.20]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>4.2 Fluticasone/LABA versus LABA</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>14</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>13004</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Odds Ratio (M‐H, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>1.06 [0.96, 1.16]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p class="subgroupTitle">5 All pneumonia events <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i aria-hidden="true" class="fa fa-caret-down"></i></span></p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>11</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>15377</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Odds Ratio (M‐H, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>1.68 [1.49, 1.90]</p> </td> </tr> <tr class="figure-image"> <td colspan="5"></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>5.1 Fluticasone versus placebo</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>6</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>4971</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Odds Ratio (M‐H, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>1.62 [1.33, 1.97]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>5.2 Fluticasone/LABA versus LABA</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>9</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>10406</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Odds Ratio (M‐H, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>1.72 [1.47, 2.01]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p class="subgroupTitle">6 Withdrawals <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i aria-hidden="true" class="fa fa-caret-down"></i></span></p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>26</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>21243</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Odds Ratio (M‐H, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>0.81 [0.77, 0.86]</p> </td> </tr> <tr class="figure-image"> <td colspan="5"></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>6.1 Fluticasone versus placebo</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>18</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>8227</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Odds Ratio (M‐H, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>0.76 [0.70, 0.84]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>6.2 Fluticasone/LABA versus LABA</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>15</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>13016</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Odds Ratio (M‐H, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>0.85 [0.79, 0.92]</p> </td> </tr> </tbody> </table> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="table-viewer-caption"> <div class="table-heading"><span class="table-label">Comparison 1.</span> <span class="table-title">Fluticasone versus controls (all outcomes by treatment)</span></div> </div> <div class="tools"><a class="tableList" href="/cdsr/doi/10.1002/14651858.CD010115.pub2/references#CD010115-tbl-0007">Navigate to table in review</a></div> </div> <div class="table"> <table class="comparison" data-id="CD010115-tbl-0008"> <div class="table-heading"><span class="table-label">Comparison 2.</span> <span class="table-title">Subgroup analyses—fluticasone versus controls</span></div> <thead> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>Outcome or subgroup title</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>No. of studies</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>No. of participants</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Statistical method</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>Effect size</p> </td> </tr> </thead> <tbody> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p class="subgroupTitle">1 Dose—Non‐fatal, serious adverse pneumonia events <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i aria-hidden="true" class="fa fa-caret-down"></i></span></p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>17</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>19504</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Odds Ratio (M‐H, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>1.76 [1.48, 2.08]</p> </td> </tr> <tr class="figure-image"> <td colspan="5"></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>1.1 Fluticasone propionate 500 mcg (250 mcg bid)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>6</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>3857</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Odds Ratio (M‐H, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>1.46 [0.91, 2.36]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>1.2 Fluticasone propionate 1000 mcg (500 mcg bid)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>9</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>10138</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Odds Ratio (M‐H, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>1.78 [1.47, 2.16]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>1.3 Fluticasone furoate 50 mcg</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>2</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>1366</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Odds Ratio (M‐H, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>2.10 [0.73, 6.06]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>1.4 Fluticasone furoate 100 mcg</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>3</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>2447</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Odds Ratio (M‐H, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>1.61 [0.70, 3.70]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>1.5 Fluticasone furoate 200 mcg</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>2</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>1696</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Odds Ratio (M‐H, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>2.38 [0.87, 6.51]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p class="subgroupTitle">2 Duration—Non‐fatal, serious adverse pneumonia events <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i aria-hidden="true" class="fa fa-caret-down"></i></span></p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>17</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>19504</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Odds Ratio (M‐H, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>1.79 [1.51, 2.12]</p> </td> </tr> <tr class="figure-image"> <td colspan="5"></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>2.1 Duration ≤ one year</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>14</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>13078</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Odds Ratio (M‐H, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>1.91 [1.39, 2.63]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>2.2 Duration &gt; one year</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>3</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>6426</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Odds Ratio (M‐H, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>1.74 [1.42, 2.13]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p class="subgroupTitle">3 % FEV<sub>1</sub> predicted normal—Non‐fatal, serious adverse pneumonia events <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i aria-hidden="true" class="fa fa-caret-down"></i></span></p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>12</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>17211</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Odds Ratio (M‐H, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>1.82 [1.53, 2.17]</p> </td> </tr> <tr class="figure-image"> <td colspan="5"></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>3.1 FEV1 &lt; 50% predicted</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>10</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>17133</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Odds Ratio (M‐H, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>1.84 [1.55, 2.20]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>3.2 FEV1 ≥ 50% predicted</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>2</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>78</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Odds Ratio (M‐H, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>0.21 [0.01, 4.53]</p> </td> </tr> </tbody> </table> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="table-viewer-caption"> <div class="table-heading"><span class="table-label">Comparison 2.</span> <span class="table-title">Subgroup analyses—fluticasone versus controls</span></div> </div> <div class="tools"><a class="tableList" href="/cdsr/doi/10.1002/14651858.CD010115.pub2/references#CD010115-tbl-0008">Navigate to table in review</a></div> </div> <div class="table"> <table class="comparison" data-id="CD010115-tbl-0009"> <div class="table-heading"><span class="table-label">Comparison 3.</span> <span class="table-title">Budesonide versus controls (all outcomes by treatment)</span></div> <thead> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>Outcome or subgroup title</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>No. of studies</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>No. of participants</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Statistical method</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>Effect size</p> </td> </tr> </thead> <tbody> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p class="subgroupTitle">1 Non‐fatal, serious adverse pneumonia events <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i aria-hidden="true" class="fa fa-caret-down"></i></span></p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>7</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>6472</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Odds Ratio (M‐H, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>1.62 [1.00, 2.62]</p> </td> </tr> <tr class="figure-image"> <td colspan="5"></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>1.1 Budesonide versus placebo</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>3</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>867</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Odds Ratio (M‐H, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>3.47 [1.11, 10.83]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>1.2 Budesonide/formoterol versus formoterol</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>5</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>5605</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Odds Ratio (M‐H, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>1.33 [0.78, 2.28]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p class="subgroupTitle">2 Mortality, all‐cause <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i aria-hidden="true" class="fa fa-caret-down"></i></span></p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>12</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>10009</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Odds Ratio (M‐H, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>0.90 [0.65, 1.24]</p> </td> </tr> <tr class="figure-image"> <td colspan="5"></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>2.1 Budesonide versus placebo</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>8</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>3487</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Odds Ratio (M‐H, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>0.85 [0.52, 1.37]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>2.2 Budesonide/formoterol versus formoterol</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>7</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>6522</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Odds Ratio (M‐H, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>0.94 [0.61, 1.46]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p class="subgroupTitle">3 Mortality, due to pneumonia <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i aria-hidden="true" class="fa fa-caret-down"></i></span></p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>3</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>1511</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Peto Odds Ratio (Peto, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>4.46 [0.07, 286.99]</p> </td> </tr> <tr class="figure-image"> <td colspan="5"></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>3.1 Budesonide versus placebo</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>2</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>292</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Peto Odds Ratio (Peto, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>0.0 [0.0, 0.0]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>3.2 Budesonide/formoterol versus formoterol</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>1219</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Peto Odds Ratio (Peto, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>4.46 [0.07, 286.99]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p class="subgroupTitle">4 Non‐fatal, serious adverse events (all) <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i aria-hidden="true" class="fa fa-caret-down"></i></span></p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>12</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>10009</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Odds Ratio (M‐H, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>1.01 [0.83, 1.22]</p> </td> </tr> <tr class="figure-image"> <td colspan="5"></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>4.1 Budesonide versus placebo</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>8</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>3487</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Odds Ratio (M‐H, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>1.02 [0.69, 1.50]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>4.2 Budesonide/formoterol versus formoterol</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>7</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>6522</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Odds Ratio (M‐H, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>0.93 [0.78, 1.11]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p class="subgroupTitle">5 All pneumonia events <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i aria-hidden="true" class="fa fa-caret-down"></i></span></p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>6</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>7011</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Odds Ratio (M‐H, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>1.12 [0.83, 1.51]</p> </td> </tr> <tr class="figure-image"> <td colspan="5"></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>5.1 Budesonide versus placebo</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>3</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>1378</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Odds Ratio (M‐H, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>0.87 [0.50, 1.50]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>5.2 Budesonide/formoterol versus formoterol</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>5</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>5633</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Odds Ratio (M‐H, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>1.24 [0.87, 1.77]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p class="subgroupTitle">6 Withdrawals <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i aria-hidden="true" class="fa fa-caret-down"></i></span></p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>15</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>10150</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Odds Ratio (M‐H, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>0.78 [0.71, 0.85]</p> </td> </tr> <tr class="figure-image"> <td colspan="5"></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>6.1 Budesonide versus placebo</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>11</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>3627</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Odds Ratio (M‐H, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>0.80 [0.69, 0.93]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>6.2 Budesonide/formoterol versus formoterol</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>7</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>6523</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Odds Ratio (M‐H, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>0.76 [0.67, 0.86]</p> </td> </tr> </tbody> </table> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="table-viewer-caption"> <div class="table-heading"><span class="table-label">Comparison 3.</span> <span class="table-title">Budesonide versus controls (all outcomes by treatment)</span></div> </div> <div class="tools"><a class="tableList" href="/cdsr/doi/10.1002/14651858.CD010115.pub2/references#CD010115-tbl-0009">Navigate to table in review</a></div> </div> <div class="table"> <table class="comparison" data-id="CD010115-tbl-0010"> <div class="table-heading"><span class="table-label">Comparison 4.</span> <span class="table-title">Subgroup analyses—budesonide versus controls</span></div> <thead> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>Outcome or subgroup title</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>No. of studies</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>No. of participants</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Statistical method</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>Effect size</p> </td> </tr> </thead> <tbody> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p class="subgroupTitle">1 Dose ‐ Non‐fatal, serious adverse pneumonia events <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i aria-hidden="true" class="fa fa-caret-down"></i></span></p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>7</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>6472</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Odds Ratio (M‐H, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>1.54 [0.96, 2.48]</p> </td> </tr> <tr class="figure-image"> <td colspan="5"></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>1.1 Budesonide 320 mcg (160 mcg bid)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>3</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>1775</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Odds Ratio (M‐H, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>0.68 [0.27, 1.71]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>1.2 Budesonide 640 mcg (320 mcg bid)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>6</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>4659</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Odds Ratio (M‐H, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>2.02 [1.15, 3.57]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>1.3 Budesonide 1280 mcg (640 mcg bid)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>38</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Odds Ratio (M‐H, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>0.0 [0.0, 0.0]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p class="subgroupTitle">2 Duration ‐ Non‐fatal, serious adverse pneumonia events <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i aria-hidden="true" class="fa fa-caret-down"></i></span></p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>7</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>6471</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Odds Ratio (M‐H, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>1.62 [1.00, 2.62]</p> </td> </tr> <tr class="figure-image"> <td colspan="5"></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>2.1 Duration ≤ one year</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>6</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>6217</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Odds Ratio (M‐H, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>1.41 [0.83, 2.37]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>2.2 Duration &gt; one year</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>254</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Odds Ratio (M‐H, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>3.53 [0.95, 13.15]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p class="subgroupTitle">3 % FEV<sub>1</sub> predicted normal ‐ Non‐fatal, serious adverse pneumonia events <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i aria-hidden="true" class="fa fa-caret-down"></i></span></p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>7</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>6471</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Odds Ratio (M‐H, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>1.60 [0.99, 2.59]</p> </td> </tr> <tr class="figure-image"> <td colspan="5"></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>3.1 FEV1 &lt; 50% predicted</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>6</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>6217</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Odds Ratio (M‐H, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>1.39 [0.82, 2.34]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>3.2 FEV1 ≥ 50% predicted</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>254</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Odds Ratio (M‐H, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>3.53 [0.95, 13.15]</p> </td> </tr> </tbody> </table> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="table-viewer-caption"> <div class="table-heading"><span class="table-label">Comparison 4.</span> <span class="table-title">Subgroup analyses—budesonide versus controls</span></div> </div> <div class="tools"><a class="tableList" href="/cdsr/doi/10.1002/14651858.CD010115.pub2/references#CD010115-tbl-0010">Navigate to table in review</a></div> </div> <div class="table"> <table class="comparison" data-id="CD010115-tbl-0011"> <div class="table-heading"><span class="table-label">Comparison 5.</span> <span class="table-title">Sensitivity analysis—risk of bias</span></div> <thead> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>Outcome or subgroup title</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>No. of studies</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>No. of participants</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Statistical method</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>Effect size</p> </td> </tr> </thead> <tbody> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p class="subgroupTitle">1 Non‐fatal serious adverse pneumonia events <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i aria-hidden="true" class="fa fa-caret-down"></i></span></p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>16</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""></td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Odds Ratio (M‐H, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>Subtotals only</p> </td> </tr> <tr class="figure-image"> <td colspan="5"></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>1.1 Fluticasone versus control</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>12</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>16338</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Odds Ratio (M‐H, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>1.82 [1.52, 2.19]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>1.2 Budesonide versus control</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>4</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>3515</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Odds Ratio (M‐H, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>3.28 [1.22, 8.81]</p> </td> </tr> </tbody> </table> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="table-viewer-caption"> <div class="table-heading"><span class="table-label">Comparison 5.</span> <span class="table-title">Sensitivity analysis—risk of bias</span></div> </div> <div class="tools"><a class="tableList" href="/cdsr/doi/10.1002/14651858.CD010115.pub2/references#CD010115-tbl-0011">Navigate to table in review</a></div> </div> </div> <noscript> <img height="1" src="/scolaris-auth/report/nonjs/fulltexthtmlreg?doi=10.1002%2F14651858.CD010115.pub2&amp;rf=&amp;articleType=CDSR" style="display:none" width="1"> </img></noscript> <section class="translation-notes-modal" data-modal-class="translation-notes" data-modal-title="Translation notes" data-ok-btn-selector=".ok-btn" style="display: none"> <div class="translation-notes"> <div class="section-language-toggles"> <nav class="section-languages"> <ul> <li class="section-languages-legend">Available in</li> <li class="section-language"> <a class="" href="es#CD010115-note-0004">Español</a> </li> <li class="section-language"> <a class="" href="fa#CD010115-note-0010">فارسی</a> </li> <li class="section-language"> <a class="" href="pt#CD010115-note-0003">Português</a> </li> <li class="section-language"> <a class="" href="ru#CD010115-note-0002">Русский</a> </li> <li class="section-language"> <a class="" href="zh_HANT#CD010115-note-0001">繁體中文</a> </li> </ul> </nav> </div> <section class="translation-notes-content"> </section> <button class="btn primary ok-btn pull-right" type="button">Close</button> </div> </section></article> </div> <div class="citation-modal" style="display: none"> <div class="export-citation-header"> <p class="inset-message" data-load-error="Unable to load citation data" id="citeProcText"></p> </div> <div class="export-citation-body row-fluid"> <div class="span12"> <div class="addthis_toolbox addthis_default_style addthis_16x16_style"> <nav class="inline-nav-list is-bordered"> <li> <h4 class="heading">Save citation to:</h4> </li> <li><a class="citation-btn-refworks at300b btn btn-link" href="#" id="refWorksCitationBtn"><span class="citation-icon refworks"></span>RefWorks</a></li> <li><a class="citation-btn-sciwheel at300b btn btn-link disabled" href="#" id="sciWheelCitationBtn" target="_blank"><span class="citation-icon sciwheel"></span>SciWheel</a></li> </nav> </div> </div> </div> <div class="row-fluid"> <div class="span12"> <div class="citation-format"> <h4>Copy or download citation</h4> <a href="/en/help/exporting-search-results" rel="noopener noreferrer" target="_blank">Export help</a> </div> <nav class="inline-nav-list has-dividers"> <li class="citation-option" data-option="plain"><button class="btn btn-link" type="button">Plain text</button></li> <li class="citation-option" data-option="endnote"><button class="btn btn-link" type="button">EndNote</button></li> <li class="citation-option" data-option="refmanager"><button class="btn btn-link" type="button">Reference Manager</button></li> <li class="citation-option" data-option="procite"><button class="btn btn-link" type="button">ProCite</button></li> <li class="citation-option" data-option="bibtex"><button class="btn btn-link" type="button">BibteX</button></li> <li class="citation-option" data-option="csv"><button class="btn btn-link" type="button">CSV (Excel)</button></li> </nav> <div class="citation-content"> <pre data-load-error="Unable to load citation data" id="citationContent" tabindex="0"></pre> </div> <div class="clearfix"> <form class="download-citation-form" data-citation-citeproc-url="https://www.cochranelibrary.com/en/content?p_p_id=scolariscontentdisplay_WAR_scolariscontentdisplay&amp;p_p_lifecycle=2&amp;p_p_state=normal&amp;p_p_mode=view&amp;p_p_resource_id=citation-citeproc&amp;p_p_cacheability=cacheLevelPage&amp;p_p_col_id=column-1&amp;p_p_col_count=1" method="GET" target="citation-download-iframe"> <input id="siteId" name="siteId" type="hidden" value=""> <input id="downloadType" name="downloadType" type="hidden" value=""> <input id="style" name="style" type="hidden" value=""> <input id="articleId" name="articleId" type="hidden" value=""> <input name="p_p_id" type="hidden" value="scolariscontentdisplay_WAR_scolariscontentdisplay"><input name="p_p_lifecycle" type="hidden" value="2"><input name="p_p_state" type="hidden" value="normal"><input name="p_p_mode" type="hidden" value="view"/><input name="p_p_resource_id" type="hidden" value="citation-download"/><input name="p_p_cacheability" type="hidden" value="cacheLevelPage"/><input name="p_p_col_id" type="hidden" value="column-1"/><input name="p_p_col_count" type="hidden" value="1"/> <button class="btn primary wide pull-right" type="submit">Download</button> <div class="inline-checkbox pull-right"> <label title=" for=" withabstract"=""> <input checked="" class="checkbox" name="withAbstract" type="checkbox"/> <span class="checkbox-label">Include abstract</span> </label> </div> </input></input></input></input></input></input></input></form> <iframe aria-hidden="true" name="citation-download-iframe" src="" style="display: none; visibility: hidden" title="Citation download frame"></iframe> </div> </div> </div> </div> <div class="print-modal" data-modal-title="Print this review" style="display: none;"> <div class="print-options-wrapper"> <p><strong>All sections are selected by default</strong>, please select the sections you do not wish to print or use the select or deselect all button to add or remove sections.</p> <div class="print-options-controls"> <input checked="checked" class="print-options-select-all" title="Select/deselect all" type="checkbox"/> <span class="checkbox-label">Select/deselect all</span> </div> <ul class="print-options checkbox-list"> </ul> <button class="btn primary print-article pull-right"><i aria-hidden="true" class="fa fa-print"></i> Print</button> </div> </div> <div class="download-stats-data-modal" data-modal-title="Download data package" style="display: none;"> <div> <p> The data available are protected by copyright and may only be used in accordance with the <a class="external" href="/about/data-download" target="_blank">Terms and Conditions.</a> </p> <div class="hide-for-zip"> <p> <a class="external" href="https://revman.cochrane.org/#/rm5Converter" target="_blank">RevMan 5 files</a> can be converted to a <a class="external" href="https://links.cochrane.org/review-datapack-userguide" target="_blank">data package.</a> </p> </div> <p> Files in the data package can be imported to <a class="external" href="https://revman.cochrane.org/info" target="_blank">Review Manager software</a> or opened in other tools that support CSV and RIS. </p> <form class="download-stats-data-form" method="GET" target="_blank"> <input name="content-disposition" type="hidden" value="attachment"/> <input name="mime-type" type="hidden" value="application/octet-stream"/> <p class="print-options-controls"> <input aria-label="I agree to these terms and conditions" class="download-stats-data-toc-check-box" type="checkbox"/> <span aria-hidden="true" class="checkbox-label">I agree to these terms and conditions</span> <button class="btn primary download-stats-data pull-right" disabled=""><i aria-hidden="true" class="fa fa-download"></i> Download data</button> </p> </form> </div> </div> <div class="share-modal" data-modal-title="Share this review" style="display:none;"> </div> <div class="viewer-thumbnail-pane-html" style="display:none;"> <div class="figure-viewer-options"> <nav class="inline-nav-list"> <li class="figure-options-btn-container"><button class="btn btn-link" id="figureOptionBtn" type="button">Figures</button></li> <li class="table-options-btn-container"><button class="btn btn-link" id="tableOptionBtn" type="button">Tables</button></li> </nav> </div> <div class="figure-viewer-thumbnails"> <div class="figure-thumbnails is-visible" id="figureThumbnails"></div> <div class="table-thumbnails" id="tableThumbnails"></div> </div> </div> <div class="utilities-html" style="display:none;"> <div class="figure-viewer-utilities"> <a class="figure-viewer-menu-toggle" href="#"> <i class="fa fa-chevron-left"></i><span class="toggle-label" data-figure-hide-text="Hide thumbnails" data-figure-show-text="Show thumbnails" data-table-hide-text="Hide table list" data-table-show-text="Show table list">Hide thumbnails</span> </a> <a class="figure-viewer-navigateback" href="#"> <i class="fa fa-chevron-left"></i> </a> <a class="figure-viewer-rotate" href="#"> <i class="fa fa-undo"></i> </a> <a class="figure-viewer-download" href="#"> <i class="fa fa-download"></i> </a> <a class="figure-viewer-share" href="#"> <i class="fa fa-share-alt"></i> </a> <a class="figure-viewer-zoomin" href="#"> <i class="fa fa-plus"></i><span>zoom in</span> </a> <a class="figure-viewer-zoomout" href="#"> <i class="fa fa-minus"></i><span>zoom out</span> </a> </div> </div> <div class="controls-html" style="display:none;"> <div class="figure-viewer-navigation"> <a class="figure-viewer-nav previous" href="#"> <i class="fa fa-chevron-left"></i><span>left</span> </a> <a class="figure-viewer-nav next" href="#"> <i class="fa fa-chevron-right"></i><span>right</span> </a> </div> </div> <div class="mobile-thumbnail-selector-html" style="display:none;"> <div class="figure-viewer-mobile-thumbnails"> <select class="figure-selection"> <option>Figures</option> </select> <select class="table-selection"> <option>Tables</option> </select> </div> </div> </div> </div> </div> <div style="display:none"> <input id="freelabel" name="freelabel" type="hidden" value="Free access"/>
<input id="openlabel" name="openlabel" type="hidden" value="Open access"/>
</div>
</section>
</div>
</div>
</div>
</div>
</div>
<div class="portlet-boundary portlet-boundary_1_WAR_kaleodesignerportlet_ portlet-static portlet-static-end kaleo-designer-portlet" id="p_p_id_1_WAR_kaleodesignerportlet_">
<span id="p_1_WAR_kaleodesignerportlet"></span>
</div>
<form action="#" id="hrefFm" method="post" name="hrefFm">
<span></span>
</form>
</div>
<footer class="footer">
<div class="main-footer">
<div class="main-footer-wrapper container">
<div class="brand">
<p class="brand-name">Cochrane</p>
<a href="http://www.cochrane.org/" title="Cochrane logo">
<img alt="Cochrane logo" class="footer-logo logo-part-1" src="https://www.cochranelibrary.com/cochrane-theme/images/footer-logo-part-1.png"> <img alt="" class="footer-logo logo-part-2" src="https://www.cochranelibrary.com/cochrane-theme/images/footer-logo-part-2.png"> </img></img></a> </div> </div> </div> <div class="aux-footer"> <div class="aux-footer-nav-container container"> <nav class="aux-footer-nav"> <ul class="aux-footer-nav-list"> <li><a class="aux-footer-nav-link" href="https://onlinelibrary.wiley.com/">Browse Publications</a></li> <li><a class="aux-footer-nav-link" href="https://onlinelibrary.wiley.com/">Browse by Subject</a></li> </ul> <ul class="aux-footer-nav-list"> <li><a class="aux-footer-nav-link" href="https://onlinelibrary.wiley.com/advertisers">Advertisers &amp; Agents</a></li> <li><a class="aux-footer-nav-link" href="https://hub.wiley.com/community/support/cochrane-library">Contact Us</a></li> </ul> <ul class="aux-footer-nav-list"> <li><a class="aux-footer-nav-link" href="https://hub.wiley.com/community/support/cochrane-library">Help &amp; Support</a></li> <li><a class="aux-footer-nav-link" href="https://onlinelibrary.wiley.com/terms-and-conditions">Terms &amp; Conditions</a></li> </ul> </nav> </div> <div class="brand"> <div class="brand-container container"> <p class="copyright"> Copyright © 2000 - 2025 by <a class="" href="http://www.wiley.com">John Wiley &amp; Sons, Inc.</a> All Rights Reserved <br> Review our <a href="https://www.wiley.com/privacy"><strong>Privacy Policy</strong></a> <a href="https://www.wiley.com/cookies"><strong>Cookie Policy</strong></a> <a href="#" onclick="Osano.cm.showDrawer('osano-cm-dom-info-dialog-open')"><strong>Cookie Preferences</strong></a> </br></p> <a href="http://eu.wiley.com/"><img alt="Wiley logo" class="logo" src="https://www.cochranelibrary.com/cochrane-theme/images/en-US_wiley-footer-logo.png"/></a> </div> </div> <span class="wiley-semi-circle"></span> </div> <!--BEGIN QUALTRICS WEBSITE FEEDBACK SNIPPET--> <script type="text/javascript"> (function(){var g=function(e,h,f,g){ this.get=function(a){for(var a=a+"=",c=document.cookie.split(";"),b=0,e=c.length;b<e;b++){for(var d=c[b];" "==d.charAt(0);)d=d.substring(1,d.length);if(0==d.indexOf(a))return d.substring(a.length,d.length)}return null}; this.set=function(a,c){var b="",b=new Date;b.setTime(b.getTime()+6048E5);b="; expires="+b.toGMTString();document.cookie=a+"="+c+b+"; path=/; "}; this.check=function(){var a=this.get(f);if(a)a=a.split(":");else if(100!=e)"v"==h&&(e=Math.random()>=e/100?0:100),a=[h,e,0],this.set(f,a.join(":"));else return!0;var c=a[1];if(100==c)return!0;switch(a[0]){case "v":return!1;case "r":return c=a[2]%Math.floor(100/c),a[2]++,this.set(f,a.join(":")),!c}return!0}; this.go=function(){if(this.check()){var a=document.createElement("script");a.type="text/javascript";a.src=g;document.body&&document.body.appendChild(a)}}; this.start=function(){var t=this;"complete"!==document.readyState?window.addEventListener?window.addEventListener("load",function(){t.go()},!1):window.attachEvent&&window.attachEvent("onload",function(){t.go()}):t.go()};}; try{(new g(100,"r","QSI_S_ZN_cGCHHvWNpnJb1zf","https://zncgchhvwnpnjb1zf-wiley.siteintercept.qualtrics.com/SIE/?Q_ZID=ZN_cGCHHvWNpnJb1zf")).start()}catch(i){}})(); </script><div id="ZN_cGCHHvWNpnJb1zf"><!--DO NOT REMOVE-CONTENTS PLACED HERE--></div> <!--END WEBSITE FEEDBACK SNIPPET--> </footer> <div class="scolaris-modal-overlay"></div> <div class="scolaris-modal"> <div class="scolaris-modal-titlebar clearfix"> <p class="scolaris-modal-title"></p> <a class="scolaris-modal-close" href="#"><span>close</span><span class="icon fa fa-times"></span></a> <div class="scolaris-modal-ui"></div> </div> <!-- Static injection of addtoAny as dynamic injection not working properly--> <div class="scolaris-share-modal-content clearfix"> <div class="scolaris-modal-ui clearfix"> <div class="a2a_kit a2a_kit_size_32 a2a_default_style"> <a class="a2a_button_facebook share-button">  Facebook</a> <a class="a2a_button_x share-button">  X(Twitter)</a> <a class="a2a_button_whatsapp share-button">  WhatsApp</a> <a class="a2a_dd share-button">  View more</a> </div> </div> </div> <div class="scolaris-modal-content clearfix"> <div class="scolaris-modal-ui clearfix"></div> </div> <div class="scolaris-modal-ui clearfix"></div> </div> <div class="english-only-modal-wrapper" data-modal-class="english-only-modal" data-modal-title="Feature in English only" style="display: none"> <div class="english-only-modal"> <p class="message"></p> <button class="btn primary ok-btn pull-right" type="button">OK</button> <button class="btn primary border-only cancel-btn pull-right" type="button">Cancel</button> </div> </div> <!--[if gte IE 9]><!--> <script src="/cochrane-theme/vendor/ie9.js?t=1738735355000" type="text/javascript"></script> <!--<![endif]--> <script src="https://www.cochranelibrary.com/cochrane-theme/js/theme.js?t=1738735355000" type="text/javascript"></script> <script src="https://content.readcube.com/cochrane/checkout.js"></script> <script src="https://content.readcube.com/cochrane/epdf_linker.js" type="text/javascript"></script> <script src="https://crossmark-cdn.crossref.org/widget/v2.0/widget.js" type="text/javascript"></script> <script src="https://d1bxh8uas1mnw7.cloudfront.net/assets/embed.js" type="text/javascript"></script> <script src="https://www.cochranelibrary.com/scolaris-content-display/js/hit-highlighting.js?browserId=other&amp;minifierType=js&amp;languageId=en_US&amp;b=6210&amp;t=1739773978000" type="text/javascript"></script> <script src="https://www.cochranelibrary.com/scolaris-content-display/js/topics-lookup.js?browserId=other&amp;minifierType=js&amp;languageId=en_US&amp;b=6210&amp;t=1739773978000" type="text/javascript"></script> <script src="https://www.cochranelibrary.com/scolaris-content-display/js/institution.js?browserId=other&amp;minifierType=js&amp;languageId=en_US&amp;b=6210&amp;t=1739773978000" type="text/javascript"></script> <script src="https://www.cochranelibrary.com/scolaris-content-display/js/api-manager.js?browserId=other&amp;minifierType=js&amp;languageId=en_US&amp;b=6210&amp;t=1739773978000" type="text/javascript"></script> <script src="https://www.cochranelibrary.com/scolaris-content-display/js/pico.js?browserId=other&amp;minifierType=js&amp;languageId=en_US&amp;b=6210&amp;t=1739773978000" type="text/javascript"></script> <script src="https://www.cochranelibrary.com/scolaris-content-display/js/reference-linking.js?browserId=other&amp;minifierType=js&amp;languageId=en_US&amp;b=6210&amp;t=1739773978000" type="text/javascript"></script> <script src="https://www.cochranelibrary.com/scolaris-content-display/js/rightsLink.js?browserId=other&amp;minifierType=js&amp;languageId=en_US&amp;b=6210&amp;t=1739773978000" type="text/javascript"></script> <script src="https://www.cochranelibrary.com/scolaris-content-display/js/ui.submit.failed.js?browserId=other&amp;minifierType=js&amp;languageId=en_US&amp;b=6210&amp;t=1739773978000" type="text/javascript"></script> <script src="https://www.cochranelibrary.com/scolaris-content-display/js/ui.comment.form.js?browserId=other&amp;minifierType=js&amp;languageId=en_US&amp;b=6210&amp;t=1739773978000" type="text/javascript"></script> <script src="https://www.cochranelibrary.com/scolaris-content-display/js/safety-alerts.js?browserId=other&amp;minifierType=js&amp;languageId=en_US&amp;b=6210&amp;t=1739773978000" type="text/javascript"></script> <script src="https://www.cochranelibrary.com/scolaris-content-display/js/ui.translation-notes-modal.js?browserId=other&amp;minifierType=js&amp;languageId=en_US&amp;b=6210&amp;t=1739773978000" type="text/javascript"></script> <script src="https://www.cochranelibrary.com/scolaris-content-display/js/main.js?browserId=other&amp;minifierType=js&amp;languageId=en_US&amp;b=6210&amp;t=1739773978000" type="text/javascript"></script> <script src="https://www.cochranelibrary.com/notifications-portlet/notifications/js/main.js?browserId=other&amp;minifierType=js&amp;languageId=en_US&amp;b=6210&amp;t=1739774000000" type="text/javascript"></script> <script src="https://www.cochranelibrary.com/scolaris-search/js/main.js?browserId=other&amp;minifierType=js&amp;languageId=en_US&amp;b=6210&amp;t=1739774074000" type="text/javascript"></script> <script src="https://www.cochranelibrary.com/scolaris-topics/js/main.js?browserId=other&amp;minifierType=js&amp;languageId=en_US&amp;b=6210&amp;t=1739774074000" type="text/javascript"></script> <script src="https://www.cochranelibrary.com/scolaris-language-portlet/js/main.js?browserId=other&amp;minifierType=js&amp;languageId=en_US&amp;b=6210&amp;t=1739774000000" type="text/javascript"></script> <script type="text/javascript">Liferay.Util.addInputFocus();</script> <script type="text/javascript">Liferay.Portlet.register("scolarislanguageselector_WAR_scolarislanguageportlet_INSTANCE_header");Liferay.Portlet.onLoad({canEditTitle:false,columnPos:0,isStatic:"end",namespacedId:"p_p_id_scolarislanguageselector_WAR_scolarislanguageportlet_INSTANCE_header_",portletId:"scolarislanguageselector_WAR_scolarislanguageportlet_INSTANCE_header",refreshURL:"\x2fen\x2fc\x2fportal\x2frender_portlet\x3fp_l_id\x3d20757\x26p_p_id\x3dscolarislanguageselector_WAR_scolarislanguageportlet_INSTANCE_header\x26p_p_lifecycle\x3d0\x26p_t_lifecycle\x3d0\x26p_p_state\x3dnormal\x26p_p_mode\x3dview\x26p_p_col_id\x3dnull\x26p_p_col_pos\x3dnull\x26p_p_col_count\x3dnull\x26p_p_static\x3d1\x26p_p_isolated\x3d1\x26currentURL\x3d\x252Fweb\x252Fcochrane\x252Fcontent\x253FtemplateType\x253Dfull\x2526urlTitle\x253D\x252Fcdsr\x252Fdoi\x252F10\x2e1002\x252F14651858\x2eCD010115\x2epub2\x2526doi\x253D10\x2e1002\x252F14651858\x2eCD010115\x2epub2\x2526type\x253Dcdsr\x2526contentLanguage\x253D\x26templateType\x3dfull\x26urlTitle\x3d\x252Fcdsr\x252Fdoi\x252F10\x2e1002\x252F14651858\x2eCD010115\x2epub2\x26contentLanguage\x3d\x26type\x3dcdsr\x26doi\x3d10\x2e1002\x252F14651858\x2eCD010115\x2epub2"});Liferay.Portlet.register("scolariscontentdisplay_WAR_scolariscontentdisplay");Liferay.Portlet.onLoad({canEditTitle:false,columnPos:0,isStatic:"end",namespacedId:"p_p_id_scolariscontentdisplay_WAR_scolariscontentdisplay_",portletId:"scolariscontentdisplay_WAR_scolariscontentdisplay",refreshURL:"\x2fen\x2fc\x2fportal\x2frender_portlet\x3fp_l_id\x3d20757\x26p_p_id\x3dscolariscontentdisplay_WAR_scolariscontentdisplay\x26p_p_lifecycle\x3d0\x26p_t_lifecycle\x3d0\x26p_p_state\x3dnormal\x26p_p_mode\x3dview\x26p_p_col_id\x3dcolumn-1\x26p_p_col_pos\x3d0\x26p_p_col_count\x3d1\x26p_p_isolated\x3d1\x26currentURL\x3d\x252Fweb\x252Fcochrane\x252Fcontent\x253FtemplateType\x253Dfull\x2526urlTitle\x253D\x252Fcdsr\x252Fdoi\x252F10\x2e1002\x252F14651858\x2eCD010115\x2epub2\x2526doi\x253D10\x2e1002\x252F14651858\x2eCD010115\x2epub2\x2526type\x253Dcdsr\x2526contentLanguage\x253D"});Liferay.provide(Liferay.Util,"openKaleoDesignerPortlet",function(c){var b=AUI();var e=Liferay.PortletURL.createURL("https://www.cochranelibrary.com/en/content?p_p_id=2_WAR_kaleodesignerportlet&p_p_lifecycle=0");e.setParameter("mvcPath","/designer/edit_kaleo_draft_definition.jsp");e.setParameter("availableFields",c.availableFields);e.setParameter("availablePropertyModels",c.availablePropertyModels);e.setParameter("ddmStructureId",c.ddmStructureId);e.setParameter("draftVersion",c.draftVersion);e.setParameter("kaleoProcessId",c.kaleoProcessId);e.setParameter("name",c.name);e.setParameter("openerWindowName",c.openerWindowName);e.setParameter("portletResourceNamespace",c.portletResourceNamespace);e.setParameter("propertiesSaveCallback",c.propertiesSaveCallback);e.setParameter("refreshOpenerOnClose",c.refreshOpenerOnClose);e.setParameter("saveCallback",c.saveCallback);e.setParameter("version",c.version);e.setWindowState("pop_up");c.uri=e.toString();var d=c.dialog;if(!d){var f=b.one(Liferay.Util.getOpener()).get("region");d={destroyOnHide:true};c.dialog=d}if(!("align" in d)){d.align=Liferay.Util.Window.ALIGN_CENTER}var a=c.dialogIframe;if(!a){a={closeOnEscape:false};c.dialogIframe=a}Liferay.Util.openWindow(c)},["liferay-portlet-url"]);Liferay.Portlet.register("1_WAR_kaleodesignerportlet");Liferay.Portlet.onLoad({canEditTitle:false,columnPos:0,isStatic:"end",namespacedId:"p_p_id_1_WAR_kaleodesignerportlet_",portletId:"1_WAR_kaleodesignerportlet",refreshURL:"\x2fen\x2fc\x2fportal\x2frender_portlet\x3fp_l_id\x3d20757\x26p_p_id\x3d1_WAR_kaleodesignerportlet\x26p_p_lifecycle\x3d0\x26p_t_lifecycle\x3d0\x26p_p_state\x3dnormal\x26p_p_mode\x3dview\x26p_p_col_id\x3dnull\x26p_p_col_pos\x3dnull\x26p_p_col_count\x3dnull\x26p_p_static\x3d1\x26p_p_isolated\x3d1\x26currentURL\x3d\x252Fweb\x252Fcochrane\x252Fcontent\x253FtemplateType\x253Dfull\x2526urlTitle\x253D\x252Fcdsr\x252Fdoi\x252F10\x2e1002\x252F14651858\x2eCD010115\x2epub2\x2526doi\x253D10\x2e1002\x252F14651858\x2eCD010115\x2epub2\x2526type\x253Dcdsr\x2526contentLanguage\x253D\x26templateType\x3dfull\x26urlTitle\x3d\x252Fcdsr\x252Fdoi\x252F10\x2e1002\x252F14651858\x2eCD010115\x2epub2\x26contentLanguage\x3d\x26type\x3dcdsr\x26doi\x3d10\x2e1002\x252F14651858\x2eCD010115\x2epub2"});Liferay.Portlet.register("scolarissearchportlet_WAR_scolarissearch");Liferay.Portlet.onLoad({canEditTitle:false,columnPos:0,isStatic:"end",namespacedId:"p_p_id_scolarissearchportlet_WAR_scolarissearch_",portletId:"scolarissearchportlet_WAR_scolarissearch",refreshURL:"\x2fen\x2fc\x2fportal\x2frender_portlet\x3fp_l_id\x3d20757\x26p_p_id\x3dscolarissearchportlet_WAR_scolarissearch\x26p_p_lifecycle\x3d0\x26p_t_lifecycle\x3d0\x26p_p_state\x3dnormal\x26p_p_mode\x3dview\x26p_p_col_id\x3dnull\x26p_p_col_pos\x3dnull\x26p_p_col_count\x3dnull\x26p_p_static\x3d1\x26p_p_isolated\x3d1\x26currentURL\x3d\x252Fweb\x252Fcochrane\x252Fcontent\x253FtemplateType\x253Dfull\x2526urlTitle\x253D\x252Fcdsr\x252Fdoi\x252F10\x2e1002\x252F14651858\x2eCD010115\x2epub2\x2526doi\x253D10\x2e1002\x252F14651858\x2eCD010115\x2epub2\x2526type\x253Dcdsr\x2526contentLanguage\x253D\x26templateType\x3dfull\x26urlTitle\x3d\x252Fcdsr\x252Fdoi\x252F10\x2e1002\x252F14651858\x2eCD010115\x2epub2\x26contentLanguage\x3d\x26type\x3dcdsr\x26doi\x3d10\x2e1002\x252F14651858\x2eCD010115\x2epub2"});Liferay.Portlet.register("scolariscontentlanguagebanner_WAR_scolarislanguageportlet");Liferay.Portlet.onLoad({canEditTitle:false,columnPos:0,isStatic:"end",namespacedId:"p_p_id_scolariscontentlanguagebanner_WAR_scolarislanguageportlet_",portletId:"scolariscontentlanguagebanner_WAR_scolarislanguageportlet",refreshURL:"\x2fen\x2fc\x2fportal\x2frender_portlet\x3fp_l_id\x3d20757\x26p_p_id\x3dscolariscontentlanguagebanner_WAR_scolarislanguageportlet\x26p_p_lifecycle\x3d0\x26p_t_lifecycle\x3d0\x26p_p_state\x3dnormal\x26p_p_mode\x3dview\x26p_p_col_id\x3dnull\x26p_p_col_pos\x3dnull\x26p_p_col_count\x3dnull\x26p_p_static\x3d1\x26p_p_isolated\x3d1\x26currentURL\x3d\x252Fweb\x252Fcochrane\x252Fcontent\x253FtemplateType\x253Dfull\x2526urlTitle\x253D\x252Fcdsr\x252Fdoi\x252F10\x2e1002\x252F14651858\x2eCD010115\x2epub2\x2526doi\x253D10\x2e1002\x252F14651858\x2eCD010115\x2epub2\x2526type\x253Dcdsr\x2526contentLanguage\x253D\x26templateType\x3dfull\x26urlTitle\x3d\x252Fcdsr\x252Fdoi\x252F10\x2e1002\x252F14651858\x2eCD010115\x2epub2\x26contentLanguage\x3d\x26type\x3dcdsr\x26doi\x3d10\x2e1002\x252F14651858\x2eCD010115\x2epub2"});AUI().use("aui-base","liferay-menu","liferay-notice","liferay-poller","liferay-session",function(a){(function(){Liferay.Util.addInputType();Liferay.Portlet.ready(function(b,c){Liferay.Util.addInputType(c)});if(a.UA.mobile){Liferay.Util.addInputCancel()}})();(function(){new Liferay.Menu();var b=Liferay.Data.notices;for(var c=1;c<b.length;c++){new Liferay.Notice(b[c])}})();(function(){Liferay.Session=new Liferay.SessionBase({autoExtend:true,sessionLength:1800,redirectOnExpire:false,redirectUrl:"https\x3a\x2f\x2fwww\x2ecochranelibrary\x2ecom\x2fweb\x2fcochrane",warningLength:0})})()});</script> <script src="https://www.cochranelibrary.com/cochrane-theme/js/main.js?browserId=other&amp;minifierType=js&amp;languageId=en_US&amp;b=6210&amp;t=1738735355000" type="text/javascript"></script> <script type="text/javascript"></script> <div class="mobile-righthand-nav"> <a class="rh-nav-close-btn" href="#"> <span>Close</span> <span class="fa fa-chevron-down"></span> </a> <div class="wrapper"> </div> <a class="rh-nav-open-btn" href="#"> <span>Review tools &amp; navigation</span> </a> </div> <iframe aria-hidden="true" id="printframe" name="printframe" style="position: absolute; left: -2000px; top: 0;" title="Print frame"></iframe> <iframe aria-hidden="true" id="citationExportFrame" name="citationExportFrame" style="position: absolute; left: -2000px; top: 0;" title="scolaris.citation.export.frame"></iframe> <nav> <div class="mobile-navigation"> <div class="close-container"> <a aria-label="Navigate back" class="main-nav-back-btn" href="#"><i class="fa fa-chevron-left"></i></a> <a class="main-nav-close-btn" href="#" title="Close menu">Close menu <i class="fa fa-times"></i></a> </div> <div class="mobile-search basic-search-container"> <div class="portlet-boundary portlet-boundary_scolarissearchportlet_WAR_scolarissearch_ portlet-static portlet-static-end" id="p_p_id_scolarissearchportlet_WAR_scolarissearch_"> <span id="p_scolarissearchportlet_WAR_scolarissearch"></span> <section class="portlet" id="portlet_scolarissearchportlet_WAR_scolarissearch"> <header class="portlet-topper"> <h1 class="portlet-title"> <span class="" onmouseover="Liferay.Portal.ToolTip.show(this, 'Scolaris\x20Search\x20Portlet')"> <img alt="" id="ymag__null__null" src="/scolaris-search/icon.png"> <span class="taglib-text hide-accessible">Scolaris Search Portlet</span> </img></span> <span class="portlet-title-text">Scolaris Search Portlet</span> </h1> <menu class="portlet-topper-toolbar" id="portlet-topper-toolbar_scolarissearchportlet_WAR_scolarissearch" type="toolbar"> </menu> </header> <div class="portlet-content"> <div class="portlet-content-container"> <div class="portlet-body"> <div class="header-search"> <form action="https://www.cochranelibrary.com/en/content?p_auth=afU96cMv&amp;p_p_id=scolarissearchportlet_WAR_scolarissearch&amp;p_p_lifecycle=1&amp;p_p_state=normal&amp;p_p_mode=view&amp;_scolarissearchportlet_WAR_scolarissearch_scolarisAction=redirectSearchResult" method="post"> <input name="searchType" type="hidden" value="basic"> <input name="facetDisplayName" type="hidden" value=""> <input name="facetQueryTerm" type="hidden" value=""/> <input name="facetQueryField" type="hidden" value=""/> <input name="facetCategory" type="hidden" value=""/> <fieldset class="fieldset"> <legend class="sr-only">Basic Search</legend> <div class="select search-by"> <select aria-label="Search by options" class="custom-select-enabled search-type" name="searchBy" title="Search by options"> <option value="1">Title Abstract Keyword</option> <option value="2">Record Title</option> <option value="3">Abstract</option> <option value="4">Author</option> <option value="5">Keyword</option> <option value="6">All Text</option> <option value="7">Publication Type</option> <option value="8">Source</option> <option value="9">DOI</option> <option value="14">Language</option> <option value="10">Accession Number</option> <option value="11">Trial Registry Number</option> <option value="12">Cochrane Group</option> <option value="13">Cochrane Topic</option> </select> </div> <div class="search-select-crg-container select" style="display: none;"> <select class="search-select-crg-list"></select> </div> <div class="search-select-topic-container select" data-topic-list-url="https://www.cochranelibrary.com/en/content?p_p_id=scolaristopics_WAR_scolaristopics&amp;p_p_lifecycle=2&amp;p_p_state=normal&amp;p_p_mode=view&amp;p_p_resource_id=topics-list&amp;p_p_cacheability=cacheLevelPage" style="display: none;"> <select class="search-select-topic-list"></select> </div> <div class="search-select-cl-container select" style="display: none;"> <select class="search-select-cl-list"></select> </div> <div class="search-text-container"> <div class="control-group control-group-inline search-input-wrapper"> <input aria-label="Enter search term" class="field browser-search search-text ui-autocomplete-input" id="searchText" name="searchText" placeholder="Search" size="30" type="text" value=""/>
<div id="autocomplete-results"></div>
</div>
<div class="control-group control-group-inline search-button-wrapper">
<button aria-label="Search" class="searchByBtn" type="submit">
<i aria-hidden="true" class="fa fa-search"></i>
</button>
</div>
</div>
</fieldset>
</input></input></form>
</div>
<script>
    window.displayResultURL = 'https://www.cochranelibrary.com/en/content?p_p_id=scolarissearchportlet_WAR_scolarissearch&p_p_lifecycle=2&p_p_state=normal&p_p_mode=view&p_p_resource_id=getSuggestions&p_p_cacheability=cacheLevelPage&_scolarissearchportlet_WAR_scolarissearch_templateType=full&_scolarissearchportlet_WAR_scolarissearch_urlTitle=%2Fcdsr%2Fdoi%2F10.1002%2F14651858.CD010115.pub2&_scolarissearchportlet_WAR_scolarissearch_contentLanguage=&_scolarissearchportlet_WAR_scolarissearch_type=cdsr&_scolarissearchportlet_WAR_scolarissearch_doi=10.1002%2F14651858.CD010115.pub2';
    window.searchByOption = '';
</script>
</div>
</div>
</div>
<div style="display:none">
<input id="freelabel" name="freelabel" type="hidden" value="Free access"/>
<input id="openlabel" name="openlabel" type="hidden" value="Open access"/>
</div>
</section>
</div>
<a class="btn secondary" href="/en/browse-by-topic">Browse </a>
<a class="btn secondary advanced-search-button" href="/en/advanced-search">Advanced search</a>
</div>
<div class="menu-items parent">
<div>
<div class="nav-root-item parent">
<a class="language-selection-title-link" href="#" title="Select language">
<span class="mobile-nav-language-title">Select your preferred language </span></a> <span class="icon fa fa-caret-down"></span>
<div class="mob-child">
<div class="portlet-boundary portlet-boundary_scolarislanguageselector_WAR_scolarislanguageportlet_ portlet-static portlet-static-end" id="p_p_id_scolarislanguageselector_WAR_scolarislanguageportlet_INSTANCE_mobilenav_">
<span id="p_scolarislanguageselector_WAR_scolarislanguageportlet_INSTANCE_mobilenav"></span>
<section class="portlet" id="portlet_scolarislanguageselector_WAR_scolarislanguageportlet_INSTANCE_mobilenav">
<header class="portlet-topper">
<h1 class="portlet-title">
<span class="" onmouseover="Liferay.Portal.ToolTip.show(this, 'Scolaris\x20Language\x20Selector')">
<img alt="" id="fdkn__null__null" src="/scolaris-language-portlet/icon.png"> <span class="taglib-text hide-accessible">Scolaris Language Selector</span> </img></span> <span class="portlet-title-text">Scolaris Language Selector</span> </h1> <menu class="portlet-topper-toolbar" id="portlet-topper-toolbar_scolarislanguageselector_WAR_scolarislanguageportlet_INSTANCE_mobilenav" type="toolbar"> </menu> </header> <div class="portlet-content"> <div class="portlet-content-container"> <div class="portlet-body"> <div class="language-display" data-content-languages="[de, en, es, fa, fr, hi, hr, id, ja, ko, hu, ms, nl, pl, pt, ru, ro, ta, th, zh_HANT, zh_HANS]"> <a class="language-select-mobile" href="#" title="Select your preferred language"> <i class="fa fa-file-text"></i> English </a> <a class="language-select-mobile" href="#" title="Select your preferred language"> <i class="fa fa-globe"></i> English </a> </div> <div class="form-content language-selector-modal child"> <div class="row-fluid"> <h3><i class="fa fa-file-text"></i> Cochrane review language</h3> <p>Select your preferred language for Cochrane reviews and other content. Sections without translation will be in English.</p> <div class="dropdown-trigger" id="active-content-language"> <span>English</span> <i aria-hidden="true" class="fa fa-caret-down"></i> </div> <div class="language-selector-dropdown"> <a class="content-language-selector" data-languagecode="de" href="https://www.cochranelibrary.com/en/content?p_p_id=scolariscontentlanguagebanner_WAR_scolarislanguageportlet&amp;p_p_lifecycle=2&amp;p_p_state=normal&amp;p_p_mode=view&amp;p_p_resource_id=set-content-language&amp;p_p_cacheability=cacheLevelPage&amp;_scolariscontentlanguagebanner_WAR_scolarislanguageportlet_contentLanguage=de">Deutsch</a> <a class="content-language-selector is-active" data-languagecode="en" href="https://www.cochranelibrary.com/en/content?p_p_id=scolariscontentlanguagebanner_WAR_scolarislanguageportlet&amp;p_p_lifecycle=2&amp;p_p_state=normal&amp;p_p_mode=view&amp;p_p_resource_id=set-content-language&amp;p_p_cacheability=cacheLevelPage&amp;_scolariscontentlanguagebanner_WAR_scolarislanguageportlet_contentLanguage=en">English</a> <a class="content-language-selector" data-languagecode="es" href="https://www.cochranelibrary.com/en/content?p_p_id=scolariscontentlanguagebanner_WAR_scolarislanguageportlet&amp;p_p_lifecycle=2&amp;p_p_state=normal&amp;p_p_mode=view&amp;p_p_resource_id=set-content-language&amp;p_p_cacheability=cacheLevelPage&amp;_scolariscontentlanguagebanner_WAR_scolarislanguageportlet_contentLanguage=es">Español</a> <a class="content-language-selector" data-languagecode="fa" href="https://www.cochranelibrary.com/en/content?p_p_id=scolariscontentlanguagebanner_WAR_scolarislanguageportlet&amp;p_p_lifecycle=2&amp;p_p_state=normal&amp;p_p_mode=view&amp;p_p_resource_id=set-content-language&amp;p_p_cacheability=cacheLevelPage&amp;_scolariscontentlanguagebanner_WAR_scolarislanguageportlet_contentLanguage=fa">فارسی</a> <a class="content-language-selector" data-languagecode="fr" href="https://www.cochranelibrary.com/en/content?p_p_id=scolariscontentlanguagebanner_WAR_scolarislanguageportlet&amp;p_p_lifecycle=2&amp;p_p_state=normal&amp;p_p_mode=view&amp;p_p_resource_id=set-content-language&amp;p_p_cacheability=cacheLevelPage&amp;_scolariscontentlanguagebanner_WAR_scolarislanguageportlet_contentLanguage=fr">Français</a> <a class="content-language-selector" data-languagecode="hi" href="https://www.cochranelibrary.com/en/content?p_p_id=scolariscontentlanguagebanner_WAR_scolarislanguageportlet&amp;p_p_lifecycle=2&amp;p_p_state=normal&amp;p_p_mode=view&amp;p_p_resource_id=set-content-language&amp;p_p_cacheability=cacheLevelPage&amp;_scolariscontentlanguagebanner_WAR_scolarislanguageportlet_contentLanguage=hi">हिन्दी</a> <a class="content-language-selector" data-languagecode="hr" href="https://www.cochranelibrary.com/en/content?p_p_id=scolariscontentlanguagebanner_WAR_scolarislanguageportlet&amp;p_p_lifecycle=2&amp;p_p_state=normal&amp;p_p_mode=view&amp;p_p_resource_id=set-content-language&amp;p_p_cacheability=cacheLevelPage&amp;_scolariscontentlanguagebanner_WAR_scolarislanguageportlet_contentLanguage=hr">Hrvatski</a> <a class="content-language-selector" data-languagecode="id" href="https://www.cochranelibrary.com/en/content?p_p_id=scolariscontentlanguagebanner_WAR_scolarislanguageportlet&amp;p_p_lifecycle=2&amp;p_p_state=normal&amp;p_p_mode=view&amp;p_p_resource_id=set-content-language&amp;p_p_cacheability=cacheLevelPage&amp;_scolariscontentlanguagebanner_WAR_scolarislanguageportlet_contentLanguage=id">Bahasa Indonesia</a> <a class="content-language-selector" data-languagecode="ja" href="https://www.cochranelibrary.com/en/content?p_p_id=scolariscontentlanguagebanner_WAR_scolarislanguageportlet&amp;p_p_lifecycle=2&amp;p_p_state=normal&amp;p_p_mode=view&amp;p_p_resource_id=set-content-language&amp;p_p_cacheability=cacheLevelPage&amp;_scolariscontentlanguagebanner_WAR_scolarislanguageportlet_contentLanguage=ja">日本語</a> <a class="content-language-selector" data-languagecode="ko" href="https://www.cochranelibrary.com/en/content?p_p_id=scolariscontentlanguagebanner_WAR_scolarislanguageportlet&amp;p_p_lifecycle=2&amp;p_p_state=normal&amp;p_p_mode=view&amp;p_p_resource_id=set-content-language&amp;p_p_cacheability=cacheLevelPage&amp;_scolariscontentlanguagebanner_WAR_scolarislanguageportlet_contentLanguage=ko">한국어</a> <a class="content-language-selector" data-languagecode="hu" href="https://www.cochranelibrary.com/en/content?p_p_id=scolariscontentlanguagebanner_WAR_scolarislanguageportlet&amp;p_p_lifecycle=2&amp;p_p_state=normal&amp;p_p_mode=view&amp;p_p_resource_id=set-content-language&amp;p_p_cacheability=cacheLevelPage&amp;_scolariscontentlanguagebanner_WAR_scolarislanguageportlet_contentLanguage=hu">Magyar</a> <a class="content-language-selector" data-languagecode="ms" href="https://www.cochranelibrary.com/en/content?p_p_id=scolariscontentlanguagebanner_WAR_scolarislanguageportlet&amp;p_p_lifecycle=2&amp;p_p_state=normal&amp;p_p_mode=view&amp;p_p_resource_id=set-content-language&amp;p_p_cacheability=cacheLevelPage&amp;_scolariscontentlanguagebanner_WAR_scolarislanguageportlet_contentLanguage=ms">Bahasa Malaysia</a> <a class="content-language-selector" data-languagecode="nl" href="https://www.cochranelibrary.com/en/content?p_p_id=scolariscontentlanguagebanner_WAR_scolarislanguageportlet&amp;p_p_lifecycle=2&amp;p_p_state=normal&amp;p_p_mode=view&amp;p_p_resource_id=set-content-language&amp;p_p_cacheability=cacheLevelPage&amp;_scolariscontentlanguagebanner_WAR_scolarislanguageportlet_contentLanguage=nl">Nederlands</a> <a class="content-language-selector" data-languagecode="pl" href="https://www.cochranelibrary.com/en/content?p_p_id=scolariscontentlanguagebanner_WAR_scolarislanguageportlet&amp;p_p_lifecycle=2&amp;p_p_state=normal&amp;p_p_mode=view&amp;p_p_resource_id=set-content-language&amp;p_p_cacheability=cacheLevelPage&amp;_scolariscontentlanguagebanner_WAR_scolarislanguageportlet_contentLanguage=pl">Polski</a> <a class="content-language-selector" data-languagecode="pt" href="https://www.cochranelibrary.com/en/content?p_p_id=scolariscontentlanguagebanner_WAR_scolarislanguageportlet&amp;p_p_lifecycle=2&amp;p_p_state=normal&amp;p_p_mode=view&amp;p_p_resource_id=set-content-language&amp;p_p_cacheability=cacheLevelPage&amp;_scolariscontentlanguagebanner_WAR_scolarislanguageportlet_contentLanguage=pt">Português</a> <a class="content-language-selector" data-languagecode="ru" href="https://www.cochranelibrary.com/en/content?p_p_id=scolariscontentlanguagebanner_WAR_scolarislanguageportlet&amp;p_p_lifecycle=2&amp;p_p_state=normal&amp;p_p_mode=view&amp;p_p_resource_id=set-content-language&amp;p_p_cacheability=cacheLevelPage&amp;_scolariscontentlanguagebanner_WAR_scolarislanguageportlet_contentLanguage=ru">Русский</a> <a class="content-language-selector" data-languagecode="ro" href="https://www.cochranelibrary.com/en/content?p_p_id=scolariscontentlanguagebanner_WAR_scolarislanguageportlet&amp;p_p_lifecycle=2&amp;p_p_state=normal&amp;p_p_mode=view&amp;p_p_resource_id=set-content-language&amp;p_p_cacheability=cacheLevelPage&amp;_scolariscontentlanguagebanner_WAR_scolarislanguageportlet_contentLanguage=ro">Română</a> <a class="content-language-selector" data-languagecode="ta" href="https://www.cochranelibrary.com/en/content?p_p_id=scolariscontentlanguagebanner_WAR_scolarislanguageportlet&amp;p_p_lifecycle=2&amp;p_p_state=normal&amp;p_p_mode=view&amp;p_p_resource_id=set-content-language&amp;p_p_cacheability=cacheLevelPage&amp;_scolariscontentlanguagebanner_WAR_scolarislanguageportlet_contentLanguage=ta">தமிழ்</a> <a class="content-language-selector" data-languagecode="th" href="https://www.cochranelibrary.com/en/content?p_p_id=scolariscontentlanguagebanner_WAR_scolarislanguageportlet&amp;p_p_lifecycle=2&amp;p_p_state=normal&amp;p_p_mode=view&amp;p_p_resource_id=set-content-language&amp;p_p_cacheability=cacheLevelPage&amp;_scolariscontentlanguagebanner_WAR_scolarislanguageportlet_contentLanguage=th">ภาษาไทย</a> <a class="content-language-selector" data-languagecode="zh_HANT" href="https://www.cochranelibrary.com/en/content?p_p_id=scolariscontentlanguagebanner_WAR_scolarislanguageportlet&amp;p_p_lifecycle=2&amp;p_p_state=normal&amp;p_p_mode=view&amp;p_p_resource_id=set-content-language&amp;p_p_cacheability=cacheLevelPage&amp;_scolariscontentlanguagebanner_WAR_scolarislanguageportlet_contentLanguage=zh_HANT">繁體中文</a> <a class="content-language-selector" data-languagecode="zh_HANS" href="https://www.cochranelibrary.com/en/content?p_p_id=scolariscontentlanguagebanner_WAR_scolarislanguageportlet&amp;p_p_lifecycle=2&amp;p_p_state=normal&amp;p_p_mode=view&amp;p_p_resource_id=set-content-language&amp;p_p_cacheability=cacheLevelPage&amp;_scolariscontentlanguagebanner_WAR_scolarislanguageportlet_contentLanguage=zh_HANS">简体中文</a> </div> </div> <div class="row-fluid"> <h3 class="portal-language-header"><i class="fa fa-globe"></i> Website language</h3> <p>Select your preferred language for the Cochrane Library website.</p> <div class="dropdown-trigger" id="active-portal-language"> <span>English</span> <i aria-hidden="true" class="fa fa-caret-down"></i> </div> <div class="language-selector-dropdown"> <a class="portal-language-selector is-active" data-portallanguage="en" href="/en/cdsr/doi/10.1002/14651858.CD010115.pub2/full/en">English</a> <a class="portal-language-selector" data-portallanguage="es" href="/es/cdsr/doi/10.1002/14651858.CD010115.pub2/full/es">Español</a> </div> </div> <a class="btn secondary ok-btn pull-right" href="https://www.cochranelibrary.com/en/content?p_p_id=scolariscontentlanguagebanner_WAR_scolarislanguageportlet&amp;p_p_lifecycle=2&amp;p_p_state=normal&amp;p_p_mode=view&amp;p_p_resource_id=set-content-language&amp;p_p_cacheability=cacheLevelPage">Save</a> </div> </div> </div> </div> <div style="display:none"> <input id="freelabel" name="freelabel" type="hidden" value="Free access"/>
<input id="openlabel" name="openlabel" type="hidden" value="Open access"/>
</div>
</section>
</div>
</div>
</div>
<div class="parent">
<a class="mobile-link signin" data-redirect="false" href="https://www.cochranelibrary.com/c/portal/login?p_l_id=20757&amp;redirect=%2Fcdsr%2Fdoi%2F10.1002%2F14651858.CD010115.pub2%2Ffull" rel="nofollow">
                        Sign In
                    </a>
</div>
</div>
<div class="menu-items-footer">
<div class="utility-links">
<a class="cochrane-link" href="http://www.cochrane.org/" target="_blank">Visit Cochrane.org</a>
</div>
</div>
</div>
<div class="menu-items child"></div>
</div>
</nav><div class="basic-login-form-content" data-modal-title="Sign in" style="display: none;">
<div class="form-content">
<div class="row-fluid">
<div class="span12">
<div class="portlet-boundary portlet-boundary_58_ portlet-static portlet-static-end portlet-login" id="p_p_id_58_INSTANCE_MODAL_">
<span id="p_58_INSTANCE_MODAL"></span>
<section class="portlet" id="portlet_58_INSTANCE_MODAL">
<header class="portlet-topper">
<h1 class="portlet-title">
<span class="" onmouseover="Liferay.Portal.ToolTip.show(this, 'Sign\x20In')">
<img alt="" id="dbam__null__null" src="https://www.cochranelibrary.com/cochrane-theme/images/spacer.png" style="background-image: url('https://www.cochranelibrary.com/sprite/html/icons/_sprite.png'); background-position: 50% -592px; background-repeat: no-repeat; height: 16px; width: 16px;"> <span class="taglib-text hide-accessible">Sign In</span> </img></span> <span class="portlet-title-text">Sign In</span> </h1> <menu class="portlet-topper-toolbar" id="portlet-topper-toolbar_58_INSTANCE_MODAL" type="toolbar"> </menu> </header> <div class="portlet-content"> <div class="portlet-content-container"> <div class="portlet-body"> <form action="https://www.cochranelibrary.com/en/content?p_p_id=58_INSTANCE_MODAL&amp;p_p_lifecycle=1&amp;p_p_state=normal&amp;p_p_mode=view&amp;_58_INSTANCE_MODAL_struts_action=%2Flogin%2Flogin" autocomplete="on" class="form sign-in-form" id="_58_INSTANCE_MODAL_fm" method="post" name="_58_INSTANCE_MODAL_fm"> <fieldset class="input-container" disabled="disabled"> <legend class="sr-only">Cochrane Login</legend> <input name="_58_INSTANCE_MODAL_formDate" type="hidden" value="1740715818097"> <input class="field" id="_58_INSTANCE_MODAL_saveLastPath" name="_58_INSTANCE_MODAL_saveLastPath" type="hidden" value="false"> <input class="field" id="_58_INSTANCE_MODAL_redirect" name="_58_INSTANCE_MODAL_redirect" type="hidden" value="/cdsr/doi/10.1002/14651858.CD010115.pub2/full"> <input class="field" id="_58_INSTANCE_MODAL_doActionAfterLogin" name="_58_INSTANCE_MODAL_doActionAfterLogin" type="hidden" value="false"> <div class="control-group input-text-wrapper"> <label class="control-label" for="_58_INSTANCE_MODAL_login"> Email Address </label> <input class="field clearable" id="_58_INSTANCE_MODAL_login" name="_58_INSTANCE_MODAL_login" type="text" value=""> </input></div> <div class="control-group input-text-wrapper"> <label class="control-label" for="_58_INSTANCE_MODAL_password"> Password </label> <input class="field" id="_58_INSTANCE_MODAL_password" name="_58_INSTANCE_MODAL_password" type="password" value=""/> </div> <span id="_58_INSTANCE_MODAL_passwordCapsLockSpan" style="display: none;"> Caps Lock is on. </span> <div class="clearfix"> <div class="checkbox-list pull-left"> <div class="checkbox-list-item"> <div class="control-group form-inline input-checkbox-wrapper"> <label for="_58_INSTANCE_MODAL_rememberMeCheckbox"> <input id="_58_INSTANCE_MODAL_rememberMe" name="_58_INSTANCE_MODAL_rememberMe" type="hidden" value="true"/> <input checked="" class="field" id="_58_INSTANCE_MODAL_rememberMeCheckbox" name="_58_INSTANCE_MODAL_rememberMeCheckbox" onclick="Liferay.Util.updateCheckboxValue(this); " type="checkbox" value="true"/> Remember Me </label> </div> </div> </div> <div class="pull-right"> <a href="https://onlinelibrary.wiley.com/user/forgottenpassword" target="_blank">Forgotten password?</a> </div> </div> <div class="login-form-footer clearfix"> <div class="pull-left"> <button class="btn primary" type="submit">Sign in</button> <a class="btn secondary" href="https://onlinelibrary.wiley.com/user-registration" target="_blank">Register</a> </div> <div class="pull-right"> <a class="institutional-login-form-button" href="https://www.cochranelibrary.com/en/content?p_p_id=scolariscontentdisplay_WAR_scolariscontentdisplay&amp;p_p_lifecycle=0&amp;p_p_state=normal&amp;p_p_mode=view&amp;_scolariscontentdisplay_WAR_scolariscontentdisplay_action=institution-access">Institutional login</a> </div> </div> </input></input></input></input></fieldset> </form> </div> </div> </div> <div style="display:none"> <input id="freelabel" name="freelabel" type="hidden" value="Free access"/>
<input id="openlabel" name="openlabel" type="hidden" value="Open access"/>
</div>
</section>
</div>
</div>
</div>
</div></div>
<div class="institution-login-form-content" data-modal-title="Institutional login" style="display: none;">
<div class="form-content">
<div class="row-fluid access-content-wrapper">
<div class="span12">
<div class="section">
<div class="portlet-boundary portlet-boundary_scolariscontentdisplay_WAR_scolariscontentdisplay_ portlet-static portlet-static-end scolaris-content-display-portlet" id="p_p_id_scolariscontentdisplay_WAR_scolariscontentdisplay_INSTANCE_combinedloginform_">
<span id="p_scolariscontentdisplay_WAR_scolariscontentdisplay_INSTANCE_combinedloginform"></span>
<section class="portlet" id="portlet_scolariscontentdisplay_WAR_scolariscontentdisplay_INSTANCE_combinedloginform">
<header class="portlet-topper">
<h1 class="portlet-title">
<span class="" onmouseover="Liferay.Portal.ToolTip.show(this, 'Scolaris\x20Content\x20Display')">
<img alt="" id="obft__null__null" src="/scolaris-content-display/icon.png"> <span class="taglib-text hide-accessible">Scolaris Content Display</span> </img></span> <span class="portlet-title-text">Scolaris Content Display</span> </h1> <menu class="portlet-topper-toolbar" id="portlet-topper-toolbar_scolariscontentdisplay_WAR_scolariscontentdisplay_INSTANCE_combinedloginform" type="toolbar"> </menu> </header> <div class="portlet-content"> <div class="portlet-content-container"> <div class="portlet-body"> <div class="access-content-section"> <div class="section-content"> <p>Search for your institution's name below to login via Shibboleth</p> <form action="/shibboleth" id="institutionLoginForm" method="post"> <div class="fieldset"> <div class="form-group access-input-wrapper"> <div class="ui-widget ui-front"> <label class="sr-only" for="institutionName">Institution name</label> <input class="field" id="institutionName" name="institutionName" type="text" value=""/>
</div>
<button class="btn primary" name="button" type="submit">Go</button>
</div>
<div class="message error" id="institutionLookupErrorDiv" style="display:none">
                        '<span id="enteredInstitionNameSpan"></span>' is not set up for this type of access on Wiley Online Library. Please contact your institution's administrator to ask about access.
                    </div>
</div>
<input id="entityId" name="entityId" type="hidden" value=""/>
</form>
<h4>Previously accessed institutions</h4>
<ul class="plain" id="previousInstitutions">
<li>(none)</li>
</ul>
</div>
<div class="section-content">
<div class="open-athens-login">
                Login using <a href="/openathens">OpenAthens</a>
</div>
</div>
</div>
</div>
</div>
</div>
<div style="display:none">
<input id="freelabel" name="freelabel" type="hidden" value="Free access"/>
<input id="openlabel" name="openlabel" type="hidden" value="Open access"/>
</div>
</section>
</div>
<div class="portlet-boundary portlet-boundary_58_ portlet-static portlet-static-end portlet-login" id="p_p_id_58_INSTANCE_4_">
<span id="p_58_INSTANCE_4"></span>
<section class="portlet" id="portlet_58_INSTANCE_4">
<header class="portlet-topper">
<h1 class="portlet-title">
<span class="" onmouseover="Liferay.Portal.ToolTip.show(this, 'Sign\x20In')">
<img alt="" id="joiu__null__null" src="https://www.cochranelibrary.com/cochrane-theme/images/spacer.png" style="background-image: url('https://www.cochranelibrary.com/sprite/html/icons/_sprite.png'); background-position: 50% -592px; background-repeat: no-repeat; height: 16px; width: 16px;"> <span class="taglib-text hide-accessible">Sign In</span> </img></span> <span class="portlet-title-text">Sign In</span> </h1> <menu class="portlet-topper-toolbar" id="portlet-topper-toolbar_58_INSTANCE_4" type="toolbar"> </menu> </header> <div class="portlet-content"> <div class="portlet-content-container"> <div class="portlet-body"> <p>If you have a <strong>Wiley Online Library</strong> institutional username and password, enter them here.</p> <form action="https://www.cochranelibrary.com/en/content?p_p_id=58_INSTANCE_4&amp;p_p_lifecycle=1&amp;p_p_state=normal&amp;p_p_mode=view&amp;_58_INSTANCE_4_struts_action=%2Flogin%2Flogin" autocomplete="on" class="form sign-in-form" id="_58_INSTANCE_4_fm" method="post" name="_58_INSTANCE_4_fm"> <fieldset class="input-container" disabled="disabled"> <legend class="sr-only">Cochrane Login</legend> <input name="_58_INSTANCE_4_formDate" type="hidden" value="1740715818103"> <input class="field" id="_58_INSTANCE_4_saveLastPath" name="_58_INSTANCE_4_saveLastPath" type="hidden" value="false"> <input class="field" id="_58_INSTANCE_4_redirect" name="_58_INSTANCE_4_redirect" type="hidden" value="/cdsr/doi/10.1002/14651858.CD010115.pub2/full"> <input class="field" id="_58_INSTANCE_4_doActionAfterLogin" name="_58_INSTANCE_4_doActionAfterLogin" type="hidden" value="false"> <div class="control-group input-text-wrapper"> <label class="control-label" for="_58_INSTANCE_4_login"> Username </label> <input class="field clearable" id="_58_INSTANCE_4_login" name="_58_INSTANCE_4_login" type="text" value=""> </input></div> <div class="control-group input-text-wrapper"> <label class="control-label" for="_58_INSTANCE_4_password"> Password </label> <input class="field" id="_58_INSTANCE_4_password" name="_58_INSTANCE_4_password" type="password" value=""> </input></div> <input class="field" id="_58_INSTANCE_4_institutionalLogin" name="_58_INSTANCE_4_institutionalLogin" type="hidden" value="true"/> <span id="_58_INSTANCE_4_passwordCapsLockSpan" style="display: none;"> Caps Lock is on. </span> <div class="login-form-footer clearfix"> <div class="pull-left"> <button class="btn primary" type="submit">Sign in</button> </div> </div> </input></input></input></input></fieldset> </form> </div> </div> </div> <div style="display:none"> <input id="freelabel" name="freelabel" type="hidden" value="Free access"/>
<input id="openlabel" name="openlabel" type="hidden" value="Open access"/>
</div>
</section>
</div>
</div>
</div>
</div>
</div></div>
<div class="get-access-form-content" data-modal-title="Unlock gold-standard Cochrane evidence" style="display: none;">
<div class="portlet-boundary portlet-boundary_scolariscontentdisplay_WAR_scolariscontentdisplay_ portlet-static portlet-static-end scolaris-content-display-portlet" id="p_p_id_scolariscontentdisplay_WAR_scolariscontentdisplay_INSTANCE_getaccessform_">
<span id="p_scolariscontentdisplay_WAR_scolariscontentdisplay_INSTANCE_getaccessform"></span>
<section class="portlet" id="portlet_scolariscontentdisplay_WAR_scolariscontentdisplay_INSTANCE_getaccessform">
<header class="portlet-topper">
<h1 class="portlet-title">
<span class="" onmouseover="Liferay.Portal.ToolTip.show(this, 'Scolaris\x20Content\x20Display')">
<img alt="" id="wpdq__null__null" src="/scolaris-content-display/icon.png"> <span class="taglib-text hide-accessible">Scolaris Content Display</span> </img></span> <span class="portlet-title-text">Scolaris Content Display</span> </h1> <menu class="portlet-topper-toolbar" id="portlet-topper-toolbar_scolariscontentdisplay_WAR_scolariscontentdisplay_INSTANCE_getaccessform" type="toolbar"> </menu> </header> <div class="portlet-content"> <div class="portlet-content-container"> <div class="portlet-body"> <div class="readcube-checkout-container-outer"> <div class="row-fluid access-content-wrapper"> <div class="span6 access-left-content"> <div class="section"> <div class="section-content"> <p>Improve your health decisions with access to trusted, independent evidence from the Cochrane Library. Unlock this review for uninterrupted access.</p> <p>Still deciding? <a href="https://m.info.wiley.com/webApp/cochranenewsletter"> Sign up to our newsletter to learn more </a> </p> </div> </div> <div class="section"> <div class="access-content-section"> <h3 class="title">Institutional users</h3> <div class="section-content"> <p>Search for your institution's name below to login via Shibboleth</p> <form action="/shibboleth" id="institutionLoginForm" method="post"> <div class="fieldset"> <div class="form-group access-input-wrapper"> <div class="ui-widget ui-front"> <label class="sr-only" for="institutionName">Institution name</label> <input class="field" id="institutionName" name="institutionName" type="text" value=""/> </div> <button class="btn primary" name="button" type="submit">Go</button> </div> <div class="message error" id="institutionLookupErrorDiv" style="display:none"> '<span id="enteredInstitionNameSpan"></span>' is not set up for this type of access on Wiley Online Library. Please contact your institution's administrator to ask about access. </div> </div> <input id="entityId" name="entityId" type="hidden" value=""/> </form> <h4>Previously accessed institutions</h4> <ul class="plain" id="previousInstitutions"> <li>(none)</li> </ul> </div> <div class="section-content"> <div class="open-athens-login"> Login using <a href="/openathens">OpenAthens</a> </div> </div> </div> </div> <div class="section"> <div class="access-content-section"> <h3 class="title"> Other access options </h3> <div class="section-content"> <ul class="plain"> <li> <a class="get-access-individual-login-button" href="/c/portal/login"> Individual access - via Wiley Online Library </a> </li> </ul> </div> </div> </div> </div> <div class="span6 access-right-content readcube-checkout-container"> <div class="section"> </div> </div> </div> </div> </div> </div> </div> <div style="display:none"> <input id="freelabel" name="freelabel" type="hidden" value="Free access"/> <input id="openlabel" name="openlabel" type="hidden" value="Open access"/> </div> </section> </div> </div> <!-- Scolaris Version: --> <script type="text/javascript">if(window._satellite){_satellite.pageBottom()};</script> </div> <script>(function(){function c(){var b=a.contentDocument||a.contentWindow.document;if(b){var d=b.createElement('script');d.innerHTML="window.__CF$cv$params={r:'918d905c6dcff55f',t:'MTc0MDcxNTgxOC4wMDAwMDA='};var a=document.createElement('script');a.nonce='';a.src='/cdn-cgi/challenge-platform/scripts/jsd/main.js';document.getElementsByTagName('head')[0].appendChild(a);";b.getElementsByTagName('head')[0].appendChild(d)}}if(document.body){var a=document.createElement('iframe');a.height=1;a.width=1;a.style.position='absolute';a.style.top=0;a.style.left=0;a.style.border='none';a.style.visibility='hidden';document.body.appendChild(a);if('loading'!==document.readyState)c();else if(window.addEventListener)document.addEventListener('DOMContentLoaded',c);else{var e=document.onreadystatechange||function(){};document.onreadystatechange=function(b){e(b);'loading'!==document.readyState&&(document.onreadystatechange=e,c())}}}})();</script></body> </html> 